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Abstract 
 
 The zinc finger recombinase (ZFR) is a chimeric enzyme system for use in targeted 
genomic editing. The ZFR is comprised of a recombinase catalytic domain, which is able to 
catalyse recombination reactions between DNA molecules, and a zinc finger array DNA-
binding domain, which is able to target the enzyme to a desired genetic sequence. 
Currently the ZFR is in an early stage of development and will require several crucial 
improvements before it can be adopted as a useful genome editing tool by researchers. 
Two major challenges involve two important parameters of ZFR-catalysed integration 
reactions: specificity of the orientation of the integration, and stability of the integration. 
Currently, the ZFR system is unable to select the orientation of integrations, and because 
the recombination reactions are reversible, the integrations are not stable (and, in fact, 
are stochastically disfavoured). This project aimed to impart the ZFR system with the 
ability to perform stable, orientation-specific integrations. 
 
 In order to achieve the project aims, the experiments of this project sought to 
generate new pairs of ZFR mutants that were differentially modified at either their 
catalytic domain or DNA-binding domain, and characterize their behaviour in an E. coli-
based recombination assay. The overall strategy was to exploit the interactions within the 
protein-protein interfaces of the ZFR tetramer to produce selective compatibility, and to 
generate differences in enzyme activity when two mutants (one active, and one inactive 
or less active) were either paired as heterodimers or as homodimers. During ZFR 
recombination reactions heterodimers rearrange to form homodimers, and thus the 
production of a significant difference in activity between heterodimers and homodimers 
represents a recombination reaction directionality bias. Both the catalytic domain 
modification and DNA-binding domain modification approaches proved able to produce 
the desired bias in the directionality of ZFR recombination reactions, which is predicted to 
lead to both stability of an integration, and specificity of integration orientation through a 
stochastic process. Of particular note, was a strategy utilizing a heterodimer that 
consisted of one ZFR subunit targeted specifically to the DNA, paired with a recombinase 
subunit (with its native DNA-binding domain) targeted non-specifically to the DNA. The 
difference in activity between these subunits paired in heterodimer and homodimer 
configurations appeared to produce a completely irreversible recombination reaction 
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without any apparent reduction in recombination reaction efficiency. Furthermore, the 
results of the catalytic domain modification and DNA-binding domain modification 
experiments suggest that it should be possible to generate a combination strategy in 
which the recombinase subunit with the native DNA-binding domain is catalytically 
inactive unless operating within an intended heterodimer, overcoming the potential 
problem of unwanted off-target activity from homodimers of this subunit.    
 
 The success of this work in producing ZFR reactions with the potential to catalyse 
stable, orientation-specific integration reactions potentially represents a major leap 
forward in ZFR research; however, these results must be further validated in a 
mammalian cell system. Although genome editing systems such as the CRISPR-Cas9 RNA-
guided endonuclease now allow researchers to modify genomes within embryos and cell 
culture with ease, off-target effects, reliance on endogenous homology directed repair 
(HDR) activity, unfavourable ratios of HDR to non-homologous end joining (NHEJ) activity 
at the target site, and low efficiency make targeted endonuclease technology impractical 
for use in in vivo gene therapy applications and genome editing in some cell types (e.g. 
non-dividing cells such as neurons and myocytes). Therefore, the ZFR is envisioned as a 
genome editing tool that can fill this vacant niche for gene editing in non-dividing cell 
types and human in vivo gene therapy.  
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Chapter 1: Introduction  
 
1.1 The dream of targeted genomic sequence editing 
 Coding the instructions for all the processes, in all of life's organisms, is DNA. 
Structural materials and enzymes, how they are assembled and modified, and the 
immense regulatory networks in which they are contained, are all guided by DNA 
instructions. That all of this reduces down to a single type of code contained within a 
single type of molecule is profound; more profound, is the idea that we might be able to 
intelligently alter this code at will. The creation of powerful new enzymes with 
engineered programmable DNA-binding domains, such as chimeric endonucleases and 
chimeric recombinases have, for the first time, allowed humans to easily perform a 
variety of genetic sequence manipulations, including targeted sequence replacement. 
Thus, the nascent field of targeted genomic sequence editing is beginning to open new 
doors in the fields of experimental genetics, genetic engineering, and gene therapy. 
However, this technology is far from perfected, and many challenges must be overcome 
before it can achieve its full potential. Because the applications of targeted genomic 
sequence editing technology are vast, this chapter will primarily focus on its development 
and use as it relates to the modification of human cells and gene therapy. The realization 
of targeted genomic sequence editing represents an unparalleled opportunity to 
investigate and decipher the instructions of life, alter the organisms in the world around 
us, and better the human organism itself. 
 
1.2 Current gene therapy 
1.2.1 Gene therapy background 
 Gene therapy is a medical approach that aims to deliver genes with therapeutic 
effects in order to treat a wide range of pathologies including cancer, genetic disorders, 
and heart disease. Currently, over 60% of the ongoing gene therapy clinical trials 
worldwide are focused on the treatment of cancer (Wirth et al., 2013). Although over 
1800 gene therapy clinical trials have been conducted or are ongoing, few gene therapy 
products have actually made it to market (Wirth et al., 2013). The first gene therapy ever 
to be approved for use was Gendicine® (SiBiono GeneTech Co., Ltd; Shenzhen, China), 
which was approved in China, in 2003, for treating head and neck squamous cell 
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carcinomas (Wilson, 2005, Pearson et al., 2004). Gendicine® is based on a non-replicative 
adenoviral vector and therapeutically expresses functional p53 tumour suppressor in 
tumour cells. Following Gendicine®, in 2005, another cancer gene therapy, Oncorine® 
(Sunway Biotech Co., Ltd; Shanghai, China), was also approved for use in China (Wirth et 
al., 2013). Oncorine® is based on a conditionally replicative adenovirus that contains a 
deletion in the viral genome allowing the virus to replicate only in p53-deficient cells. In 
2012, Glybera® (UniQure; Amsterdam, Netherlands), a gene therapy designed to treat 
familial lipoprotein lipase deficiency, became the first to be recommended for approval in 
the EU (Buning, 2013, Yla-Herttuala, 2012). Glybera® uses an adeno-associated viral 
vector to express lipoprotein lipase from within muscle tissue. Incidentally, Glybera® will 
be the most expensive treatment in the world, with an expected price tag of €1.1 million 
for a one-time treatment that is expected to be permanently corrective (Yla-Herttuala, 
2015).  
 
1.2.2 Gene therapy characteristics 
 Gene therapy may involve either in vivo strategies, where therapeutic genes are 
directly introduced into cells within the body, or ex vivo strategies, where cells extracted 
from the body are reintroduced after treatment with gene therapy vectors. The simplest 
form of in vivo delivery involves direct injection of the gene therapy vector into the target 
tissue, and this is the method used for the Gendicine®, Oncorine® and Glybera® therapies 
mentioned above. More complex in vivo gene therapy delivery strategies involve systemic 
administration with the use of vectors that are capable of tissue targeting. Although many 
gene therapies utilizing systemically administered tissue targeting vectors or ex vivo 
strategies have entered trials, none have yet been approved (Kaufmann et al., 2013). The 
efficacy of a gene therapy vector will be based on several factors including: targeting to, 
and internalization within, the target cell type; trafficking within the cell; protection from 
degradation; nuclear localization; gene expression levels; and stability and persistence of 
the transfected DNA or transfected cells (Douglas, 2008, Gardlik et al., 2005).  
 
 Currently, gene therapy approaches can be broadly categorized into those 
mediated by viral vectors (such as retroviral, adenoviral, and adeno-associated vectors) 
and those mediated by non-viral vectors (such as liposomes, charged polymers, lipid 
polymer combinations, and peptide-based) (Douglas, 2008). Viral vectors often consist of 
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replication-deficient viruses with recombinant genomes that express a therapeutic gene. 
Viral vectors have the advantage of introducing DNA to target cells with higher efficiency 
and produce higher levels of gene expression than non-viral vectors (Gardlik et al., 2005). 
The drawbacks to using viral vectors can include: possible reactivation of replication 
competence, pre-existing antibody response from past viral infections, and, in some 
cases, transient expression (Waehler et al., 2007, Gardlik et al., 2005). Non-viral vectors 
consist of artificial vesicle-like structures that carry an expression plasmid. Non-viral 
vectors have the advantage of being less immunogenic than viral vectors, but are 
significantly limited in nuclear translocation and by transient expression (Douglas, 2008). 
Another important distinction among gene therapy vectors, which impacts gene 
expression and stability, is between those that integrate their genetic material into the 
genome and those that do not. Integrating vectors such as retroviral vectors maintain 
better gene expression and persistence over time, but suffer the disadvantage that their 
integration is random, and thus can be oncogenic (Sadelain, 2004).  
 
1.2.3 Targeted genome editing enzymes for gene therapy 
 Recently, enzymes that mediate targeted genomic sequence editing have 
presented themselves as a more elegant modality for gene therapy. Targeted genome 
editing enzymes have the theoretical advantage that they could be used to produce gene 
insertions with stable, long term gene expression like retroviruses do, but with a reduced 
risk of random mutagenesis (although this depends largely on the fidelity of the gene 
editing technology). In addition, these enzymes could be used to perform gene 
correction, rather than randomly introducing a functional copy of a defective gene into 
the genome. The gene correction approach would open up the possibility of treating 
disorders caused by the presence of a dominant negative allele (e.g. Huntington’s 
disease). Gene correction also provides an advantage over current gene therapy 
modalities in that corrected genes will be expressed in their endogenous genomic 
context, providing the naturally intended level of expression and regulation for the gene.  
 
 Unlike viral vectors, targeted genome editing enzymes do not come with their 
own cell-delivery system; however, the currently available gene therapy vectors provide 
options for this delivery (see Section 1.4.5). The DNA molecules encoding targeted 
genome editing enzymes are essentially therapeutic genes, so, in a sense, this modality 
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simply represents an enhancement to the cargo options that gene therapy vectors 
currently carry. The following sections will discuss the development of targeted genomic 
editing technology while referencing its relationship in gene therapy. 
 
1.3 A brief history of targeted genomic sequence editing 
1.3.1 The development of gene targeting 
1.3.1.1 Insertion and replacement vectors 
 The first report of a targeted genomic sequence alteration in mammalian cells was 
published in the mid eighties by Smithies et al. (1985) (Smithies et al., 1985). Smithies' 
approach involved transfecting Hu 11 cells (a hybrid murine erythroleukemia cell line 
containing human chromosome 11) with a plasmid vector containing extensive homology 
to the β-globin locus, in order to integrate the plasmid at that locus through the 
endogenous homologous recombination activity of the cell. Because this approach 
integrated the entire plasmid, it was not gene editing in the sense of a discrete 
replacement of genetic sequence. However, this proof-of-concept based on homologous 
recombination, was built upon extensively throughout the late eighties and nineties to 
allow researchers to perform site-specific deletions, insertions, and sequence 
replacements of DNA at desired genomic loci, becoming known as 'gene targeting'.  
 
 The available suite of gene targeting techniques allow researchers to effectively 
disrupt genes using targeted 'insertion vectors' that rely on a single homologous 
recombination cross-over event (such as in Smithies' experiment), or by using targeted 
'replacement vectors' that rely on two cross-over events in order to effect a cassette 
replacement (Figure 1-1 A and B, respectively) (Muller, 1999). However, because these 
recombination events happen at a very low frequency, the use of both insertion vectors 
and replacement vectors typically involves the permanent introduction of selectable 
markers (e.g. neomycin resistance) in order to make the techniques practicable.  
 
1.3.1.2 Hit-and-run and tag-and-exchange 
 Subtle genetic code changes (such as a point mutation) that do not permanently 
introduce a selectable marker can be accomplished by gene targeting techniques called 
'hit-and-run' and 'tag-and-exchange'. The hit-and-run (also known as 'in-and-out') and 
tag-and-exchange techniques are based on the use of an insertion vector or replacement 
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Figure 1-1: Gene targeting strategies using an insertion vector and a replacement vector.  A) Insertion 
vector gene targeting. A vector with homology (indicated by pink) between exon 1 and 2, and carrying a 
neomycin resistance gene (neo) in order to allow for positive selection, is shown. The break indicates that 
the vector has been linearized in the region of homology, which increases the efficiency of the homologous 
recombination. Homologous recombination happens at the crossover site indicated by the crossed lines. 
The product 'targeted' locus contains some duplication of the target sequence due to total integration of 
the plasmid vector.  B) Replacement vector gene targeting. The vector contains a neomycin resistance 
marker flanked by two regions of homology to the genomic locus. Outside the region of homology the 
vector also contains an HSV thymidine kinase gene (tk), which acts as a conditional negative selective maker 
against improper vector integration (e.g. when only one cross-over event takes place) when used in 
conjunction with fialuridine or gancyclovir. Homologous recombination happens at two crossover sites. In 
the product targeted locus, exon 2 has been replaced with the neo cassette. PCR primers (P1 and P2) allow 
for confirmation of correct cassette replacement. Note that the inclusion of exons in the figure is primarily 
to help with visual orientation. Adapted from Müller (1999).
vector, respectively, but utilize the transient introduction of a negative selectable marker 
(e.g. the HSV thymidine kinase gene in conjunction with fialuridine or gancyclovir) and a 
positive selectable marker (e.g. neomycin). 
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Figure 1-2: Hit-and-run gene targeting.  The figure displays the hit-and-run gene targeting approach being 
used to replace exon 2 at a genomic locus with a variant of exon 2 containing a point mutation. The insertion 
vector contains an exon 2 variant with a point mutation (2*) flanked by sequences homologous to the 
genomic locus (pink), as well as genes for HSV thymidine kinase (tk) and neomycin resistance (neo) in the 
vector backbone. In the 'hit' stage, a homologous recombination crossover event introduces the entire 
plasmid into the genomic locus. Screening for successful integration is carried out with neomycin. In the 
'run' stage, a subsequent intrachromosomal recombination event between the repeat regions removes the 
repeat, as well as the neomycin and thymidine kinase genes. Selection with fialuridine (FIAU) is used to 
detect the recombination event. It should be noted, that depending on the location of the 
intrachromosomal crossover event, the wild-type allele may also be restored (not shown). Adapted from 
Müller (1999). 
 In the hit-and-run approach (Figure 1-2), the insertion vector contains a genetic 
sequence that is homologous to the target site but contains a desired mutation, as well as  
both positive and negative selectable markers within the vector backbone (Muller, 1999). 
Targeted integration of the insertion vector results in a direct repeat of the target 
sequence, where one repeat contains the desired mutation and the repeats are separated 
by the vector backbone containing the selectable markers. After a positive selection step 
has identified cells that have integrated the insertion vector, a subsequent 
intrachromosomal homologous recombination event, which deletes the unwanted 
sequence that includes the two selectable markers, can be detected by a negative 
selection step. The result is that only the desired sequence replacement remains in the 
genomes of cells that pass the second selection step. 
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Figure 1-3: Tag-and-exchange gene targeting.  The figure depicts tag-and-exchange being used to replace 
exon 2 at a genomic locus, with a variant of exon 2 containing a point mutation. In the 'tag' stage, the 
replacement vector contains thymidine kinase (tk) and neomycin (neo) genes flanked by regions of 
homology to the genomic locus (pink). Two homologous recombination crossover events replace exon 2 
with a thymidine kinase and neomycin resistance cassette. Screening for successful cassette replacement is 
carried out using neomycin. In the 'exchange' stage, a second vector is used to replace the kinase and 
neomycin resistance gene with a variant of exon 2 containing a point mutation (2*) via the same type of 
homologous recombination-mediated cassette exchange as in the previous stage. Screening for successful 
cassette replacement is carried out with fialuridine (FIAU). Adapted from Müller (1999). 
 In the tag-and-exchange approach (Figure 1-3), a replacement vector is first used 
to facilitate a cassette exchange that replaces the target endogenous sequence with only 
the positive and negative selectable markers (Muller, 1999). After positive selection has 
identified cells that have undergone this cassette exchange, a second replacement vector 
is used to replace the positive and negative selectable marker cassette with the desired 
replacement sequence via another cassette replacement event, which can be detected by 
negative selection. The result is that only the desired sequence replacement remains in 
the genomes of cells that pass the second selection step. Although the hit-and-run and 
tag-and-exchange methods are able to effectively 'edit' genomic sequences for cell 
culture experiments or for genetically engineering murine embryos, the positive and 
negative selection steps make these techniques inapplicable to gene therapy, and these 
techniques are labour-intensive. 
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1.3.1.3 Site-specific recombinase-enhanced gene targeting 
 Site-specific recombinases, such as Cre recombinase, FLP recombinase, and ΦC31 
integrase, can also be used for gene targeting using a strategy that is similar to hit-and-
run and tag-and-exchange, but with greatly increased efficiency (Muller, 1999). These 
site-specific recombinases act on specific target sequences to produce a DNA 
recombination event, with higher efficiency than that of endogenous intracellular 
homologous recombination. For example, the Cre recombinase acts on two 34 bp targets 
called loxP sites (Figure 1-4 A), and will either excise or invert an intervening sequence 
sandwiched between loxP sites depending on whether the sites are arranged in direct or 
inverted repeat, respectively (Figure 1-4 B).  
 
 In a Cre recombinase-based gene targeting strategy (Figure 1-4 C), a replacement-
type plasmid vector is used to facilitate a cassette exchange, which replaces the target 
DNA sequence with a sequence containing the desired mutation as well as positive and 
negative selectable markers (Muller, 1999). Additionally, the selectable markers are 
flanked by a direct repeat of loxP sites. After detection of the initial cassette replacement 
by positive selection, transient transfection with a Cre recombinase expressing plasmid 
causes the positive and negative selectable markers to be excised with high efficiency. 
Negative selection can then be used to detect this excision event, which will take place 
with greatly improved efficiency compared to the homologous recombination excision 
that the previously described tag-and-exchange approach relies on at this stage.  
 
 However, Cre recombinase-based gene targeting does not result in a discrete DNA 
sequence edit because it leaves behind a genetic 'scar' consisting of one loxP site. Thus, 
although gene targeting strategies involving natural site-specific recombinases have a 
performance improvement due to the increased efficiency of the second step, they are 
still not applicable for some applications, including gene therapy, due to their use of 
selection steps and the sequence scar that is left behind. 
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Figure 1-4:  Cre/loxP system in gene targeting.  A) Structure of a loxP site. The Cre recombinase binds two 
13-bp inverted repeats separated by an 8-bp spacer sequence (blue arrow). The spacer sequence 
determines the orientation of the loxP site.  B) Cre recombinase-mediated recombination reactions. When 
loxP sites (blue triangles) are arranged in direct repeat, Cre recombinase will mediate an excision reaction 
where the intervening sequence is circularized. One loxP site will remain in both the substrate molecule and 
the circularized excision product. When loxP sites are arranged in inverted repeat, Cre recombinase will 
mediate an inversion reaction where the intervening sequence becomes reversed in orientation.  C) 
Cre/loxP-mediated gene targeting. In the first stage a replacement vector is used which contains a cassette 
with genes for neomycin resistance (neo) and HSV thymidine kinase (tk) flanked by loxP sites, as well as an 
exon 2 variant with a point mutation (2*). This cassette is further flanked by regions of homology (pink) to a 
genomic locus. Outside of these regions of homology, the replacement vector also contains a gene coding 
for diphtheria toxin A-fragment (DT-A), which kills cells that undergo improper integration of the vector 
(e.g. when only a single crossover event takes place). Homologous recombination at two crossover sites 
replaces exon 2 in the genomic locus with the cassette. Screening with neomycin confirms cassette 
replacement. In the second stage, Cre recombinase is introduced by transient transfection, causing the 
neomycin resistance and thymidine kinase genes to be excised, leaving only the exon 2 variant with the 
point mutation and one loxP site. Screening with FIAU confirms Cre recombinase-mediated excision. Introns 
are not necessarily truncated in this process as shown. Adapted from Müller (1999). 
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1.3.2 'Classical' targeted gene repair   
 During the mid 1990s through to the mid 2000s another method for performing 
simple gene edits was developed in the form of 'targeted gene repair'(TGR). The early 
TGR strategies involved the introduction of short single- or double-stranded 
oligonucleotides that form heteroduplexes with target DNA and facilitate small sequence 
alterations (usually a point mutation) via the activity of the various endogenous DNA 
repair pathways. The TGR strategies have an advantage over the previously discussed 
gene targeting strategies in that they do not involve the introduction of selectable 
markers and are thus more suitable for gene therapy applications. Screening for a 
successful chromosomal sequence change can be accomplished by PCR assay or 
commercial gene sequencing. However, the frequency of successful chromosomal 
sequence change using the early targeted gene repair strategies is low enough to limit 
their application for in vivo gene therapy.  
 
 Four noteworthy targeted gene repair methods that will be discussed below 
involve the use of: single-stranded oligo-deoxyribonucleotides (ssODNs), small DNA-
fragments (SDFs), triplex-forming oligonucleotides (TFOs), and peptide nucleic acids 
(PNAs). The specific interactions with endogenous DNA repair pathways involved in each 
of these TGR approaches are incompletely understood, but a detailed review of what is 
currently known about them has been published by Jensen et al. (2011) (Jensen et al., 
2011). It should be noted that the currently popular programmable site-specific nuclease 
gene editing techniques, which rely on homologous repair, are also an important TGR 
strategy, but since they require a more in-depth discussion, they will be covered 
separately in a Section 1.4.  
 
 Single-stranded oligo-deoxyribonucleotides (ssODNs) can be use in targeted gene 
repair applications where a single base change is desired. Typically, ssODNs consist of 
several dozen nucleotides with complementarity to a target locus, but containing one 
mismatch (the desired change) in the centre of the sequence (Aarts and te Riele, 2011, 
Jensen et al., 2011). Strand invasion leads to the formation of a heteroduplex between 
the ssODNs and target DNA. The nucleotide excision repair pathway may then act on the 
mismatch-containing heteroduplex to cause the desired base substitution in the target 
chromosomal sequence (although, alternative mechanisms involving base excision repair, 
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replication, transcription, and homology-dependent repair have also been proposed) 
(Jensen et al., 2011, Aarts and te Riele, 2011). Using the ssODNs approach, gene 
correction efficiencies of 0.1–5% have been achieved in somatic cells, while efficiencies of 
approximately 0.1% have been observed in embryonic stem cells (ESCs) (Jensen et al., 
2011).  
 
 Small DNA-fragments (SDFs) are another early TGR vector, which have the 
capacity to change the identity of up to four sequential base pairs of a target genomic 
sequence (Jensen et al., 2011). SDFs typically consist of 400–1000 bp of single- or double-
stranded DNA, with homology to the target sequence except for the desired base pair 
changes that are contained within it. The SDF method is known to exploit the small 
fragment homologous replacement (SFHR) process within eukaryotic cells in order to 
effect replacement of the endogenous target DNA with the exogenous SDFs; however, 
the details of the SFHR process itself are not well understood. SDFs have been used to 
achieve 0.2–20% gene correction efficiencies in somatic cells, and 0.025% correction 
efficiencies in ESCs (Jensen et al., 2011). 
 
 Triplex-forming oligonucleotides (TFOs) can also be used for TGR. TFOs are short 
oligonucleotides (RNA, DNA, and synthetic derivatives) of 10–50 bp that bind in the major 
groove of homopurine tracts of DNA in a triplex fashion via Hoogsteen bonds (Jensen et 
al., 2011). TFOs were originally envisioned as useful for antigene strategies that interfere 
with transcription (Giovannangeli and Helene, 1997, Maher, 1996, Praseuth et al., 1999, 
Vasquez and Wilson, 1998), and targeted mutagenesis by tethering them to mutagens 
such as psoralen (Wang et al., 1995). However, it was later found that TFO binding, itself, 
could stimulate DNA repair and homologous recombination as an intrinsic property of 
triplex formation itself (Wang et al., 1996). The discovery that TFOs could promote DNA 
repair and homologous recombination led to TGR strategies involving so called bi-
functional TFOs. A bi-functional TFO is a TFO linked to a segment of double- or single-
stranded DNA with homology to a target sequence, but including one to a few desired 
base changes (Richardson et al., 2002, Knauert and Glazer, 2001, Culver et al., 1999, 
Knauert et al., 2006). The DNA repair pathways involved in TFO-mediated TGR are not 
fully understood but are believed to involve nucleotide excision repair (NER) and 
homology-directed repair (HDR), but may also involve mismatch repair and non-
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homologous end joining (NHEJ) (Jensen et al., 2011, Ricciardi et al., 2014, Richardson et 
al., 2002, Knauert and Glazer, 2001). 
 
 A more recent enhancement to the TFOs strategy is the use of peptide nucleic 
acids (PNAs). PNAs are synthetic nucleic acid analogues (typically with a length of 12–18 
nucleotides) that have had the charged phosphodiester DNA backbone substituted for an 
uncharged polyamide backbone (Nielsen, 2004). PNAs are nuclease- and protease-
resistant, which greatly increases the stability of the molecule. Additionally, some 
varieties of PNAs allow for additional binding modalities (e.g. a double PNA/DNA duplex, 
or a PNA/DNA/PNA triplex, where the second strand of the target DNA is displaced as a 
loop) that increase the strength of binding, and, in the case of double duplex formation, 
are exempt from the homopurine target restriction of TFOs (Nielsen et al., 1994, Ricciardi 
et al., 2014, Lonkar et al., 2009, Jensen et al., 2011). Strategies based on TFOs and PNAs 
have achieved correction efficiencies of 0.1–2.5% in somatic cells (Jensen et al., 2011, 
Chin et al., 2008, Schleifman et al., 2011). 
 
1.3.3 Adeno-associated viruses (AAVs) 
 While adeno-associated viruses (AAVs) are frequently associated with episomal 
gene addition gene therapy (Daya and Berns, 2008), AAVs can also be used as a TGR 
vector (Jensen et al., 2011, Hendrie and Russell, 2005). The AAV genome consists of a 4.7 
kb linear DNA molecule, containing genes for viral replication (rep) and capsid formation 
(cap), and flanked at both ends by inverted terminal repeats (ITRs). For the purpose of 
TGR, the entire viral genome, apart from the ITRs that are required for viral packing, can 
be replaced with a 4.5 kb sequence containing homology to a desired target sequence. 
This 4.5 kb sequence of homology to a target site may contain subtle sequence changes, 
such as point mutations, deletions, or small insertions (<20 nucleotides); although, larger 
insertions are possible when selectable markers are included within the insertion 
(Hendrie and Russell, 2005).  
 
 Recombinant AAV-mediated TGR is thought to rely on the HDR pathways. Strand 
invasion and heteroduplex formation are believed to precede a recombination event, 
although repair synthesis may also be involved (Hendrie and Russell, 2005). Additional 
lines of evidence also suggest the involvement of NHEJ (Jensen et al., 2011). TGR 
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mediated by recombinant AAVs can reach correction efficiencies of 1% in fibroblasts, ESCs, 
and iPSCs, without the use of selection (Hendrie and Russell, 2005, Khan et al., 2010). Up 
to 65% correction efficiencies have been achieved in somatic cells using strategies 
employing additional methods, such as selection and double-strand breaks (Gellhaus et 
al., 2010, Jensen et al., 2011). One noteworthy downside of using AAVs for TGR strategies 
is that random integration of the recombinant AAV DNA into the host genome happens at 
tenfold the rate of correction, and this occurs in about 10% of the cells that have been 
successfully corrected (Hendrie and Russell, 2005).   
 
1.4 Where we're at today: current genome editing 
techniques 
1.4.1 Programmable site-specific nucleases and nickases 
1.4.1.1 Background 
  Over the last 10 years, great advances have been made in the development of 
tools for targeted genome editing. The most popular tools currently in use and under 
development are the programmable site-specific nucleases and nickases. Programmable 
site-specific nucleases and nickases are enzymes with nuclease or nickase activity that 
have DNA binding domains with programmable site-specificity. These enzymes have the 
ability to catalyse deletion, insertion, and sequence replacement events at desired 
locations within a target genome through the introduction of single- or double-strand 
breaks (SSBs and DSBs, respectively), and the subsequent induction of HDR and NHEJ 
within the cell (Figure 1-5) (Segal and Meckler, 2013). Examples of programmable site-
specific nucleases and nickases include: engineered homing endonucleases, zinc finger 
nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), RNA-guided 
endonucleases (RGENs) such as the CRISPR-Cas system, and nickase adaptations of all the 
foregoing nuclease systems. These examples will be described further in the following 
sections after a brief treatment of the general characteristics of programmable site-
specific nucleases and nickases that follows. 
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1.4.1.2 Types of sequence edits 
 Small indels (small insertion or deletions typically of 1–25 bp in length) may be 
introduced to a target locus through the introduction of a single DSB (Figure 1-5) (Segal 
and Meckler, 2013). The DNA ends that are produced are then processed predominantly 
by the NHEJ pathway. This processing typically involves exonuclease and polymerase 
activities leading to small truncations or additions to the DNA ends before ligation, 
resulting in the creation of indels. Additionally, programmable site-specific nickases, 
which place adjacent nicks on opposite strands of the target DNA, may also be used to 
generate indels. Site-specific nickases are generated by inactivating one domain or 
subunit (depending on whether the enzyme is monomeric or dimeric, respectively) in a 
site-specific nuclease system. The nickase strategy has the advantage of reducing off-
target DSBs, as individual nickases produce off-target DSBs at a much lower frequency 
than off-target activity by nucleases (Cho et al., 2014). In one study it was shown that the 
use of programmable site-specific nickases reduced off-target mutagenesis by over 100-
fold compared with their nuclease counterparts (Ran et al., 2013). The use of nickases 
also has the advantage of increasing the on-target specificity of the enzyme system as 
twice the number of site-specific proteins (i.e. two or four proteins, depending whether 
the parent system was monomeric or dimeric, respectively) must bind to the target site in 
order for a DSB to be achieved, and thus more base pairs are specified at the target site.  
Precise nucleotide alterations Insertion or deletion mutation 
HDR-mediated repair NHEJ-mediated repair 
Nuclease-induced DSB 
Donor template Donor template 
Precise sequence insertion 
Figure 1-5: Nuclease-induced genome editing.  Nuclease-induced DSB can either lead to NHEJ-mediated 
repair or HDR-mediated repair, depending on whether a donor template is present. When a donor template 
is absent, NHEJ results in the formation of either small insertion or small deletion mutations. When a donor 
template is present, HDR can use the donor template to repair the DSB, causing precise nucleotide 
substitution or precise insertions, depending on the donor template used. Adapted Joung and Sander 
(2013). 
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 When larger deletions are desired, two DSBs may be introduced into a 
chromosome by site-specific nucleases, which act to delete the intervening DNA segment 
(Carlson et al., 2012). The resulting DNA ends flanking the deletion are, again, 
predominantly repaired by NHEJ. However, because of the NHEJ exonuclease and 
polymerase activity, the boundaries of the deletion may be somewhat imprecise. 
Inversion of the chromosomal segment flanked by the DSBs is also a potential outcome, 
although this outcome occurs at a much lower frequency than deletion. In a similar 
fashion, a pair of site-specific nickases may also be used to generate large deletions of up 
to 1.1 kb (Cho et al., 2014). In this case, it appears that deletion of the intervening 
chromosomal segment does not occur as the result of both nicks being converted to 
DSBs, and it is also unlikely that two SSBs separated by more than 100 bp lead to the 
production of a single DSB with large overhangs (because the melting temperature is very 
high under physiological conditions). Instead, deletions have been proposed to take place 
as a result of a more complex recurrent process involving strand displacement, BER, 
generation of a single DSB, and NHEJ (Cho et al., 2014).  
 
 Precise insertions and DNA sequence edits can also be accomplished through the 
use of programmable site-specific nucleases and nickases. In this case, DSBs or SSBs are 
introduced to stimulate HDR, which when accompanied by the introduction of donor DNA 
molecules (circular, linear, or single-stranded) with homology to a genomic target 
sequence, can stimulate replacement of a target sequence with the donor sequence 
(Figure 1-5) (Moehle et al., 2007, Joung and Sander, 2013). The size of the conversion 
tracts in mammalian cells typically ranges from 100–200 bp (Carroll, 2014, Elliott et al., 
1998), but can be as long as 7.6 kb (Moehle et al., 2007, Joung and Sander, 2013). The 
length of homology typically required for the donor molecule ranges from 1–4 kb (usually 
distributed equally relative to both sides of the DSB) (Carroll, 2014), although 
oligonucleotides as short as 40 bp have been used successfully (Carroll, 2014, Chen et al., 
2011). The introduction of DSBs can stimulate a 1000-fold increase in HDR activity 
compared with classical gene targeting strategies (see Section 1.3.1), without the use of 
selection, and also reduces the length of homologous donor sequence needed for the 
reaction (Segal and Meckler, 2013).  
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1.4.1.3 Challenges, and strategies to overcome them 
 One problem that arises in many cell types when using site-specific nucleases to 
generate DSBs in order to facilitate gene conversion, is that the activity of the NHEJ 
pathway is equal to, or dominates over, the HDR pathway, resulting in unwanted indels at 
the target site instead of the desired gene conversion events (Ramirez et al., 2012, Kim et 
al., 2012, Wang et al., 2012). This is further complicated by the fact that in many 
instances, the product of gene conversion still retains the target site for the site-specific 
nuclease, allowing the corrected allele to be altered by a subsequent DSB, and NHEJ 
repair (Segal and Meckler, 2013). Because the indels produced by NHEJ may not leave the 
site-specific nuclease site intact, this could even lead to stochastic selection for an indel 
end-product over gene conversion.  
 
 For cell culture experiments or ex vivo gene therapy applications, screening may 
be sufficient to identify correctly corrected clones; however, in cell types such as ESCs and 
iPSCs in which the frequency of nuclease-mediated HDR is low, this may require the 
screening of 120–240 clones (Segal and Meckler, 2013, Soldner et al., 2011). Alternatively, 
selection strategies similar to those used in classical gene targeting strategies, involving 
selectable markers flanked by loxP sites that can be introduced and subsequently 
removed (see Section 1.3.1.3), may also be employed where appropriate (Hockemeyer et 
al., 2009, Segal and Meckler, 2013). A similar selection strategy has also been devised 
using the piggyBac transposon, which allows the selectable marker to be removed 
without the generation of a loxP sequence scar (see Figure 1-4), provided there is a 
natural TTAA site within the targeting region (Yusa et al., 2011, Segal and Meckler, 2013).  
 
 The generation of site-specific nickases from site-specific nuclease systems is one 
approach to addressing the problem of unwanted NHEJ activity. Single nickase-induced 
SSBs can stimulate HDR, while at the same time greatly reducing the level of NHEJ activity 
(some conversion of SSBs to DSBs does still occur, perhaps as the result of a replication 
fork proceeding to the SSB) (Segal and Meckler, 2013, McConnell Smith et al., 2009, 
Sander and Joung, 2014). However, in most cases the level of HDR stimulated by nickases 
has been shown to be greatly reduced (3–10-fold lower) compared with that of site-
specific nucleases (Ran et al., 2013, McConnell Smith et al., 2009, Ramirez et al., 2012, 
Kim et al., 2012, Wang et al., 2012); although, the proportional reduction in NHEJ is far 
greater (Ramirez et al., 2012, Kim et al., 2012, Wang et al., 2012). The diversity in the 
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efficiency of nickase-mediated HDR reactions arises as a result of factors such as: which 
nicking system was being use, the chosen target site, the cell type the experiments were 
conducted in, the technique used to measure the efficiency, and whether gene correction 
or gene addition was being attempted (gene addition appears to be more efficient (Wang 
et al., 2012)). Additionally, some studies have actually reported high levels of site-specific 
nickase induced indels at some sites (Sander and Joung, 2014). The use of site-specific 
nickases may reduce off-target mutagenesis, since off-target SSBs are most likely to be 
repaired by BER (Dianov and Hubscher, 2013, Hsu et al., 2014); although, off-target DSBs 
may also be produced at a lower level.  
 
 The level of site-specific nickase-induced HDR can be increased to a level 
comparable to that of site-specific nucleases by using a double nicking strategy. A double 
nicking strategy generates DSBs, while at the same retaining the benefit of greatly 
reduced off-target mutagenesis by the individual nickase enzymes (Ran et al., 2013). This 
approach may be especially worthwhile in light of that fact that, in cell types such as ESCs, 
the lower HDR activity induced by single nickase-induced SSBs has produced only limited 
success (Hsu et al., 2013b). Finally, perhaps one of the most interesting applications of 
site-specific nickases for targeted genome editing, is their use in a quadruple nicking 
strategy that creates overhangs allowing the precise insertion of a double-stranded 
oligonucleotide with compatible overhangs (repair is predicted to occur through NHEJ-
mediated ligation) (Maresca et al., 2013). In a paper that described this strategy, it was 
found that 1 out 37 clones screened contained the correct insert (Ran et al., 2013). 
However, no description was given about the frequency at which aberrant mutagenesis 
might occur at the target site. Because site-specific nickases do possess the potential for 
off-target DSB creation, increasing the variety of site-specific nickase enzymes involved in 
a reaction might increase these events (Sander and Joung, 2014). 
 
1.4.2 Engineered homing endonucleases 
1.4.2.1 Engineered homing endonuclease background 
 Homing endonucleases (also known as meganucleases) are a class of naturally 
occurring site-specific nucleases that possess high targeting fidelity, and specify long 
target sites (e.g. I-SceI, 18 bp; I-AniI, 19/201 bp; I-CreI, 22 bp). Some of the seminal work 
                                                     
1 The number of bp recognized by I-AniI is variously described in the literature as being either 19 or 20. 
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demonstrating that DSBs could enhance gene targeting efficiency by driving HDR was 
performed with the homing endonuclease I-SceI (Smih et al., 1995), and I-SceI remains 
the standard for high activity and site-specificity that other site-specific nucleases used 
for gene targeting are compared to (Silva et al., 2011). Engineered homing endonucleases 
are homing endonucleases that have had their binding specificity altered in order to 
achieve desired site-specificity.  
 
1.4.2.2 Engineered homing endonuclease characteristics 
 There are five families of homing endonucleases classified by their sequence and 
structural motifs (LAGLIDADG, GIY-YIG, HNH, His-Cys box and PD-(D/E)XK), of which the 
LAGLIDADG family have the highest level of site-specificity and have been best studied 
(Silva et al., 2011, Eastberg et al., 2007). Homing endonucleases of the LAGLIDADG family 
contain a characteristic α/β fold (αββαββα) that is responsible for both DNA recognition 
and cleavage (and the core subunit-subunit interaction in dimeric proteins) (Silva et al., 
2011). All LAGLIDADG homing endonucleases bind to DNA through contacts spread out 
over two α/β fold motifs; however, these two motifs may be contained within one 
monomeric enzyme (e.g. I-SceI and I-Anil), or shared between two subunits of a dimeric 
enzyme (e.g. I-CreI and I-MsoI) (Silva et al., 2011, Eastberg et al., 2007). 
 
 Because the DNA-binding activity of the protein is structurally linked to its 
cleavage activity, retargeting of the enzyme's site-specificity cannot be performed by a 
modular binding domain swap, as is done in the creation of ZFNs and TALENs (described 
in Section 1.4.3). Instead, LAGLIDADG engineered homing endonucleases are generated 
through: recombination of binding elements from several LAGLIDADG homing 
endonucleases (Chevalier et al., 2002, Epinat et al., 2003, Silva et al., 2006); semi-rational 
design, where residues are mutated based on structural or functional knowledge 
(Seligman et al., 2002, Sussman et al., 2004, Arnould et al., 2006, Joshi et al., 2011); 
directed evolution (Doyon et al., 2006, Chen et al., 2009, Chen and Zhao, 2005); 
computational approaches involving in silico optimization and screening (Ashworth et al., 
2006, Ashworth et al., 2010, Thyme et al., 2009); or combinations of the above (Silva et 
al., 2011, Rosen et al., 2006, Smith et al., 2006, Arnould et al., 2007, Thyme et al., 2014). 
However, reprogramming the site-specificity of homing endonucleases is nontrivial, and 
certain characteristics of these enzymes such as differences in binding specificity from the 
two α/β fold motifs and differential binding and catalytic transition-state contributions 
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from the two α/β fold motifs (Spiegel et al., 2006, Thyme et al., 2009), balancing of 
differential thermodynamic contributions to affinity and specificity (Eastberg et al., 2007), 
and contributions to binding from outside the α/β fold motifs present challenges for 
construction (Prieto et al., 2007).  
 
 Another problem which exists is that when using engineered homing 
endonucleases based on naturally homodimeric proteins (one α/β fold motif per subunit) 
to generate site-specific heterodimers capable of recognizing a chosen asymmetric target 
site, the possibility exists for cleavage activity from three species of dimers (two of which 
are undesired homodimers). As with other site-specific nuclease systems (see the 
following Section 1.4.3), obligate heterodimers have been generated by reengineering the 
dimer interface in order to overcome this problem (Fajardo-Sanchez et al., 2008). Another 
unique approach to overcoming the unwanted homodimer problem is to generate single 
protein chains from two site-specific subunits, mimicking the subfamily of monomeric 
LAGLIDADG homing endonucleases that contain two α/β fold domains in a single protein 
(Grizot et al., 2009, Li et al., 2009). Finally, the first experiments to generate site-specific 
nickases (see Section 1.4.1 for a description of the utility of site-specific nickases), were 
carried out in engineered homing endonuclease systems (Niu et al., 2008, McConnell 
Smith et al., 2009). 
 
1.4.2.3 Engineered homing endonuclease performance 
 Engineered homing endonucleases have been successfully used to target about 10 
different unique human disease targets (a relatively small number compared the other 
site-specific nuclease systems) (Segal and Meckler, 2013). In one example, gene targeting 
frequencies of 6% were achieved at the RAG1 locus (a gene involved in severe combined 
immunodeficiency; SCID) in 293H cells (transformed primary embryonic human kidney 
cells) using a fully redesigned single-chain variant of the I-CreI homing endonuclease 
(Grizot et al., 2009). This RAG1-targeting endonuclease was also shown to have a toxicity 
and off-target cleavage profile comparable to I-SceI (Grizot et al., 2009, Silva et al., 2011). 
However, experiments with homing endonucleases and engineered homing 
endonucleases have demonstrated that the ability to successfully correct a target locus 
may drop precipitously the farther the polymorphism is located away from the DSB (i.e. 
shorter gene conversion tracts occur more frequently than longer ones), although overall 
levels of efficiency can be highly variable between experimental designs (Silva et al., 
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2011). Thus, the challenges that exist in designing the site-specificity of engineered 
homing endonucleases may significantly limit their versatility for gene editing 
applications.   
 
1.4.3 Chimeric restriction enzymes with programmable binding 
domains: ZFNs and TALENs 
1.4.3.1 ZFN and TALEN background and characteristics 
 Among the most popular and versatile systems of site-specific nucleases are the 
ZFNs and TALENs: chimeric enzymes that typically utilize the nuclease catalytic domain 
from the Type IIS restriction endonuclease FokI combined in a modular fashion with a 
programmable site-specific DNA binding domain (Figure 1-6). The programmable binding 
domain of a ZFN or TALEN consists of either a zinc finger array (ZFA) or the binding 
domain of a transcription activator-like effector (TALE), respectively (these binding 
domains will be described in detail in Section 1.7). The FokI endonuclease cleaves DNA at 
a site distal to its recognition sequence. In 1992, Chandrasegaran and colleagues 
demonstrated that the binding and cleavage activities of FokI were physically separated 
into two domains of the protein (Li et al., 1992). This discovery lead Chandrasegaran's 
group to experiments that demonstrated the FokI catalytic domain could be combined 
with other binding domains, including zinc finger binding domains, in order to retarget 
the nuclease activity (Kim and Chandrasegaran, 1994, Kim et al., 1996). This became an 
increasingly important discovery for the field of genome engineering, as in the years that 
followed, great advances were made in the development of engineered ZFAs with 
designed site-specificity (Ramirez and Joung, 2013, Ochiai and Yamamoto, 2015). More 
recently, an even more versatile binding domain from TALEs of bacterial plant pathogens 
has been discovered, and this has led to the creation of FokI-based TALENs.  
 
 The FokI endonuclease exists as monomers in solution (Kaczorowski et al., 1989), 
but it requires dimerization at its DNA target site for activation and cleavage (Vanamee et 
al., 2001, Bitinaite et al., 1998). Likewise, site-specific nucleases based on FokI also 
require dimer formation at the active site for cleavage (Smith et al., 2000). ZFN and TALEN 
monomers usually recognize 9–18 bp and 15–20 bp (Kim and Kim, 2014), respectively, 
allowing their active dimers to specify sequences that are statistically unique within a 
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Figure 1-6: Architecture of ZFN and TALEN.  A) At the top of the figure is shown a schematic of a ZFN 
binding as a dimer to its target site. Each ZFN subunit contains a FokI nuclease domain connected to a ZFA 
via a linker. Each zinc finger in the ZFA specifies 3 bp of the target site. ZFA binding sites (shown in orange 
and green) are separated by a spacer sequence which is bound non-specifically by the FokI domain.  B) At 
the bottom of the figure is shown a schematic of a TALEN binding as a dimer to its target site. Each TALEN 
subunit contains a FokI nuclease domain connected to a TALE binding domain via a linker. Each repeat 
module of the TALE domain specifies 1 bp of the target site. TALE binding sites (shown in orange and green) 
are separated by a spacer when bound non-specifically by the FokI domain. The thymine at the 5′ of each 
TALE binding site (indicated in red), is specified by an element of the TALE binding domain which is typically 
not programmable. Adapted from Kim and Kim (2014). 
human-size genome (>17 bp in a 3x109 bp genome)2. The inactive nature of the monomer 
has allowed the development of several useful modifications of the FokI catalytic domain 
including: a hyperactive mutant (Guo et al., 2010), obligate heterodimer forming 
monomers (Miller et al., 2007, Szczepek et al., 2007, Doyon et al., 2011, Guo et al., 2010), 
and an inactive subunit for use in a nickase heterodimer system (Kim et al., 2012, Wang et 
al., 2012, Ramirez et al., 2012). 
 
 
 
 
 
  
 
 
  
  
 
                                                     
2 In order to achieve statistical uniqueness in a human-sized genome, a target site must be at least 17 bp. 
This is determined by considering a target site whose length dictates that the inverse of its probability of 
occurrence is greater than the sample space of both strands of a 3 billion bp genome (417 > 3 x 109 x 2). 
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1.4.3.2 ZFN and TALEN performance 
 Most of the milestones in genome engineering have been accomplished using 
ZFNs (Segal and Meckler, 2013), and the number of human genes modified by them is too 
numerous to list here (although they are reviewed in Segal and Meckler, 2013). In one 
landmark study, ZFNs were shown to be able to mediate gene conversion at the IL2Rγ 
gene (associated with X-linked SCID) in 18% of K562 cells (immortalized myelogenous 
leukaemia cells) after transfection with both ZFN and donor constructs (Urnov et al., 
2005). Although it was necessary for the experimenters to arrest the cell cycle for 30 
hours at the G2/M cell cycle boundary to achieve such high efficiency, even in the 
absence of cell cycle arrest, 10% of cells were modified. In a follow up study, the same 
group was able to induce gene addition at the CCR5 gene (whose protein product is 
associated with HIV cell entry) in 5% of treated ESCs, using a lentiviral vector to deliver 
the ZFN expression cassettes and donor construct (Lombardo et al., 2007). However, the 
same study demonstrated only 0.11% efficiency in human CD34+ hematopoietic 
progenitor cells, indicating that ZFNs may not be universally successful in all cell types.  
 
 ZFNs also hold the special honour of being the first site-specific nuclease system to 
be used in clinical trials. Sangamo Bioscience's (Richmond, CA, USA) SB-728-T is a ZFN-
based autologous T-cell therapy designed to disrupt the CCR5 gene coding for C-C 
chemokine receptor type 5, the cell surface receptor that HIV uses to gain entry into CD4 
T cells (Maier et al., 2013, Tebas et al., 2014). The CCR5Δ32 loss-of-function mutation is 
known to impart resistance to the most prevalent strains of HIV, and was the crucial 
factor in the 2008 'Berlin patient', the first person to be cured of HIV, via a bone marrow 
transplant from a homozygous CCR5Δ32 donor (Hutter et al., 2009, Allers et al., 2011). In 
the latest reports from SB-728-T phase I and II trials, it was reported that CCR5 was 
successfully disrupted in 11–28% of patients' CD4 T cells ex vivo, using four-fingered ZFNs 
(Tebas et al., 2014). These T-cells were well tolerated after reintroduction, and viral load 
was reduced in the majority of the patient cohort that was taken off conventional anti-
HIV therapy, with one patient's viral load dropping below detectable levels.  
 
 Although ZFNs represent a major breakthrough for targeted genome engineering, 
there are still significant limitations in the targeting density that ZFNs can achieve, owing 
to the reliance on ZFAs (ZFAs will be covered in detail in Section 1.7.1). It has been 
estimated that successful ZFN target sites can be found at a frequency of eight sites per   
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1 kb of random genomic sequence, with guanine-rich sites being more easily targeted 
(Kim et al., 2009). However, there are many different methods of ZFA design, and even 
the most successful of the publically available methods still result in failure rates of 18–
77% for the individual ZFN pairs into which they have been incorporated (Gupta et al., 
2012, Bhakta et al., 2013, Sander et al., 2011b, Kim et al., 2011, Zhu et al., 2011), and can 
be >90% using some design methods (Joung et al., 2010).  
 
 TALENs have much more versatile targeting capability than ZFNs, as their TALE 
binding domains can be programmed to recognize virtually any sequence, with the only 
restriction being a thymine at the 5′ end of the site (TALEs will be described in detail in 
Section 1.7.2) (Kim and Kim, 2014). One study, in which 96 TALEN pairs were constructed 
to target an equal number of human genes, found that 84 of these TALEN pairs were 
successful in producing indels at efficiencies ranging from 2.5–55.8% (Reyon et al., 2012). 
Furthermore, there is evidence that TALEN targeting success rates can reach 100% if 
heavily methylated target sites are avoided (Kim et al., 2013). Additionally, TALENs are 
reported to produce equal or substantially improved off-target cleavage and cytotoxicity 
profiles compared with ZFNs 
(Segal and Meckler, 2013, Mussolino et al., 2011, Kim and Kim, 2014). However, in a 
comprehensive analysis of TALENs off-target activity, it was found that individual TALENs 
still may act at hundreds of off-target sites throughout the human genome (Frock et al., 
2015). Additionally, a high level of repetition in the TALE binding domain coding 
sequences makes TALEN construction challenging and requires non-standard molecular 
biology cloning procedures (see Section 1.7.2.4) (Sander and Joung, 2014).  
 
1.4.3.3 Alternative ZFN and TALEN architectures 
 Finally, it should be mentioned that ZFNs and TALENs based on the PvuII Type IIP 
restriction endonuclease have also been reported (Schierling et al., 2012, Yanik et al., 
2013). These enzymes were designed to address the off-target activity that arises from 
FokI-based ZFNs and TALENs as a result of the lack of specificity of the cleavage domain, 
with possible binding specificity degeneracy of the ZFA or TALE domains allowing 
unwanted activity at partial recognition sites. The cleavage module of PvuII-based ZFNs 
and TALENs recognizes and cleaves DNA with high specificity at the 6 bp PvuII recognition 
site. In spite of their somewhat more restricted targeting capability, these enzymes 
indeed show notably improved off-target cleavage and toxicity profiles when compared 
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to FokI-based ZFNs and TALENs targeted to the same sites, and with high fidelity 
persisting even under conditions of increased enzyme concentration and reaction 
duration. The PvuII-based TALENs, in particular, had a toxicity profile in HEK293T cells 
similar to I-SceI (Yanik et al., 2013). Although the use of PvuII-based ZFNs and TALENs has 
been demonstrated, they have not been widely adopted. An alternative ZFN architecture 
has been also described in which staphylococcal nuclease, which cleaves as a monomer, 
has been sandwiched between two ZFAs (Mineta et al., 2008). Additionally, a chimeric 
Cas9-FokI RGEN has also been described (see Section 1.4.4.4) (Tsai et al., 2014b). 
 
1.4.4 RGENs: the CRISPR-Cas9 system  
1.4.4.1 Cas9 RGEN background 
 Over the last few years a new and important player has emerged as a leading tool 
for targeted genome editing. The CRISPR-Cas9 system is one of a new class of site-specific 
nucleases: RGENs (RNA-guided endonucleases). CRISPR, which stands for clustered 
regularly interspaced short palindromic repeats, is an adaptive immune system that has 
been discovered in prokaryotes. CRISPR systems function to protection their bacterial and 
archaeal hosts from viruses and plasmids by retaining exogenous genetic sequences from 
previous infections (within a genomically encoded 'CRISPR array'), which are then used to 
transcribe RNA that facilitate targeting of similar sequences upon re-infection. Three 
types of CRISPR systems (Type I–III) have been described thus far, with the Type II system 
being the best characterized and least complex. The Type II CRISPR system utilizes a 
monomeric endonuclease enzyme (Cas9) complexed with two mutually bound strands of 
RNA (crRNA and tracrRNA; see below), which are used to direct the complex to cleave 
invading genetic material. The Cas9 RGEN from Streptococcus pyogenes has become the 
most popular and well studied RGEN system for targeted genome editing, and it is this 
system that will be discussed in the following sections. For a review of CRISPR biology and 
research history, see Hsu, Lander, and Zhang (2014). 
 
1.4.4.2 Cas9 RGEN characteristics 
 The advantage of using the Cas9 RGEN for targeted genomic editing is its 
versatility and ease of use. Unlike ZFNs and TALENs, the targeting capacity of RGENs is 
afforded by simple Watson-Crick base pairing rules between guide RNA and target DNA, 
instead of protein-DNA interactions (Sander and Joung, 2014). In the natural CRISPR-Cas9 
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system, the Cas9 enzyme is bound to a trans-activating CRISPR RNA (tracrRNA) that 
mediates contact between Cas9 and the CRISPR RNA (crRNA), which targets the enzyme 
to invading DNA (Deltcheva et al., 2011). Typically, in the Cas9 RGEN system used for 
targeted genomic editing, the tracrRNA and crRNA are fused together to create a single 
guide RNA (sgRNA) that recognizes a 20 bp target site (Jinek et al., 2012, Sander and 
Joung, 2014). Because the sgRNA is the primary component of Cas9 RGENs responsible 
for DNA targeting, programming Cas9 to target desired sequences can be done through 
the design of a simple sgRNA expression construct. Another feature of versatility in the 
Cas9 RGEN system is that, owing to the chemical independence of Cas9 and its sgRNA, a 
single Cas9 protein can be introduced to a cell simultaneously with a variety of sgRNAs to 
facilitated multiplexed genome editing (Cong et al., 2013).   
 
 In addition to the recognition specificity of the crRNA (or sgRNA), Cas9 has 
another recognition requirement called a protospacer-adjacent motif (PAM) that 
facilitates target searching and serves to allow Cas9 to discriminate between new 
invading genetic material and the genetic sequences that have been previously captured 
into the CRISPR array (Shah et al., 2013). The PAM is a short DNA sequence that is bound 
by the PAM-interacting C-terminal region of Cas9 (Nishimasu et al., 2014). The PAM 
sequence for the S. pyogenes Cas9 is 5′-NGG (where 'N' can be any base), and must be 
located directly 3′ of the 20 bp target sequence that is recognized by the sgRNA (Jinek et 
al., 2012). Strategies to circumvent the PAM restriction include: trading reduced 
efficiency for alternate PAM recognition (5′-NAG and 5′-NNGG sequences are also 
accepted); utilizing Cas9 orthologues with altered PAM preference; and orthologous 
replacement of the PAM-interacting C-terminal region of Cas9 (Hsu et al., 2014, Sander 
and Joung, 2014). See Figure 1-7 for a schematic of the Cas9 RGEN and its features. 
 
 The choice of promoter used to express the sgRNA can also impose a restriction 
on the target site (Sander and Joung, 2014). Promoters such as the RNA polymerase III-
dependent promoter or the T7 promoter require that a G or GG, respectively, be located 
at the 5′ end of the sequence to be transcribed. Therefore, the sequences that can be 
targeted by the Cas9 RGEN may take the form of GN20-NGG or GGN20-NGG, which would 
be expected to occur every 32 bp or 128 bp of random genomic sequence, respectively 
(given that either the Watson or Crick strand could be targeted) (Sander and Joung, 
2014). 
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Figure 1-7: The Cas9 RGEN.  A) A schematic of the Cas9 RGEN bound to a target site. The complementary 
strand of the target DNA molecule (grey bases) pairs with the guide sequence (yellow bases) of the sgRNA. 
The sgRNA is colour-coded to indicate the origin of its segments. Yellow and orange indicate the component 
which is derived from crRNA, brown indicates the fusion linker, and green indicates tracrRNA. Watson-Crick 
base pairing is indicated by a series of dots, while single grey dots indicate weak bonding.  B) Target DNA 
cleaved by the Cas9 RGEN yielding blunt ends. Adapted from Kim and Kim (2014). 
 
 
   
 
 
 
 
1.4.4.3 Cas9 RGEN performance 
 Since the first two papers (published simultaneously) demonstrating the use of the 
Cas9 RGEN for targeted genomic editing were published in 2013 (Cong et al., 2013, Mali 
et al., 2013), the tool has been rapidly adopted by the scientific community, with papers 
being published describing its use in a wide variety of organisms and at a wide variety of 
targets (Sander and Joung, 2014). Cas9 RGENs have been reported to be successful at 
about 90% of target sites, and can produce targeted gene disruptions with about 20% 
efficiency (Kim and Kim, 2014). Notably, the Cas9 RGEN was used in the first ever site-
specific genomic editing experiment in human embryos (Liang et al., 2015). This 
experiment attempted to use RGEN-mediated HDR to correct the β-globin gene 
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(associated with β-thalassaemia, a potentially fatal blood disorder) in non-viable 
triplonuclear human zygotes; however, the technique was found to be inefficient, and 
also resulted in substantial off-target activity.  
 
 It has been estimated that for any Cas9 RGEN, the number of potential off-target 
sites may number in the thousands when used in a human-sized genomic context (Sander 
and Joung, 2014). Furthermore, activity at these off-target sites has been measured at 
over 2–5%, and can be as high as Cas9 activity at on-target sites (Fu et al., 2014, Fu et al., 
2013, Cradick et al., 2013, Sander and Joung, 2014). In the two most robust 
characterizations of Cas9 off-target activity to date, it was found that Cas9 RGENs may 
tolerate up to six or seven mismatches in their 20 bp target sequences, in addition to a 
variety of mismatches in the PAM sequence (Tsai et al., 2015, Frock et al., 2015). These 
widespread low-level off-target reactions were found to cause genomic rearrangements 
including translocations, inversions, and large deletions. Furthermore, one of these 
studies found that in some cases, the Cas9 RGENs were actually more active at off-target 
sites than at their on-target site (Tsai et al., 2015). However, both studies also found that 
although some Cas9 RGENs had off-target sites numbering in the hundreds, others 
showed no detectable off-target activity at all (Tsai et al., 2015, Frock et al., 2015). The 
reasons for this disparity in off-target potential are not yet clear. Additionally, it was 
shown that all of the RGENs may produce translocation events between homologous 
chromosomes (including dicentric chromosome production) as a result of their on-target 
reactions (Frock et al., 2015). Genomic rearrangements were also found to occur between 
the on-target sites and naturally occurring breakpoint hotspots within the genome (Frock 
et al., 2015, Tsai et al., 2015).   
 
1.4.4.4 Improvements to the Cas9 RGEN system 
 Several modification to the Cas9 RGEN system have been developed to reduce off-
target activity, including the generation of Cas9 nickases (see Section 1.4.1 for a 
description of nickases), and reduction of the sgRNA length (Sander and Joung, 2014). It 
has been demonstrated that Cas9 is more tolerant of base pairing mismatches at the 5′ 
end of the 20 bp target sequence (the end most distal to the PAM sequence) (Cong et al., 
2013, Fu et al., 2013, Hsu et al., 2013a); therefore, truncated sgRNAs (tru-sgRNAs) have 
been created that omit 2 or 3 bp of recognition from the 5′ end of the target sequence (Fu 
et al., 2014). These tru-sgRNAs recognize a 17 or 18 bp target sequence, and facilitate 
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Cas9 activity with similar efficiency and higher specificity than sgRNAs recognizing a 20 bp 
target sequence. The two previously mentioned robust characterizations of RGEN off-
target activity verified that the Cas9 nickase (Frock et al., 2015) and tru-sgRNAs (Tsai et 
al., 2015) strategies do indeed substantially reduce off-target activity, although they do 
not reduce translocation events between homologous chromosomes resulting from on-
target activity. 
 
 Finally, it should be noted that an additional class of RGENs, consisting of a 
catalytically inactivated Cas9 fused to a FokI cleavage domain, have been described in the 
literature (Guilinger et al., 2014, Tsai et al., 2014a). The Cas9-FokI RGENs, which act as 
dimers, may have the advantage of allowing more sequence selectivity than monomeric 
Cas9 RGENs, and may allow obligate heterodimer RGENs to be easily produced (as 
obligate heterodimer variants of the FokI cleavage domain already exist). Although Cas9-
FokI RGENs have promising features, they have not yet been widely put into use.   
 
1.4.5 Delivery of site-specific nucleases 
1.4.5.1 Cell culture delivery 
 Delivery of site-specific nuclease and homologous DNA template reagents into 
cultured cells can be accomplished by plasmid DNA transfection, transfection of in vitro 
transcribed mRNA, viral vector delivery, and direct delivery of protein (Carroll, 2014). 
Microinjection has also been used to deliver site-specific nuclease constructs to fertilized 
mammalian embryos for the purpose of generating a variety of genetically modified 
animals (Carbery et al., 2010, Cui et al., 2011, Geurts et al., 2009, Meyer et al., 2010, 
Carlson et al., 2012, Niu et al., 2014). A nuclear localization signal (NLS) coding region and 
poly-A tail are typically incorporated into site-specific nuclease constructs (Gaj et al., 
2012, Sanjana et al., 2012, Mali et al., 2013). It has been reported that the ratio of 
expression plasmid to correction template can affect correction efficiency in site-specific 
nuclease-mediated HDR reactions (Pruett-Miller et al., 2008b, Porteus, 2006, Connelly et 
al., 2010). Ideally, a transfection mix should contain 10% expression plasmid and 90% 
corrective template (Connelly et al., 2010).    
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 Some cell types, such as haematopoietic stem cells, differentiated immune cells, 
and ESCs, are resistant to common transfection methods, such as electroporation and 
lipofection (Hsu et al., 2014, Gaj et al., 2013a, Kim and Kim, 2014). AAV has been used 
successfully as a viral vector for ZFNs (Ellis et al., 2013, Handel et al., 2012), and was the 
method used to transduce T-cells ex vivo with ZFNs in the SB-728-T HIV therapy clinical 
trials (see Section 1.4.3.2) (Maier et al., 2013, Tebas et al., 2014). However, the sizes of 
TALEN and Cas9 constructs make them difficult to deliver efficiently using AAV, due to the 
small packaging limit of AAV vectors (optimally <4.2 kb) (Gaj et al., 2013a, Hsu et al., 
2014). This packaging constraint of AAV on the Cas9 RGEN system might be overcome in 
the future by using smaller Cas9 orthologues that have recently been discovered (Hsu et 
al., 2014). TALENs and Cas9 RGENs have, however, been successfully delivered to human 
cells using adenoviral vector delivery (Maggio et al., 2014, Holkers et al., 2013). 
 
 Integrase-deficient lentiviral vectors (IDLVs) have been another choice for viral 
vector delivery of ZFNs (Lombardo et al., 2007). However, IDLVs are incompatible with 
TALEN constructs, as the template switching activity of reverse transcriptase leads to 
recombinogenic events among the multiple repeats within the TALE domain during TALEN 
DNA synthesis in cells (Holkers et al., 2013). Cas9 RGENs have been successfully delivered 
to human cells using integrating lentiviral vectors (ILVs), producing nearly 100% mutation 
rates (Shalem et al., 2014, Wang et al., 2014, Kim and Kim, 2014). However, using 
integration-competent vectors that continually express the RGEN may increase the 
likelihood of unwanted off-target effects (Kim and Kim, 2014).  
 
 Direct delivery of site-specific nuclease proteins into the cell has also been 
demonstrated. ZFNs, because of the positive charge of the protein, have the innate ability 
to cross cell membranes, and produce efficient activity when added directly to cell culture 
(Gaj et al., 2012). But TALENs and RGENs do not have this ability (Carroll, 2014). Instead, 
TALENs and RGENs can be delivered directly to cells by chemically conjugating them to a 
cell-penetrating peptide (and in the case of RGENs, additionally complexing the sgRNA to 
cell-penetrating peptides via charged interaction) (Ramakrishna et al., 2014, Liu et al., 
2014). Chemical conjugation of the cell-penetrating peptide was necessary because cell-
penetrating peptide fusion proteins proved hard to purify. Additionally, both TALENs and 
RGENs can be directly delivered to cells using cationic lipid-mediated delivery (Zuris et al., 
2015). Direct protein delivery has the advantages of allowing delivery to cell types that 
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are resistant to viral or non-viral gene delivery, reducing the length of time enzymes are 
active (thereby reducing the risk of off-target activity), and avoiding unwanted genomic 
integration of genetic material (Gaj et al., 2013a, Kim and Kim, 2014).  
 
1.4.5.2 In vivo delivery 
 ZFNs and a corrective cDNA cassette have been delivered in vivo using an AAV 
vector, in order to facilitate correction of a human F9 gene (coding for blood coagulation 
factor IX) within liver cells in a humanized transgenic mouse model of haemophilia B (Li et 
al., 2011a). This experiment achieved 3–7% restoration of circulating levels of human 
factor IX (in humans, 5% restoration would be required to convert severe haemophilia B 
to a mild form of the disease) (Li et al., 2011a). Additionally, hydrodynamic tail vein 
injection (rapid injection of a large volume of DNA) of Cas9-expressing plasmids, sgRNA, 
and ssDNA correction template, has been used to correct the Fah (fumarylacetoacetate 
hydrolase) gene in a mouse model of hereditary tyrosinemia type I (Yin et al., 2014). The 
initial correction frequency was about 1/250 hepatocytes; however, after 33 days, 
selective pressure within the liver had expanded the corrected cell population, leading to 
a 9% correction rate and correction of the disease phenotype.  
 
1.4.6 Limitations of the site-specific nuclease approach 
 Although engineered site-specific nucleases are powerful tools for genetic 
research, and, in combination with careful screening procedures, may be successful for ex 
vivo gene therapy strategies, their suitability for in vivo gene therapy applications is less 
clear. The off-target cleavage potential of site-specific nucleases presents an inherent 
danger to their use within the living human organism. So far, only some RGENs look like 
they might have the potential to produce on-target-only reactions, and even in this case, 
chromosomal rearrangements are still possible between homologous chromosomes on 
which the target site is located (Frock et al., 2015), and between the intended target site 
and naturally occurring DSBs (Frock et al., 2015, Tsai et al., 2015). Such chromosomal 
rearrangements might lead to breakage-fusion-bridge cycles (Frock et al., 2015). 
Breakage-fusion-bridge cycles occur when dicentric chromosomes are generated and 
stressed between opposite poles during mitosis until further breakage occurs, in a pattern 
that repeats, leading  to the type of gene alterations and amplifications that are key to 
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oncogenesis and chemotherapy resistance (Hu et al., 2014, Zhu et al., 2002, 
Difilippantonio et al., 2002).     
 
 Another problem that exists with the site-specific nuclease approach to gene 
repair is that it relies on HDR proteins that are primarily expressed during the G2 phase of 
the cell cycle (Hsu et al., 2014). This reliance on HDR limits the cell types in which site-
specific nucleases can be used to those undergoing mitosis; neurons and cardiac 
myocytes, for example, are post-mitotic cells. Additionally, reliance on HDR activity often 
limits gene correction activity to below optimal levels even in cell types in which HDR is 
active. The site-specific nuclease approach to targeted genome editing is fundamentally 
limited by the nature of a system, which breaks DNA, but does not have its own DNA 
repair capability. A comparison of the three most popular site-specific nuclease systems is 
shown in Table 1-1. 
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Table 1-1: Comparisons between the three most popular programmable nuclease systems* 
 ZFNs TALENs RGENs 
DNA targeting specificity 
determinant 
ZFAs TALEs sgRNA 
Nuclease FokI FokI Cas9 
Average success rate at 
any given target site† 
Low (~24%) High (>99%) High (~90%) 
Average mutation rate‡ Low or variable 
(~10%) 
High (~20%) High (~20%) 
Number of bases 
specified at target site 
18–36 bp 30–40 bp 20 bp + 2 bp (PAM) 
Target site restrictions Often G-rich Start with T and 
end with A 
5′ end NGG or NAG (PAM)‽ 
Targeting site density 1/100 bp All sites¤ 1/8 bp (NGG PAM), 1/4 bp 
(NGG and NAG PAM)‽ 
Off-target activity High Relatively low Variable 
Cytotoxicity Variable to high Low Low 
Size of reading frame ~1 kb × 2 ~3 kb × 2 4.2 kb (S. pyogenes Cas9) + 
0.1 kb (sgRNA) 
*This table has been adapted from Kim and Kim (2014), and is based on their data collected in HEK293 cells, 
published in several of their previous reports; references can be found within (Kim and Kim, 2014). 
Mutation frequencies are higher in other cell types such as K652 cells and HeLa cells. 
†The success rate is defined as the proportion of nucleases that induce mutations at frequencies >0.5% in 
HEK293 cells. 
‡The average mutation rate is based on the frequency of non-homologous end-joining-mediated insertions 
and deletions obtained at the nuclease target site. 
‽This does not include any consideration of restrictions placed on the sgRNA from its expression promoter 
(see Section 1.4.4). 
¤Given that the length of each TALEN subunit binding site can be varied by 5 bases, all sites should be 
statistically targetable by using that leeway to circumvent the restriction of the thymine that is required at 
the 5′ end of the site. 
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1.5 Chimeric recombinases with programmable binding 
domains: ZFRs and TALERs 
1.5.1 Introduction 
 Another approach to targeted genome editing, which provides a theoretical 
advantage over other systems, is the use of chimeric recombinases with programmable 
binding domains. Recombinases are enzymes that catalyse site-specific reactions with 
DNA such as insertions, deletions, and inversions (see Section 1.6). These enzymes have 
the advantage of being able to carry out genome editing-type reactions without the 
assistance of endogenous cellular processes, thus, making these reactions potentially 
viable in all cell types, including both mitotic and post-mitotic cells (although, chromatin 
accessibility may still need to be considered). Recombinases such as φC31 integrase, Cre 
recombinase, and FLP recombinase are already popular tools for molecular biology; 
however, these recombinases are limited by the integrated site-specificity parameters of 
the natural enzyme. In an attempt to combine the power of recombinases with the 
versatility of engineered site-specific binding domains, chimeric recombinases have been 
developed by fusing a recombinase catalytic domain to engineered DNA-binding domains 
in a modular fashion.  
 
 The best studied chimeric recombinases with programmable binding domains to 
date consist of a catalytic domain from one of several small serine recombinases fused to 
either a ZFA (zinc finger recombinase; ZFR) (Akopian et al., 2003, Gordley et al., 2007) or 
TALE binding domain (TALE recombinase; TALER) (Mercer et al., 2012). Alternatively, 
chimeric recombinase enzymes based on HIV integrase (Tan et al., 2004), sleeping beauty 
transposase (Wilson et al., 2005), PiggyBac transposase (Wu et al., 2006, Owens et al., 
2013), and ISY100 transposase (Feng et al., 2010) have also been reported. The modular 
architecture of the recombinases from the small serine recombinase family makes them 
ideal candidates for the creation of fusion proteins. Additionally, crystal structures have 
been published for small serine recombinase family members γδ resolvase (Yang and 
Steitz, 1995), and Gin invertase (Ritacco et al., 2013), aiding chimeric enzyme design. 
Furthermore, at the time the first ZFR was created, activating mutations for Tn3 resolvase 
(a close homologue of γδ resolvase) had been characterized (see Sections 1.6.4 and 
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1.6.5), which facilitated the use of the Tn3 resolvase catalytic domain in ZFR creation 
(Arnold et al., 1999, Akopian et al., 2003). 
 
 The archetypal ZFR architecture consists of a Tn3 resolvase catalytic domain fused 
via a linker to a Zif268 ZFA (Akopian et al., 2003). The ZFR binds its target (termed a 'Z-
site') as a dimer, with site-specific contacts being mediated by both the catalytic module 
and the Zif268 ZFA DNA-targeting module. The Tn3 catalytic module is comprised of a 
catalytic domain and an arm region that interacts with the minor groove of the Z-site 
before connecting, via a short linker, to a ZFA that interacts with the major groove. The 
Zif268 targeting module may be replaced with other Zif268-like engineered ZFAs, or TALE 
binding domains, in order to partially reprogram the site-specificity of the chimeric 
recombinase (see Section 1.7 for details on ZFA and TALE binding domains). Figure 1-8 
provides a schematic representation of the ZFR bound to a Z-site.      
 
 The Tn3 resolvase catalytic domain of the ZFR carries several activating mutations, 
which free the domain from its restrictive wild-type regulatory requirements (see Section 
1.6 for details). The current ZFR architecture within the Stark lab utilizes a short Thr-Ser 
linker fused at Tn3 resolvase residue Arg148, which links the catalytic and binding 
modules. Arg148 has been chosen as the chimeric fusion point for the catalytic module in 
order to retain the minor groove DNA interactions of the Tn3 arm region, and the crystal 
structure of γδ resolvase (a close Tn3 resolvase homologue) suggests that this is an ideal 
location for the linker to cross over the DNA backbone to enable the major groove 
interactions of the ZFA module. Additionally, experimental evidence has shown this linker 
arrangement to be superior to several other possible arrangements (Prorocic et al., 2011). 
Thr and Ser residues are used for the linker because they are small and polar, making the 
linker both flexible and favourable to its local environment. The Thr-Ser linker also allows 
the inclusion of a SpeI restriction site that facilitates replacement of the binding module.  
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 A Z-site is 40 bp and comprised of a central 20 bp region derived from Tn3 
resolvase site I, which is bound by the catalytic modules of a ZFR dimer (each specifying 
10 bp), which is flanked by 11 bp regions recognized by the ZFA modules that comprise 
the outermost portion of the Z-site (Figure 1-8). It should be noted, that depending on 
whether the ZFAs specify a 5′ extended position base, and/or whether finger 1 of the ZFAs 
have 3′ overlap specificity (see Section 1.7.1.2), the Z-site may also be described as being 
comprised of a 22 bp central sequence flanked by 9 bp ZFA binding sites. Although the 
ZFR binds a Z-site with site-specific contacts from both the catalytic module and the ZFA 
module, only the site-specificity of the ZFA module may be easily reprogrammed, while 
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Zif268 binding site 
central  sequence 
N– 
arm region 
linker 
Side view 
Top view 
Tn3 catalytic module  Zif268 targeting module  
C 
catalytic domain 
Figure 1-8:  Architecture of a ZFR and Z-site.  The figure depicts a schematic of a Tn3–Zif268 ZFR bound to 
its Z-site as a dimer. The two subunits are shown in two shades of orange. Since the catalytic domain of Tn3 
resolvase is primarily composed of four α-helices (see Section 1.6), cylinders are used to depict its structure. 
Yellow bases are used to indicate the portion of the central sequence which is site-specifically contacted by 
the Tn3 catalytic modules. Green bases indicate the portions of the Z-site which are bound by Zif268 
binding modules. Darker green indicates the specific base contacts of Zif268 (see Section 1.7.1.2). Top and 
bottom views are shown to help with visualization of the structure. 
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the site-specificity from the catalytic module remains a limiting target-site parameter. The 
ZFA targeting module usually consists of three contiguous zinc finger motifs. Each zinc 
finger typically specifies up to four bp of DNA but with overlapping recognition sites such 
that a three-fingered ZFA has up to 10 bp of total recognition specificity, plus 1 bp of 
possible recognition specificity from the a 5′ extended position base recognition (Section 
1.7.1.2). Alternatively, longer ZFAs or a TALE domain may be used to provide additional 
sequence recognition. Because a three-fingered ZFA allows each targeting module to 
recognize as many as 11 bp specifically, when ZFR dimers are bound to a Z-site, the 
targeting modules contribute up to 22 bp of recognition specificity—a statistically unique 
sequence in a human genomic context (see Footnote 2 on page 42). 
 
 The ZFR catalytic module facilitates a recombination reaction between two ZFR-
bound Z-sites. Following tetramer formation by two Z-site-bound ZFR dimers, the catalytic 
modules catalyse cleavage of the DNA phosphodiester backbone at the centre of the Z-
site, the ZFR subunits rearrange half-Z-sites, and then re-ligate the DNA to produce 
recombinant DNA products (Figure 1-9 A; also see Section 1.6.2 for a more detailed 
description of the reaction). Depending on the initial parameters of the reaction, this ZFR-
mediated DNA recombination may lead to inversion, integration, or excision DNA 
products (Figure 1-9 B; also see Section 1.5.3). 
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A) 
B) 
Figure 1-9: Recombination of Z-sites by a ZFR tetramer.  A) The figure depicts a simplified representation of 
a ZFR tetramer bound to two Z-sites. The catalytic modules are depicted in orange, while three-fingered ZFA 
binding modules are depicted in maroon (the arm region and linker are not shown). The top strand of DNA 
(yellow) is bound by one ZFR dimer, while the bottom strand of DNA (green) is bound by another, and both 
Z-site bound dimers have formed a tetramer. The curved arrow beside the Z-site/tetramer complex on the 
right indicates that catalysis with subunit rotation has taken place, and it can be seen from the colour of the 
DNA that the Z-site half-sites have been rearranged.  B) The figure depicts the three types of recombination 
reactions which can be produced by ZFRs: inversion, excision, and integration. For simplicity, the figure does 
not display the full complement of plasmid recombination possibilities (these are displayed in Figure 1-10). 
A plasmid is shown with three types of elements indicated: origin of replication (circle), Z-sites (yellow and 
green rectangles), and a gene (arrow) which indicates the directionality of the plasmid segment which 
contains it. If the ZFRs bring the Z-sites together directly across the plasmid, a recombination reaction will 
produce an inversion of the plasmid segment carrying the gene between the Z-sites. However, if the Z-sites 
are brought together in a reversed orientation in such as way that the plasmid becomes twisted, an excision 
of the plasmid segment carrying the gene between the Z-sites will take place. Alternatively, ZFRs may also 
mediate the reverse reaction and integrate a circularized segment of DNA containing a Z-site. Because both 
integration and excision reactions are possible, both reactions are inherently reversible within the ZFR 
system. However, since only one of the two circularized segments of DNA contains an origin or replication, 
the reaction equilibrium will tend toward an excision end product, as the circularized DNA segment without 
the origin of replication is typically lost as cells replicate. 
59 
 
1.5.2 ZFR studies to date  
1.5.2.1 Introduction 
Since the first publication describing a ZFR in 2003 (Akopian et al., 2003), efforts 
have been made to test and improve the system. Experiments have involved assessments 
of the ability of ZFRs to catalyse reactions in human cells, improvements to the ZFR 
architecture, and attempts to overcome the sequence-specificity limitations present in 
the catalytic module. So far only three groups have published ZFR papers (the Stark lab at 
the University of Glasgow, the Barbas lab at the Scripts Research Institute in California, 
and the Tamamura lab at Tokyo Medical and Dental University), and of those, only two 
have published multiple papers on the subject (Stark and Barbas), with most being 
published by the Barbas lab. With the unfortunate and untimely passing of Carlos Barbas 
in 2014, it now appears that only Stark's group remains active. However, the lab of 
Charles Gersbach (a former graduate student of Barbas and author on several ZFR 
papers), at Duke University, also appears to be actively pursuing ZFR research.   
 
1.5.2.2 Activity in mammalian cells 
ZFRs have been used to catalyse both excision and integration reactions in 
mammalian cells. In two experiments using a reporter cell line in which a genomically 
integrated cassette containing EGFP was flanked by Z-sites, ZFRs were shown to catalyse 
excision in 17% and 19% of cells that received ZFR expression constructs via retroviral 
transduction or plasmid transfection, respectively (Gordley et al., 2007, Nomura et al., 
2012). The similarity in efficiency is notable, given that different methods of ZFR delivery 
and different cell types were used in the experiments (HEK293 cells versus CHO cells). 
Additionally, several successful experiments demonstrating ZFR- or TALER-mediated 
excision using episomal reporter assays in human cells, have also been reported (Mercer 
et al., 2012, Gaj et al., 2013b, Gaj et al., 2014). ZFRs have also been used to perform 
targeted integration (at both introduced and endogenous sites) in mammalian cells 
(HEK293 cells, HuH-7 cells, and NIH3T3 cells) with efficiency that ranged from 0.13–1.6% 
(percentage of successfully transfected cells with insertions), and specificity that range 
from 8.3–99% (percentage of detectable insertions found at the target site) (Gordley et 
al., 2009, Gersbach et al., 2011, Gaj et al., 2011, Gaj et al., 2013b, Gaj et al., 2014). 
Notably, the ZFR-mediated integration efficiency in HEK293 cells is comparable to that 
reported for φC31 integrase (Thyagarajan et al., 2001). This comparable level of 
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integration efficiency is perhaps somewhat surprising, given that φC31 integrase 
produces a non-reversible integration reaction, while ZFR integration is reversible and 
excision is the stochastically favoured outcome (see Figure 1-9, and Section 1.5.3).    
 
1.5.2.3 Architecture optimization 
Various experiments have been conducted to optimize or alter the architecture of 
chimeric recombinases with programmable binding domains including: the inclusion of 
catalytic modules from a variety of small serine recombinases, alteration of the targeting 
module, linker and Z-site central sequence length optimization, and the creation of 
obligate heterodimers. Experiments have demonstrated the successful construction of 
active ZFRs utilizing catalytic modules from hyperactivated variants of Tn3 and Sin 
resolvases, Hin and Gin invertases, and β recombinase (Akopian et al., 2003, Gordley et 
al., 2007, Sirk et al., 2014). These catalytic modules vary in efficiency and offer differing 
sequence-specificity requirements.  
 
Attempts to vary the number of zinc finger motifs in the ZFA binding module have 
demonstrated that ZFAs comprised of four or five fingers may impart ZFRs with higher 
efficiency and specificity than ZFAs comprised of two, three, or six fingers (Nomura et al., 
2012, Gordley et al., 2009). However, this interpretation may be a simplification of the 
underlying reality as various individual zinc finger motifs may contribute differing levels of 
affinity and specificity to a ZFA and the effect may be context-dependent (i.e. some 
motifs may cooperate or interfere with each other; see Section 1.7.1) (Bhakta et al., 
2013). Furthermore, it has been suggested by some that longer ZFAs (>3 fingers) benefit 
from modifications to the ZFA architecture (Klug, 2010). Thus, the number of fingers in a 
ZFA will not always reliably correlate with affinity and specificity parameters. The ZFA 
binding module of the ZFR has also been replaced with a TALE binding module to 
generate a TALER (Mercer et al., 2012). TALERs show reduced recombination efficiency in 
human cells compared with ZFRs, bind longer target sites than ZFRs, and have been 
demonstrated to work successfully in ZFR/TALER heterodimer complexes.  
 
The ZFR linker and Z-site central sequence length (the sequence that the ZFA 
binding sites flank) has also been a target for optimization (Akopian et al., 2003, Prorocic 
et al., 2011, Nomura et al., 2012). The two formats for Tn3-based ZFR linker and central 
sequence arrangement that are currently favoured are a SGS linker starting at Tn3 Thr145 
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with a 20 bp (or 18 bp if ZFAs have 3′ overlap specificity) Z-site central sequence (Gordley 
et al., 2007), or a TS linker starting at Tn3 residue Arg148 with a 22 bp (or 20 bp if ZFAs 
have overlap specificity) Z-site central sequence (Prorocic et al., 2011).  
 
Finally, an obligate heterodimer architecture has been designed that allows ZFRs 
to form intended heterodimers at Z-site, while limiting the occurrence of unwanted off-
target homodimer by-products of the reaction (Gaj et al., 2014). The enhanced ZFRs 
(eZFRs) were generated by making a complementary set of mutations within the ZFR 
dimer interface. These mutations discourage homodimerization by producing steric 
clashes between same-type subunits while accommodating alternative-type subunits 
during heterodimerization. In order to compensate for a reduction in recombination 
efficiency caused by the dimer interface mutations, the eZFR pairs also include an 
additional activating mutation that results in eZFR activity comparable to that of the 
parental non-obligate enzymes when assayed in HEK293 cells. These eZFR pairs show a 
>200 fold decrease in the formation of unwanted homodimers when compared with the 
non-obligate parental enzymes. In a test of targeted integration at an endogenous locus 
on human chromosome 4, the eZFRs were shown to be capable of improved targeted 
integration specificity and had an improved toxicity profile compared with their parental 
ZFR enzymes. 
 
1.5.2.4 Catalytic module specificity alteration 
One of the primary limitations of the ZFR system is the sequence specificity bias 
provided by the catalytic module. About half of the ZFR papers published to date have 
focused on this challenge and have described the creation of catalytic modules with 
either broadened or altered site-specificity profiles. Random mutagenesis of the ZFR 
catalytic module followed by selection, has been used to generate catalytic modules with 
broadened site-specificity that tolerate a range of base pair changes throughout the core 
of the Z-site central sequence that is contacted by the catalytic module (see Figure 1-8) 
(Gordley et al., 2007, Proudfoot et al., 2011, Gersbach et al., 2010). One drawback to this 
approach though, is that the extra site-specificity the catalytic module provides may be 
desirable in that it increases the overall site-specificity of the ZFR. Because ZFRs tolerate 
minor variations in Z-site core length (Nomura et al., 2012, Prorocic et al., 2011, Gordley 
et al., 2007, Akopian et al., 2003), it is also possible that broadening specificity could lead 
to reactions where the dinucleotide target of catalysis (see Section 1.6) at the centre of 
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the Z-site core deviates slightly from the intended position, which might lead to undesired 
codon changes in a targeted reading frame. Therefore, other studies have focused on 
switching the catalytic module site-specificity rather than abrogating it. 
 
ZFR catalytic module variants with switched site-specificity have been generated 
through the use of semi-rational design, and the incorporation of catalytic modules from 
other small serine recombinases into the ZFR system. Site-directed saturation 
mutagenesis of specificity-determining DNA-binding residues of the ZFR arm region was 
used to generate Tn3 resolvase- and Gin invertase-based ZFRs that could recombine Gin- 
and Tn3-based Z-sites, respectively (i.e. they could recombine the non-cognate site), with 
the same level of efficiency as their parent enzymes on the cognate Z-site (Gaj et al., 
2011). The core of the central sequences of the Gin invertase- and Tn3 resolvase-based Z-
sites share only 30% sequence identity. These switched specificity ZFRs also showed an 
inability to recombine the cognate Z-sites of their parent enzymes, with a level of 
inhibition comparable to that of the parent enzymes on the non-cognate Z-sites. A pure 
rational design approach, involving swapping key specificity-determining arm region 
residues, has also been used to successfully switch the specificity bias of a Gin invertase-
based ZFR to that of Tn3 resolvase-based ZFR (Sirk et al., 2014). 
 
A subsequent study set out to generate ZFR catalytic modules that could target 
endogenous sites in the human genome (Gaj et al., 2013b). Gaj et al. first characterized 
the Z-site core sequence specificity tolerance of a Gin-based ZFR. This work showed 
complete single-base change tolerance in positions 10, 9, 8, and 7 (the four base pairs 
flanking the ZFA binding sites), single A to T base pair substitution tolerance at positions 
6, 5, and 4, limited dinucleotide substitution tolerance at positions 3 and 2 (4 of 16 
possibilities tolerated), and broad dinucleotide substitution tolerance in the central 
dinucleotide of the core sequence (i.e. positions -1 and 1; 12 of 16 possibilities tolerated). 
Random mutagenesis of the ZFR arm region residues responsible for contact at positions 
2 and 3 was then used to generate Gin invertase-based ZFRs that could target five new 
dinucleotide substitutions at those positions. Using a combination of the Gin-base ZFR 
sequence specificity profile they had previously generated and the new ZFR catalytic 
modules, they then successfully demonstrated targeted integration at non-protein coding 
regions on chromosomes 4 and X, but with relatively low specificity (8–14%).  
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In order to overcome the A or T sequence requirements at core sequence 
positions 4, 5 and 6 detected in the preceding study, a subsequent study attempted to 
generate ZFRs from the catalytic domains of other small serine recombinases with 
different binding specificity biases (Sirk et al., 2014). The Sin resolvase and β recombinase 
were chosen as the basis for new ZFRs because they naturally prefer guanines and 
cytosines at positions 4, 5 and 6 within the core for their binding sites. The Sin resolvase 
and β recombinase catalytic modules were hyperactivated by a directed evolution 
strategy, and binding specificity profiles were generated as done in the previous study. A 
β recombinase-based ZFR was then tested in E. coli using split gene reassembly (see 
below) on 17 Z-sites with cores sequences based on human genomic loci, and was found 
to be active on six of them, with recombination efficiencies ranging from 3–95%. 
 
Finally, the directed evolution strategy that was used to generate both broadened 
site-specificity catalytic domains (Gersbach et al., 2010), and switched site-specificity 
catalytic domains (Gaj et al., 2011, Gaj et al., 2013b, Sirk et al., 2014), itself has technical 
merit worth describing. This approach called 'split gene reassembly' involves the use of a 
'substrate-linked' ZFR expression vector; that is, an expression vector that also acts as a 
ZFR substrate for recombination. The substrate-linked expression vector contains a β-
lactamase gene (conferring resistance to β-lactam antibiotics such as carbenicillin) that is 
interrupted by a GFPuv cassette flanked by Z-sites. Recombination of the Z-sites deletes 
the GFPuv cassette, and reconstitutes the β-lactamase gene. Libraries of ZFR mutants are 
cloned into the substrate-linked expression vector, and active mutants cause deletion of 
the GFPuv cassette and restoration of β-lactamase function. After transformation of cells 
with a library of mutants encoded in the substrate-linked expression vector, and 
incubation, DNA is harvested from cells. The DNA can then be retransformed into cells, 
which are plated on selective (carbenicillin) and non-selective media, in order to ascertain 
the ratio of active to non-active mutants, and identify successful active mutant clones. 
Successful clones can then be amplified, and the ZFR coding sequences extracted for new 
rounds of selection in order to enrich the library. The ZFR recombination reaction time 
can also be varied by reducing the incubation time, in order to increase the site-
recognition stringency of the enrichment procedure.  
 
 
 
64 
 
1.5.2.5 Remaining challenges 
 In order for ZFRs to become successful tools for targeted genomic editing, 
several problems with the system must first be overcome. Zinc finger recombinases are 
currently not able to specify the orientation of the integrations that they catalyse. 
Additionally, the recombination activity in the ZFR system is currently bidirectional; that 
is, the reactions ZFRs catalyse are reversible. This is problematic because one of the chief 
goals for the ZFR system is to use it for integration reactions. If an integration reaction is 
reversible, then the product of the reaction will not be stable, and the reverse excision 
reaction will be stochastically favoured (see Figure 1-9). Given that integration reactions 
can currently be catalysed with up to 1.4% efficiency in human cells (Gordley et al., 2009), 
while excision reactions can be catalysed with up to 19% efficiency (Nomura et al., 2012), 
there appears to be substantial room to improve the system.  
 
 It is perhaps surprising that integrations catalysed using the eZFR (obligate 
heterodimer) architecture (Section 1.5.2.3) do not result in a preponderance of one 
insertion orientation (Gaj et al., 2014). ZFRs may integrate DNA in one of two possible 
orientations. When ZFR heterodimers are used to perform an integration reaction, the 
product Z-sites flanking the insertions will be heterodimer-binding Z-sites if the DNA is 
integrated in one orientation, or homodimer-binding Z-sites if the DNA in integrated in 
the other orientation (see Section 1.5.3). Because the homodimer-binding Z-site products 
of one insertion orientation would be bound by incompatible eZFRs, this might have 
made those reactions irreversible, leading to a preponderance of that insertion 
orientation in the results, and this did not occur. This effect might also have been 
expected to produce a notable increase in integration efficiency, as half of the insertions 
produced by the eZFRs would be stable, and this also did not occur. In any case, the use of 
eZFRs does not appear to be a successful strategy for either controlling the orientation of 
insertions or increasing their stability.  
 
 Finally, although ZFRs with altered catalytic module sequence specificity have 
been generated, these often act with a reduced overall specificity compared to 
unmodified ZFRs (Gaj et al., 2013b), and thus, the sequence specificity bias of the catalytic 
module continues to present a challenge to the effective and flexible use of the ZFR 
system.    
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1.5.3 ZFR system parameters and outcomes: dimer-dimer 
orientation specificity and reaction directionality 
 Although three types of recombination reactions are possible using ZFRs 
(inversion, excision and integration), each has unique system configuration parameters 
that affect the outcome. These system parameters are primarily: the two possible 
orientations of the dimers with respect to one another during tetramer formation (Figure 
1-10 A); and whether recombination reactions may be followed by a directionally 
reversed reaction. ZFRs rely on hyperactivated recombinase catalytic domains, which 
have lost much of the regulatory control that exists in the wild-type systems from which 
they were taken (see Section 1.6.4). Currently, neither dimer-dimer orientation during 
tetramer formation, nor reaction directionality may be controlled. These are important 
limitations to the current ZFR system as they greatly impinge on the reaction outcomes 
that may be generated, as will be discussed below. 
 
 Dimer-dimer orientation during tetramer formation, and reaction directionality, 
are both important parameters for inversion reactions (Figure 1-10 B). If the dimer-dimer 
orientation in a ZFR reaction is unconstrained, the generation of inversion end products 
will be limited to 50% efficiency, as 50% of the products of the reaction will be excision 
products. If the ZFR recombination reaction is reversible, production of inversion end 
products will also be limited to 50% efficiency, as 50% of the reaction products will be 
transformed back into their original state. Additionally, if a ZFR reaction has neither 
dimer-dimer orientation specificity constraint, nor reaction directionality control, then 
inversion end products will be heavily disfavoured as excision end products will dominate 
the reaction outcome (see below). 
 
 Although ZFR excision reactions are affected by both dimer-dimer orientation and 
reaction directionality, these parameters do not limit excision reactions in the way that 
they do other types of ZFR reactions (Figure 1-10 B). Excision reactions, alone, produce a 
stable end product in any ZFR reaction in which dimer-dimer orientation specificity is 
unconstrained and the reaction is bidirectional. If all of the ZFR reaction outcomes are 
reversible and there is no dimer-dimer orientation control, then the excision outcome in 
the reaction will be uniquely stable, as the replication of the cells which host the reaction 
will cause the excision product (which cannot replicate) to be lost. However, if a ZFR 
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system were used in which the reactions were irreversible, but there was no dimer-dimer 
orientation control, then the lack of dimer-dimer orientation control would limit the 
efficiency of excision reactions, as half the reaction outcomes would get stuck as 
inversion products. 
 
 In the case of ZFR-mediated integration reactions, both dimer-dimer orientation 
and reaction directionality are key parameters to the outcome (Figure 1-10 B). If dimer-
dimer orientation during tetramer formation is not constrained, the orientation of an 
integrated DNA segment will be stochastically specified. In such cases, 50% of the 
reaction products will likely contain integrations in one orientation, and 50% will contain 
integrations in the other orientation. This is obviously an undesirable feature of the 
current ZFR system, as many foreseeable applications of the technology would require 
control over the orientation of the integrated genetic material. Reaction directionality is 
also a key parameter for ZFR-mediated integration reactions. If a ZFR integration reaction 
is reversible, then as mentioned above, reactions will tend towards excision products, as 
the excision product is more stable. This also an undesirable feature of the current ZFR 
technology because it likely greatly reduces the efficiency of integration reactions. Since 
integration reactions are perhaps the most important type of reaction the ZFR system 
could be used to catalyse, these limitations in the system represent important challenges 
to its utility. The need to provide exogenous DNA to be integrated also constitutes a 
system parameter for ZFR-mediated integration reactions. 
 
 It should be noted that in some recombinase systems, the central dinucleotide of 
the catalytic site will prevent reactions from completing in one of the two possible dimer-
dimer orientations. If both bases of the central dinucleotide are the same, then the DNA 
can only be re-ligated if the reaction happens in one dimer-dimer orientation. However, 
the catalytic site of Tn3 resolvase contains an AT dinucleotide, and thus, the DNA may be 
re-ligated in either dimer-dimer orientation. Operating over the central dinucleotide is 
not considered to be a good option for controlling the orientation of reactions, such as 
integrations, in the ZFR system, because the DNA can still be cut, it just cannot be re-
ligated. 
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A) 
B) 
Figure 1-10:  ZFR dimer-dimer orientation and reaction outcomes.  A) A simplified representation of two 
ZFR tetramers bound to DNA, depicting both possible dimer-dimer orientations of the tetramer. The DNA is 
shown by yellow and green bars, the ZFA modules of the ZFR are depicted as maroon ovals, and the 
catalytic modules are depicted as orange rectangles. The colour of the DNA half Z-sites and the shade of the 
catalytic domains, provide the visual cues for recognizing the two possible orientations of the ZFR dimer-
dimer interaction.  B) A diagram showing all possible recombination pathways for ZFR reactions. The top 
half of the figure depicts integration and excision, and the bottom half of the figure depicts inversion. 
Plasmids are depicted in dark grey, with the origin of replication indicated by a circle, Z-sites depicted as 
yellow and green rectangles, and a gene, which provides a sense of orientation of the segment which 
contains it, is depicted with a thick curved arrow. X indicates a ZFR-mediated DNA recombination crossover 
event. Black straight arrows indicate steps in which the shape of the plasmids is altered in order to bring the 
Z-sites together, and/or which rearrange the orientation of the Z-sites with respect to one another. In the 
steps where the Z-sites are brought together, the colours of the half Z-site indicate the orientation of the 
dimer-dimer interaction of the ZFR tetramer, as the ZFRs themselves are not shown. Red arrows indicate 
steps after DNA recombination has taken place, with smaller arrows indicating less favourable reaction 
equilibrium. 
68 
 
1.6 Tn3 resolvase 
1.6.1 Origin 
 Tn3 resolvase is encoded by the Tn3 transposon, which is involved in transmitting 
β-lactam antibiotic (e.g. ampicillin) resistance between bacteria (Lett, 1988). The Tn3 
transposon is a 4957 bp mobile gene element containing three genes, bla (β-lactamase), 
tnpA (Tn3 transposase), and tnpR (Tn3 resolvase), which are collectively flanked by 
terminal inverted-repeats. Tn3 resolvase binds a site called 'res', which overlaps the 
promoters of the tnpA and tnpR genes, repressing them. During replicative transposition, 
Tn3 transposase facilitates the integration of the donor plasmid (containing the 
transposon) into a host plasmid, to produce a 'cointegrate' plasmid. This process results in 
the replication of the transposon. The cointegrate plasmid contains two res sites, which 
allow Tn3 resolvase to perform a 'resolution' DNA recombination reaction, resulting in the 
formation of two plasmids, each containing one copy of the Tn3 transposon. 
 
1.6.2 Structure of Tn3 resolvase  
 Tn3 resolvase is a 183 amino acid protein from the small serine recombinase 
family. It contains a C-terminal helix-turn-helix (HTH) DNA-binding domain connected by a 
flexible 'arm region' to a catalytic N-terminal domain. The catalytic domains is comprised 
of a long α-helix, known as the E-helix, which terminates around position 102, and is 
followed by a large N-terminal ββαβαβαβ-fold sub-domain (hereafter referred to as the 
α/β sub-domain) comprised of three α-helices (A, B, and D) and a β-sheet (see Figure 1-12 
in Section 1.6.3). The mechanisms that regulate Tn3 resolvase are incompletely 
understood, although it is generally accepted that: Tn3 resolvase forms dimers on DNA; 
has three distinct dimer binding sites, which are separated by spacers, known as site I, II 
and III (collectively termed res); forms a complex DNA-bound structure involving three 
tetramers called the synaptosome (see below); cleaves the phosphodiester backbone of 
the DNA via nucleophilic attack from residue Ser10; and rearranges the cleaved DNA via 
subunit rotation (Figure 1-11). The synaptosome is comprised of dimers bound to two res 
sites, two of which form the catalytic module bound to site I, and four of which form a 
regulatory module bound to sites II and III (see (Rowland et al., 2009) and (Rice et al., 
2010) for more information on the small serine recombinase synaptosome structure). 
There is also strong evidence to support an activating interaction between the catalytic 
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Figure 1-11:  Subunit rotation model of Tn3 resolvase recombination.  DNA bound dimers (drawn in blue 
and red) come together to form a tetramer. Synapsis is followed by strand cleavage via nucleophilic attack 
of the DNA phosphodiester backbone by Ser10, which results in a covalent bond between DNA and protein. 
A 180° subunit rotation then occurs around the central vertical plane, temporarily separating the dimer 
interfaces. The DNA is rejoined and strand exchange is complete. Adapted from Olorunniji and Stark (2009). 
 
 
tetramer and the accessory tetramers of the synaptosome, at a location known as the 2-3′ 
interface of the N-terminal domain (Hughes et al., 1990, Murley and Grindley, 1998).   
 
 
 
 
 
 
 
1.6.3 Crystal structures of γδ resolvase  
 Tn3 resolvase has a close homologue called γδ resolvase with approximately 80% 
sequence similarity. However, most of the sequence difference lies in the C-terminal 
binding domain, and throughout the catalytic domain there are very few amino acid 
changes. There are several crystallographic structures of γδ resolvase, which greatly aid in 
the understanding of Tn3 resolvase structure and function. Two structures of particular 
note are the 1GDT dimer structure (Yang and Steitz, 1995), and the 1ZR4 tetramer 
structure (Li et al., 2005) (see Figure 1-12). The 1GDT dimer structure depicts resolvase in 
an 'inactivated' form, having not yet undergone necessary conformational changes that 
lead to tetramer formation and strand cleavage. The 1GDT structure contains useful 
information regarding the dimer interface, as well as depicting the DNA-binding contacts 
to site I. Conversely, the 1ZR4 structure depicts an activated resolvase tetramer that is 
covalently bound by Ser10, post-cleavage, to the phosphodiester backbone of the DNA. 
Several large conformational changes are seen in the tetramer structure compared with 
the dimer structure, including a large change in the position of the N-terminal domain 
that brings it within reach of the DNA backbone, and a splaying of the E-helices that now 
make the primary contacts of the tetrameric interface between antiparallel-oriented E-
helices of counterpart dimers (see Figure 1-13).  
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Figure 1-12:  Crystal structures of γδ resolvase.  The resolvase subunits are displayed in cartoon using 
green, yellow, cyan, and red. The DNA is shown using molecular surface and is orange-brown.  A) The 1GDT 
structure shows γδ resolvase bound to DNA (site I) as an inactive dimer.  B) The 1ZR4 structure shows γδ 
resolvase in an activated tetramer conformation (again bound to site I) with Ser10 covalently linked to 
phosphate at the 5′ ends of the cleaved DNA backbone. The purple circles indicate the approximate location 
of a residue cluster which facilitates catalysis. Adapted from Olorunniji and Stark (2009).    
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1.6.4 Hyperactive Tn3 resolvase mutants 
 Previous work within the Stark lab has identified several mutations that lead to a 
so-called 'hyperactive' phenotype (Burke et al., 2004). Originally the term 'hyperactive' 
was used to describe Tn3 resolvase mutants that had the capability to produce 
recombination of either a site I x res substrates, or a site I x site I substrates. However, 
this term has since fallen out of favour within the Stark lab, and will be repurposed within 
this work to specifically describe Tn3 resolvase mutants that have the ability to recombine 
site I x site I substrates, with lesser levels of activation simply being referred to as 
'activated'. This definition of 'hyperactive' specifically implies that the resolvase no longer 
has any need of the subunits bound to accessory sites, and thus, is the activation 
threshold where mutations that knock out the 2-3′ interface increase the activity of the 
protein rather than abolishing it (see Section 1.6.5). Tn3 resolvase always requires at least 
two mutations for hyperactivity. The most important mutation is made at Asp102, and a 
tyrosine is usually used for this. There are a number of secondary mutations, which 
complement D102Y to produce hyperactivation, located in various regions throughout 
Tn3 resolvase (see the following Section 1.6.5). Commonly within the Start lab, the 
hyperactivation mutation set of choice is R2A + E56K (collectively termed 'N') and G101S + 
137 
137 
137 
137 
101 
101 
101 
101 
Figure 1-13:  Antiparallel interaction of E-helices 
across the tetrameric interface.  The E-helices of 
the subunits of dimer pairs (displayed in yellow and 
green, and red and blue) make contacts with their 
counterparts in antiparallel fashion creating a two-
fold symmetry from the centre of the interaction. 
Residue numbers are given to indicate where the 
portion of the structure which is displayed 
terminates. Adapted from Kamtekar et al. (2006). 
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D102Y + M103I + Q105L (collectively termed 'M'), which were derived in the Burke et al. 
study (Burke et al., 2004).  
  
 Hyperactivation greatly simplifies the requirements for the recombination 
reaction and makes hyperactivated Tn3 resolvase an attractive potential tool for directing 
genetic modification. However, much of the regulatory function of Tn3 resolvase is 
provided as a result of the complex interactions in the wild-type synaptosome utilizing 
the resolvase subunits bound to the accessory sites. For example, the synaptosome-
substrate arrangement ensures the recombination reaction between the sites of DNA 
catalysis is unidirectional, and also specifies the dimer-dimer orientation within the 
catalytic tetramer. By freeing the resolvase of its cumbersome accessory subunit aids, 
these features are lost as well.  
 
1.6.5 'Primary', 'secondary', and 'tertiary' activating mutations 
 For the purpose of this project, it will be helpful to place the known activating 
mutations into three categories based on their behaviour in the mutant screen performed 
by Burke et al. (2004) (Burke et al., 2004): 'primary' activating mutations, 'secondary' 
activating mutations and 'tertiary' activating mutations (Figure 1-14). Primary activating 
mutations are any of the activating amino acid substitutions at position 102, which are 
required in order to hyperactivate Tn3 resolvase (e.g. D102Y). Secondary activating 
mutations are those that are required in addition to the primary activating mutation, and 
these can be found at various positions throughout the protein (e.g. G70C, G101S, M103I, 
and Q105L). Tertiary activating mutations are those that will produce an activating effect, 
but only if the hyperactivation threshold has already been met through the inclusion of 
primary and secondary activating mutations (e.g. R2A and E56K). Tertiary mutations will, 
in fact, kill the activity of Tn3 resolvase if the hyperactivation threshold has not been 
achieved. The reason that tertiary activating mutations can kill the activity of the 
resolvase is that these mutations knock out the 2-3′ interface interaction that allows the 
regulatory module of the synaptosome to activate the catalytic module. Thus, without 
hyperactivation, Tn3 resolvase still requires the 2-3′ interface in order to function (Burke 
et al., 2004). 
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Primary (red) Secondary (blue) Tertiary (orange) Catalytic (black spheres) 
D102Y/I/F/V/T/W L66I/F, G70A/C, I77T, 
A89T, F92S, T99S, 
G101S/C, M103I/V, 
Q105L, V107M, T109I, 
A117V, R121K/M/S, 
E124Q 
R2A, E56K S10 (A) 
Figure 1-14:  Locations of Tn3 resolvase activating mutations and categories.  The figure shows a γδ 
resolvase dimer bound to site I (PDB: 1GDT) in order to indicate the locations of activating mutations of Tn3 
resolvase (a close homologue of the γδ resolvase). The ribbon representation of the two resolvase dimer 
subunits (green and yellow) is coloured to indicate the residue locations of activating mutations. A table 
below the image indicates the identities of activating mutations, and provides the categories they have 
been placed into within this work. The table is used to indicate the identities of the residues as there are 
too many to clearly label in the figure. The catalytic residue Ser10 is also indicated in the figure. An S10A 
mutation at this location is often used to inactivate the resolvase. This list of activating mutations was 
derived from the work of Burke et al. (2004). 
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1.7 Binding domains 
1.7.1 Zinc finger arrays  
1.7.1.1 Introduction 
 Developments in the engineering of ZFA DNA-binding domains with designed site-
specificity now permit the design of chimeric enzymes that can be targeted to unique 
locations within a genome. These ZFAs have been used to create designer transcription 
factors, as well as genetic manipulation tools such as ZFNs and ZFRs (Gersbach et al., 
2014). Zinc finger proteins are a class of naturally occurring DNA-binding proteins. The 
ZFAs that are constructed for targeted genomic editing purposes are primarily based on 
Zif268-like structures. Zif268 (also known as Egr-1, NGFI-A, and others) is a transcription 
factor from mice, although it has homologues in many species, including humans (EGR1) 
(Sukhatme et al., 1987, Sukhatme et al., 1988).   
 
1.7.1.2 Structure and DNA binding 
 Zif268 is the archetypal ZFA and is comprised of three tandem zinc finger motifs 
that adopt a ββα fold (Figure 1-15 A and B) (Pavletich and Pabo, 1991). This ββα fold is 
comprised of about 30 amino acids and is tetrahedrally coordinated by a zinc ion bound 
to two Cys and two His residues; hence, this family of proteins is referred to as Cys2-His2 
zinc finger proteins. The crystal structure of Zif268 (Elrod-Erickson et al., 1996) reveals 
that each zinc finger module in the array binds specifically to 3–4 bp of its target 
sequence through amino acid contacts to bases via the major groove of the DNA (Figure 
1-15 C and D). However, there is overlap in these protein-DNA contacts, with Finger 3 
supplying cooperative contacts to the first base pair bound by Finger 2, and Finger 2 
supplying cooperative contacts to the first bp bound by Finger 1. Thus, Zif268 makes 
specific contacts to 10 bp DNA. 
 
 Often, zinc finger modules are described as binding up to three base pairs 
specifically, but cooperative contacts to a fourth base pair, such as observed in Zif268, 
sometimes also need to be considered. The base pair contacts are made by four zinc 
finger recognition helix residues at positions conventionally described as -1, 2, 3, and 6 
(with contacts from position 2 mediating fourth base pair overlapping specificity; Figure 
1-15 C). Additionally, residues at positions 4 and 5 may help to enforce target specificity 
as well (Gersbach et al., 2014). It should also be noted, that although the foregoing is the 
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generally reported pattern of residue-base contact for Zif268-like ZFAs, other quite 
different patterns of contact (e.g. specification for different base positions by residues -1 
and 2, base contacts from residue 1, and fifth base pair overlap specificity) have also been 
observed for engineered Zif268-like ZFAs (Wolfe et al., 2001). Thus, alteration of the key 
residues within the zinc finger recognition helix can facilitate the creation of zinc finger 
motifs with novel DNA binding specificities. It is also worth noting, that at least two 
studies have demonstrated that some natural three-fingered ZFAs, including Zif268, have 
an extended recognition specificity preferences for the base pairs directly 5′ and 3′ of the 
sequence to which protein-DNA contacts are made (especially the 5′ base pair; hereafter 
referred to as the 5′ extended base position) (Swirnoff and Milbrandt, 1995, Wolfe et al., 
1999). In Zif268, this extended base pair specificity is not mediated by such obvious 
contacts as the core 10 bp of recognition sequence. Engineered Zif268-like ZFAs can be 
constructed by linking individual zinc finger motifs together using canonical Zif268 linkers 
TGEKP and TGQKP, and the construction of arrays with up to six-fingers have been 
reported (Liu et al., 1997).  
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Figure 1-15: The structure and DNA binding of the Zif268 ZFA.  A) Crystal structure of Zif268 bound to its 
target site (PDB: 1AAY).  B) The ββα fold conformation of Zif268 with tetrahedral coordination by a Zn2+ ion 
bound by two Cys and two His ligands.  C) The Zif268 recognition helix from finger 3 of the array, bound to 
its target site. Recognition helix residues Arg 6, Glu 3, and Arg 1 are shown making contacts with bases 
guanine, cystosine, and guanine, respectively, while Asp 2 is shown making 'overlap' contact to adenine on 
the opposite DNA strand (the first base in the target of finger two; finger 2 is not shown). Hydrogen bonds 
are shown using light blue lines (there are two hydrogen bond contacts from Arg -1 to guanine but they 
cannot be easily seen due to the orientation of the structure). Asp 2 can also be seen providing stabilizing 
hydrogen bonds to Arg -1. Glu 3 only provides specificity through hydrophobic contact, to cytosine. Non-
contacted bases have been removed for clarity.  D) A schematic representation of Zif268 binding to its 10 
bp target site. Bases contacted by finger 1, 2, and 3 (F1, F2, and F3) are shown in darker colours. 
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1.7.1.3 Construction methods 
 The labs of Aaron Klug (University of Cambridge, UK), Carlos Barbas (The Scripps 
Research Institute, USA), and Keith Joung (Harvard University, USA), as well as others, 
have over the past 20 years generated a wealth of published data on building engineered 
ZFAs from customized Cis2-His2 zinc fingers with designed site-specificity. Customized zinc 
finger modules are generated through the use of phage display, rational design, and 
exploitation of naturally occurring zinc finger proteins, and these techniques have been 
used to generate zinc fingers specifying all GNN, ANN, CNN, and several TNN DNA triplets 
(Segal et al., 1999, Dreier et al., 2000, Dreier et al., 2001, Dreier et al., 2005, Blancafort et 
al., 2003, Liu et al., 2002, Bae et al., 2003, Segal et al., 2003, Beerli et al., 1998, Carroll et 
al., 2006, Desjarlais and Berg, 1992, Sera and Uranga, 2002). Additionally, for triplets for 
which there are no available zinc finger modules, a 'structured linker', which can skip a 
triplet, can be generated by mutating all of the base contacting residues of the 
recognition helix (-1, 2, 3, and 6) to serine; however, this strategy does not appear to 
have been deployed outside of its original publication (Moore et al., 2001a, Klug, 2010). 
Many of the known zinc finger modules have been amassed into publicly available online 
databases that allow users to input desired DNA target sequences and receive an output 
of amino acid sequences for fingers that bind to the DNA targets (Mandell and Barbas, 
2006, Fu et al., 2009). However, for some individual triplets there may be several 
available zinc finger modules available, and not all of them are necessarily active in 
combination with one another. Thus, several methods exist for assembling functional 
ZFAs, including modular assembly, modular assembly with specialized libraries, and 
context-sensitive assembly (Ramirez and Joung, 2013).  
 
 The simplest method for ZFA construction is modular assembly (Bhakta and Segal, 
2010). Using this method one simply links together the known zinc finger modules and 
tests the ZFAs against target sites. Although the modular assembly method of ZFA 
construction is simple, in some cases high failure rates have been reported (e.g. 76% 
average failure rate, and 100% failure rate for the ZFA lacking GNN modules) (Ramirez et 
al., 2008, Joung et al., 2010). It has been suggested that these high failure rates result 
from a lack of consideration of context-sensitive effects (i.e. target site overlap and side-
chain interference between neighbouring zinc finger modules) in the modular assembly 
approach (Ramirez et al., 2008, Joung et al., 2010, Cathomen and Joung, 2008). However, 
there is also evidence to suggest that modular assembly failure is the result of insufficient 
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cumulative affinity of some combinations of zinc finger modules (Sander et al., 2009, Lam 
et al., 2011), and thus, the problem may be corrected simply by constructing longer ZFAs 
(Bhakta et al., 2013, Kim et al., 2009), or by affinity balancing through a module affinity-
scoring scheme (Sander et al., 2009).  
 
 One approach to improving the success rates of ZFAs constructed by modular 
assembly has been the generation of specialized libraries composed of select zinc finger 
modules that have a higher frequency of occurrence in successful ZFAs (Kim et al., 2009, 
Kim et al., 2011, Zhu et al., 2011), or which are known to work well with each other 
(Gupta et al., 2012, Sander et al., 2011b, Zhu et al., 2013). The benefit of these specialized 
library strategies is that they are simple, and they achieve high rates of success compared 
with traditional modular assembly strategies. The Context-Dependent Assembly (CoDA) 
library, for instance, produces ZFAs with over 76% chance of activity (as measured by >3-
fold transcriptional activation in a B2H assay) (Sander et al., 2011b). The drawback to 
using specialized libraries is that they are much more limited than traditional modular 
assembly in the number of sequences that can be hypothetically targeted. 
 
 Several approaches exist to generate ZFAs through context-dependent selection 
and assembly; these include: sequential optimization (Greisman and Pabo, 1997), bi-
partite selection (Isalan et al., 2001), bacterial two-hybrid (B2H) selection (Hurt et al., 
2003), and bacterial one-hybrid (B1H) selection (Meng et al., 2008). These approaches will 
be briefly described below.  
 
 Sequential optimization involves successive rounds of C-terminal ZFA finger 
truncations and N-terminal ZFA finger additions to generate a completely novel ZFA with 
a position-specific finger arrangement (i.e. the fingers used at each position in the array 
were designed for that position only) (Greisman and Pabo, 1997). First, three libraries of 
Zif268-based ZFAs are generated, where one module at each of the three finger positions 
(F1, F2 and F3) has had the key residues of its recognition helix randomized. These 
libraries are selected for site-specificity using phage display. Randomized F1 modules are 
then used to replace the Zif268 F3 module of the ZFA (generating an F1-F2-F1 array), and 
the new ZFAs are tested for site-specificity using phage display. Next, the Zif268 F1 
module of the new ZFAs is removed, and randomized F2 modules are fused to the 
opposite end of the array, connecting them to the randomized F1 modules (generating an 
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F2-F1-F2 array). After further selection, a similar step is carried out to remove the last 
Zif268 module and fuse randomized F3 modules to the randomized F2 modules 
(generating a F1-F2-F3 array). These ZFAs are then selected for the desired final site-
specificity, and thus, novel ZFAs with a F1-F2-F3 configuration are generated.  
 
 There are two finger-finger junctions within a three-fingered ZFA. In bi-partite 
construction, a three-finger ZFA is parsed into two 1.5 finger units, each of which contains 
those finger-finger junctions (Isalan et al., 2001). Two libraries of Zif268-based ZFAs, 
containing amino acid randomization at the base-contacting residues of either F1 and half 
of F2, or (the remaining) half of F2 and all of F3, are selected for desired site-specificity by 
phage display. The novel 1.5 finger units are then recombined and selected on the desired 
target site, again using phage display. Thus, the bi-partite method of construction 
accounts for compatibility and overlapping base specificity between adjacent fingers, by 
avoiding construction steps that create unproven finger-finger junctions. 
 
 B2H selection is an E. coli-based method which makes use of ZFAs that are 
tethered to a Gal11P protein, and an RNA polymerase α-subunit tethered to a Gal4 
protein (Gal11P and Gal4 are found in yeast) (Hurt et al., 2003). Gal11P binds to Gal4, 
allowing the ZFA-Gal11P fusion to act as a transcription factor (because it recruits the 
Gal4-RNA polymerase α-subunit fusion) when correctly bound to a site upstream of a 
reporter gene. The selection begins with three BCR-ABL ZFAs (a previously constructed 
ZFA based on three modified repeats of the Zif268 finger 2) (Choo et al., 1994), where 
either finger 1, 2, or 3 of BCR-ABL has been replaced with a novel module library. These 
BCR-ABL-based ZFAs with new modules at position 1, 2, or 3 of the array, are then 
selected for binding activity using the B2H assay.  The successful fingers from the first 
round of selection are then recombined in a position-specific fashion to generate entirely 
novel ZFAs, which are tested for activity, again using the B2H assay (Hurt et al., 2003). A 
B1H-based construction system also exists, which is like the B2H strategy, but uses a 
canonical Zif268 ZFA instead of BCR-ABL as the starting ZFA framework, and employs a 
selection system where the ZFAs are directly tethered to the ω-subunit of RNA 
polymerase (Meng et al., 2008).  
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 Currently, the most popular publically available system for context-specific 
construction is Oligomerized Pool ENgineering (OPEN), which is base on the B2H 
methodology (Maeder et al., 2008). The primary advance over the original B2H system is 
the provision of large plasmid libraries of context-specific modules archived by the Zinc 
Finger Consortium (www.zincfingers.org) and made available through Addgene 
(Cambridge, MA, USA; www.addgene.org/zfc). Additionally, the Zinc Finger Consortium 
also supplies an online tool (ZiFiT) to help streamline target-site identification, and this 
tool includes an affinity-based activity scoring algorithm to predict outcomes (Sander et 
al., 2010, Sander et al., 2007). Technically, all of the ZFAs produced using OPEN are active, 
because the final selection stage tests for their activity in a B2H assay (successful ZFAs are 
ones detected to produce >3-fold activation of transcription of a reporter gene in E. coli) 
(Maeder et al., 2008). However, whether these ZFAs that are active in E. coli, are active 
when used in fusion proteins, perhaps in mammalian cells, is another matter. Maeder et 
al. demonstrated that 75% of ZFNs incorporating OPEN ZFAs showed activity in human 
cells, compared to 18% of the ZFNs incorporating ZFAs constructed by traditional modular 
assembly. The construction of ZFAs through OPEN is more complicated than construction 
through modular assembly, but whether it is more labour intensive is debatable given the 
potential failure rates of traditional modular assembly ZFAs.  
 
 Finally, Sangamo Biosciences (Richmond, CA, USA) has developed a proprietary 
archive of zinc finger modules and proprietary method for constructing ZFAs. Custom 
ZFAs, in the form of a ZFN pair, can be purchased through Sangamo's licensed partner 
Sigma-Aldrich (St. Louis, MO, USA) under the CompoZr™ product line for $6000 (Segal and 
Meckler, 2013). Sigma-Aldrich claims to have readymade ZFN pairs that target all genes in 
the human, mouse, and rat genomes (Segal and Meckler, 2013). The Sangamo ZFAs are 
reported to be highly active and have featured in most of the reports of ZFN-mediated 
endogenous gene modification to date (Urnov et al., 2010, Perez-Pinera et al., 2012), 
including the first clinical trial of a ZFN-based gene therapy (see Section 1.4.3) (Tebas et 
al., 2014).  
 
 Some of the Sangamo design strategy can be gleaned from papers published by 
senior scientists who worked for the company (e.g. Sir Aaron Klug and Yen Choo who also 
founded the zinc finger technology company Gendaq, which was later bought by 
Sangamo), and from analysis of published reports that describe Sangamo ZFA architecture 
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(Ramirez and Joung, 2013, Klug, 2010). Sangamo utilizes a library of pre-validated two- 
and three-finger arrays that have been designed using phage display and the bi-partite 
construction method (which accounts for cross-contact interactions) (Isalan et al., 2001, 
Isalan and Choo, 2001, Jamieson et al., 2003, Klug, 2010). The two-finger arrays can be 
obtained from a library of three-finger arrays constructed using bi-partite assembly (Klug, 
2010). These two- and three-finger arrays are then fused using extended linkers 
(containing one or four residue additions within canonical Zif268 linkers) to generate 
four- to six-finger ZFAs (Moore et al., 2001b, Jamieson et al., 2003, Perez et al., 2008, 
Hockemeyer et al., 2009, Klug, 2010). Using ZFAs comprised of independent sub-arrays, 
separated by extended linkers, produces better target discrimination (Moore et al., 
2001b). These ZFAs have better target discrimination because the Kd of two-fingered sub-
arrays is more greatly affected by target site mismatches than that of longer contiguous 
arrays. Inclusion of a single Gly or Ser into a canonical Zif268-derived linker (e.g. TGGQKP) 
also serves to reset the register between zinc fingers and DNA, as the periodicity of the 
ZFAs does not quite match the periodicity of DNA, and strain accumulates when more 
than three fingers bind DNA (Moore et al., 2001b, Jamieson et al., 2003, Nekludova and 
Pabo, 1994, Perez et al., 2008, Hockemeyer et al., 2009, Klug, 2010). Inclusion of GGGS 
into a canonical linker (e.g. TGGGGSQKP) can reset the register and skip a base in the 
target sequence (Hockemeyer et al., 2009, Jamieson et al., 2003, Moore et al., 2001b). 
Using extended linkers that skip a base can also help accommodate sub-arrays with 
recognition helix residue 2 overlap specificity (see Section 1.7.1.2) incompatible with the 
following sub-array (Klug, 2010). It can also be observed that Sangamo ZFAs sometimes 
contain linkers within which the canonical Lys has been substituted for an Arg 
(Hockemeyer et al., 2009), and this perhaps serves some function. 
 
 The site-specificity of Sangamo ZFAs is thought to generally be higher than that of 
ZFAs produced by other methods. In one study that compared a pair of high-performing 
Sangamo ZFNs (based on four-fingered ZFAs; the same pair used in the HIV clinical trials, 
see Section 1.4.3.2) to a pair of high-performing OPEN ZFNs (based on three-fingered 
ZFAs), it was found that the Sangamo ZFNs may have 37 potential off-target sites in the 
human genome, while the OPEN ZFNs may have 2,652 (Pattanayak et al., 2011). In 
another study, CompoZr ZFNs (Sangamo via Sigma-Aldrich) were compared to ZFNs with 
CoDA derived ZFAs (Sood et al., 2013). This study showed that the CoDA ZFNs required a 
five-fold higher mRNA dose to achieve mutagenesis, and the somatic lesion frequency 
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produced by CoDA ZFNs was <5%, compared with 9-98% using the CompoZr ZFNs. 
However, a protocol has been published for optimizing ZFAs constructed through public 
methods, which may help improve their specificity (Herrmann et al., 2011). This protocol 
is based on semi-randomization of the key residues in the recognition helices, and 
selection using an adaptation of a commercial yeast one-hybrid kit. Crucially, this method 
overcomes a limitation of many publically available methods, allowing users to add 
additional fingers to their constructs to create ZFAs of four to six fingers in length (OPEN, 
CoDA and bi-partite construction, for example, allow only three-fingered ZFAs to be 
constructed).  
 
1.7.2 TALE array binding domains 
1.7.2.1 Introduction 
 Although methods to engineer custom ZFAs have improved greatly over the last 
20 years, they are still limited in the range of sequences that they can target. Recently, 
TALE binding domains, which have much more versatile targeting capability than ZFAs, 
have been used to build chimeric site-specific enzymes such as TALERs and TALENs 
(Mercer et al., 2012, Joung and Sander, 2013). TALEs are transcriptional activators derived 
from bacterial plant pathogens of the genus Xanthomonas (TALE-like proteins are also 
found in phytopathogenic bacteria of the genus Ralstonia) (Kim and Kim, 2014), which 
bind and regulate genes within host plants (Boch and Bonas, 2010, Bogdanove et al., 
2010, Kay and Bonas, 2009, Kay et al., 2007, Romer et al., 2007).  
 
1.7.2.2 Structure 
 The TALE binding domain is comprised of arrays of 33–35 amino acid repeats (with 
the exception of the final repeat that is a half repeat) each of which recognize a single 
base pair (Mak et al., 2012, Deng et al., 2012a). These TALE repeat domains specify bases 
through contacts made by hypervariable residues at positions 12 and 13, known as the 
repeat-variable diresidues (RVDs) (Boch et al., 2009, Moscou and Bogdanove, 2009) RVDs 
recognize DNA via a simple recognition code (Boch et al., 2009, Moscou and Bogdanove, 
2009, Cong et al., 2012, Streubel et al., 2012, Yang et al., 2014, Miller et al., 2015), which 
is an attractive feature for engineering site-specific binding domains. The TALE repeats 
take the form of two helices connected by a short loop containing the RVD (Mak et al., 
2012, Deng et al., 2012a). The RVD loop sits in the major groove of the DNA, and the array 
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of TALE repeats coils around the DNA molecule in a right-handed superhelical structure 
(Figure 1-16).  
 
1.7.2.3 Using TALE binding domains for chimeric enzyme creation 
 In order to use TALE binding domains for chimeric enzyme creation, a truncation 
architecture is usually designed to reduce the size of the protein and reveal the minimal 
domain required for efficient DNA binding (Mussolino et al., 2011, Miller et al., 2011, 
Mercer et al., 2012, Bedell et al., 2012, Christian et al., 2010). The truncation 
architectures also remove unnecessary native TALE elements such as the C-terminal 
transcriptional activation domain, and the N-terminal region up to residue 152 specifying 
transport into plant cells. These truncation architectures must account for the fact that 
different fusion points will lead to different degrees of proper protein folding and DNA 
binding, and they must be compatible with the catalytic domain that they are to be fused 
to. TALEN fusion protein designs include the addition of an N-terminal NLS (the native C-
terminal NLS is usually removed with the truncations), while the only published TALER 
design does not include an NLS.  It may be noted that full length TALEs (no truncation 
architecture) may also be used to generate TALENs (Li et al., 2011b, Li et al., 2011c).  
 
 Because TALENs have the binding module fused to the catalytic domain by its C-
terminus, while TALERs have the binding module fused to the catalytic domains by its N-
terminus, the optimal truncation architectures might not be directly compatible between 
both systems. However, the TALER designed by Mercer et al. used the C-terminal TALE 
truncation point from a TALEN designed by Miller et al., and selected an N-terminal 
truncation point similar to that of the TALEN construction by Mussolino et al. (Mercer et 
al., 2012, Miller et al., 2011, Mussolino et al., 2011). An appropriately designed amino 
acid linker to mediate fusion to the catalytic domain must be also generated, in addition 
to the use of appropriate spacers between TALE binding sites within the target sequence, 
with consideration given to the chimeric enzyme system being used.  
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 Using one of the aforementioned architectures, one may then assemble an array 
of TALE repeats with RVDs specifying a desired base pair sequence. The target sequence 
for a TALE must be at least 10–12 bp, but is usually designed to be 15–21 bp (Carroll, 
2014). The only limitation in the sequence design is presented by two cryptic modules 
A) 
B) 
Asp13 
Hys12 
N C 
C) 
Figure 1-16: Structure and DNA binding of a TALE binding domain.  A) The Image shows the crystal 
structure of the PthXo1 TALE binding domain bound to its DNA target from a side view (PDB: 3UGM). A 
rainbow colour transition across the protein is used to aid with clarity of the image.  B) The Image shown is 
the same structure as in A) but rotated 90° looking at the DNA head on.  C) A single 34 amino acid TALE 
repeat binding to DNA via the major groove. The two RVD residues are shown and labelled. Bases of the 
DNA helix are shown, and hydrogen bonds between base pairs are indicated with light blue lines to aid the 
clarity of the image. A hydrogen bond contact from RVD residue Asp13 to a cytosine base is indicated by a 
short orange line. 
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(resembling TALE repeats in structure but less so in sequence) at the N-terminus of the 
array, which specify a thymine directly 5′ of the designed target sequence (Mak et al., 
2012). However, efforts have been made to overcome this limitation by mutating 
residues in one of the cryptic modules (Lamb et al., 2013, Doyle et al., 2013). Another 
challenge that may present itself is that methylation of carbon-5 of a cytosine within a 
target sequence interferes with binding by TALE arrays. However, this limitation may be 
overcome through the use of a TALE repeat that recognizes thymine, since the RVD 
recognition of thymine occurs at its carbon-5 methyl group, which is indistinguishable 
from that of methylated cytosine (Deng et al., 2012b, Valton et al., 2012). It should be 
noted that this solution results in some loss of specificity, as either thymine or methylated 
cytosine may now be recognized at these positions. Additionally, because the RVDs that 
specify thymine make lower affinity contacts, some loss of TALE binding domain affinity 
may also occur. 
 
1.7.2.4 Construction of TALE binding domains 
 Because of the highly repetitive nature of the TALE array, they cannot be 
generated by ordinary gene synthesis, and assembly from repeat monomers is somewhat 
nontrivial. Several methods for TALE array construction have been described in the 
literature, including: iterative hierarchical cloning (Sander et al., 2011a, Huang et al., 
2011), Golden Gate-based and Golden Gate-like cloning (Cermak et al., 2011, Kim et al., 
2013, Liang et al., 2014, Li et al., 2011c), ligation-independent cloning (Schmid-Burgk et 
al., 2013), PCR preparation and ligation assembly (Yang et al., 2013, Zhang et al., 2013), 
and solid-phase assembly (Reyon et al., 2012, Briggs et al., 2012). For these methods, 
cloning steps are the factor limiting how quickly a chimeric gene-editing enzyme 
incorporating a TALE domain can be generated. The number of cloning steps required 
varies from 1–6 steps depending on the method used (see Table 1-2). TALE array 
assembly methods require libraries of TALE repeats, with the faster versions of each 
method being enabled by libraries of 2–4 TALE repeat modules. These libraries, which 
must either be generated or acquired, range in size from 12–424 modules. In addition, 
several of the TALE assembly methods, including two of the Golden Gate-based 
approaches (Kim et al., 2013, Liang et al., 2014), ligation-independent cloning (Schmid-
Burgk et al., 2013), and the solid-phase assembly approaches (Reyon et al., 2012, Briggs et 
al., 2012), can be adapted for high-throughput to produce large numbers of TALE arrays 
at once. Figure 1-17 shows a basic diagram illustrating three common assembly 
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platforms: iterative hierarchical cloning, Golden Gate cloning, and FLASH (solid-phase 
assembly).  
 
Table 1-2: Comparison of TALE assembly methods 
Source Method Module size Library size HT # of cloning steps 
Sander et al. (2011) IHC 1 34† (12)‡  6 
Huang et al. (2011) IHC 2 16  5 
Li et al. (2011) GGC‽ 1 48  2 
Cermak et al. (2011) GGC 1 44 (55)º  2 
Kim et al. (2013) GGC 1–3 424 ✓ 1 
Liang et al. (2014) GGC 1 & 2 308 ✓ 1 
Schmid-Burgk et al. (2012) LIC 2 64 ✓ 2 
Zhang et al (2013) PCR 4 (1–4)* 256 (340)*   1 (>1)* 
Yang et al. (2013) PCR 3 64  1 
Reyon et al. (2012) SPA 1–4 376 ✓ 1 
Briggs et al. (2012) SPA 1 12 ✓ 1 
Abbreviations: IHC = iterative hierarchical cloning, GGC = Golden Gate cloning, LIC = ligation independent 
cloning, PCR = PCR preparation and ligation assembly, SPA = solid-phase assembly, HT = high-throughput. 
Module size indicates the number of repeats in the modules of the library. 
† The published library is missing three N- and C-terminal modules specifying G, and A and G, respectively. 
The library size shown assumes the inclusion of the missing modules. 
‡ The published library utilizes module variants with backbone sequences varied through codon redundancy 
to reduce the repetitiveness of the sequences. However, this was an early report on TALE assembly and 
subsequently published methods of TALE assembly do not make use of this. Thus, the library might be 
reduced to 12 modules by eliminating the backbone variants. 
‽ This method was published before the Golden Gate cloning method but is Golden Gate-like. 
º This library includes an extra 11 modules with alternative RVD specificity for G. However, these modules 
could be omitted. 
*Optionally, this library may include modules of 1–3 repeats (in addition to the 4 repeat modules); 
however, using these may increase the number of cloning steps required. 
 
 Finally, TALE arrays (often in the form of TALEN pairs) may also be purchased for 
$1500–$5000 from commercial vendors such as Life Technologies (Carlsbad, CA, USA), 
Cellectis Bioresearch (Romainville, France), ToolGen (Soul, Korea), CoWin Biotech (Beijing, 
China), Transposagen Biopharmaceuticals (Lexington, KY, USA), and others (Segal and 
Meckler, 2013). Additionally, several American universities (e.g. the University of San 
Francisco, the University of Utah, and the University of Wisconsin) now have dedicated 
TALEN production facilities. 
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Figure 1-17: Three common TALE array construction platforms: Iterative hierarchical cloning, Golden Gate 
cloning, and FLASH.  For all examples, four different coloured discs (yellow, red, blue, and green) are used 
to represent four different varieties of TALE repeat modules.  Iterative hierarchical cloning (top). Coding 
sequences for four module types with the same pair of compatible 3′ and 5' end overhang sequences are 
used to assemble monomers in parallel. Each iteration of the process doubles the size of the units being 
ligated until a 16 mer TALE array is achieved. The N- and C-terminal modules contain unique 5' and '3 
overhangs (not shown), which allow the TALE array to be cloned into a desired fusion context (e.g. ZFN 
framework) containing the TALE N- and C-terminal regions of the chosen TALE architecture (also not 
shown).  Golden Gate cloning (bottom left). Coding sequences for modules which contain 10 pairs with 
unique 3′ and 5' end overhangs are extracted from library plasmids using TypeIIS restriction enzymes and 
used to assemble up to 10 modules at once. Two parallel reaction pots (rxn 1a + rxn 1b) are used to 
produce one 10-mer and one 6-mer array (rxn 2) which are then assembled into a 16-mer array (TALE).  
FLASH (botton right) Iterative ligations are performed on a streptavidin-coated solid-phase surface using 
modules containing up to four TALE repeats. Adapted from Joung and Sander (2014). 
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1.8 Project objectives 
 This project attempts to deduce structural and mechanistic information about the 
Tn3 resolvase-based ZFR reaction so that three enhancements to the system can be made 
to enable its use for targeted gene editing applications: capability for orientation-specific 
integration, irreversibility of ZFR-catalysed reactions, and relaxation of the ZFR target-site 
specificity requirements. 
 
 Currently, the ZFR system is unable to control the orientation of integration 
reactions, and insertions are randomly produced in both orientations, resulting in an 
approximately a 50:50 ratio of both insertion orientations. Two broad approaches were 
taken in this project to control this parameter of the reaction. The first broad approach 
was to attempt to generate orientation specificity in the dimer-dimer interface. These 
efforts included analysis and alteration of residues that may be involved at the initial 
contact point during dimer-dimer formation, and the use of rationally designed mutations 
to operate over a hypothesised mechanism of catalytic activation and regulation. The 
second broad approach was to allow integration reactions to take place in both 
orientations, but to try to make integration in one orientation irreversible, while leaving 
integration in the other orientation capable of being reversed. These efforts included 
attempts to modify the catalytic domain, or binding domain, such that after integration in 
one orientation, the ZFR no longer functioned on its Z-sites.    
 
 Irreversible ZFR reaction catalysis would likely greatly improve integration 
efficiency, preventing subsequent excision reactions that stochastically favour an excision 
end product. Two approaches taken in this project to generate unidirectional ZFR reaction 
are: rationally designed mutations that operate over a hypothesised fundamental aspect 
of catalytic regulation, and the generation of ZFR subunits with differential binding 
affinity in order to generate a reaction that produces product Z-sites that are no longer 
capable of being bound by binding-competent ZFR dimers (this approach is related to the 
approach for integration orientation specificity outlined above). 
 
 Relaxation of ZFR target site recognition requirements would allow the ZFR system 
to be used to target more sites within a given genome. Currently, the ZFR system is 
limited in its targeting capability both by the sequence specificity bias of the catalytic 
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module, and by the lack of available ZFAs. To date, much effort has been focused on 
attempting to relax or alter the recognition requirements of the catalytic module (Gaj et 
al., 2011, Gaj et al., 2013b, Sirk et al., 2014, Gersbach et al., 2010, Gordley et al., 2007, 
Proudfoot et al., 2011). However, it appears that the possibility of reducing the specificity 
requirements of one binding module in a ZFR dimer has not been considered. This is a 
hypothetically feasible approach since the combined sequence recognition capability of 
two catalytic modules and one three-fingered binding module of a dimer, appears to 
provide enough sequence specificity to target a unique site in a human genome (see 
Section 5.1.2.2). However, the recognition degeneracy of a ZFR has never been fully 
characterized (the study by Gaj et al. (2013) only characterized a limited set of mutation 
combinations (Gaj et al., 2013b); see Section 1.5.2.4), and it is not known how many base 
pair changes a ZFR actually will tolerate within its target site. Tolerance of target site 
degeneracy will likely depend on the activating mutations incorporated in the catalytic 
module, and on the identities and positions of the base pair changes themselves. 
 
 Since the sequence specificity requirements of the catalytic module must be 
accommodated anyway, reduction of ZFR site-specificity requirements, by reducing those 
of a single binding module in a ZFR dimer, could expand the repertoire of target sites that 
are only limited by the availability of ZFAs. The challenge to this approach is in producing 
specificity-reduced ZFRs that are able to cooperate as site-specific heterodimers, but are 
unable to catalyse reactions as less site-specific homodimers (which might participate in 
off-target reactions in a genomic context). It should be noted, that at the time this project 
was started TALERs had not yet been developed. However, due to the large size of TALE 
arrays (TALE repeat motifs are slightly larger than zinc finger motifs, but specify only 1 
base instead of 3, and TALE arrays are comprised of many more motifs than ZFAs), the 
difficulty of their construction, and the potentially reduced activity of TALERs compared 
to ZFRs (Mercer et al., 2012), the reduced-specificity ZFR approach may still have some 
value. 
 
Goals summary 
 1  Engineer orientation-specific integration capability. 
 2 Engineer irreversibility of the ZFR recombination reaction. 
 3 Relaxation of the ZFR target site recognition requirements.  
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Chapter 2: Methods and Materials 
 
2.1 Basic procedures 
2.1.1 Restriction digests 
 Restriction digests of plasmid DNA were performed in 15 μL volumes according to 
the instructions of the restriction enzyme providers (i.e. NEB, Invitrogen, and Promega). 
NEB enzymes were preferred where an option was available. 
 
2.1.2 Gel electrophoresis 
 Agarose gels were made at using UltraPure™ Agarose (Life Technologies, Carlsbad, 
CA, USA). Preparative gels were made at 0.7% agarose, while analytic gels were made at 
1.2% agarose. Gels were made approximately 1 cm thick. Gels were run 3.5–4.5 h (e.g. 80 
V, 165 mA). Gels were stained for 20 min in 0.6 mg/mL EtBr using the running buffer, and 
de-stained twice in H2O for 20 min per wash.   
 
2.1.3 DNA extraction from gels  
 DNA extraction from gels was performed using either a Qiagen QIAquick Gel 
Extraction kit or Costar® Spin-X® (Corning®, Corning, NY, USA) centrifuge tube filters (0.45 
µm pore size) by spinning for 1 min at RCF =  16,000 × g. 
 
2.1.4 Ligations 
 Ligation of DNA constructs were performed in 20 μL volumes using approximately 
a 1:1 ratio of DNA molecules for each reaction. Invitrogen T4 ligase was used according to 
the manufacturer's protocol.   
 
2.1.5 Ethanol precipitation 
 To 20 µL ligation mixtures was added 1 uL of tRNA (Sigma-Aldrich, R5636 - 
Ribonucleic acid, transfer from baker's yeast (S. cerevisiae), conc. 9-11 mg/mL). Mixtures 
were then briefly vortexed. Next, 10 µL of 5 M ammonium acetate solution was added to 
the mixtures, and the mixtures were again briefly vortexed. 70 µL of 100% ethanol was 
then added to the tube. The ligations were then set on ice for 15 min before being 
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centrifuged at maximum for 50 min. Afterward the supernatant was removed from the 
tubes using thin gel loading pipette tips. 100 µL of cold 70% ethanol was added to the 
tubes to wash the pellet. The tubes were briefly spun again for approximately 5–10 s 
before the supernatant was again removed from the tubes using the thin gel loading 
pipette tips. The pellets were then allowed to dry for approximately 15 min before 15 µL 
of ddH2O was added to re-suspend the DNA for use for transformations. 
 
2.1.6 High-density overnight cultures 
 Colonies were picked from plates using toothpicks that were then used to 
inoculate 5 mL of 2YT in 15 mL conical tubes. Five small holes where punched in the lid for 
better air circulation. The tubes were set up at an approximately 45° angle in a shaker set 
at 225 rpm and 37°C. The cultures were collected approximately 16 h later. 
 
2.1.7 Gel image transformation 
 All gel images were transformed for display using the Quality One GelDoc software 
(Bio-Rad, Hercules, CA, USA). Within the transform menu the Invert display option was 
selected, and then the Gamma option was set to either 0.25 or 4.00, depending on 
whether the Image Mode had been set to UV or White, respectively, at the time the 
image was taken. Taking images in either UV or White mode appears to reverse the way 
the image information is coded, allowing opposite ends of the gamma transform curve to 
be applied to the image. The preferred method for transforming an image for display was 
to acquire the image in White mode, invert it, and then apply a gamma transformation of 
4.00 to it. From the point at which the preferred mode was discovered, all images were 
prepared this way, though many images were prepared from UV mode acquisitions with 
inversion and a 0.25 gamma transformation, before this point. This type of 
transformation was used because it was found to display some of the faint bands in the 
figures most clearly. 
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2.2 Protocols 
2.2.1 Preparation of electrocompetent cells 
Step 1) Three x 500 mL of L-broth were placed in three 2 L Erlenmeyer flasks and each 
were inoculated 500 µL of with fresh overnight E. coli culture. 
 
Step 2) Cells were grown at 37°C with shaking (300 rpm). Samples were taken from the 
cultures periodically and analysed using a spectrophotometer. When cultures reached an 
OD600 between 0.5–0.7 (indicating early- to mid-log phase), they were placed on ice in the 
cold room for approximately 20 min. Cells were then transferred to centrifuge bottles and 
spun for at 4000 x g for 15 min at 4°C.  
 
Step 3) The supernatant was carefully poured off the pellets. 
 
Step 4) Each pellet was then gently resuspended in 500 mL of ice-cold 10% glycerol, 
centrifuged again at 4000 x g for 15 min at 4°C, and again the supernatant was gently 
poured off.  
 
Step 5) Each pellet was then gently resuspended in 250 mL of ice-cold 10% glycerol, 
centrifuged again at 4000 x g for 15 min at 4°C, and again the supernatant was gently 
poured off.  
 
Step 6) Each pellet was then gently resuspended 2 mL ice-cold 10% glycerol and a 20 µL 
sample was taken from each tube and pulsed with the micropulser. If the pulse time was 
between 5.7 and 5.9 ms (preferably 5.8 or 5.9 ms) the stocks from which they were taken 
were marked with the pulse time and kept on ice. If the pulse time was lower than 5.7 
ms, a further 20 mL of ice-cold 10% glycerol was added to each stock, and they were 
again centrifuged again at 4000 x g for 15 min at 4°C, and afterward the supernatant was 
gently poured off. 
 
Step 7) Each pellet was then gently resuspended in 2 mL of ice-cold 10% glycerol, and the 
cells were then separated into 100 µL aliquots. 20 µL samples were taken from each lot 
and pulsed using the micropulser. The pulse times were recording and lots were labelled 
accordingly. 
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Step 8) Cell aliquots were then flash frozen in liquid nitrogen and subsequently stored at -
70°C until use. 
 
Final note: The efficiency of the cells depended on how thoroughly the supernatant was 
poured off, how gently the cells were resuspended (waiting a few minutes and then 
gently swirling worked best; although, gently pipetting up and down with an electronic 
pipette was also effective; resuspending the pellet by manual shaking produced poor 
quality electrocompetent cells), and whether it was possible to reduce the number of 
centrifugation steps (see Step 6).   
 
2.2.2 Electroporation 
Step 1) Electrocompetent E.coli cells (see Section 2.2.1) were thawed on ice for 
approximately 15 min, and 0.2 cm cuvettes were placed on ice alongside the cells.  
 
Step 2) For single plasmid transformations the cells were diluted tenfold in 10% glycerol. 
For double plasmid transformations the cells were diluted fourfold in 10% glycerol. For 
triple plasmid transformations the cells were diluted twofold in 10% glycerol.  
 
Step 3) When experimental work was done from plasmid minipreps 0.5 µL of each 
plasmid stock was added to 20 µL of cells, the tubes were flicked or gently pipette up and 
down to mix, and the cells put on ice for 1 min.  For ligation transformations, 5 µL of 
purified DNA in ddH2O (see Section 2.1.5) was used instead. 
 
Step 4) The cell and DNA mixture was placed in a cuvette, and pulsed using the 
MicroPulser (setting Ec2). Immediately after the pulse, 1 mL of 2-YT broth was added to 
the cuvette, and the cell suspension transferred to a to a 5 mL conical tube.  The pulse 
time was recorded.  
 
Step 5) The conical tube containing the cell suspension was placed in the shaker at 37°C, 
at 225 rpm for 1 h.  
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Step 6) The cell suspension was placed on selective media and incubated at 37°C 
overnight. 
 
2.2.3 17 Hour Recombination Assay 
 For all of the following steps the cells were kept on ice throughout. 
 
Step 1)  E. coli DS941 cells were simultaneously transformed with one or two expression 
plasmids and substrate plasmid by electroporation (0.5 μL of each plasmid stock in 20 μL 
of cells). The cells were then plated on selective media (ampicillin for pMS140-based 
plasmids; chloramphenicol for pSA3017-based and pSA3022-based plasmids; and 
kanamycin for pMS184Δ-based plasmids) and incubated for approximately 17 h at 37°C.  
 
Step 2)  Cells were then harvested by pipetting 6 mL of cold Luria Broth onto the plates 
and then resuspending by agitation with the side of a clear gel loading pipette tip (bend 
the end to avoid tearing into the agar). Approximately 5 mL of cell suspension was then 
aspirated from each plate and pipetted into 15 mL conical tubes that were set on ice. 
 
Step 3)  The optical density of the cell suspensions was measured by spectrophotometry 
at a 1:100 dilution and reading at OD600. Cell suspensions were vortexed before each 
reading to thoroughly re-suspend the cells. 
 
Step 4)  A calculation (see below) was then performed on the OD600 readings in order to 
determine what volume ( ) from the 5 mL cell suspensions was equal to 5 mL of high 
density (grown in 2YT) overnight culture. (High density overnight cultures had previously 
been measured to have an OD600 of 0.046 at a 1:100 dilution.) 
 
  
   
           
 
 
Optional step 4b)  If a cell passage was required, the volume ( ) determined in the Step 
4, was removed from each cell suspension added to a new 15 mL conical tube (tube 1) 
and the volume of suspension was topped up to 5 mL with 2YT broth. The suspension was 
then vortexed to mix, and 0.5 μL of suspension was then added to a new 15 mL conical 
tube (tube 2) containing 5 mL 2YT broth, and placed in the shaker at 37°C on 250 rpm. 
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Step 5)  If no cell passage was required, the volume ( ) determined in Step 4a, was 
removed from each cell suspension and a QIAprep Spin Miniprep Kit (Qiagen, Venlo, 
Netherlands) was used (elusion in 50 μL) in order to harvest DNA from the cells. If a cell 
passage was required then suspension from tube 1 from Step 4b was used for the 
miniprep instead. In both cases, the initial centrifugation step for the miniprep was 
conducted in the 15 mL connical tubes because the volume of suspension surpassed the 
capacity of the 2 mL Eppendorph tubes (additional 2TY broth was added to the connical 
tubes if their volumes were sufficiently different to unbalance the centrifuge rotor).  
 
Step 6)  14 μL of each Miniprep was then digested with FspI + KpnI-HF® + PvuII-HF® (see 
below for reaction conditions) and analysed by  gel electrophoresis on a 1.2% agarose gel. 
In one instance, when the desired enzymes were not available, an alternative set of 
enzymes (AgeI-HF® + KpnI-HF®) were used to achieve similar discrimination of product 
bands. The same reaction conditions were used as below, but using 1 μL each enzyme. 
 
Cut Smart buffer = 222  2.00 μL  
FspI = 0.50 μL  
KpnI-HF = 0.75 μL  
PvuII-HF = 0.75 μL  
DNA = 16.0 μL  
Total volume = 20.0 μL  
Time =  1.5 h  
 
2.3 Constructions  
2.3.1 Construction of substrates  
2.3.1.1 Four-part oligonucleotide annealing 
 The double-stranded oligonucleotides containing the Z-sites that were used for 
substrate construction were constructed through a four-part annealing strategy with two 
annealing steps (Figure 2-1). Single-stranded oligonucleotides containing Z-site half-sites 
(Table 2-1) were ordered from Eurofins Genomics (Ebersberg, Germany) and resuspended 
in Tris-EDTA buffer (10 nM, pH 8.2) to a final concentration of 100 pmol/μL. The first 
annealing step was designed to created double-stranded oligonucleotides containing Z-
site half-sites. 1 μL of oligonucleotide suspension for the oligonucleotides corresponding 
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to both top and bottom strands of the left or right halves of a Z-site (see Table 2-1) were 
mixed in a 1:1 ratio in an Eppendorf tube and combined with 20 μL of 0.5 M NaCl and 78 
μL of Tris-EDTA buffer (10 nM, pH 8.2) to make 100 μL total volume. The annealing mix 
was heated on a heating block at 85°C for 10 min, then covered with tin foil (to slow 
cooling) and left to cool overnight. The second annealing step was designed to generate 
double-stranded oligonucleotide Z-site full-sites. The double-stranded oligonucleotides 
generated in the first annealing step, which comprise the left and right halves of Z-sites 
were mixed in 1:1 ratios corresponding to full Z-sites in new Eppendorf tubes, and then 
heated to 49°C and cooled using the same procedure as before. A lower temperature 
(49°C instead of 85°C) was used in the second annealing step in order to prevent the 
melting of the desired intermolecular bonds between oligonucleotides that had formed 
during the first annealing step (see Figure 2-1). Oligonucleotide melting temperatures 
were calculated using Oligo Calc: Oligonucleotide Properties Calculator (Northwestern 
University Feinberg School of Medicine, Chicago, IL, USA; 
http://www.basic.northwestern.edu/biotools/oligocalc.html). A list of all double-stranded 
oligonucleotides that were generated is given in Table 2-2. 
 
Table 2-1: Single-stranded Z-site oligonucleotides 
ID and sequence Position* site 
Z1o1:  CTAGACTTGCGTGGGCGTCG Top-left Z1 
Z1o2:  AAATATTATAAATTATCAGCGCCCACGCAACTAGTG Top-right Z1 
Z1o3:  TGATAATTTATAATATTTCGACGCCCACGCAAGT Bottom-left Z1 
Z1o4:  GTACCACTAGTTGCGTGGGCGC Bottom-right Z1 
Z2o1:  CTAGACTTGACGCTGCTCCG Top-left Z2 
Z2o2:  AAATATTATAAATTATCAGTCCTCACTCAACTAGTG Top-right Z2 
Z2o3:  TGATAATTTATAATATTTCGGAGCAGCGTCAAGT Bottom-left Z2 
Z2o4:  GTACCACTAGTTGAGTGAGGAC Bottom-right Z2 
Z3o1:  CTAGACTTGAGTGAGGACCG Top-left Z3 
Z3o2:  AAATATTATAAATTATCAGTCCTCACTCAACTAGTG Top-right Z3 
Z3o3:  TGATAATTTATAATATTTCGGTCCTCACTCAAGT Bottom-left Z3 
Z3o4:  GTACCACTAGTTGAGTGAGGAC Bottom-right Z3 
Z4o1:  CTAGACTTGCGGCGGACCCG Top-left Z4 
Z4o2:  AAATATTATAAATTATCAGGTCCGCCGCAACTAGTG Top-right Z4 
Z4o3:  TGATAATTTATAATATTTCGGGTCCGCCGCAAGT Bottom-left Z4 
Z4o4:  GTACCACTAGTTGCGGCGGACC Bottom-right Z4 
Z5o1:  CTAGACTTTGGGGTGCCCCG Top-left Z5 
Z5o2:  AAATATTATAAATTATCAGGGCACCCCAAACTAGTG Top-right Z5 
Z5o3:  TGATAATTTATAATATTTCGGGGCACCCCAAAGT Bottom-left Z5 
Z5o4:  GTACCACTAGTTTGGGGTGCCC Bottom-right Z5 
*Position is the same as that depicted in Figure 2-1. 
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Figure 2-1:  Four-part oligonucleotide annealing strategy.  This figure depicts the strategy that was used to 
generate double-stranded Z-site oligonucleotides from four single-stranded oligonucleotides in two steps, using 
the construction of oligonucleotide α (containing the Z-site Z2/Z2) as an example. 
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Table 2-2: All constructed double-stranded oligonucleotides 
Half-sites construction  
Homodimer Z-sites 
construction 
 
Heterodimer Z-sites 
construction (set A) 
 
Heterodimer Z-sites 
construction (set B) 
               
Α Z2o1 + Z2o3 Z2/  α   Α + Β Z2/Z2  ε Α + Δ Z2/Z3  λ Γ + Β Z3/Z2 
Β Z2o2 + Z2o4 /Z2  β   Γ + Δ Z3/Z3  ζ Α + Ζ Z2/Z4  μ Ε + Β Z4/Z2 
Γ Z3o1 + Z3o3 Z3/  γ   Ε + Ζ Z4/Z4  η Α + Θ Z2/Z5  ν Η + Β Z5/Z2 
Δ Z3o2 + Z3o4 /Z3  δ   Η + Θ Z5/Z5  θ Γ + Ζ Z3/Z4  ξ Ε + Δ Z4/Z3 
Ε Z4o1 + Z4o3 Z4/      ι Γ + Θ Z3/Z5  ο Η + Δ Z5/Z3 
Ζ Z4o2 + Z4o4 /Z4  ρ Ι + Κ Z1/Z1  κ Ε + Θ Z4/Z5  π Η + Ζ Z5/Z4 
Η Z5o1 + Z5o3 Z5/             
Θ Z5o2 + Z5o4 /Z5      σ Ι + Β Z1/Z2  χ Α + Κ Z2/Z1 
        τ Ι + Δ Z1/Z3  ψ Γ + Κ Z3/Z1 
Ι Z1o1 + Z1o3 Z1/      υ Ι + Ζ Z1/Z4  ω Ε + Κ Z4/Z1 
Κ Z1o3 + Z1o4 /Z1      φ Ι + Θ Z1/Z5  ϡ Η + Κ Z5/Z1 
 
 
2.3.1.2 Construction of substrate plasmids 
 Figure 2-2 provides a diagram of the following construction procedure using the 
construction of pJK193 (Z2/Z2 x Z2/Z2) as an example. Substrates were constructed by 
first digesting pMS183Δ with either XbaI + Asp718I or NheI + BsrGI (which cut at two 
different polycloning sites within pMS183Δ) and then extracting the linear DNA from a 
0.7% UltraPure Agarose gel. The double-stranded oligonucleotides containing the various 
Z-sites were then ligated into the polycloning sites, generating two sets of plasmids with 
Z-sites located at either of the polycloning sites. After amplifying the products plasmids in 
E. coli, the product plasmids were digested using AlwNI + BlpI, separated on a 0.7% 
UltraPure Agarose gel, and the fragments containing the Z-sites were extracted. The 
AlwNI - BlpI and BlpI - AlwNI fragments containing the Z-sites were then ligated to one 
another to generate substrates containing two Z-sites. A table of all the substrate 
plasmids constructed by this method can be found later in Chapter 3 (Table 3-2). A 
diagram of pMS183Δ, and the two polycloning sites into which the Z-sites were ligated, is 
also given in Chapter 3 (Figure 3-2).  
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Figure 2-2:  Substrate plasmid construction.   The figure depicts a diagram of the construction strategy for new 
substrate plasmids using the construction of pJK193 as an example. Note that the oligonucleotides are indicated 
as being 52 bp, which does not include the four base overhangs on either side. Also note that the 'insert' in the 
diagram is labelled 'Start (0) - End (56),' which is the length of the top strand of the oligonucleotide (a labelling 
convention employed by the program Snap Gene, which was used to generate the figure).  
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2.3.2 Construction of ZFRs 
 Figure 2-3 provides a diagram of the following construction procedure using the 
construction of Tn3[NM]-Z2 as an example. The plasmids p12AAMO2P, p12AAMOZP, 
p12AAMOYP, and p12AAMOXP (containing Z2, Z3, Z4, and Z5, respectively), along with 
pAMC11 (containing Tn3[NM V107F-Z1) were digested using SpeI and SacI. The DNA 
fragments from the plasmids containing the Z2, Z3, Z4, and Z5 were then separated by gel 
electrophoresis on a 3% MetaPhor Agarose gel. The DNA fragments from pAMC11 were 
separated by gel electrophoresis on a 0.7% UltraPure Agarose gel. The 264 bp bands 
containing the ZFAs, and a 5.35 kb containing the Tn3[NM V107F] catalytic domain and 
pAMC11 backbone, were extracted from the gels and ligated. It was necessarily to clone 
these Z2, Z3, Z4, and Z5 into a pAMC11, or pAMC11-like framework, because not all ZFR 
expression plasmids in the Stark lab have the required SacI site at the end of the ZFR 
reading frame. The resulting plasmids containing Tn3[NM V107F]-Z2, Tn3[NM V107F]-Z3, 
Tn3[NM V107F]-Z4, and Tn3[NM V107F]-Z5 were then digested using their BsaI and EagI 
restriction sites to replace the Tn3 catalytic module with other varieties of previously 
generated Tn3 catalytic module, and the multiple restriction sites throughout the ZFR 
reading frame were used to clone in oligonucleotides in order to generate novel mutants. 
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Figure 2-3: ZFR construction method.  The figure depicts a diagram of the construction strategy for new 
ZFRs using the construction of Tn3[NM]-Z2 as an example. 
ZFR reading frame with 
 restriction sites  
(pJK070) 
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2.4 Plasmids 
NAME DESCRIPTION   AB SELECTION 
Chapter 3, Section 3.5 
pJK321 Tn3[NY G70C]-Z2 (pSA3017 vector) Chlr 
pJK322 Tn3[NY G70C]-Z3 (pSA3017 vector) Chlr 
pJK323 Tn3[NY G70C]-Z4 (pSA3017 vector) Chlr 
pJK324 Tn3[NY G70C]-Z5 (pSA3017 vector) Chlr 
pJK290 Tn3[NY G70C]-Z2 (pMS140 vector) Ampr 
pJK291 Tn3[NY G70C]-Z3 (pMS140 vector) Ampr 
pJK292 Tn3[NY G70C]-Z4 (pMS140 vector) Ampr 
pJK293 Tn3[NY G70C]-Z5 (pMS140 vector) Ampr 
pJK294 Tn3[NY G70C]-Z2 (pSA3022 vector) Chlr 
pJK295 Tn3[NY G70C]-Z3 (pSA3022 vector) Chlr 
pJK296 Tn3[NY G70C]-Z4 (pSA3022 vector) Chlr 
pJK297 Tn3[NY G70C]-Z5 (pSA3022 vector) Chlr 
pJK193 Z2/Z2 x Z2/Z2 Kanr 
pJK194 Z3/Z3 x Z3/Z3 Kanr 
pJK195 Z4/Z4 x Z4/Z4 Kanr 
pJK196 Z5/Z5 x Z5/Z5 Kanr 
Chapter, Section 3.6 
pJK070 Tn3[NM]-Z2 Ampr 
pJK072 Tn3[NM]-Z2 Chlr 
pJK193 Z2/Z2 x Z2/Z2 Kanr 
pJK197 Z2/Z2 x Z3/Z3 Kanr 
pJK198 Z2/Z2 x Z4/Z4 Kanr 
pJK199 Z2/Z2 x Z5/Z5 Kanr 
pJK209 Z2/Z3 x Z2/Z3 Kanr 
pJK210 Z2/Z4 x Z2/Z4 Kanr 
pJK211 Z2/Z5 x Z2/Z5 Kanr 
pJK221 Z2/Z3 x Z3/Z2 Kanr 
pJK222 Z2/Z4 x Z4/Z2 Kanr 
pJK223 Z2/Z5 x Z5/Z2 Kanr 
pJK071 Tn3[NM]-Z3 Ampr 
pJK073 Tn3[NM]-Z3 Chlr 
pJK194 Z3/Z3 x Z3/Z3 Kanr 
pJK200 Z3/Z3 x Z2/Z2 Kanr 
pJK201 Z3/Z3 x Z4/Z4 Kanr 
pJK202 Z3/Z3 x Z5/Z5 Kanr 
pJK212 Z3/Z2 x Z3/Z2 Kanr 
pJK213 Z3/Z4 x Z3/Z4 Kanr 
pJK214 Z3/Z5 x Z3/Z5 Kanr 
pJK224 Z3/Z2 x Z2/Z3 Kanr 
pJK225 Z3/Z4 x Z4/Z3 Kanr 
pJK226 Z3/Z5 x Z5/Z3 Kanr 
pJK108 Tn3[NM]-Z4 Ampr 
pJK068 Tn3[NM]-Z4 Chlr 
pJK195 Z4/Z4 x Z4/Z4 Kanr 
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pJK203 Z4/Z4 x Z2/Z2 Kanr 
pJK204 Z4/Z4 x Z3/Z3 Kanr 
pJK205 Z4/Z4 x Z5/Z5 Kanr 
pJK215 Z4/Z2 x Z4/Z2 Kanr 
pJK216 Z4/Z3 x Z4/Z3 Kanr 
pJK217 Z4/Z5 x Z4/Z5 Kanr 
pJK227 Z4/Z2 x Z2/Z4 Kanr 
pJK228 Z4/Z3 x Z3/Z4 Kanr 
pJK229 Z4/Z5 x Z5/Z4 Kanr 
pJK109 Tn3[NM]-Z5 Ampr 
pJK069 Tn3[NM]-Z5 Chlr 
pJK196 Z5/Z5 x Z5/Z5 Kanr 
pJK206 Z5/Z5 x Z2/Z2 Kanr 
pJK207 Z5/Z5 x Z3/Z3 Kanr 
pJK208 Z5/Z5 x Z4/Z4 Kanr 
pJK218 Z5/Z2 x Z5/Z2 Kanr 
pJK219 Z5/Z3 x Z5/Z3 Kanr 
pJK220 Z5/Z4 x Z5/Z4 Kanr 
pJK230 Z5/Z2 x Z2/Z5 Kanr 
pJK231 Z5/Z3 x Z3/Z5 Kanr 
pJK232 Z5/Z4 x Z4/Z5 Kanr 
Chapter 3, Section 3.7 
pJK325 Tn3[NY G70C]-L6-Z2 Ampr 
pJK326 Tn3[NY G70C]-L6-Z3 Ampr 
pJK327 Tn3[NY G70C]-L6-Z4 Ampr 
pJK328 Tn3[NY G70C]-L6-Z5 Ampr 
pJK193 Z2/Z2 x z2/Z2 Kanr 
pJK194 Z3/Z3 x Z3/Z3 Kanr 
pJK195 Z4/Z4 x Z4/Z4 Kanr 
pJK196 Z5/Z5 x Z5/Z5 Kanr 
Chapter 3, Section 3.8 
pJK498 Tn3[NY G70C]-Z1  (pSA3017 vector) Chlr 
pJK322 Tn3[NY G70C]-Z3   (pSA3017 vector) Chlr 
pJK499 Tn3[NY G70C]-Z1   (pMS140 vector) Ampr 
pJK291 Tn3[NY G70C]-Z3  (pMS140 vector) Ampr 
pJK358 Tn3[NY G70C]-Z1  (pSA3022 vector) Chlr 
pJK295 Tn3[NY G70C]-Z3  (pSA3022 vector) Chlr 
pMP53 Z1/Z1 x Z1/Z1 Kanr 
pJK194 Z3/Z3 x Z3/Z3 Kanr 
pJK500 Tn3[NM]-Z1 Ampr 
pJK098 Tn3[NM]-Z1 Chlr 
pJK263 Z2/Z2 x Z1/Z1 Kanr 
pJK264 Z3/Z3 x Z1/Z1 Kanr 
pJK102 Z4/Z4 x Z1/Z1 Kanr 
pJK265 Z5/Z5 x Z1/Z1 Kanr 
pJK269 Z1/Z2 x Z1/Z2 Kanr 
pJK270 Z1/Z3 x Z1/Z3 Kanr 
pJK257 Z1/Z4 x Z1/Z4 Kanr 
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pJK271 Z1/Z5 x Z1/Z5 Kanr 
pJK275 Z1/Z2 x Z2/Z1 Kanr 
pJK276 Z1/Z3 x Z3/Z1 Kanr 
pJK258 Z1/Z4 x Z4/Z1 Kanr 
pJK277 Z1/Z5 x Z5/Z1 Kanr 
pJK070 Tn3[NM]-Z2 Ampr 
pJK072 Tn3[NM]-Z2 Chlr 
pJK071 Tn3[NM]-Z3 Ampr 
pJK073 Tn3[NM]-Z3 Chlr 
pJK108 Tn3[NM]-Z4 Ampr 
pJK068 Tn3[NM]-Z4 Chlr 
pJK109 Tn3[NM]-Z5 Ampr 
pJK069 Tn3[NM]-Z5 Chlr 
Chapter 3, Section 3.9 
pJK290 Tn3[NY G70C]-Z2 Ampr 
pJK291 Tn3[NY G70C]-Z3 Ampr 
pJK380 Tn3[NY G70C]-Z2 (slot #1) | Tn3[NY G70C]-Z3 (slot #2) Ampr 
pJK381 Tn3[NY G70C]-Z3 (slot #1) | Tn3[NY G70C]-Z2 (slot #2) Ampr 
pJK294 Tn3[NY G70C]-Z2 Chlr 
pJK295 Tn3[NY G70C]-Z3 Chlr 
pJK385 Tn3[NY G70C]-Z2 (slot #1) | Tn3[NY G70C]-Z3 (slot #2) Chlr 
pJK386 Tn3[NY G70C]-Z3 (slot #1) | Tn3[NY G70C]-Z2 (slot #2) Chlr 
pJK193 Z2/Z2 x Z2/Z2 Kanr 
pJK194 Z3/Z3 x Z3/Z3 Kanr 
Chapter 4, Section 4.2 
pJK155 Tn3[N D102D G70C]-Z2 Chlr 
pJK046 Tn3[N D102E G70C]-Z2 Chlr 
pJK510 Tn3[N D102H G70C]-Z2 Chlr 
pJK511 Tn3[N D102K G70C]-Z2 Chlr 
pJK512 Tn3[N D102R G70C]-Z2 Chlr 
pJK151 Tn3[N D102D G70C]-Z3 Ampr 
pJK104 Tn3[N D102E G70C]-Z3 Ampr 
pJK105 Tn3[N D102H G70C]-Z3 Ampr 
pJK106 Tn3[N D102K G70C]-Z3 Ampr 
pJK107 Tn3[N D102R G70C]-Z3 Ampr 
pJK197 Z2/Z2 x Z3/Z3 Kanr 
Chapter 4, Section 4.3 
pJK286 Tn3[NY]-Z2 Chlr 
pJK291 Tn3[NY G70C]-Z3 Ampr 
pJK193 Z2/Z2 x Z2/Z2 Kanr 
pJK194 Z3/Z3 x Z3/Z3 Kanr 
pJK197 Z2/Z2 x Z3/Z3 Kanr 
pJK200 Z3/Z3 x Z2/Z2 Kanr 
pJK209 Z2/Z3 x Z2/Z3 Kanr 
pJK212 Z3/Z2 x Z3/Z2 Kanr 
pJK221 Z2/Z3 x Z3/Z2 Kanr 
pJK224 Z3/Z2 x Z2/Z3 Kanr 
pJK294 Tn3[NY G70C]-Z2 Chlr 
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pJK283 Tn3[NY]-Z3 Ampr 
pJK390 Tn3[NY]-Z2 | Tn3[NY]-Z2 Chlr 
pJK379 Tn3[NY G70C]-Z3 | Tn3[NY G70C]-Z3 Ampr 
pJK152 Tn3[N G70C]-Z3 Ampr 
pJK397 Tn3[NY L66I]-Z3 Ampr 
pJK398 Tn3[NY L66F]-Z3 Ampr 
pJK333 Tn3[NY G70A]-Z3 Ampr 
pJK363 Tn3[NY G70C]-Z3 Ampr 
pJK334 Tn3[NY I77T]-Z3 Ampr 
pJK335 Tn3[NY A89T]-Z3 Ampr 
pJK336 Tn3[NY F92S]-Z3 Ampr 
pJK337 Tn3[NY I97M]-Z3 Ampr 
pJK338 Tn3[NY T99S]-Z3 Ampr 
pJK339 Tn3[NY G101C]-Z3 Ampr 
pJK340 Tn3[NY G101S]-Z3 Ampr 
pJK341 Tn3[NY M103I]-Z3 Ampr 
pJK342 Tn3[NY M103V]-Z3 Ampr 
pJK343 Tn3[NY Q105L]-Z3 Ampr 
pJK375 Tn3[NY V107F]-Z3 Ampr 
pJK344 Tn3[NY V107M]-Z3 Ampr 
pJK345 Tn3[NY V108A]-Z3 Ampr 
pJK346 Tn3[NY T109I]-Z3 Ampr 
pJK347 Tn3[NY A117V]-Z3 Ampr 
pJK348 Tn3[NY R121G]-Z3 Ampr 
pJK349 Tn3[NY R121K]-Z3 Ampr 
pJK350 Tn3[NY R121M]-Z3 Ampr 
pJK351 Tn3[NY R121S]-Z3 Ampr 
pJK352 Tn3[NY E124Q]-Z3 Ampr 
pJK071 Tn3[NM]-Z3 Ampr 
pJK451 Tn3[NY L66I]-Z3 | Tn3[NY L66I]-Z3 Ampr 
pJK452 Tn3[NY L66F]-Z3 | Tn3[NY L66F]-Z3 Ampr 
pJK453 Tn3[NY G70A]-Z3 | Tn3[NY G70A]-Z3 Ampr 
pJK454 Tn3[NY I77T]-Z3 | Tn3[NY I77T]-Z3 Ampr 
pJK455 Tn3[NY A89T]-Z3 | Tn3[NY A89T]-Z3 Ampr 
pJK456 Tn3[NY F92S]-Z3 | Tn3[NY F92S]-Z3 Ampr 
pJK457 Tn3[NY I97M]-Z3 | Tn3[NY I97M]-Z3 Ampr 
pJK458 Tn3[NY T99S]-Z3 | Tn3[NY T99S]-Z3 Ampr 
pJK459 Tn3[NY G101C]-Z3 | Tn3[NY G101C]-Z3 Ampr 
pJK460 Tn3[NY G101S]-Z3 | Tn3[NY G101S]-Z3 Ampr 
pJK461 Tn3[NY M103I]-Z3 | Tn3[NY M103I]-Z3 Ampr 
pJK462 Tn3[NY M103V]-Z3 | Tn3[NY M103V]-Z3 Ampr 
pJK463 Tn3[NY Q105L]-Z3 | Tn3[NY Q105L]-Z3 Ampr 
pJK464 Tn3[NY V107F]-Z3 | Tn3[NY V107F]-Z3 Ampr 
pJK465 Tn3[NY V107M]-Z3 | Tn3[NY V107M]-Z3 Ampr 
pJK466 Tn3[NY V108A]-Z3 | Tn3[NY V108A]-Z3 Ampr 
pJK467 Tn3[NY T109I]-Z3 | Tn3[NY T109I]-Z3 Ampr 
pJK468 Tn3[NY A117V]-Z3 | Tn3[NY A117V]-Z3 Ampr 
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pJK469 Tn3[NY R121G]-Z3 | Tn3[NY R121G]-Z3 Ampr 
pJK470 Tn3[NY R121K]-Z3 | Tn3[NY R121K]-Z3 Ampr 
pJK471 Tn3[NY R121M]-Z3 | Tn3[NY R121M]-Z3 Ampr 
pJK472 Tn3[NY R121S]-Z3 | Tn3[NY R121S]-Z3 Ampr 
pJK473 Tn3[NY E124Q]-Z3 | Tn3[NY E124Q]-Z3 Ampr 
pJK549 Tn3[NY T109I]-Z2 Chlr 
pJK550 Tn3[NY A117V]-Z2 Chlr 
pJK551 Tn3[NY R121G]-Z2 Chlr 
pJK552 Tn3[NY R121K]-Z2 Chlr 
pJK553 Tn3[NY R121M]-Z2 Chlr 
pJK554 Tn3[NY R121S]-Z2 Chlr 
pJK555 Tn3[NY E124Q]-Z2 Chlr 
Chapter 4, Section 4.4 
pJK155 Tn3[N G70C]-Z2 Chlr 
pJK363 Tn3[NY G70C]-Z3 Ampr 
pJK061 Tn3[N]-Z2 Chlr 
pJK071 Tn3[NM]-Z3 Ampr 
pJK393 Tn3[NY]-Z2 Chlr 
pJK197 Z2/Z2 x Z3/Z3 Kanr 
pJK209 Z2/Z3 x Z2/Z3 Kanr 
pJK221 Z2/Z3 x Z3/Z2 Kanr 
Chapter 5, Section 5.2 
pJK513 Tn3[NY G70C]-AAA Ampr 
pJK514 Tn3[NY G70C]-AAB Ampr 
pJK515 Tn3[NY G70C]-AAC Ampr 
pJK516 Tn3[NY G70C]-ABA Ampr 
pJK517 Tn3[NY G70C]-ABB Ampr 
pJK518 Tn3[NY G70C]-ABC Ampr 
pJK519 Tn3[NY G70C]-ACA Ampr 
pJK520 Tn3[NY G70C]-ACB Ampr 
pJK521 Tn3[NY G70C]-ACC Ampr 
pJK522 Tn3[NY G70C]-BAA Ampr 
pJK523 Tn3[NY G70C]-BAB Ampr 
pJK524 Tn3[NY G70C]-BAC Ampr 
pJK525 Tn3[NY G70C]-BBA Ampr 
pJK526 Tn3[NY G70C]-BBB Ampr 
pJK527 Tn3[NY G70C]-BBC Ampr 
pJK528 Tn3[NY G70C]-BCA Ampr 
pJK529 Tn3[NY G70C]-BCB Ampr 
pJK530 Tn3[NY G70C]-BCC Ampr 
pJK531 Tn3[NY G70C]-CAA Ampr 
pJK532 Tn3[NY G70C]-CAB Ampr 
pJK534 Tn3[NY G70C]-CBA Ampr 
pJK535 Tn3[NY G70C]-CBB Ampr 
pJK536 Tn3[NY G70C]-CBC Ampr 
pJK537 Tn3[NY G70C]-CCA Ampr 
pJK538 Tn3[NY G70C]-CCB Ampr 
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pJK539 Tn3[NY G70C]-CCC Ampr 
pJK209 Z2/Z3 x Z2/Z3 Kanr 
pJK501 Tn3[NY G70C]-AA Ampr 
pJK502 Tn3[NY G70C]-AB Ampr 
pJK503 Tn3[NY G70C]-AC Ampr 
pJK504 Tn3[NY G70C]-BA Ampr 
pJK505 Tn3[NY G70C]-BB Ampr 
pJK506 Tn3[NY G70C]-BC Ampr 
pJK507 Tn3[NY G70C]-CA Ampr 
pJK508 Tn3[NY G70C]-CB Ampr 
pJK509 Tn3[NY G70C]-CC Ampr 
Chapter 5, Section 5.3 
pJK294 Tn3[NY G70C]-Z2 Chlr 
pJK295 Tn3[NY G70C]-Z3 Chlr 
pJK329 Tn3[NY G70C]-Z2F2 Ampr 
pJK330 Tn3[NY G70C]-Z3F2 Ampr 
pJK331 Tn3[NY G70C]-Z4F2 Ampr 
pJK332 Tn3[NY G70C]-Z5F2 Ampr 
pJK193 Z2/Z2 x Z2/Z2 Kanr 
pJK194 Z3/Z3 x Z3/Z3 Kanr 
pJK195 Z4/Z4 x Z4/Z4 Kanr 
pJK196 Z5/Z5 x Z5/Z5 Kanr 
pJK197 Z2/Z2 x Z3/Z3 Kanr 
pJK198 Z2/Z2 x Z4/Z4 Kanr 
pJK199 Z2/Z2 x Z5/Z5 Kanr 
pJK209 Z2/Z3 x Z2/Z3 Kanr 
pJK210 Z2/Z4 x Z2/Z4 Kanr 
pJK211 Z2/Z5 x Z2/Z5 Kanr 
pJK478 Tn3[NY G70C]-Z2F1 Ampr 
pJK479 Tn3[NY G70C]-Z3F1 Ampr 
pJK480 Tn3[NY G70C]-Z4F1 Ampr 
pJK481 Tn3[NY G70C]-Z5F1 Ampr 
Chapter 5, Section 5.4 
pJK400 Tn3[NY G70C]-H1 Ampr 
pJK396 Tn3[NY G70C]-Z3 Chlr 
pMP53 Z1/Z1 x Z1/Z1 Kanr 
pMP96 H1/Z1 x H1/Z1 Kanr 
pJK270 Z1/Z3 x Z1/Z3 Kanr 
pJK209 Z2/Z3 x Z2/Z3 Kanr 
pJK216 Z4/Z3 x Z4/Z3 Kanr 
pJK219 Z5/Z3 x Z5/Z3 Kanr 
pJK264 Z3/Z3 x Z1/Z1 Kanr 
pJK200 Z3/Z3 x Z2/Z2 Kanr 
pJK201 Z3/Z3 x Z4/Z4 Kanr 
pJK202 Z3/Z3 x Z5/Z5 Kanr 
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2.5 Software 
 Sequence preparation and analysis was carried using CLC Genomics Workbench 
(CLC bio, Aarhus, Denmark). Molecular modelling was performed using YASARA 
(http://www.yasara.org/) and UCSF Chimera (Resource for Biocomputing, Visualization, 
and Informatics at the University of California, San Francisco; 
http://www.cgl.ucsf.edu/chimera). The plasmid maps for figures were created using 
SnapGene (GSL Biotech, Chicago, IL, USA). Oligonucleotide melting temperatures were 
calculated using Oligo Calc: Oligonucleotide Properties Calculator (Northwestern 
University Feinberg School of Medicine, Chicago, IL, USA; 
http://www.basic.northwestern.edu/biotools/oligocalc.html). 
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Chapter 3: New Components for the ZFR System 
 
3.1 Necessity of new zinc finger arrays 
 In order to achieve the project aims of generating orientation specificity at the 
dimer-dimer interface and producing a unidirectional reaction, at least two types of 
mutant subunits, each with unique binding specificity, are required. Through their mutual 
interface, these two subunit types would be able to discriminate between each other 
within the tetramer, and this differential interaction would give rise to either productive 
or unproductive reactions. Even more complex reactions could be envisioned that require 
four types of subunits (each having unique binding specificity), where higher degrees of 
discrimination between the subunit interfaces would lead to either a more robust 
orientation specificity, or unidirectional reaction effect, or a simultaneous combination of 
these two effects (see Chapter 6). Therefore, as a starting point, an effort was made to 
incorporate four new zinc finger array (ZFA) binding domains into the ZFR system. 
Correspondingly, a new set of substrates was also designed and tested. These substrates, 
which incorporate new Z-sites cognate to the new ZFAs, allow the detection of active and 
inactive subunit configurations, with respect to recombination reactions. Finally, in order 
to enable the expression of four ZFR subunits simultaneously, double expression vectors 
(DEVs) were also designed and tested. 
 
3.2 New zinc finger arrays 
3.2.1 ZFA criteria and background 
 Ideally, new ZFAs to be incorporated into the ZFR system should possess two 
qualities. Firstly, they should provide their ZFRs with relatively equal binding affinity, 
which should translate into relatively equal enzyme activity given the same catalytic 
domain. Secondly, they should bind to their target sites with high specificity in general, 
and more specifically, should not produce ZFRs that are cross-reactive on one another's Z-
sites.  
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 A previous attempt was made within our group by Chris Proudfoot, to select two 
engineered ZFAs from the literature (Isalan and Choo, 2001), and incorporate them into 
the ZFR system (Proudfoot et al., 2011). These domains, called ZifA and ZifB, performed 
with modest success in the ZFR context, but were not without problems. Notably, the 
enzyme activity of the ZFR utilizing ZifB was substantially reduced in comparison with that 
utilizing ZifA. This was in spite of these ZFAs being reported as having similar Kd, as 
measured by phage ELISA (Isalan et al., 2001). In addition, the ZFR utilizing ZifA appeared 
to be cross-reactive for the Zif268-based Z-site, although this possibility was not 
prohibited by the data given in the original paper describing these ZFAs. In fact, this cross-
reactivity might not be entirely contrary to expectation, given that one half of ZifA was 
identical to Zif268, as the result of its bipartite construction (see Section 1.7.1.3 for a 
description of bipartite construction).  
 
 Because of the problems encountered during Proudfoot's previous attempt to 
incorporate new ZFAs, in addition to searching for domains with equal binding affinity 
and high binding specificity a further consideration was taken: the new domains should 
have their binding properties characterized in a system that is as similar as possible to the 
in vivo E. coli system being used for the ZFR experiments throughout this project. This 
would reduce the possibly for variation between expectation and result that might arise 
due to unpredictable idiosyncratic effects inherent to different experimental systems.  
 
3.2.2 ZFA selection and rationale 
 After a thorough review of the current literature on engineered ZFAs, four were 
selected that had been generated through the OPEN (Oligomerized Pool ENgineering) 
platform designed by Maeder and colleagues (see Section 1.7.1.3) (Maeder et al., 2008). 
OPEN involves the generation and screening of three-fingered ZFA libraries by 
recombining pools of position-specific fingers (i.e. zinc fingers that always occupy the 
same location in the array). The arrays themselves are architecturally based on a triple 
repeat of Zif268 F2 (the central finger in the array). The OPEN system generally yields 
higher quality ZFAs than other open-access platforms (Pruett-Miller et al., 2008a, Maeder 
et al., 2008). Additionally, OPEN ZFA amino acid sequences are freely available through 
the Zinc Finger Consortium's web-accessible database, ZiFDB 
(http://www.zincfingers.org/) (Fu et al., 2009), making them accessible. Furthermore, 
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OPEN constructions employ a bacterial two-hybrid (B2H) binding activity screen carried 
out using E. coli, and so these data may be reliable within our experimental system.  
 
 The four ZFAs that were chosen (OZ217, OZ227, OZ246 and OZ345) were selected 
because Maeder and colleagues themselves had included them among domains they 
selected for more advanced work from a large number of ZFAs that appeared active in 
their B2H screen (Maeder et al., 2008). It is possible that unreported results could have 
contributed to their confidence in these domains (or lack of confidence in the ones that 
were not carried forward), and certainly their subsequent experiments provide further 
validation for the chosen ZFAs. Domains OZ217, OZ227, OZ246 and OZ345 also produced 
relatively similar activity scores in the B2H assay (see Table 3-1). Additionally, two of 
these ZFAs (OZ217 and OZ227) were further characterized for their binding specificity in a 
zinc finger nuclease (ZFN) context and compared with two top-performing Sangamo ZFAs 
in a more recent publication by the same group (Pattanayak et al., 2011). This provided 
further information about the potential for cross-reactivity with the sites of the other two 
chosen ZFAs (OZ246 and OZ345). The inclusion of OZ217 and OZ227 in the subsequent 
study was also taken as a potential indication of an additional degree of confidence in 
these two ZFAs by this group. 
 
Table 3-1: B2H activity scores (adapted from Maeder et al. 2008) 
ID Mean B2H fold-activation S.D. of B2H fold-activation 
OZ217 7.19 2.15 
OZ227 11.59 1.15 
OZ246 10.16 0.55 
OZ345 8.15 0.73 
 
 
3.2.3 ZFA integration into the ZFR framework, and sequence 
modifications 
 Amino acid sequences for OZ217, OZ227, OZ246 and OZ345 were acquired from 
ZiFDB (Fu et al., 2013). A DNA sequence was then generated for each amino acid 
sequence using the reverse translate function of CLC Genomics Workbench with the “Use 
only the most frequently used codon” for E. coli option selected. These sequences were 
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then used as a starting point for necessary codon changes, coding sequence additions, 
and the insertion of various useful restriction sites, through silent changes and the 
addition of flanking sequence.  
 
 The amino acid sequences of the new ZFAs were first aligned with that of ZFR: 
Tn3-Zif268 (where 'Tn3' indicates the type of catalytic domain, and 'Zif268' indicates the 
identity of the ZFA) to observe how well they fit with the ZFR architecture (see Figure 3-1 
A). In order to create the Tn3 arm region / zinc finger junction at the 5′ end of the OZ217, 
OZ227, OZ246 and OZ345 coding sequences, a small segment of DNA coding for an N-
terminal Pro-His (which is not included in the Stark lab ZFR architecture (Prorocic et al., 
2011)) was replaced with a sequence coding for Thr-Ser. The Thr-Ser junction sequence 
also includes a SpeI restriction site, which (along with a SacI site at the 3′ end of a ZFA 
coding sequence), facilitates the removal and insertion of ZFAs within the ZFR framework.  
 
 Although the OPEN ZFAs are Zif268-like (based on a triple repeat of the Zif268 F2 
finger; see Section 1.7.1.3), several Zif268 residues that are typically included in the C-
terminus of the Tn3-Zif268 ZFR architecture, are missing from the amino acid sequences 
provided by ZiFDB. The coding sequence of these missing C-terminal residues is required 
for inclusion of the aforementioned SacI site that facilitates swapping of ZFAs in the ZFR 
architecture. Because the backbone geometry of the F2 triplet array used for the OPEN 
ZFAs might be slightly different from that of the natural Zif268 array (there is variation in 
the amino acid sequences of fingers F1, F2, and F3, even apart from that within their 
recognition helices), it is possible that the missing C-terminal residues from Zif268 could 
be incompatible with the OPEN ZFAs. Therefore, published work on ZFNs that include the 
OZ217 and OZ227 ZFAs was used as a guide for completing the sequence (see Figure 3-1 
A).   
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 Two ZFN sequences, which incorporate OZ217 and OZ227 (VF2468 [-] and VF2468 
[+], respectively), described in Pattanayak et al. (2011), include the first two C-terminal 
Zif268 residues (Leu-Arg) missing from the ZFA sequences given by ZiFDB (Figure 3-1 A) 
(Pattanayak et al., 2011). This was taken as evidence they could be included without 
detriment to function. The C-terminus of the Tn3-Zif268 ZFR sequence has an additional 
six residues after the Leu-Arg dipeptide, three of which are Zif268 derived, and the final 
three of which are a non-native serine triplet that allows the inclusion of the SacI site 
(Figure 3-1 A). Conversely, following the Leu-Arg residues in the sequences from 
Pattanayak et al. (2011), there is a Gly-Ser dipeptide linker before the start of the FokI 
domain sequence (note that a difference between the ZFN and ZFR architecture is that 
the ZFA is attached to the C-terminal of the catalytic domain instead of the N-terminal, 
respectively). Although this Ser-Gly dipeptide is not found in the Zif268 sequence, it does 
not appear to interfere with function in the ZFN context. By adding an additional serine 
residue to the end of the Ser-Gly dipeptide, a SacI site can be introduced into the codons 
for these amino acids such that the site would be frame-compatible with the existing SacI 
site in the current Tn3-Zif268 ZFR framework. Because the OPEN ZFAs have not been 
demonstrated as compatible with the six C-terminal ZFR residues of Zif268, the most 
conservative approach was to deviate as little as possible from the ZFN sequence where 
functionality has been demonstrated. Additionally, although beginning three residues 
earlier, this Gly-Ser-Ser C-terminus would be similar to the Ser-Ser-Ser C-terminus of the 
current Tn3-Zif268 architecture. Therefore, the sequences from the Pattanayak et al. 
(2011) ZFNs were used as the basis for the C-terminal region of the new ZFAs in the ZFR 
context, and a sequence coding for Leu-Arg-Gly-Ser-Ser was appended to the 3′ ends of all 
the coding sequences derived from the ZiFDB ZFAs.  
 
 It should be noted that an additional difference between the ZFA sequences 
OZ217 and OZ227, and the ZFN sequences VF2468 [–] and VF2468 [+] was spotted in the 
alignment (Figure 3-1 A). Within the ZFN sequences, the final arginine found in the ZFA 
portion of the sequence, which is part of the otherwise canonical OPEN Zif268 F2-triplet 
framework, has been replaced by a lysine residue. No explanation for this was provided 
by Pattanayak et al. (2011), and the canonical arginine was retained for the new 
sequences. 
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 Additional modifications to the coding sequences were also made to allow 
alterations of the ZFAs required by later experiments. Restriction sites AleI and BsiWI 
were introduced through silent DNA sequence changes, to allow the sequential removal 
of fingers F3 and F2, respectively, while preserving the C-terminal ZFA architecture and 
corresponding 3′ coding sequence containing the SacI site (used to transport the reading 
frame). Restriction sites SrgAI and AgeI were introduced to allow non-specific fingers 
(described in Chapter 5) to be introduced to the array. Restriction sites NsiI, AflIII, NdeI, 
SnaBI, and SphI were also introduced into the regions flanking each of the recognition 
helices, in order to allow the recognition helices to be replaced, or the ZFA to be 
otherwise reassembled and modified (see Figure 3-1 B).  
 
 After modification, the sequences for OZ217, OZ227, OZ246 and OZ345 were 
renamed Z2, Z3, Z4 and Z5, respectively, and were synthesized through GeneArt® (Life 
Technologies, Carlsbad, CA, USA), and delivered within plasmids p12AAMO2P, 
p12AAMOZP, 12AAMOYP and p12AAMOXP, respectively. The sequences were extracted 
from their respective plasmids by digestion with SpeI and SacI restriction enzymes, 
separated on a 3% MetaPhor® agarose gel, and ligated between the SpeI and SacI sites of 
the Tn3(NM3 V107F)-Zif268 expression plasmid pAMC11 (Prorocic et al., 2011), replacing 
the Zif268 ZFA coding region. The ZFA coding regions were then ligated to coding 
sequences for mutant catalytic domains to create various novel ZFRs (see Chapter 2). 
 
3.3 New ZFR substrates  
3.3.1 Substrate configurations and function 
 New substrates were also designed to allow experiments with ZFRs utilizing the 
new ZFAs. These substrates were based on a GalK assay substrate plasmid similar that 
used by Akopian et al. (2003), Prorocic et al. (2011), and Proudfoot et al. (2011) (and 
similar to pDB35 (Arnold et al., 1999)), and were of five configurations (Table 3-2):  (1) 
The single-mutant homodimer Z-site (1MutHomDim) substrates contain two identical ZFR 
homodimer binding sites (targeted by one of the four ZFAs).  (2) The two-mutant 
homodimer Z-site (2MutHomDim) substrates contain two alternate homodimer binding 
sites (targeted by two of the four ZFAs).  (3) The two-mutant heterodimer Z-sites in direct-
                                                     
3 A description of 'NM' can be found in Section 1.6.4. 
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repeat (2MutHetDim-DR) substrates contain two identical heterodimer binding sites in 
direct repeat orientation with respect to one another (targeted by two of the four of 
ZFAs).  (4) The two-mutant heterodimer Z-sites in inverted-repeat (2MutHetDim-IR) 
substrates contain two heterodimer binding sites, arranged in inverted repeat with 
respect to one another (targeted by two of the four of ZFAs).  (5) Finally, the four-mutant 
heterodimer Z-site (4MutHetDim) substrates contain two different heterodimer binding 
sites (targeted by four ZFAs). These substrates enable the detection of activity of various 
tetramer configurations consisting of one to four types of mutant subunits, and are 
important for the work described in the following chapters. The half Z-sites, containing 
binding targets for Z2, Z3, Z4 and Z5 domains, were likewise labelled Z2, Z3, Z4 and Z5, 
respectively, and the identity of full Z-sites is indicated using the convention ZN/ZN 
(where 'N' indicates the numeric designation of the ZFA). Table 3-2 lists all substrate 
configurations that were constructed at this stage.  
 
Table 3-2:  List of generated substrates*  
1MutHomDim 2MutHomDim 2MutHetDim-DR 2MutHetDim-IR 4MutHetDim 
Z2/Z2 x Z2/Z2 Z2/Z2 x Z3/Z3 Z2/Z3 x Z2/Z3 Z2/Z3 x Z3/Z2 Z2/Z3 x Z4/Z5 
Z3/Z3 x Z3/Z3 Z2/Z2 x Z4/Z4 Z2/Z4 x Z2/Z4 Z2/Z4 x Z4/Z2 Z2/Z3 x Z5/Z4 
Z4/Z4 x Z4/Z4 Z2/Z2 x Z5/Z5 Z2/Z5 x Z2/Z5 Z2/Z5 x Z5/Z2 Z2/Z4 x Z3/Z5 
Z5/Z5 x Z5/Z5 Z3/Z3 x Z2/Z2 Z3/Z2 x Z3/Z2 Z3/Z2 x Z2/Z3 Z2/Z4 x Z5/Z3 
 Z3/Z3 x Z4/Z4 Z3/Z4 x Z3/Z4 Z3/Z4 x Z4/Z3 Z2/Z5 x Z3/Z4 
 Z3/Z3 x Z5/Z5 Z3/Z5 x Z3/Z5 Z3/Z5 x Z5/Z3 Z2/Z5 x Z4/Z3 
 Z4/Z4 x Z2/Z2 Z4/Z2 x Z4/Z2 Z4/Z2 x Z2/Z4 Z3/Z4 x Z2/Z5 
 Z4/Z4 x Z3/Z3 Z4/Z3 x Z4/Z3 Z4/Z3 x Z4/Z3 Z3/Z4 x Z5/Z2 
 Z4/Z4 x Z5/Z5 Z4/Z5 x Z4/Z5 Z4/Z5 x Z5/Z4 Z3/Z5 x Z2/Z4 
 Z5/Z5 x Z2/Z2 Z5/Z2 x Z5/Z2 Z5/Z2 x Z2/Z5 Z3/Z5 x Z4/Z2 
 Z5/Z5 x Z3/Z3 Z5/Z3 x Z5/Z3 Z5/Z3 x Z3/Z5 Z4/Z5 x Z2/Z3 
 Z5/Z5 x Z4/Z4 Z5/Z4 x Z5/Z4 Z5/Z4 x Z4/Z5 Z4/Z5 x Z3/Z2 
*Substrates are given in the format where the first Z-site is that between Asp718 and XbaI, and the second 
Z-site is that between BsrGI and NheI (see Figure 3-2 B for a plasmid map of the substrate). A useful feature 
of this format is that the sites are arranged so that those half-sites that are adjacent to the 'x', are those 
that are on either side of the origin of replication in the plasmid. So, for instance, when an excision reaction 
is performed on any of the above substrates, the surviving product of the excision reaction will contain one 
Z-site composed of the two half Z-sites closest to the 'x'. 
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3.3.2 Z-site design and substrate construction 
 The Z-sites for the Z2, Z3, Z4 and Z5 ZFAs were designed to contain 20 bp of the 
Tn3 resolvase site I central sequence (the core 16 bp of which are involved in Tn3 arm 
region contacts, see Section 1.5.1), flanked by 10 bp sequences that code for the ZFA 
binding sites, plus 1 additional base pair 5′ of the ZFA binding sites that may influence 
binding (Figure 3-2 A). Although a three-fingered ZFA is often said to specify up to 9 bp of 
recognition sequence, 3′ overlap specificity from F1 of the array can increase this length 
of the binding site to 10 bp (see Section 1.7.1.2). Additionally, some studies suggest that 
some three-fingered ZFAs may have a preference a base pair at an extended position 5′ of 
the 10 bp binding site (Swirnoff and Milbrandt, 1995, Wolfe et al., 1999, Pattanayak et al., 
2011).   
 
 The paper that describes the creation of OZ217, OZ227, OZ246 and OZ345 (Z2, Z3, 
Z4 and Z5), describes their binding specificity in terms of a 9 bp binding site (3 bp for each 
finger), and does not mention overlap specificity from F1 to a 10th base pair 3′ end of the 
9 base pair binding site, nor the potential importance of an 11th base pair flanking the 5′ 
end of the binding site (Maeder et al., 2008). The Pattanayak et al. characterization of 
binding specificity for VF2468 [–] and VF2468 [+] (ZFNs based on OZ217 and OZ227, 
respectively) does, however, indicate that there is a modest selective preference for 
specific bases 3′ and 5′ of the 9 bp recognition site (Pattanayak et al., 2011). It is 
interesting to note, that Pattanayak et al.'s characterization suggests that the 5′ extended 
position contributes more specificity than the 3′ F1 overlap position. In both the case of 
OZ217 and OZ227, the base pair preference is cytosine at the potential 3′ F1 overlap 
position, and thymine at the extended 5′ position. Therefore, since there was no binding 
specificity characterization for OZ246 and OZ345, in all of the Z-sites that were created 
(for the Z2, Z3, Z4 and Z5 ZFAs), a cytosine was used at the potential 3′ F1 overlap position 
and thymine at the extended 5′ position (Figure 3-2 A).  
 
  
 
 
 
 
118 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2:  Z-site architecture and substrate framework plasmid.  A) The figure shows the architecture of 
the Z-site oligonucleotides using the Z2/Z2 Z-site as an example. The central sequence derived from Tn3 site 
I is depicted in yellow, with lighter shades used to indicate those bases which are not important for Tn3 
resolvase arm region contacts. The ZFA binding sites for Z2 are shown in blue, with lighter shades used to 
indicate their importance to binding relative to the specificity profile generated by Pattanayak et al. (2011). 
The SpeI restriction site, used for confirmation of oligonucleotide insertion during cloning, is indicated in 
red. The flanking XbaI (NheI) and Asp718I (BsrGI) overhangs which are used for cloning into the substrate 
framework plasmid are depicted in mauve and green, respectively. Finally, faint grey lines are used to depict 
the central dinucleotide of the crossover site which separates the left and right halves of the binding site.  B) 
Shows a plasmid map of pMS183Δ, the framework plasmid used to construct the substrate (Misiura et al. 
2013). Note that pMS183Δ does not already have Z-sites within it. A pSC101 origin of replication is shown in 
burgundy, while the related rep101 gene which controls copy number is indicated in vermilion. The 
kanamycin resistance gene (aminoglycoside 3′-phosphotransferase) is indicated in olive, and the 
galactokinase gene, which the Z-sites flank, is indicated in chartreuse. The Asp718I and XbaI, and BsrGI and 
NheI restriction sites, between which the Z-site oligonucleotides are inserted, are also indicated on the map. 
The restriction sites for NheI and BsrGI are eliminated when the Z-site oligonucleotides are cloned in. 
B) 
A) 
 XbaI                Z2         Tn3 site I central sequence         Z2            SpeI   Asp718I  
CTAGACTTGACGCTGCTCCGAAATATTATAAATTATCAGAGCAGCGTCAACTAGTG                                
    TGAACTGCGACGAGGCTTTATAATATTTAATAGTCTCGTCGCAGTTGATCACCATG
              
 1 + 10 10 + 1 16 bp core 
(NheI) (BsrGI) 
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 However, after all the experimental work for this project was completed, it was 
realized through reading a description in a subsequent publication of the OPEN protocol, 
that the designers of OPEN do consider the 5′ extended position and the 3′ F1 overlap 
position to be potentially important, and thus, OPEN ZFAs are selected on 11 bp sites 
(Maeder et al., 2009). The 11 bp sites for OZ217, OZ227, OZ246 and OZ345 can be found 
in the supplementary information that accompanies the paper describing their 
construction (Maeder et al., 2008). It is interesting to note, that the specificity indicated 
for the 5′ extended position determined by the specificity profile generated by Pattanayak 
et al., does not match the selection sequences used for the creation of OZ217 and OZ227; 
however, the base identity at the 3′ F1 overlap position does (Pattanayak et al., 2011, 
Maeder et al., 2008). Therefore, an obviously better strategy for the creation of the Z4 
binding site would have been to include at least the 3′ F1 overlap position base from the 
sequences on which OZ246 and OZ345 were generated. In the case of the Z5 binding site, 
the 3′ F1 overlap position in the selection site is also a cytosine (i.e. the base that was 
used for all of the Z-sites at this position). 
 
 The right-side half-Z-sites, within the Z-site construction oligonucleotides, were 
flanked by a SpeI site that was used to confirm insertion of full length Z-sites into a 
substrate framework plasmid, pMS183Δ (Misiura et al., 2013) (Figure 3-2). The SpeI site 
was then further flanked by a guanine, and then a 5′ overhang that is compatible with 
both Asp718 and BsrGI restriction sites, in order to facilitate cloning into the pMS183Δ 
polycloning sites (the cytosine retains the Asp718 sites but eliminates the BsrGI site after 
ligation). The left-side half-Z-sites were flanked by an ACT trinucleotide, and then a 5′ 
overhang that is compatible with NheI and XbaI, in order to facilitate ligation of the full 
length Z-sites into pMS183Δ polycloning sites (the adenine of the trinucleotide preserves 
the XbaI site but not the NheI site after cloning). 
 
 Oligonucleotides were synthesized by Eurofins Genomics (Ebersberg, Germany), 
and sites were assembled using a four-part ligation strategy that allowed all combinations 
of half-sites to be assembled from the minimal number of oligonucleotides. The strategy 
involved first annealing oligonucleotides to generate half-sites with long 18 bp 3′ 
overhangs within the central sequence, which is identical for all sites. These segments, 
containing half Z-sites Z2–Z5, were then further annealed to one another in all 
permutations to generate all possible full Z-sites. All desired substrate plasmids were 
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created by sequentially cloning the full sites into the two target regions flanking galK in 
pMS183Δ (see Figure 3-2 B) in a two-step cloning procedure. 
 
3.4 17 Hour Recombination Assay 
 ZFR-mediated substrate recombination was assayed using the '17 Hour 
Recombination Assay'. This is a simple bacterial in vivo assay that produces a quick 
turnover of results (within 24 hours) and a reasonably high differential resolution of 
substrate plasmid recombination products. Briefly, the procedure is as follows: E. coli 
DS941 is simultaneously co-transformed with relevant expression vectors and substrate 
plasmids, followed by an approximately 17–17.5 hour incubation period on selective plate 
media. All plasmids are then harvested from the plates, subjected to restriction digest, 
and subsequently analysed by gel electrophoresis (see Section 2.2.3).  
 
 ZFR-mediated recombination of substrate plasmids typically produces two types 
of products: An inversion product plasmid may be produced, where the segment of DNA 
containing galK, which is flanked by the Z-sites, has been reversed in orientation. An 
excision product plasmid may be produced where the segment of DNA containing galK 
has been excised. Additionally, if an interaction between the ZFRs and substrate is not 
productive, the unchanged substrate will be present at the end of the reaction. However, 
the unchanged substrate form can also be reproduced as inversion products undergo 
subsequent inversion reactions, returning the plasmid to its original form. Productive 
interaction between the ZFR tetramer and substrate is predicted to produce 
approximately initially equal quantities of inversion and excision product. However, 
because the excision product is an end product, and the inversion product can be further 
converted back into the unchanged substrate form or excision product through 
subsequent reactions, reactions will tend to produce a preponderance of excision 
products on extended incubation (see Section 1.5.3). For the restriction digest, enzymes 
FspI, KpnI, and PvuII were selected in order to produce a cleavage pattern where the 
unchanged substrate, the inversion product, and the excision product could be clearly 
differentiated from one another and from the expression plasmids (see Figure 3-3). 
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D) 
F) 
A) 
C) 
E) 
B) 
INV 
UNC 
UNC 
EXP 
EXP 
DEL 
(Z2/Z2 x Z3/Z3) 
 
(Z3/Z2 x Z3/Z2) 
 
Z3/Z2 
(Z3/Z2) 
pJK197 
pJK070 pJK072 
(rxn product) 
(rxn product) 
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3.5 Binding activity and vector expression level assay  
3.5.1 Rationale and design of the binding activity assay 
 Ideally, all of the new ZFRs would bind their cognate Z- sites with equal affinity. 
Dissimilar levels of binding activity within complementation experiments could lead to 
inconsistent results. Additionally, were there some cross-reactivity of the ZFRs on non-
cognate sites, dissimilar levels of binding activity would need to be taken into account 
when designing complementation experiments so as to minimize these effects. For 
example, it would be a poor experimental design to pair a weakly binding ZFR with a 
strongly binding ZFR that is cross-reactive for the weakly binding ZFR's binding site. It is 
therefore desirable to assess the binding activity of new ZFR binding domain variants 
before their use.  
 
 The simplest way to accomplish this test is by indirectly measuring the binding 
activity through a comparative ZFR recombination activity assay, where the catalytic 
domain for all ZFRs is of the same type, while binding domain type is used as an 
independent variable. This assay can also screen for any effects that result not from 
difference in binding activity, but from unexpected incompatibility between the Tn3 
catalytic domain and ZFA. A Tn3 resolvase catalytic domain containing the four mutations 
Figure 3-3:  Expression plasmids and substrate products in the 17 Hour Recombination Assay.  Maps for 
expression vectors and substrate plasmids are shown with relevant features and the 17 Hour Resolution 
Assay restriction digest sites (FspI, KpnI, and PvuII) indicated. ZFA binding sites are indicated using small blue 
(Z2) and orange (Z3) rectangles. The Z-site identities are written on the substrates in the format that is given 
in Table 3-2, in order to allow the reader to understand the convention that was used for describing the 
plasmids. The ZN/ZN x ZN/ZN description reads as if you looking at a plasmid that has been linearized with a 
cut at the bottom.  A) Expression vector #1, based on pBR322, confers ampicillin resistance, and is cut into 
small fragments by the digest of the assay.  B) Expression vector #2, based on pACYC184, confers 
chloramphenicol resistance, and is cut into small fragments by the digest of the assay.  C) The unchanged 
substrate (UNC) is based on pSC101, confers kanamycin resistance, and is cut at two sites.  Pairs of ZFA 
binding sites are alternatively coloured blue and orange and the identity of the Z-site is provided beside 
them. The galK gene is shown to indicate the orientation of the fragment between the binding sites.  D) The 
inversion product product (INV) substrate is the same as the UNC substrate, but the segment of DNA 
containing galK has been reversed in orientation, which changes the restriction pattern, and the pair of blue 
and orange ZFA sites has been rearranged.  E) The deletion (excision) product (DEL) substrate is the same as 
the UNC and INV substrates, but the segment of DNA containing galK has been excised and only one 
restriction site and one pair of rearranged ZFR sites remain.  F) A virtual agarose gel indicating restriction 
patterns for each plasmid. Lane 1 = EXPRESSION #1, lane 2 = EXPRESSION #2, lane 3 = SUBSTRATE - UNC, 
lane 4 = SUBSTRATE - INV, lane 5 = SUBSTRATE - DEL. Note: the slow bands in the image are given extra 
thickness to indicate signal strength and are not to be interpreted as multiple overlapping bands.  
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R2A E56K D102Y G70C was selected for this work. As described in Section 1.6.4 of Chapter 
1, hyperactivation of Tn3 resolvase is typically accomplished through the introduction of 
both a primary activating mutation at position 102 (usually D102Y; hereafter referred to 
simply as 'Y'), and any one of a collection of secondary activating mutations that occur at 
locations throughout the protein (in this case G70C). In addition, a tertiary set of 
activating mutations can be included (in this case R2A E56K; hereafter collectively 
referred to as 'N'), which only produce an up-regulating effect when used in combination 
with primary and secondary mutations (see Section 1.6.5 for more details). The NY 
mutations were selected because they are regularly utilized within our group, and are 
thus predictable in their behaviour. The G70C secondary mutation was selected because 
it produces a high level of activation and had been chosen for use in much of the 
experimental work of the following chapters. Therefore, this catalytic domain (NY G70C) 
was selected for these activity level tests and assembled with Z2, Z3. Z4 and Z5 in 
expression vector pMS140, to create Tn3[NY G70C]-Z2, Tn3[NY G70C]-Z3, Tn3[NY G70C]-
Z4 and Tn3[NY G70C]-Z5 ZFRs. 
 
3.5.2 Rationale and design of the vector expression level test 
 Within in vivo complementation experiments, the expression level of ZFRs is an 
important factor. Virtually all of the experimental designs in this project involve 
complementation assays utilizing simultaneous ZFR expression from two vectors. Ideally 
the level of expression from the two vectors should be equal; dissimilar levels of 
expression could lead to inconsistent results. Additionally, were any problems in binding 
fidelity present, unintentionally placing the less specific ZFR in a higher expression vector 
than the higher specificity ZFR it was complemented with, would exacerbate the problem.  
 
 A series of variants of the pACYC184 expression vector with variably attenuated 
Shine-Dalgarno sequences was previously generated by Sally Rowland within the Stark lab 
(S. J. Rowland; unpublished work), in order to produce a compatible expression vector 
with a similar expression level to the pMS140 vector. pACYC184 is based on a p15A 
replicon, which has a copy number of 18–22 (Chang and Cohen, 1978), while the pMS140 
is based on the compatible  pMB1/ColE1 replicon, which has an copy number of 15–20 
(Bolivar et al., 1977). Two variants of pACYC184 (pSA3017 and pSA3022) appeared, in 
MacConkey assays Rowland conducted, to have potentially similar activity levels to the 
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pMS140 expression vector. Of the two, the pSA3017 vector appeared potentially less 
active, and the pSA3022 vector appeared potentially more active, than the pMS140 
vector. However, the comparative levels of expression from expression vectors can be 
hard to gauge effectively from the MacConkey assay when the activity levels are not 
drastically different from one another, such as in the case of pSA3017 and pSA3022. 
Therefore, pSA3017 and pSA3022 were selected for further characterization in an activity 
level test using the 17 Hour Recombination Assay, which provides a much higher level of 
resolution in gauging relative activity level. Coding sequences for Tn3[NY G70C]-Z2, 
Tn3[NY G70C]-Z3, Tn3[NY G70C]-Z4 and Tn3[NY G70C]-Z5 were subsequently inserted 
into pSA3017 and pSA3022. All ZFRs were assayed against their cognate 1MutHomDim 
substrates (substrates with two copies of the same homodimer binding site), expressed 
from all three expression vectors (pSA3017, pMS140, and pSA3022).  
 
3.5.3 Results of the vector expression level test 
 The results, which are displayed in Figure 3-4, show the outcome of the 17 Hour 
Recombination Assay as determined by agarose gel electrophoresis. This experiment 
expressed four different ZFRs, which varied by their ZFA (Tn3[NY G70C]-Z2, Tn3[NY G70C]-
Z3, Tn3[NY G70C]-Z4 and Tn3[NY G70C]-Z5), from three expression vectors (pSA3017, 
pMS140, and pSA3022). The aim was to infer the level of binding activity provided by the 
ZFAs, and level of expression provided by the expression vectors. With one exception, the 
comparison indicated the same pattern of activity between the ZFA variants when 
expressed from each vector (see below).  
 
 The result displayed in lane 2, representing Tn3[NY G70C]-Z2 expressed from 
pSA3017, is not consistent with the rest. In this lane there is a large band between the 
identifiable 4.4 kb band of the unchanged substrate, and the 5.1 kb marker of the 1 kb 
ladder. It is unclear how this unexpected large band has arisen; although, it might be 
single cut (i.e. incompletely digested) unchanged plasmid (e.g. if FspI didn't not cut; refer 
back to Figure 3-3), or partially digested expression plasmid, both of which could run at 
about this location. There is also a faint band just below the 3 kb mark that would suggest 
some partial digestion of the expression plasmid, as it has fragments that if incompletely 
digested would run there (e.g. a PvuII to PvuII fragment, if FspI didn't not cut well; refer 
back to Figure 3-3). This single lane does not present a problem for interpreting the 
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results of this experiment though because of the redundancy of information represented 
by expression of the same comparative set of ZFRs from the two other expression 
vectors, and because the other lanes within the pSA3017 set show the expected bands. 
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Figure 3-4:  New ZFR activity level comparative assay results.  The image shows the results of the FspI, 
KpnI, and PvuII restriction digest on a 1.2% agarose gel. To the right of the image, indications are given for 
bands corresponding to the unchanged substrate (UNC), inverted substrate product (INV), deletion 
substrate product (DEL), and the expression plasmids (EXP). To the left of the image, sizes are given for the 1 
kb marker ladder which is contained in lane 1. Lanes 2–5, 7–10, and 12–15 contain the results of 1MutHomo 
substrate reactions with their cognate ZFR (Tn3[NG70CY]-Z2–Z4) expressed from pSA3017, pMS140, and 
pSA3022 vectors, respectively, as indicated above the image.  
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3.5.4 Vector expression level determined 
 The first piece of information, from the gel shown in Figure 3-4, that is notable is 
the overall ZFR expression level from each vector. The recombination activity level seen 
for each ZFR variant when produced from each vector indicates that the expression level 
from the vectors is ordered as follows: pSA3017 < pMS140 < pSA3022. This can be best 
visualized from the Tn3[NY G70C]-Z5 results (lanes 5, 10 and 15) where the reaction is 
apparently slowest and the substrate has not been completely converted to product. 
Because the recombination activity measured in a 17 Hour Recombination Assay is only 
assessed at the end of the experiment, when some reactions in a comparative set go all 
the way to completion, discriminative information becomes lost as the slower reactions 
continue. This is most obvious in a case where the slow reactions subsequently run until 
completion as well as well as the faster reaction, hiding the difference in reaction rate of 
the faster reactions. The results of the vector expression level component of this 
experiment, are consistent with the prediction made based on the previously referred to 
results of S. Rowland's MacConkey plate assay, but have allowed for a more accurate 
scaling of the activity of pSA3017 and SA3022 relative to that of pMS140.  
 
3.5.5 Binding activity level determined 
 The comparative activity level imparted to the ZFRs by their ZFAs is the next piece 
of information that can be observed from the results in Figure 3-4. The Tn3[NY G70C]-Z2 
and Tn3[NY G70C]-Z3 ZFRs appear to have approximately the same level of activity, with 
Tn3[NY G70C]-Z3 appearing slightly more active when expressed from the pMS140 vector 
(Figure 3-4, lanes 7 and 8). Although the Tn3[NY G70C]-Z5 ZFR appears to be active, it is 
notably less so than the ZFR with other ZFAs. Finally, ZFR Tn3[NY G70C]-Z4 appears to be 
most active, but produces an anomalous effect when expressed from the two vectors 
with higher expression level. The product bands for Tn3[NY G70C]-Z4 expressed from 
pMS140 and pSA3022, appear to be significantly attenuated in signal strength (discussed 
in Section 3.10.5). 
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3.5.6 Best expression vector / ZFA match for further 
experiments 
 The most similar expression vector and binding domain variant combinations are 
probably Tn3[NY G70C]-Z3 expressed from pMS140, and Tn3[NY G70C]-Z2 expressed 
from pSA3022. This takes into consideration the higher expression level from pSA3022, 
and the higher activity level of Tn3[NY G70C]-Z3.  The level of activity of Tn3[NY G70C]-Z4 
expressed from pSA3017, and Tn3[NY G70C]-Z2 expressed from pMS140, is also broadly 
comparable. The activity levels produced by Tn3[NY G70C]-Z4 expressed from pSA3017, 
and Tn3[NY G70C]-Z5 expressed from pSA3022 are similar, but these two vectors cannot 
be used in conjunction for complementation assays because they are both derivatives of 
pACYC184 (i.e. they have the same origin of replication and antibiotic resistance).  
 
3.6 Binding specificity test 
3.6.1 Rationale and design for the experiment 
 Another important aspect of ZFR binding domain variants is their binding 
specificity. Cross-reactivity between ZFR binding domain variants and non-cognate 
binding sites will inherently confound the results of ZFR complementation experiments, 
which rely on site-specificity. In order to test the binding fidelity of the new ZFR binding 
domain variants, an experiment was constructed utilizing three types of 
complementation substrates: 2MutHomDim, 2MutHetDim-DR, 2MutHetDim-IR (see Table 
3-2). In this experiment, ZFR binding domain variant types were expressed in isolation, 
and reacted with complementation substrates for which they had 50% site-specificity.  
 
 The 2MutHomDim substrate contains two different homodimer binding sites. It 
can detect aberrant activity if a properly bound homodimer forms a productive tetramer 
with another improperly bound homodimer at the other Z-site. The 2MutHetDim-DR and 
2MutHetDim-IR substrates, which are bound by heterodimers, can detect aberrant 
activity when subunits properly bound at their cognate half-sites, co-opt other same-type 
subunits to improperly bind the other half of the heterodimer site. The contacts of the 
dimer interface of the Tn3 resolvase catalytic domain are extensive. In conjunction with 
the DNA binding contacts of the Tn3 resolvase arm region, which are invariant in these 
experiments, homodimers might improperly bind heterodimer sites if their DNA binding 
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domains are sufficiently permissive to allow this. Preliminary experiments (data not 
shown) demonstrated this possibility in a Tn3[NY G70C]-Zif268 plus Tn3[NY G70C]-HTH 
complementation (HTH is the Tn3 resolvase binding domain, see Section 1.6.2), where the 
HTH domain was found to be sufficiently permissive to allow homodimers to improperly 
bind heterodimer binding sites and produce recombination. The 2MutHetDim-DR and 
2MutHetDim-IR substrates were expected to give comparable results, but both were 
included in order to observe any unexpected effects, and because redundancy in the 
experiment increases the reliability of the results.  
 
 In this experiment, the Tn3[NM] catalytic domain (where 'N' represents the 
mutations R2A and E56K, and 'M' represents G102S, D102Y, M103I, and Q105L; see Burke 
et al. (2004)(Burke et al., 2004)) was chosen because it was believed to confer a higher 
level of recombination activity to the ZFR than the Tn3[NY G70C] domain used for the 
previous activity level tests. The higher activity of Tn3[NM] increases the sensitivity of the 
experiment to any cross-reactivity. The Tn3[NM] domain is also considered to be a 'well 
behaved' high activity catalytic domain, in that it is thought to produce minimal levels of 
DNA breakage from aberrant catalytic reactions, unlike some other known high activity 
domains ((Olorunniji et al., 2008), and unpublished work within the Stark lab).   
 
 For the binding specificity assay, both pMS140 and pSA3022 vectors were used to 
simultaneously express the same type of each ZFR binding domain variant.  It can be seen 
from the activity level experiments in Section 3.5 that activity level varies with expression 
plasmid, and by implication, with the level of enzyme production. This indicates that the 
binding sites are not saturated with ZFRs at these levels of enzyme production. Therefore, 
increasing the production of ZFRs within the cell has the potential to increase stringency 
of the test. A 17 Hour Recombination Assay was thus performed using two expression 
vectors.    
 
3.6.2 New ZFRs perform with high-level binding specificity 
 The results, shown in Figure 3-5, indicate that all ZFR binding domain variants 
appear to be highly specific for their binding sites, within the level of detection of the 
assay. With the exception of one faintly detectable band in lane 9 of Figure 3-5C, no other 
off-target activity was detectable.  
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 Curiously, the product signal attenuation effect that was observable for Tn3[NY 
G70C]-Z4 in Figure 3-4, was again observable, not only in the control lane 2, containing 
Tn3[NM]-Z4 in conjunction with its cognate 1MutHomDim substrate, but also in lanes 4–
6, containing Tn3[NM]-Z4 in conjunction with the 2MutHomDim substrate (Figure 3-5 C). 
This is interesting because the attenuated signals in lanes 4–6 represent the unchanged 
substrate products of the reaction, indicating that the plasmid level reduction might not 
be dependent on tetramer formation and recombination activity. Also interestingly, the 
signal attenuation effect does not appear as pronounced with 2MutHetDim-DR and 
2MutHetDim-IR substrates, indicating that properly bound homodimers appear to be 
more facilitative to this effect.  
 
 The signal level in lanes 8–10 and 12–14 of Figure 3-5 C, might suggest an 
attenuation effect happening for Tn3[NM]-Z4 on the 2MutHetDim-DR and 2MutHetDim-
IR substrates as well, to a lesser degree. However, the variability in the signal strength 
across the tracks in Figure 3-5 A, B and D, suggests that there is also some 'normal' 
variability in signal strength within this experiment. Presumably the normal range of 
variability in signal strength, which can be observed across the tracks of the gels, is simply 
the result of variability in the DNA yield from the 17 Hour Recombination Assay plasmid 
harvest. The bands representing the expression plasmids provide a good control to 
differentiate between differences in signal strength that arise from the interesting 
reduction in substrate plasmid concentration within the cells, and overall reductions in 
signal strength resulting from variations in DNA yield of the 17 Hour Recombination 
Assay. 
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3.7 Alteration of ZFR linker  
3.7.1 Rationale and design for the experiment 
 The ZFAs (Z2, Z3, Z4 and Z5) were predicted from bacterial-2-hybrid (B2H) assay 
data in the Maeder et al. (2008) study (see Table 3-1) to impart ZFRs with similar levels of 
binding affinity, and thus recombination activity (Maeder et al., 2008). However, not only 
are the ZFR variants not as similar in activity as expected, but the activity also does not 
vary predictably with the variation in B2H activity scores of the ZFA domains. Additionally, 
the product signal attenuation effect observed in the last two experiments for reactions 
involving ZFRs with the Z4 ZFA, would make the use of Z4 in ZFRs for future experiments 
problematic.  
 
 One possible explanation for these variations was that not all ZFAs are equally 
compatible with the current ZFR architecture. The ZFR amino acid linker (named 'TS 
linker') that currently connects the Tn3 arm region of the catalytic module (ending at 
Arg148) to the ZFA, was optimized for attachment of the Zif268 ZFA, and is very short, 
consisting of only a Thr-Ser dipeptide (see Figure 3-1 A). The docking geometry of ZFAs 
may be somewhat variable depending on the residue-base contacts that are required for 
DNA sequence recognition. It is possible that the TS linker, though optimal for the Tn3-
Zif268 ZFR, does not provide sufficient flexibility at the attachment point to permit proper 
residue-base contacts for all attached ZFAs.  
 
 
Figure 3-5:  New ZFRs: targeting specificity assay results.  The images show the results of the FspI + KpnI + 
PvuII restriction digest on a 1.2% agarose gel. To the right of the images, indications are given for bands 
corresponding to the unchanged substrate (UNC), inverted substrate product (INV), deletion substrate 
product (DEL), and the expression plasmids (EXP). To the left of the images A) and C), sizes are given for the 
1 kb marker ladder which is contained in lane 1 of all gels. Lane 2 in all images displays a positive control 
which consists of a ZFR reaction on its cognate 1MutHomo substrate. Lanes 4–6, 8–10, and 12–14 in each 
gel image show the results of ZFRs in conjunction with 2MutHomDim, 2MutHet-DR, or 2MutHetDim-IR 
substrates, respectively, as indicated above the image.  The experimental substrates contain combination 
binding sites consisting of cognate half-sites and the half-site indicated above the image.  A) ZFR= Tn3[NM]-
Z2.  B) ZFR = Tn3[NM]-Z3.  C) ZFR = Tn3[NM]-Z4.  D) ZFR = Tn3[NM]-Z5. All ZFRs were used in dual 
expression mode, i.e. expressed from pMS140 and pSA3022 vectors simultaneously in each of the 
experiments shown.  
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 The original experiments with Tn3[NM]-Zif268 performed by Akopian et al. (2003) 
utilized much longer peptide linkers that could be safely assumed to provide sufficient 
flexibility at the attachment point to allow proper binding of any ZFA (Akopian et al., 
2003). Therefore, one of the top performing linkers from the Akopian study ('L6') was 
used to replace the current linker in the current ZFR architecture. This linker is composed 
of four Gly-Ser-Gly repeats followed by Thr-Ser. Compared with the TS linker architecture, 
the attachment point of L6 to the Tn3 catalytic domain replaces more of the Tn3 arm 
region. Linker L6 begins after Tn3 residue Arg144, whereas the TS linker, begins after 
residue Arg148. Therefore, the total difference in peptide length is nine residues, rather 
than 12. The Gly-Ser-Gly repeat sequence was originally used because it was shown in 
early ZFA engineering studies to be fit for making flexible peptide linkers connecting zinc 
fingers (Moore et al., 2001b, Moore et al., 2001a).  
 
 Four new ZFRs were constructed (Tn3[NY G70C]-L6-Z2, Tn3[NY G70C]-L6-Z3, 
Tn3[NY G70C]-L6-Z4, and Tn3[NY G70C]-L6-Z5) in order to replicate the activity level 
experiment of Section 3.5 using ZFRs incorporating the L6 linker. The purpose of this was 
simply to look for a normalization of the pattern of activity witnessed in Section 3.5, and 
only ZFRs utilizing linker L6 were used for this experiment. 
 
3.7.2 ZFR linker is not responsible for the product attenuation 
anomaly 
 The results from this experiment, which are displayed in Figure 3-6, show a 
virtually identical pattern of activity using the L6 linker as was observed in Section 3.5 
(Figure 3-4) using the TS linker. This demonstrates clearly, that neither the variability in 
activity between the ZFR binding domain variants, nor the product signal attenuation 
effect seen in reactions using ZFRs with Z4, are the result of the linker sequence. The only 
noteworthy feature in the results, is that compared with the previous activity test using 
the TS linker and the same ZFR catalytic and binding modules, also expressed from a 
pMS140-type vector (Figure 3-4, lanes 7–10), there does appear to be an overall 
reduction in activity when using L6 linker (Figure 3-6, lanes 2–5). This reduction in activity 
is indicated by some remaining unchanged substrate in the reaction with Tn3[NY G70C]-
L6-Z3 (lane3), and almost no recombination activity from Tn3[NY G70C]-L6-Z5 (lane 5), 
relative to the comparable reactions in Figure 3-4 (lanes 8 and 10, respectively). This 
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result, indicating that ZFRs containing the L6 linker are less active than those containing 
the TS linker, is consistent with the results of an in vitro recombination assay reported in 
Prorocic et al. (2011), although difference is less pronounced in the in vivo assay reported 
here. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-6:  Results of Junction 
Modification Experiment.  The image 
shows the results of the FspI + KpnI + 
PvuII restriction digest on a 1.2% 
agarose gel. To the right of the image, 
indications are given for bands 
corresponding to the unchanged 
substrate (UNC), inverted substrate 
product (INV), deletion/excision 
substrate product (DEL), and the 
expression plasmids (EXP). To the left 
of the image, sizes are given for the 
1kb marker ladder, which is contained 
in lane 1. Lanes 2–5 show the results 
of the reactions of the junction 
modified ZFRs (Tn3[NY G70C]-L6-Z2–
Z4) on their cognate 1MutHomo 
substrates, expressed from pMS140-
based expression vectors. 
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3.8 Binding activity and specificity comparisons with the 
Tn3-Zif268 ZFR 
3.8.1 Rationale and design of the experiment 
 Because of the product signal attenuation effect encountered when Tn3-Z4 ZFRs 
were expressed from the pMS140 and pSA3022 vectors, and because of the relatively low 
level of activity of the Tn3-Z5 ZFRs compared with the other binding domain variants, it 
was thought the Zif268 (hereafter referred to as Z1) ZFA might be required as a substitute 
for use in conjunction with the other binding domain variants in further experiments. It 
was therefore necessary to compare Tn3-Z1 ZFR activity and binding specificity to activity 
and specificity of the other ZFR binding domain variants. In addition, these experiments 
also provide a performance comparison between ZFRs utilizing OPEN engineered ZFAs 
and that utilizing the Z1 ZFA, which is a well known natural ZFA considered to have a good 
activity and specificity profile.  
 
  Substrates containing combinations of Z-sites based on Z1–Z5 ZFRs were 
constructed in the fashion described in Section 3.3. It should be noted, that the 
sequences for these Z-sites were derived from a pre-existing Z1 ZFR Z-site that does not 
have the correct base at the 3′ F1 overlap position (see Section 1.7.1.2) in the right half of 
the Z-site. This Z-site has a cytosine at the right side 3′ F1 overlap position, whereas a 
thymine or guanine base is specified by Zif268 (Swirnoff and Milbrandt, 1995, Wolfe et 
al., 1999). This was not noticed at the time of construction or it would have been 
corrected. It should also be noted, that the Z1 1MutHomDim substrate used in the 
following experiment was a pre-existing substrate that, additionally, does not have 
correct 5′ extended position bases. The 5′ extended position bases in the 1MutHomDim 
substrate are a cytosine in the left half of the Z-site and an adenine in the right half of the 
Z-site, instead of the thymines that should be at these positions (Swirnoff and Milbrandt, 
1995, Wolfe et al., 1999). Therefore, in all but the case of the 1MutHomDim substrate, 
within the new substrates when a Z1 ZFR half-site occurs on the right half of the Z-site, 
this 3′ F1 overlap position base is incorrect, as described above. In all other cases, except 
the 1MutHomDim substrate, both the 5′ extended position (also see Section 1.7.1.2) and 
3′ F1 overlap positions are correct.  
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 The activity and specificity tests were carried out as described in Sections 3.5 and 
3.6, respectively. For the activity test, a Tn3[NY G70C] catalytic domain was used in 
conjunction with the Z1 and Z3 ZFAs, which were paired with their cognate 1MutHomDim 
substrates. For the fidelity test, a Tn3[NM] catalytic domain was used in conjunction with 
the Z1, Z2, Z3, Z4, and Z5 ZFAs, which were paired with 2MutHomDim, 2MutHetDim-IR 
and 2MutHetDim-DR substrates (on which they bind half of the binding sites; see Table 
3-2). All experiments were carried out using the 17 Hour Recombination Assay. 
 
3.8.2 Results of a binding activity assay comparing ZFRs using 
the Z1 and Z3 ZFAs. 
 The results of the binding activity assay (displayed in Figure 3-7), show that the 
activity level of the ZFR using Z1 is virtually identical to the activity of the ZFR using Z3. 
One curious feature though, is the appearance of a strong inversion product signal in lane 
2, versus its near absence in lane 3. Usually in reactions involving active ZFRs and 
1MutHomDim substrates, the inversion product signal is weak, because the inversion 
product is subsequently converted to either excision product, or back into unchanged 
substrate (sees Figure 1-10). The Z1/Z1 x Z1/Z1 substrate was constructed using a 
different cloning strategy than the Z3/Z3 x Z3/Z3 substrate, which resulted in a small 
difference in plasmid size (responsible for the slight difference in the size of the small 
'unchanged substrate' bands on the gel), but no obvious differences between the 
substrates exist that might lead to a difference in their ability to be converted to inversion 
product.  
 
 One explanation for the discrepancy between the inversion product signal 
strength in lane 2 and 3 of Figure 3-7 is that the inversion product from the Z1 ZFR 
reaction was more stable than the inversion product of the Z3 ZFR reaction. As described 
in Section 3.8.1, there is a difference in the 5′ extended positions between the right and 
left half sites of the 1MutHomDim substrate. Additionally, (also described in Section 
3.8.1) because the 3′ F1 overlap position base was correct in the left half of the Z-sites of 
the 1MutHomDim substrate, but incorrect in the right half of the Z-sites (Z1/Z1 x Z1/Z1), 
inversion reactions would have produced a product substrate where one whole Z-site 
contained incorrect 3′ F1 overlap bases (Z1/Z1 x Z1/Z1), as well as the difference in 5′ 
extended positions that would also co-localize to the same Z-sites within the inversion 
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product. Having Z-sites with incorrect 3′ F1 overlap positions and the same incorrect 5′ 
extended position bases (adenine or cytosine) within the half-sites, might have slowed 
down subsequent recombination reactions on these substrates enough to produce the 
lane 2 and lane 3 discrepancy observed (since in both lanes 2 and 3 the reactions were 
slow enough that they did not go to completion). The experiment was not repeated to 
confirm the result due to time constraints. This result suggests, if the foregoing 
interpretation of it is correct, that differential binding affinity among ZFRs in a 
complementation reaction may be used to stabilize a recombination product that 
contains homodimer Z-sites (that pair the more weakly binding subunits). 
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Figure 3-7:  Comparative activity test of ZFRs with Z1 and Z3.  The results of a 17 Hour Recombination 
Assay are shown. To the left of the gel image, are given the sizes of each band of the molecular marker 
ladder shown in lane 1. To the right of the image, indicators are given to describe the origin of the bands on 
the gel (UNC = unchanged substrate, INV = inversion product, DEL = deletion product, and EXP = expression 
vector plasmid). Above the gel image is a table which indicates which ZFRs were used in conjunction with 
each substrate for the complementation reactions. Please note, the difference in the small unchanged 
substrate band size is due to the fact that the Z1/Z1 x Z1/Z1 substrate was constructed using a different 
cloning strategy from the Z3/Z3 x Z3/Z3 substrate, which resulted in a small difference in the size of the 
plasmids.  
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3.8.3 Results of a binding specificity test comparing the ZFR 
using the Z1 ZFA to ZFRs using the Z2, Z3, Z4 and Z5 ZFAs 
 An experiment was conducted that tested the binding specificity of the Tn3[NM]-
Z1 ZFR on substrates that bore 50% Z1 site specificity, and 50% site specificity to Z2, Z3, 
Z4, and Z5. The Tn3[NM] catalytic domain was used because it was thought be more 
active than the Tn3[NY G70C] domain, and thus, could produce a more rigorous test 
(although, a later experiment in Chapter 4 suggests these catalytic domains may have 
similar activity; see Figure 4-20). The ZFR was expressed from two expression vectors 
(pMS140-based and pSA3022-based) simultaneously to increase the concentration of ZFR 
in the cells, again producing the most rigorous test possible. This experiment is similar to 
the previous binding activity experiment characterizing the Z2, Z3, Z4, and Z5 (Section 3.6)  
 
 The results of this experiment (shown in Figure 3-8) indicate that the Tn3[NM]-Z1 
ZFR is slightly cross-reactive on all heterodimer binding sites (lanes 7–10, 12–15). Also 
worth noting, the unchanged substrate and recombination product signal attenuation 
effect appeared again on all 2MutHomDim substrates (although the effect was less 
pronounced on the Z5/Z5 x Z1/Z1 substrate; lane 5). Lane 5 might have a bit more DNA in 
it, as the slowest running expression plasmid signal in lane 5 also appears to be slightly 
stronger than the others in the 2MutHomDim set (lanes 2–5). It is curious that this 
substrate contains Z5 sites, and that it is the Tn3-Z5 ZFRs on Z5 containing substrates that 
produce the least amount of signal attenuation effect. However, only the Tn3-Z1 ZFR is 
used in this reaction, and if it bound to the Z5 homodimer Z-site, it would likely produce 
detectable recombination activity. Therefore, no further explanation of this anomaly can 
be provided. 
 
 There is also an anomalous weak signal at about 4.1 kb in lanes 2–5 and 7–9 (it 
cannot easily be see without the aid of a computer screen). It is distinct from the 
unchanged substrate signal and might indicate either, trace levels of undigested 
expression plasmid, or perhaps low-level inappropriate cleavage of the substrate.  
 
 Another experiment was conducted to test the binding specificity of ZFRs using 
the Z2, Z3, Z4, and Z5 ZFAs on substrates that were 50% cognate and 50% cognate for Z1. 
The Tn3[NM] catalytic domain was again used for the ZFRs, which were also expressed 
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from two expression vectors simultaneously (pMS140-based and pSA3022-based) in 
order to increase the rigorousness of the test. The results of these experiments (shown in 
Figure 3-9) indicate that there is no cross-reactivity of any of the ZFRs for the substrates 
containing 50% Z1 sites. It is noteworthy that the substrate attenuation effect again 
appeared for the Tn3[NM]-Z4  ZFR on all substrate types (lanes 4, 9, and 14), and also for 
the Tn3[NM]-Z2 and Tn3[NM]-Z3  ZFRs on the 2MutHomDim substrates (lanes 2 and 3). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 3-8:  Binding specificity of a ZFR with the Z1 ZFA on substrates for other available binding domain 
variant ZFRs.  The results of a 17 Hour Recombination Assay are shown. To the left of the gel image, are 
given the sizes of each band of the molecular marker ladder shown in lane 1. To the right of the image, 
indicators are given to describe the origin of the bands on the gel (UNC = unchanged substrate, DEL = 
deletion product, and EXP = expression vector plasmid). Above the gel image is a table which indicates 
which ZFRs were used in conjunction with each substrate for the complementation reactions.  
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Figure 3-9:  Binding specificity test of ZFRs on substrates containing Z1 ZFA binding sites.  The results of a 
17 Hour Recombination Assay are shown. To the left of the gel image, are given the sizes of each band of 
the molecular marker ladder shown in lane 1. To the right of the image, indicators are given to describe the 
origin of the bands on the gel (UNC = unchanged substrate, INV = inversion product, DEL = deletion product, 
and EXP = expression vector plasmid). Above the gel image is a table which indicates which ZFRs were used 
in conjunction with each substrate for the complementation reactions. 
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3.9 Construction and testing of double expression vectors  
3.9.1 Rationale and design 
 Because later experiments in this work involve detecting the activity of tetramers 
composed of four unique ZFR subunits, a system for the simultaneous expression of four 
ZFRs in E. coli is required. Transformation of E. coli with four separate expression vectors 
plus one substrate plasmid is impractical. Simultaneous transformation of five plasmids 
would not be sufficiently efficient, sequential transformation of multiple plasmids to 
create multi-plasmid E. coli strains would be time-consuming, simultaneous use of five 
antibiotics might be problematic, and finding four compatible low-level expression 
vectors with comparable levels of expression would likely be very difficult.  
 
 A double-expression vector (DEV) based on pMS140 had been previously designed 
and constructed (Proudfoot et al., 2011). This design allowed two ZFR coding sequences, 
each with their upstream Shine-Dalgarno sequence, to be placed in tandem (separated by 
a short nucleotide sequence) downstream of a promoter within the ordinary ZFR 
expression region of pMS140. To accomplish this, the Tn3 resolvase reading frame within 
pMS140 was replaced with a short segment of DNA that allowed two ZFR coding 
sequences to be sequentially ligated into the plasmid using isocaudomer sites (restriction 
sites with different recognition sequences, but which produce identical overhangs).  
 
 Two new DEV frameworks for the pMS140 and pSA3022 expression vectors were 
designed based on a similar approach where two reading frames, each with their Shine-
Dalgarno sequence, are placed downstream of one promoter and separated by a short 
sequence of DNA (see Figure 3-10). However, in order to speed up construction, this 
framework utilizes a short double-stranded oligonucleotide in a three-part ligation 
strategy to create the DEV in one step, instead of the sequential insertion of two coding 
regions. In this design, two single-ZFR expression vectors are cut at a backbone restriction 
site, and a restriction site at either the 3’ or 5’ end of their coding sequence, depending 
on whether the ZFR coding sequence is to be placed in the first or second expression 
‘slot’, respectively. An oligonucleotide is then used to separate the 3’ end of the first 
reading frame, and the 5’ end of the second. The three pieces of DNA are then ligated 
together. 
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DEV spacer for pSA3022 
Asp718I  SalI  BsrGI  XhoI 
 
  GTACC GTCGAC TGTACA C 
      G CAGCTG ACATGT GAGCT 
B) 
Asp718I  SalI  BsrGI  EcoRI 
 
  GTACC GTCGAC TGTACA G 
      G CAGCTG ACATGT CTTAA 
   
 
DEV spacer for pMS140 A) 
ZFR coding sequence #2 + 
ZFR double expression vector  
ZFR slot #1 ZFR slot #2 
ZFR coding sequence #1 + Spacer 
Figure 3-10:  DEV construction strategy.  A) The figure shows the sequences, including restrictions sites, of 
the DEV-enabling oligonucleotide spacers for pMS140 and pSA3022.  B) The figure depicts the DEV 
construction framework. ZFR coding sequences are depicted as horizontal rectangles with overhangs. Blue 
and orange colours are used to indicate the coding regions, while green indicates the Shine-Dalgarno 
sequence which is included within the fragments. A purple circle is used to depict the restriction site used 
for cutting and ligating the backbones of the two expression vectors containing the ZFR coding sequences. 
Light grey dots and the faded out portions of the rectangles, are used to indicate the parts of the vector 
plasmids which are not retained for the assembly of the DEV. Dark grey is used to depict restriction site 
overhangs which are used for ligation. The spacer sequence is shown in pink. The expression vector 
backbone is shown with upstream promoter element indicated by a yellow arrow. Below, the product DEV 
is shown with ZFR 'slots' #1 and #2 labelled and the colour scheme depicting the organization of the DEV 
framework.  
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 For the pMS140-based DEV, coding sequences to be placed in slot 1 are taken 
from BsaI to Asp718, while coding regions to be placed in slot 2 are taken from EcoRI to 
BsaI. The pMS140-based DEV oligonucleotide spacer has Asp718- and EcoRI-compatible 
overhangs. For the pSA3022-based DEV, coding sequences to be placed in slot 1 are taken 
from NcoI to Asp718, and coding sequences to be placed in slot 2 are taken from XhoI to 
NcoI sites. The pSA3022-based DEV oligonucleotide spacer has XhoI- and SalI-compatible 
overhangs.   
 
 A SalI restriction site was included in the oligonucleotide spacers in order to 
confirm their insertion by restriction digest after assembly. A BsrGI site was also added to 
the oligonucleotides to allow assembled DEVs to be easily rearranged into new 
combinations (including the possibility for testing triple or even quadruple expression 
arrangements) should that have been deemed interesting. 
 
 Ideally, each ZFR encoded by the DEV would be expressed at approximately the 
same level, so a new experiment was constructed in order to test the individual 
expression level of each ZFR coding cassette. Each DEV (pMS140- or pSA3022-based) was 
loaded with both the arrangement 'Tn3[NY G70C]-Z2 followed by Tn3[NY G70C]-Z3', and 
the arrangement 'Tn3[NY G70C]-Z3 followed by Tn3[NY G70C]-Z2'. These DEVs were then 
transformed into E. coli, along with either the Z2 or Z3 1MutHomDim substrate for a 17 
Hour Recombination Assay. Thus, for each of the four constructed DEVs, two activity tests 
were performed: one assaying the expression level of Tn3[NY G70C]-Z2, and the other the 
expression level of Tn3[NY G70C]-Z3, in both upstream and downstream cassette 
positions. This design also provides redundancy in the results which increases their 
reliability. 
 
3.9.2 Results of the DEV expression tests 
 The results from the DEV experiment (shown in Figure 3-11) indicate that the DEVs 
express equal levels of ZFR from each expression slot, at least within the limit of detection 
of the assay. The primary concern was that the second slots might have markedly reduced 
levels of expression, and this is clearly not the case.   
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 Compared with the single ZFR expression, positive controls in lanes 3, 7, 12 and 16 
there again appears to be a recombination product signal attenuation effect present in 
the DEV tracks (lanes 4, 5, 8, 9, 13, 14, 17 and 18). Importantly, it can be seen from this 
experiment that the product signal attenuation effect is enhanced by the co-expression of 
ZFRs that are non-cognate for any Z-sites. Compared with the reactions in which only the 
cognate ZFR was expressed (lanes 3, 7, 12 and 16), it can been seen that the signal level of 
the product is decreased in the reactions where a non-cognate ZFR was also expressed 
(lanes 4, 5, 8, 9, 13, 14, 17 and 18). 
 
Figure 3-11:  Experiment to check expression level from each DEV expression 'slot'.  The results of a 17 
Hour Recombination Assay are shown. To the left of the gel image, are given the sizes of each band of the 
molecular marker ladder shown in lane 1. To the right of the image, indicators are given to describe the 
origin of the bands on the gel (UNC = unchanged substrate, INV = inversion product, DEL = deletion product, 
and EXP = expression vector plasmid). Above the gel image is a table that indicates which ZFRs were used in 
conjunction with each substrate for the complementation reactions. Please note that the digest shown in 
lane 3 did not run to completion and there is some partially digested expression plasmid in this lane. The 
band between 4 kb and 5 kb in lane 3 is not substrate but expression plasmid. 
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3.10 Conclusions 
3.10.1 New ZFA binding domains: activity and specificity 
 New ZFAs were required for incorporation into the ZFR system. Four ZFAs (Z1, Z2, 
Z3, and Z4) were selected from published literature on engineered ZFAs. New ZFRs 
incorporating the new ZFAs were tested for recombination activity (Section 3.5) and 
binding specificity (Section 3.6). These experiments indicated that the Z2, Z3, Z4, and Z5 
ZFAs bind with high specificity. However, the new ZFRs did not produce equal levels of 
recombination activity in the assays, which indicates that Z2, Z3, Z4, and Z5 ZFAs do not 
bind with equal binding affinity. The Z2 and Z3 ZFAs appeared ideal for use in further 
experiments, imparting their respective ZFRs with equal levels of recombination activity in 
the assays. The Z5 domain can be inferred to bind somewhat more weakly than the other 
three ZFAs since its ZFRs produced less recombination activity in the assays. ZFRs with the 
Z4 domain appeared to produce the highest level of recombination, and thus, the Z4 
domain can be inferred to have the highest binding activity of the all the new ZFAs. It is 
worth noting that the mismatch in the target site at the Z4 ZFA F1 3′ overlap specificity 
position (see Section 3.3.2) did not appear to significantly impede the function of Z4. 
 
 In reactions involving the Z4 ZFR the amount of substrate and reaction products 
appeared noticeably attenuated when compared with reactions involving other the ZFRs. 
Data from an experiment using a vector with lower expression, suggested that the 
anomalous substrate and product attenuation effect result from Z4 binding more strongly 
than the other ZFAs, as the effect did not appear for the Z4 ZFR in the lower expression 
condition. See Section 3.10.5 for a full discussion on the product signal attenuation effect.
  
3.10.2 Linker experiment 
 In Section 3.7, an experiment, in which a longer linker was used to connect the 
Tn3 catalytic domain to the new ZFAs, tested whether the difference in the capabilities of 
the ZFA to impart ZFRs with recombination activity, or the substrate and product signal 
attenuation effect, were the result of using a linker that was too short. This experiment 
showed that linker length had no effect on the differences in ZFR activity, or product 
signal attenuation effect. 
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3.10.3 Comparisons of new ZFAs with Zif268 
 Recombination activity and binding specificity tests were also carried out 
comparing ZFRs with the new ZFAs, to ZFRs utilizing the Zif268 (Z1) ZFA. These 
experiments showed that Z3 (and by inference Z2) impart the ZFR with approximately the 
same level of recombination activity as Z1. However, ZFRs using Z2 and Z3 appear to bind 
their Z-sites with higher specificity than ZFRs using Z1, which showed a low level of cross-
specificity for the other ZFA sites.  
 
3.10.4 Double expression vectors 
 In Section 3.9, double expression vectors (DEVs) were designed, constructed, and 
tested in order to increase the number of ZFRs that could be expressed simultaneously 
within E. coli. These experiments demonstrated that the DEVs work well, and produce 
equal levels of enzyme activity for both Z2- and Z3-based ZFRs that were expressed from 
them. 
 
3.10.5 The product signal attenuation effect 
3.10.5.1 Description 
 A product signal attenuation effect was observed in several of the experiments 
described in this chapter. This signal attenuation effect is marked by a notable reduction 
in recombination product signal observed during agarose gel electrophoresis analysis, 
when compared to lanes where this effect is not present.  
 
3.10.5.2 Instances of occurrence within the experiments 
 In Section 3.5, an experiment was conducted to observe the difference in activity 
level conferred to the ZFRs by the new ZFAs, and to observe the difference in activity level 
conferred by expression of ZFRs from three different expression vectors, which were 
expected to produce enzyme at different levels. The ZFRs were tested for activity on 
substrates with cognate Z-sites (1MutHomDim substrates). In this experiment, the signal 
attenuation effect was correlated with the ZFA (Z4), which appeared to confer the highest 
level of activity to its ZFR (Figure 3-4). The effect did not appear when the Z4 ZFR was 
expressed from the vector assessed to have the lowest level of enzyme production 
(pSA3017-based), and the effect appeared most pronounced when the Z4 ZFR was 
expressed from the vector assessed to have the highest level of enzyme production. An 
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experiment of Section 3.7 also demonstrated the attenuation effect using a Z4 ZFR (this 
time with altered linker) on its 1MutHomDim cognate substrate (Figure 3-6). The 
experiments in Section 3.5 and 3.7 both used NY G70C Tn3 catalytic domains. 
 
 The signal attenuation effect was again observed in the experiment of Section 3.6 
that was designed to test the new ZFRs (and new ZFAs) on substrates for which they only 
bound to half of the binding sites. This experiment utilized simultaneous expression of the 
same ZFR from two expression vectors in order to approximately double the cellular 
enzyme concentration. In this experiment, the signal attenuation effect was even more 
pronounced in the reactions involving the Z4 ZFR, than it was in the previously mentioned 
experiments (Figure 3-5 C). The effect was most notable on the 1MutHomDim substrate 
and the 2MutHomDim substrate (which contains one full cognate Z-site and one full non-
cognate Z-site). The attenuation effect may have also been present in the Z4 ZFR 
reactions on the 2MutHetDim substrates (containing Z-sites that were half-cognate to 
ZFRs used); however, the effect was more subtle. In this experiment the attenuation 
effect was less obvious for the ZFRs utilizing the other ZFAs (i.e. Z2, Z3, and Z5); although, 
it may have also been present in the Z2 and Z3 ZFR reaction on the 1MutHomDim and 
2MutHomDim substrates. The experiments in Section 3.6 used NM Tn3 catalytic domains. 
 
 An experiment in Section 3.8 contains some of the same reactions as those just 
discussed for Section 3.6, but in a more useful comparative arrangement, allowing 
additional observations to be made. In Figure 3-9, the reactions of double expressed ZFRs 
with each binding domain type (i.e. Z2, Z3, Z4, and Z5) on both the 2MutHomDim and 
2MutHetDim substrates, are shown side-by-side. It can be seen in Figure 3-9 that the Z4 
ZFR has the most pronounced signal attenuation effect on the 2MutHomDim substrate, 
but the effect is also quite pronounced on the 2MutHetDim substrates. It can also be 
observed that the Z2 and Z3 ZFRs do, in fact, produce some signal attenuation effect 
when compared with the Z5 ZFR (the weakest binding activity ZFR, see Section 3.5 and 
Figure 3-4) on the 2MutHomDim substrates, but the effect does not appear to occur with 
the 2MutHetDim substrates. Another experiment, also in Section 3.8, produced the signal 
attenuation effect, this time using a Z1 (Zif268) ZFR on a 2MutHomDim substrate for 
which it was 50% cognate (Figure 3-8). These experiments from Section 3.8 used NM Tn3 
catalytic domains.  
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 Finally, in Section 3.9, an experiment was carried out in which different ZFRs were 
expressed from two DEVs producing approximately two-fold cellular concentration of 
each ZFR, and a four-fold cellular concentration of total ZFRs in the reaction. This 
experiment utilized 1MutHetDim substrates that had cognate Z-sites for one of the two 
ZFRs included in the reaction. This experiment was informative because it showed that 
the product signals were attenuated in reactions where both a ZFR cognate and a ZFR 
non-cognate for the substrate were co-expressed, compared with those reactions where 
only the cognate ZFR was expressed (Figure 3-11). This indicates that the signal 
attenuation effect is increased by non-DNA-bound enzyme. The experiment in Section 3.9 
utilized ZFRs with Tn3[NY G70C] catalytic domains. 
 
3.10.5.3 Key observations 
 Several general observations can be made from the data above:  1) There is a 
relationship between the appearance of the signal attenuation effect and the binding 
activity of the enzyme, as the ZFR with what is presumed to be the high binding activity 
binding domain (Z4) is associated with this effect, even at single expression vector 
enzyme production levels (Figure 3-4 and Figure 3-5). Likewise, the ZFR with what is 
presumed to be the lowest binding activity binding domain (Z5) is not associated with this 
effect, even at two-fold enzyme production levels.  2) There is a relationship between the 
cellular enzyme concentration of a ZFR with cognate sites on a substrate and the signal 
attenuation effect. Increase in cellular enzyme concentration, whether as the result of the 
use of different expression vectors, different enzyme production levels, the use of 
multiple expression vectors at once, or the use of DEVs, increases this attenuation effect.  
3) There is a relationship between the concentration of non-bound ZFRs and the signal 
attenuation effect, in reactions where bound ZFRs are also present. That is, in reactions in 
which one ZFR has cognate Z-sites on a substrate, co-expression of a ZFR for which there 
are no cognate Z-sites, appears to increase the signal attenuation effect.  4) There is a 
relationship between the type of substrate used with respect to the Z-sites and the signal 
attenuation effect. Substrates that bind homodimers appear to be most permissive to this 
effect, with no detectable difference being observed between reactions involving 
1MutHomDim substrates with two occupied Z-sites, and 2MutHomDim substrates with 
one occupied Z-site (Figure 3-5 C). In contrast, the effect is not as pronounced on 
2MutHetDim substrates under the same conditions (Figure 3-5 C and Figure 3-9).  5) The 
signal attenuation effect is produced by ZFRs utilizing either the Tn3[NM] or the Tn3[NY 
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G70C] catalytic domains, indicating that the effect is not a unique product of the Tn3[NY 
G70C] catalytic domain. 
 
3.10.5.4 Potential explanation of the SA effect 
 An explanation for the signal attenuation effect that fits all of the above 
observations is that ZFRs are, at some level, capable of cleaving DNA outside of proper 
recombination reactions. This possibility might not be entirely unexpected as the 
mutations which activate the Tn3 catalytic domain may do so by mimicking some of the 
activating effects that the accessory subunits in the wild-type system have on the enzyme 
(see Section 1.6.2 and 1.6.4). This is to say, that while wild-type Tn3 resolvase must be 
activated by complex interactions involving tetramer formation and accessory subunit 
interactions, individual hyperactive Tn3 catalytic domains may be somewhat active by 
default. Additionally, this type of activity has been observed before using some 
combinations of activating mutations of Tn3 resolvase (unpublished work within the Stark 
lab). In this scenario, there would be a predicted relationship between having either a 
more active binding domain, or higher enzyme concentration, both of which would 
increase occupancy at the binding sites. If the ZFRs are capable of cleaving DNA outside of 
recombination reactions, then presumably this takes place at the Z-site where they are 
frequently bound.  
 
 The explanation that hyperactive Tn3 catalytic domains may be capable of 
inappropriate DNA cleavage might also be consistent with the observation that non-DNA-
bound ZFRs increase the signal attenuation effect, as interaction with non-DNA-bound 
ZFRs might help activate the DNA-bound ZFRs through protein-protein interactions. 
Additionally, this explanation may also be consistent with the observation that the signal 
attenuation effect is more pronounced on homodimer-binding substrates (1MutHomDim 
and 2MutHomDim) than heterodimer substrates (2MutHetDim-DR and 2MutHetDim-IR). 
Dimers on the 2MutHomDim substrate would be capable of cleaving both strands, 
whereas a single ZFR subunit bound to only half Z-sites within the 2MutHetDim substrates 
would either only cleave one strand, or would have to co-opt the binding of another 
subunit to cleave both strands (see below). 
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 It important to remember that cleavage, as it relates to ZFR reactions, implies not 
only that the ZFR has cut the DNA, but that the ZFR, itself, remains covalently attached to 
the DNA unless the DNA is re-ligated (see Section 1.6.2). Having a single ZFR subunit 
covalently attached to the DNA would likely interfere with plasmid replication, and this 
might explain why the signal attenuation effect is also possible in single ZFR reactions on 
2MutHetDim-DR and 2MutHetDim-IR substrates. This activity may be analogous to the 
way that DNA topoisomerases I (topo I) remains covalently attached to DNA when the 
camptothecin class of chemotherapeutic drugs inhibit their re-ligation step, resulting in 
lethal collisions between topo-I DNA complexes and advancing replication forks (Lisby et 
al., 1998, Liu et al., 2000).  
 
 Results in the next chapter provide further support that the cause of the signal 
attenuation effect is caused by inappropriate cleavage of the DNA by ZFRs. The signal 
attenuation effect observations made in this chapter will be important when considering 
results in the following chapter.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
152 
 
Chapter 4: Catalytic Domain Modifications 
 
4.1 Conspectus 
4.1.1 Three types of predictions from structure-based analysis 
and mutagenesis studies 
 The general approach taken in this chapter to accomplish the project aims of 
achieving a dimer-dimer orientation specificity bias and a recombination reaction 
directionality bias (i.e. a non-reversible ZFR reaction), was to analyse crystallographic 
structures of γδ resolvase, and hypothesise explanations for the locations of Tn3 
resolvase activating mutations, to derive mechanistic theories about resolvase catalysis 
that might be exploited to force new parameters within the reaction.  Three models of 
Tn3 resolvase regulation were proposed, and were used as the bases of experiments that 
attempted to generate a dimer-dimer orientation specificity or recombination reaction 
directionality bias.   
 
4.1.2 Interactions between counterpart residues at position 102 
during tetramer formation 
 The first hypothesis postulated that the reason activating mutations at amino acid 
position Asp102 are so critical for Tn3 resolvase activation (see Chapter 1, Section 1.6.4), 
is because this residue is key to a negative regulation system within the protein. Aspartic 
acid is negatively charged, and modelling of γδ resolvase (a close Tn3 resolvase 
homologue; see Section 1.6.3) dimer-dimer synapsis suggested that counterpart 102 
residues (Glu102 in γδ resolvase) might come within close proximity of one another at the 
point of initial contact (Li et al., 2005). It was hypothesized that this close proximity of 
negative charges might act as a barrier to synapsis, which could either be overcome by 
the energetic interactions of a properly formed resolvase regulatory synaptosome, or 
alleviated by amino acid substitutions at this position. Evidence from mutagenesis studies 
indicate that several uncharged amino acids will activate the protein when substituted at 
this position (Burke et al. (2004) (Burke et al., 2004), see Figure 1-14; and Stark, 
unpublished work), which is a pattern consistent with the alleviation of negative 
regulation. Therefore, an attempt was made to force new parameters in the reaction by 
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generating pairs of complementary subunits with oppositely charged residues at position 
102. However, the experiments (described in Section 4.2) produced negative results and 
were unable to provide support for the theory that Asp102 acts in a negative regulatory 
interaction with its counterpart residues in opposing subunits at the initiation of synapsis.  
 
4.1.3 ZFR activation via pairs of differentially disrupted 'locking 
interface' mutants 
 The second hypothesis tested was based on a model of Tn3 resolvase activation 
involving a sub-region of the catalytic tetramer dimer-dimer interface that is stabilized by 
interactions between the E-helix and α/β sub-domain of adjacent subunits. A model of 
Tn3 resolvase activation was proposed where this region of the dimer interface acts to 
lock dimers in an inactive conformation, until contact is made by the subunits of the 
regulatory module (see Chapter1, Section 1.6.2), which releases this 'lock' through 
allosteric regulation. The release of this dimer interface lock was proposed to allow 
tetramerization of the site I dimers that form the catalytic module (see Section 1.6.2). A 
key feature of this model of Tn3 resolvase activation, is that the two dimers of a catalytic 
tetramer are unlocked asymmetrically (i.e. on one side of the tetramer only), at or before 
the point of tetramer formation. The reasons the tetramer is proposed to be unlocked 
asymmetrically, is because the regulatory module of the synaptosome is located on one 
side of the tetramer only (see Section 4.3).  
 
 A hypothesis was generated that the asymmetric conformational change might 
facilitate a dimer-dimer orientation specificity bias during tetramer formation. The 
locations of many known secondary activating mutations suggest that they may produce 
their effect by disrupting the dimer locking interface. An attempt was made to test this 
hypothesis by generating differentially activated ZFR subunits, which when used in 
combination, mimic the postulated allosteric unlocking effect on the dimer interface to 
force dimer-dimer orientation specificity within the reaction.  
 
 The results of these experiments, described in Section 4.3, do not support the 
hypothesis that asymmetric dimer unlock can be used to produce a dimer-dimer 
orientation specificity bias. However, the experiments did result in two important 
discoveries. The first discovery was that catalytically active ZFRs are able to activate 
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catalytically inactive ZFRs when used in complementation reactions. This discovery may 
be valuable for increasing ZFR site-specificity by reducing the potential for off-target 
reactions and cytotoxicity observed when ZFRs are used in mammalian cell systems (Gaj 
et al., 2014). The second important discovery is that, unexpectedly, the pairs of 
differentially disrupted locking interface ZFR mutants did produce activity consistent with 
a recombination reaction directionality bias. Additionally, the recombination reaction 
directionality bias produced in the fashion described may be used to generate integration 
reactions with an orientation specificity bias. 
   
4.1.4 Differentially mutated ZFR pairs based on residue 102 and 
E-helix 'landing pad' mutations 
 A model was proposed to explain the function of several activating hydrophobic 
amino acid substitutions at the N-terminal end of the E-helix, termed the 'landing pad'. In 
this model, these activating mutations promote the formation of the dimer-dimer 
complex by creating favourable hydrophobic interactions between the N-terminal ends of 
counterpart E-helices that interact when two dimers are brought together. This model 
was based on analysis of available γδ resolvase structures, the tetramer initiation 
trajectory model proposed by Li et al. (2005), and the locations of several Tn3 resolvase 
activating mutations. A hypothesis was generated from this model that differential 
inclusion of hydrophobic E-helix landing pad mutations in a ZFR pair might be used to 
produce complementation reactions that produce a dimer-dimer orientation specificity or 
recombination reaction directionality bias. Although only a limited set of experiments 
could be performed due to time constraints, the results displayed activity consistent with 
the potential for a significant recombination directionality bias (see Section 4.4.3). The E-
helix landing pad model is functionally related to the dimer interface unlocking model, 
and therefore the recombination reaction directionality bias observed in Section 4.4 may 
be related to that observed in Section 4.3. Unfortunately, there was insufficient time 
available to construct experiments that could discriminate whether the mechanism 
behind the effect was actually related to the proposed E-helix landing pad model, or was 
a result of several other potential mechanistic explanations.  
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4.2 Ionic repulsion at initial dimer-dimer contact point 
4.2.1 Hypothesis overview 
 The first model tested involves the hypothesis that the Asp102 residue is involved 
in negative regulation of Tn3 resolvase. This hypothesis is based on the possibility that the 
initial dimer-dimer contact point, which initiates active-site tetramer formation, occurs 
between counterpart Asp102 residues on opposing dimer subunits across the interface 
(see Figure 4-1, based on the 1GDT crystal structure of γδ resolvase).  This interaction 
between Asp102 residues is what may take place if one were to assume that the pre-
synaptic dimers are in approximately the conformation seen within the 1GDT crystal 
structure (Yang and Steitz, 1995), and are brought directly together during synapsis, 
similar to what was proposed by Li et al. (2005) (Li et al., 2005). 
 
 Apart from structural data, an additional piece of information that could support 
the hypothesis is the importance of mutations at residue 102 for creating hyperactive Tn3 
resolvase mutants. Although many secondary activating mutations have been discovered 
in conjunction with primary mutations at position 102, amino acid substitution of Asp102 
appears to be virtually prerequisite for hyperactivation (Burke et al., 2004). Furthermore, 
it appears that several different amino acid substitutions at this position are capable of 
contributing to activation—albeit in varying degrees ((Burke et al., 2004, Olorunniji et al., 
2008); and Stark, unpublished work)—perhaps suggesting that it is the removal of 
aspartic acid at this position which is the key to activation. This observation could imply 
that Asp102 is participating in a negative regulatory barrier, which must first be relieved 
before further activation can take place. Because aspartic acid is a negatively charged 
amino acid, which is relatively short and has limited flexibility, ionic repulsion at the point 
of initial contact between dimers could be a good fit to the hypothesis that Asp102 is 
involved in negative regulation. Additionally, in the γδ resolvase system, which is virtually 
identical to the Tn3 resolvase system, a glutamic acid appears at position 102, further 
supporting the idea of negative regulation by negative charge at this position. 
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Figure 4-1: Glu102 hypothetical counterpart interactions at dimer-dimer synapsis.  A) The panel shows 
the two 1GDT dimer structures in opposite orientation with one another as they may be during the initial 
dimer-dimer contact at synapsis. The subunits have been alternatively coloured green, yellow, cyan and 
red. Glu102 residues are shown in space-filling mode and appear at the N-terminal ends of the E-helices.  B) 
The panel shows a simplified conceptual diagram of the structure in A). The representations are as follows: 
DNA, grey tubes; α/β sub-domains, ovals; E-helices, long rectangles; HTH domains, boxes with shade 
transitions; and loop regions, thick black lines. The subunits of the dimers are depicted in two shades of 
orange to aid with clarity of the image. At the N-terminal tips of the E-helices are red circles indicating the 
charge of the Glu102 residues at this location. 
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 One approach to testing this hypothesis is to use ZFR complementation 
experiments where two ZFR mutants are alternately substituted at position 102 with 
positively and negatively charged residues (Figure 4-2). If the side chains of residues at 
position 102 do form the initial point of contact during tetramer formation, then one 
would expect that when paired in opposite polarity configurations there would be a 
dramatic increase in activity over the pairings in same polarity configurations. This 
differential activity would be clearly visible when using the 2MutHomDim substrates that 
test the ability of alternate homodimers to interact (and could be visible on the 
heterodimer-binding substrates as well, producing results consistent with dimer-dimer 
orientation specificity). Of course, it is important to consider that the side chains of the 
other various charged residues might not be adequately placed to produce an 
electrostatic interaction effect, as proposed for the aspartic acid, but by attempting all 
possible charged-residue combinations, a maximum effort can be made. 
 
 
 
 
− − 
− − 
+ + 
+ + 
+ 
− 
+ 
− 
                                       Same polarity__________________            Opposite polarity____ 
Prediction: inactive Prediction: inactive Prediction: active 
Figure 4-2:  Charge complementarily arrangements and predictions.  The figure shows the three 
arrangements of charge complementarity at residue 102 to be assayed in the experiment. All the image 
representations are the same as in Figure 4-1 B, with the exception that the colour transition boxes now 
represent ZFA binding domains. 
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4.2.2 Experimental design 
 A complementation experiment was designed in which a set of ZFR mutants, 
which differed only by the identity of their charged residue at position 102, were tested 
on a 2MutHomDim substrate (Z2/Z2 x Z3/Z3). The Z2 and Z3 ZFAs and binding sites were 
selected for site-specific targeting because they performed with the most comparable 
levels of binding activity within the experiments of Chapter 3, Section 3.5. The ZFRs with 
the Z2 ZFA were expressed from pSA3022-based vectors, while those with the Z3 ZFA 
were expressed from pMS140-based vectors, as this combination appeared to produce 
the most similar level of activity in the experiments of Section 3.5. The mutations at 
position 102 were placed in the Tn3[N G70C] catalytic domain background because it was 
demonstrated to be highly active in other experiments (such as those in Chapter 3) when 
used in combination with the primary mutation D102Y. If D102Y produces its activating 
effect by eliminating a regulatory barrier resulting from ionic repulsion by counterpart 
Asp102 residues, then the ionic substitutions and complementation arrangements used in 
this experiment, also designed to eliminate this barrier, should also result in the Tn3[N 
G70C] background providing an adequate level of activation. Tn3[NY G70C] was, in fact,  
used for many experiments throughout this project, and so this domain was employed 
where possible in order to maintain a level of a comparability between experimental 
results.  
 
 Three different types of complementations were carried out in order to test the 
hypothesis that counterpart Asp102 residues produce negative regulation via ionic 
repulsion. The first set of complementations tested the ionic mutation variants against 
themselves. Because the complementation experiments involve the expression of 
alternately targeted ZFRs from two vectors, the concentration of ZFR protein in the E. coli 
cells is approximately doubled in these complementations. Therefore, when making 
observations of the base level of activity of each ionic mutation variant ZFR for 
comparison with the opposite polarity complementations, it was appropriate to also 
express alternately targeted versions of the same ionic mutation variant ZFRs from two 
expression vectors.  The second set of complementations were the primary experimental 
reactions, using opposite polarity ZFR variants. A third set of complementations, which 
was employed as an additional control, tested ionic variant ZFRs against other ionic 
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variant ZFRs of the same polarity.  The complementations were performed in the 17 Hour 
Resolution Assay (described in Chapter 3, Section 3.4). 
 
4.2.3 Results of ionic polarity complementations on 
2MutHomDim substrates fail to support the hypothesis 
 The results of the complementation experiment (shown in Figure 4-3) fail to 
support the hypothesis that there is any interaction between 102 residue side chains on 
opposing subunits at tetramer formation. None of the complementations produced any 
significant level of recombination in the 17 Hour Recombination Assay. There was no 
difference in the recombination activity between reactions where ionic charge at position 
102 would have been expected to product repulsion (lanes 2–6 and 15–18) and reactions 
where opposite charges were paired (lanes 8–13). Therefore, no ionic interaction 
between opposing dimers at residue 102 appears to exist. If Asp102 were operating in a 
negative regulator mechanism as hypothesized, then pairing oppositely charged residues 
at position 102 should have been expected to at least remove that negative regulation, if 
not produce an additional activating effect due to favourable ionic interactions. None of 
the substitutions used at position 102 were known to be substantially activating primary 
mutations when used in single mutant (i.e. not complementation) experiments, and 
therefore, only removal of the hypothesized ionic repulsion would have been expected to 
produce recombination using these mutants in complementation experiments. The lack 
of any significant level of activity among the opposite polarity complementations (lanes 8-
13), means that there is no effect taking place that is suitable for use in either generating 
a dimer-dimer orientation specificity bias, or generating a recombination reaction 
directionality bias. 
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Figure 4-3:  Ionic pairs complementation test.  The results of a 17 Hour Recombination Assay are shown in 
the figure. To the left of the gel image, are given the sizes of each band of the molecular marker ladder 
shown in lane 1. To the right of the image, indicators are given to describe the origin of the bands on the gel 
(UNC = unchanged substrate, INV = inversion product, DEL = deletion product, and EXP = expression vector 
plasmid). Above the image is a table which ZFR pair and substrate is used in each lane. The tracks are 
grouped into same ionic charge, same residue identity at amino acid position complementations (lanes 2–
6); opposite ionic charge at amino acid position 102 complementations (lanes 8–13); and same ionic charge, 
different residue identity at amino acid position 102 (lanes 15–18). Coloured shading is used within the 
table for clarity, which separates the ZFRs by ZFA type. 
   1       2       3      4      5      6     7     8     9      10   11     12    13    14   15     16     17    18     
506, 517 
396 
2036 
1636 
1018 
298 
220 
3054 
201 
154 
DEL 
INV 
UNC 
UNC 
EXP 
EXP 
  Same charge (self)  Opposite charge  Same charge  
 
M Z2/Z2 x Z3/Z3 
Tn3[N D102D G70C]-Z2  + - - - -  - - - - - -  + - - - 
Tn3[N D102E G70C]-Z2  - + - - -  - - - - - -  - - - - 
Tn3[N D102H G70C]-Z2   - - + - -  + - - + - -  - - - - 
Tn3[N D102K G70C]-Z2   - - - + -  - + - - + -  - + - - 
Tn3[N D102R G70C]-Z2  - - - - +  - - + - - +  - - + + 
Tn3[N D102D G70C]-Z3  + - - - -  + + + - - -  - - - - 
Tn3[N D102E G70C]-Z3  - + - - -  - - - + + +  + - - - 
Tn3[N D102H G70C]-Z3   - - + - -  - - - - - -  - + + - 
Tn3[N D102K G70C]-Z3  - - - + -  - - - - - -  - - - + 
Tn3[N D102R G70C]-Z3  - - - - +  - - - - - -  - - - - 
 4072 
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4.3 The dimer interface-unlocking activation model 
4.3.1 Conceptual overview 
4.3.1.1 Dimer interface locking sub-region 
 The second hypothesis involves a sub-region of the dimer interface as it appears in 
the 1GDT crystal structure, which can be interpreted as displaying a 'locking' mechanism 
that must be disengaged in order for an active tetramer to form. This lock consists of the 
dimer interface contact between the E-helix of one subunit and the α/β sub-domain of 
the adjacent subunit (see Chapter 1, Section 1.6.2 for a description of the Tn3 resolvase 
catalytic domain). The locking region contains several potential hydrogen bonds, as well 
as hydrophobic packing, which must be disrupted before the inactive dimer conformation 
witnessed in 1GDT (Figure 1-12 A) can become the active tetramer conformation seen in 
1ZR4 (Figure 1-12 B). The 1GDT dimer, which can be split into two halves about a two-fold 
axis, does not have perfect symmetry across both of those halves (Figure 4-4 A and B). 
One interpretation of that asymmetry could be that one side of the dimer has been 
captured in a partially unlocked conformation. One noteworthy example of the difference 
between dimer interface contacts between the right and left half the dimer is the 
absence of the trans-interaction seen between Gly70 and Arg121 in the unlocked half of 
the dimer (Figure 4-5).  
 
4.3.1.2 Asymmetric dimer-unlocking 
 During wild-type Tn3 resolvase catalysis, it is believed that the dimers bound at 
site I (the catalytic site) asymmetrically interface (that is, the interaction takes place on 
one side of the dimers only) with the subunits of the regulatory module via the 2-3′ 
interface (see Chapter 1, Section 1.6.2). Interaction at the 2-3′ interface between site I-
bound dimers and the subunits of the regulatory module is thought to facilitate the 
formation of the catalytic tetramer module of the synaptosome (see (Rowland et al., 
2009) and (Rice et al., 2010) for a full description of a small serine recombinase 
synaptosome). The dimer interface-unlocking activation model suggests that for each 
dimer bound at site I, one of the two locking interfaces would be unlocked by the 
allosteric action of 2-3′ contacts to the subunits of the regulatory module (Figure 4-6). 
Because only one locking interface per dimer would be unlocked, this will be referred to 
as asymmetric dimer unlocking. 
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Figure 4-4:  1GDT dimer showing locked and semi-unlocked asymmetry.  Dimer subunits are shown in 
either green or yellow, with the other subunit shown with a molecular surface in each image. The molecular 
surface been coloured by residue type (positively charged = blue, negatively charged = red, polar = 
turquoise, hydrophobic = grey).  The DNA at the top of the images is shown in space filling mode coloured 
brown-orange. A) This panel shows the locked conformation. The E-helix of the green subunit is tightly 
bound to both the charged and hydrophobic portions of the subunit shown with a molecular surface. The 
residues shown in stick form in the figure are: Met106, Thr109, Ile110, Ala113, Val114, Ala117, Gln120, 
Arg121, and Glu124.  B) This panel shows the pseudo-unlocked conformation. The E-helix of the yellow 
subunit is bound only to the hydrophobic region of the subunit shown with a molecular surface. The 
residues shown in stick form in the figure are: Met106, Thr109, Ile110, Ala113, Val114, Ala117, and Glu124. 
The residues shown in A) which no longer make dimer interface contacts have been omitted for clarity of 
the image, with the exception of the last residue, Glu124, which is displayed as a reference point for 
comparison between the figures. In A) and B), for clarity of the image, only the first and last residue of the 
set (Met106 and Glu124, respectively) have been labelled. 
164 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary (red) Secondary (blue) Tertiary (orange) 
D102Y/I/F/V/T/W L66I/F, G70A/C, I77T, A89T, F92S, T99S, 
G101S/C, M103I/V, Q105L, V107M, T109I, 
A117V, R121K/M/S, E124Q 
R2A, E56K 
R121 
Leu66 
Thr73 
3.0Å 
2.9Å 
2.8Å 
Leu66 
R121 
Thr73 
A) 
B) 
Gly70 
Gly70 
Figure 4-5: Arg121 trans-interaction with Gly70 in the locked and unlocked states.  The figures show the 
1GDT crystal structure with the resolvase subunits coloured in yellow and green. The same colouring scheme 
as used in Figure 1-14 is used to indicate the locations where activating mutations occur. On the left side of 
the figure a red square indicates the region of the Arg121 of one subunit and Gly70 of the other subunit. On 
the right side of the figure, the indicated area from the left side is shown magnified, and from a slightly 
altered angle which best displays the residues.  A) The figure shows Arg121 trans-interaction with Gly70 in 
the locked state side of the 1GDT dimer. Arg121 makes a hydrogen bond to the backbone of Gly70 which is 
indicated with a blue line. Additionally, two hydrogen bonds from Arg121 to Thr73 and to the backbone 
Leu66, respectively, are shown in orange, which are detected when the hydrogen bond angle constraints are 
relaxed. There is also a potential hydrogen bond contact (3.1 Å) between Arg121 and Met76 which is not 
displayed in the figure  B) The figure shows the same area as in A) but on the unlocked side of the 1GDT 
dimer. No hydrogen bonds are possible between the residues highlighted in A); although, Arg121 now makes 
hydrogen bond contact to the DNA backbone (not indicated in the figure).  
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A) 
90° 90° 
Plane of rotation 
Figure 4-6: Asymmetric 2-3′ interface dimer unlocking model.  A) The figure shows Th3 resolvase dimers 
(represented by orange squares) bound to site I (DNA is represented by thick grey lines) before and after 
interfacing with the regulator module of the synaptosome (large pink square). The 2-3′ interface contact 
interactions between the regulatory module and the catalytic site dimers are is indicated using yellow 
circles. The dimers, in both cases, are shown at a point before catalytic tetramer formation.  B) The figure 
shows the same scene as in A), but with more detail of the subunits, and rotated 90° so that the regulatory 
module is beyond the foreground and out of view. The DNA is represented as a grey tube. The resolvase 
subunits are coloured in two shades of orange. The resolvase HTH DNA-binding domain is represented 
using squares with a shade transition in the colouring. The resolvase E-helix is shown using long rectangles, 
and the α/β sub-domain is depicted using ovals. Flexible amino acid regions connecting the domains (such 
as the arm region) are depicted using thick curved lines. The left side of the figure shows the two Tn3 
resolvase dimers in locked conformation before interfacing with the regulatory module. The right side of 
the figure shows the dimers being asymmetrically unlocked via the 2-3′ interface by the regulatory module. 
Stars are used to indicate where locking interface contacts between the E-helices and α/β sub-domain have 
been disengaged, and pink dashed arrows indicate contact from the regulatory module. 
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4.3.1.3 E-helix and α/β sub-domain relationship 
 In order for the dimer shown in 1GDT (Figure 1-12 A) to enter into the active 
tetramer conformation seen in 1ZR4 (Figure 1-12 B), the E-helices of the resolvase 
subunits must form anti-parallel trans-interactions with one another across the tetramer 
interface (Figure 1-13). However, the interactions of the 1GDT dimer, between the E-
helices and the α/β sub-domains, block the space that the anti-parallel E-helices 
interactions of the 1ZR4 tetramer must occupy. This blocking of space occurs through 
both a trans-interaction where the α/β sub-domain of one subunit occludes space on the 
E-helix of the adjacent subunit (Figure 4-7), and as a result of the orientation of the α/β 
sub-domain, occupying space relative to its own subunit, which is incompatible with 
tetramer formation (Figure 4-8). Therefore, in order for the resolvase dimers to form a 
tetramer, the α/β sub-domains must rotate away from their trans-interaction with the E-
helices so that new anti-parallel trans-interactions can be formed between the E-helices 
of opposing subunits within the tetramer (Figure 4-8). Resolvase tetramer formation can 
be thought of in terms of two E-helix pairs that must come together, and four α/β sub-
domains that must move out of the way for this to happen (one α/β sub-domain on each 
E-helix).  
 
 At the point right before tetramer formation between two 1GDT-like resolvase 
dimers, in both dimers, the E-helix of one subunit would be locked by the α/β sub-domain 
of the second subunit, and the E-helix of the second subunit would be left unlocked by 
the α/β sub-domain of the first subunit. This difference in subunit conformations gives 
rise to an asymmetry that differentiates one of the possible dimer-dimer orientations 
from the other. According to the dimer interface-unlocking model, one of these two 
orientations should occur in the wild-type system, while the other does not (Figure 4-9). 
In the wild-type dimer-dimer orientation, both E-helices of one partnering pair of anti-
parallel E-helices are locked, while both E-helices in the other partnering pair of anti-
parallel E-helices are unlocked. In the non-wild-type dimer-dimer orientation, both 
partnering pairs of anti-parallel E-helices consist of one locked and one unlocked E-helix. 
Two 1GDT resolvase dimers can be modelled together into a synaptic initiation complex, 
and this modelling produces unique geometric docking arrangements in the wild-type and 
non-wild-type dimer-dimer orientations (Figure 4-10 A and B, respectively). However, 
while these docking arrangements are interesting, conclusions cannot be drawn from 
them. 
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A) 
B) C) 
90° 
Figure 4-7: Trans-interaction occlusion of the E-helix by the α/β sub-domain.  A) The figure shows the 
1GDT resolvase dimer with amino acid positions in the E-helix of the green subunit which are occluded by 
the α/β sub-domain of the yellow subunit, coloured magenta (Met106, Thr109, Ile110, Ala113, Val114, 
Ala117, Gln120, Arg121, and Glu124; the same positions shown in Figure 4-4 A).  B) The figure shows the 
1ZR4 structure with the same amino acid positions as indicated in A) again coloured magenta within the 
green subunit, in order to demonstrate how this contact space must be unoccupied in order for the anti-
parallel E-helix-E-helix interactions to take place.  C) The figure shows the model as in B), but rotated 90° 
for a better view of the anti-parallel E-helix-E-helix interaction between the green and cyan resolvase 
subunits. The half of the structure containing the yellow and red subunits and the DNA they bind has been 
removed for clarity. 
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Figure 4-8: Translation of the α/β sub-domain about the E-helix. 
  Figure A) and B) show one resolvase subunit from 1GDT and 1ZR4, respectively, in identical orientation 
with respect to the E-helix. Residue Val108 is shown and coloured in magenta in order to provide a visual 
cue that the orientations of the subunits are matched. Comparison of A) and B) displays the translation of 
the α/β sub-domain about the E-helix which takes place during synapsis as inactive dimers form an active 
tetramer. In figure B) it may be noticed that the E-helix has been slightly extended by the ordering of some 
of the flexible loop. However, this may or may not take place in the wild-type system as the extension of the 
E-helix seen in 1ZR4 is stabilized by two hydrogen bonds, one of which is provided by the side chain of a 
G101S activating mutation (not shown). Figure C) shows the 1ZR4 tetramer structure with the yellow 
subunit replaced with the 1GDT subunit from figure A), in order to display the geometric incompatibility of 
the position of its α/β sub-domain with the tetramer structure. The 1ZR4 subunit was replaced by first 
superpositioning E-helices of the two subunits and then removing the 1ZR4 subunit. Figure D) shows the 
normal 1ZR4 structure. The subunits from A) and B) are in identical orientation to the yellow subunits in C) 
and D), respectively. It may be noted that position of the C-terminal HTH domain is also somewhat different 
between subunits of the 1GDT and 1ZR4 structures, due a change in position of the DNA (1GDT DNA not 
shown). 
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 Wild-type dimer-dimer orientation Non-wild-type dimer-dimer orientation A) 
B) 
Unlocked 
Unlocked 
Unlocked 
Unlocked 
Locked 
Locked 
Locked 
Locked 
Figure 4-9: Wild-type and non-wild-type dimer-dimer orientation of asymmetrically unlocked resolvase 
dimers at synapsis.  A) The panel shows the 1GDT dimer structure arranged in the proposed wild-type and 
non-wild-type dimer-dimer orientations of asymmetrically unlocked dimers.  B) The panel shows a 
simplified diagram of the dimer-dimer orientations displayed in A). The structural components are 
represented as described in Figure 4-6. 
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4.3.1.4 Support from mutation studies 
 Some existing data that are consistent with the dimer interface-unlocking 
activation model can be found in the activation mutagenesis study of Burke et al. (2004) 
(Burke et al., 2004) (Burke et al., 2004). Several of the secondary activating mutations 
(mutations in addition to those at amino acid position 102 that are required for full 
activation of the enzyme; see Chapter 1, Section 1.6.5) change the amino acid identities 
of key residues that appear to stabilize the proposed locking interface (see Figure 1-14 for 
a depiction of the locations of resolvase activating mutations). Additionally, many of the 
remaining secondary activating mutation residues could also be proposed to destabilize 
that locking interface through disruptions of the N-terminal domain core. This disruption 
might mimic the allosteric action of 2-3′ interface contacts from the regulatory module to 
disengage locking contact between the E-helix and α/β sub-domain of adjacent subunits 
within the dimer. Of the 14 residue positions described by Burke et al. (2004) that 
produced secondary activation effects when mutated, most are located at positions that 
are consistent with the dimer interface-unlocking activation model. 
 
4.3.1.5 Using the locking interface to specify dimer-dimer configurations 
 It was hypothesized that asymmetric dimer interface-unlocking activation might 
allow one to generate ZFR subunits that produce dimer-dimer interface orientation 
specificity during tetramer formation. This possibility followed from the observation that, 
in the wild-type context, the two dimers of the catalytic tetramer are unlocked by 2-3′ 
Figure 4-10: Modelling of tetramer initiation using 1GDT dimers.  The tetramers are shown in the same 
orientation as in Figure 4-6 B. The DNA and HTH domains are not shown.  A) The figure shows two 1GDT 
dimers docked in the proposed wild-type dimer-dimer orientation, where the α/β sub-domains of both 
subunits in the foreground (green and cyan) provide an unlocked trans-interaction with the E-helices of 
their adjacent subunit partners within the dimers. Likewise, both subunits in the background (yellow and 
magenta) have α/β sub-domains which are involved in locking trans-interactions with the E-helices of their 
subunit partners within the dimers.  B) The figure shows two 1GDT dimers docked in the proposed non-
wild-type dimer-dimer orientation, where the α/β sub-domain of one subunit in the foreground (cyan) 
provides an unlocked trans-interaction with the E-helix of its adjacent subunit partner within the dimer, and 
the α/β sub-domain of the other subunit in the foreground (yellow) provides a locked trans-interaction with 
the E-helix of its adjacent subunit partner within the dimer. The subunits in the background share a similar 
arrangement with one (green) providing unlocked trans-interaction from its α/β sub-domain, and the other 
(magenta) providing locking trans-interaction from its α/β sub-domain. Docking of the 1GDT dimers was 
accomplished by manually moving the dimers together until steric clashes were observed between the side 
chains of opposing dimers (the sides chains are not displayed in the figure). Pairs of opposite-adjacent 
subunits are shown again at the sides of the image, rotated 90°, so that the interfacing between α/β sub-
domains can be seen more clearly. One may also note that the dimer in B) have been docked in a less 
symmetric fashion, that those in A). This was done simply because it allowed the dimers to be moved closer 
together, which was not true for the dimer in A). This is justifiable because there is reason to believe the 
dimers in B) must synapse is a symmetric fashion. 
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interface contacts on the same side, with respect to a plane that the separates subunit 
rotation pairs (Figure 4-6). It was hypothesised that since the asymmetric 2-3′ interface 
contacts to the dimers, may likewise produce an asymmetric conformational change 
within the dimers, this potential asymmetry of the dimers' conformation might make the 
dimer-dimer interface geometrically compatible in only one orientation during tetramer 
formation. This potential geometric incompatibility of one of the dimer-dimer synapsis 
orientations is not the mechanism by which the wild-type Tn3 resolvase achieves dimer-
dimer orientation specificity, but could have arisen as an incidental consequence of that 
mechanism. Therefore, it was proposed that activating mutations that either directly 
destabilize the locked interaction, or disrupt the N-terminal domain core in a way that 
results in the destabilization of the locking interaction, might be used to produce a 
differentially mutated ZFR pair where one mutant provided the locking interaction and 
the other did not. This ZFR pair might then produce heterodimers that were only 
compatible with each other in one of the two possible dimer-dimer orientation 
configurations; the active configuration would mimic the activating interactions found 
within the wild-type system.  
 
4.3.1.6 Dimer-dimer configurations 
 In order to consider the way in which pairs of differentially activated ZFR mutants 
may cooperate in different tetramer subunit configurations to produce orientation 
specificity of the dimer-dimer interface (or a non-reversible reaction), three tetramer 
subunit configuration states must be defined (see Figure 4-11). The first is that of the 
alternate homodimers dimer-dimer (AHD) configuration, which is comprised of two 
homodimers made of two different ZFR mutants. The second configuration is that of the 
mirrored orientation heterodimers dimer-dimer (MHD) configuration, which is comprised 
of two identical heterodimers, each containing two different ZFR mutants. The third 
configuration is that of the reversed orientation heterodimers dimer-dimer (RHD) 
configuration, which is also comprised of two identical heterodimers, each containing two 
different ZFR mutants. The difference between the MHD configuration and the RHD 
configuration is the orientation of the heterodimers with respect to one another. In the 
MHD configuration, same-type ZFR mutants are positioned directly across from one 
another in the dimer-dimer interface. In the RHD configuration, alternate-type ZFR 
mutants are positioned directly across from one another in the dimer-dimer interface. 
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Finally, after subunit rotation of an AHD configuration, the resulting tetramer state is the 
RHD configuration, and vice versa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.1.7 Activity predictions based on E-helix and α/β sub-domain pairing mode 
 Working from the assumption that asymmetric dimer interface-unlocking might 
also give rise to compatible and non-compatible dimer-dimer configurations based on the 
E-helix and α/β sub-domain pairing mode (see Section 4.3.1.3), predictions were made 
about which tetramer configurations would be active (Figure 4-12). The MHD 
configuration was predicted to be active because its E-helix and α/β sub-domain pairing 
mode, with respect to the anti-parallel E-helix interactions during synapsis, would be 
wild-type-like. However, both the AHD and RHD configurations were predicted to be 
inactive because they share the same non-wild-type E-helix and α/β sub-domain pairing 
mode, with respect to the anti-parallel E-helix interactions during synapsis.   
 
 
 
     AHD configuration      MHD configuration 
modimers 
      RHD configuration 
modimers 
Subunit rotation Subunit rotation Subunit rotation 
Figure 4-11: Dimer-dimer configuration states of two site-specific ZFR mutants within a tetramer. 
  This figure depicts all three possible subunit configuration states of a tetramer comprised of two site-
specific ZFR mutants. Double-stranded DNA molecules are represented by yellow and orange bars, while 
the two varieties of mutant ZFR subunits are depicted in green and blue. The green ZFR mutants bind the 
site represented by the yellow DNA, and the blue ZFR mutants binding the sites represented by the orange 
DNA. Arrows point to the post-subunit rotation state of the tetramer, which varies depending on the 
starting configuration. 
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4.3.2 Experiment design  
4.3.2.1 Premise 
 In order to test whether the asymmetric dimer interface-unlocking activation 
could be used to generate a dimer-dimer orientation specificity bias, two ZFRs were 
constructed that were intended to mimic the asymmetric dimer unlocking activity of the 
wild-type system when used in combination with one another. One of these ZFRs 
possessed normal dimer interface residues that can participate in the locking interface, 
while the other ZFR possessed the secondary mutation, G70C, which was hypothesized to 
     MHD configuration      RHD configuration 
modimers 
 Wild-type pairing mode                       Non-wild-type pairing mode _ __________ 
Prediction: active Prediction: inactive 
     AHD configuration 
modimers 
Prediction: inactive 
Figure 4-12: E-helix and α/β sub-domain dimer-dimer pairing modes.  The figure shows the three possible 
E-helix and α/β sub-domain dimer-dimer pairing modes using two ZFRs where one contains a locking 
interface knockdown mutation (the light orange subunit). The MHD configuration is proposed to be the 
wild-type pairing mode, where the anti-parallel E-helices pair in the same mode, while the MHD and AHD 
configurations contain the non-wild-type pairing mode, where the anti-parallel E-helices pair in opposite 
modes. The wild-type pairing mode was predicted to be active while the non-wild-type pairing mode was 
predicted to be inactive. The resolvase subunits are coloured in two shades of orange. The ZFR ZFA DNA-
binding domain is represented using squares with a shade transition in the colouring. The resolvase E-helix 
is shown using long rectangles, and the α/β sub-domain is depicted using ovals. Flexible amino acid regions 
connecting the domains (such as the arm region) are depicted using thick curved lines. Stars are used to 
indicate where the locking interface contact between the E-helices and α/β sub-domains has been 
disengaged. 
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disrupt the locking interaction of the dimer interface by disrupting contact from the α/β 
sub-domain side of the interaction with the E-helix (see Figure 4-5). When these two ZFRs 
form a heterodimer, the result is that only one of the two locking interfaces of the dimer 
is disrupted, which simulates the proposed asymmetric allosteric unlocking action from 
the regulatory module in a Tn3 resolvase synaptosome (see Figure 4-6).  
 
 Key to this experiment is that when the heterodimers comprised of differentially 
mutated ZFRs are in the MHD configuration, they are in the same E-helix and α/β subunit 
pairing mode as expected in the wild-type Tn3 resolvase synaptosome, with two unlocked 
locking regions being on the same side of the tetramer (Figure 4-12). Thus, the 
differentially mutated ZFR pairs were expected to produce recombination activity in the 
MHD configuration. However, if the differentially mutated ZFR pairs are in the RHD or 
AHD configurations, this produces a non-native E-helix and α/β subunit pairing mode, and 
these tetramer configurations were not expected to produce recombination activity.  
 
4.3.2.2 Choice of locking-interface knockdown mutation 
 From the aforementioned candidate secondary mutations described in Burke et al. 
(2004) (see Section 4.3.1.4), G70C was selected for this experiment because it was 
predicted to have particularly robust disruptive effect on the locking region of the dimer 
interface. The carbonyl oxygen of the Gly70 backbone participates in a hydrogen bond 
across the locking interface with Arg121 (Figure 4-5 A). Residue Arg121, itself, when 
mutated, also acts as a secondary activating mutation (Burke et al., 2004). These 
mutations are, therefore, a good fit with the predicted model. Additionally, residue 70 is a 
flexible glycine that participates in a bend, so substitution for another amino acid at this 
position may disrupt the local geometry containing other residues participating in the 
locking interface. Finally, the glycine residue also does not possess a side chain, and so 
substitution with a cysteine residue may further distort the local conformation by 
introducing mass into an otherwise compacted space. Thus, the G70C mutation appeared 
to be both an ideal fit for the model being tested, and was predicted to have a particularly 
strong effect. 
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4.3.2.3 Substrates and detection of active tetramer configurations 
 A complementation experiment was designed that utilized the three substrate 
types: 2MutHomDim, 2MutHetDim-DR, and 2MutHetDim-IR (see Table 3-2), to 
discriminate between reactions that might produce either dimer-dimer orientation 
specificity (predicted), or a non-reversible reaction (not predicted). Dimer-dimer 
orientation specificity can be detected by using either the 2MutHetDim-IR or 
2MutHetDim-DR substrates, which produce different recombination products (inversion 
product versus excision product) if only one of the two possible dimer-dimer orientations 
(MHD configuration or RHD configuration) is active (Figure 4-14 and Figure 4-15). 
However, because inversion products may themselves be subject to secondary reactions, 
analysis of the excision products from 2MutHetDim-IR and 2MutHetDim-DR substrates 
provides the most reliable information about a dimer-dimer orientation specificity bias. 
 
 In this experiment, a non-reversible reaction may be detected by comparing the 
outcomes of complementation reactions on the 2MutHomDim substrate with those on 
the 2MutHetDim-DR substrate or the 2MutHetDim-IR substrate (Figure 4-13, Figure 4-14, 
and Figure 4-15, respectively). Because the AHD configuration transforms into the RHD 
configuration after subunit rotation, and vice versa (see Figure 4-11), if one of these two 
tetramer configuration states is active while the other is not, this would likely indicate 
non-reversible reaction potential for that combination of ZFRs. That is, if the ZFRs that 
bind the product Z-sites are no longer able form an active tetramer configuration, then 
the reaction cannot be reversed.4 Recombination activity in complementation reactions 
on the 2MutHomDim substrate, indicate that the AHD configuration is active. The 
production of inversion product from complementation reactions on the 2MutHetDim-DR 
substrate indicates that the RHD configuration is active. Likewise, the production of 
excision product from complementation reactions on the 2MutHetDim-IR substrate, also 
indicates that the RHD configuration is active. Table 4-1 provides a summary of the 
relationship between substrate type, reaction outcome, and active tetramer 
configurations. 
 
                                                     
4 In the case that the AHD configuration was active, but the RHD configuration was not active, a secondary 
reaction might still be possible provided the MHD configuration was active, as the dimer-dimer interface 
could form in the other orientation. However, if the RHD configuration was active and the AHD 
configuration was not, then no secondary reaction would be possible as both dimer-dimer orientations 
produce the same AHD configuration. 
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A) 
B) 
2MutHomDim 
If active If active If active 
MHD configuration AHD configuration RHD configuration 
Figure 4-13: 2MutHomDim substrate and active tetramer configuration discrimination.  A) The panel 
shows the three tetramer configurations with a colour code below to indicate which reactions in Panel B) 
involve the given configuration.  B) The panel shows the possible reaction pathways for the 2MutHomDim 
substrate with the colour code from A) used to indicate which reactions are performed by a given tetramer 
configuration. The black arrows represent steps where the Z-sites are brought together, while the coloured 
arrows represent steps where recombination reactions take place. See Figure 1-10 if a detailed description 
of the pictorial components of the figure is needed. 
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A) 
If active If active If active 
B) 
2MutHetDim-DR 
MHD configuration AHD configuration RHD configuration 
Figure 4-14: 2MutHetDim-DR substrate and active tetramer configuration discrimination.  A) The panel 
shows the three tetramer configurations with a colour code below to indicate which reactions in panel B) 
involve the given configuration.  B) The panel shows the possible reaction pathways for the 2MutHetDim-
DR substrate with the colour code from A) used to indicate which reactions are performed by a given 
tetramer configuration. The black arrows represent steps where the Z-sites are brought together, while the 
coloured arrows represent steps where recombination reactions take place. See Figure 1-10 if a detailed 
description of the pictorial components of the figure is needed. 
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A) 
MHD configuration AHD configuration RHD configuration 
B) 
2MutHetDim-IR 
If active If active If active 
Figure 4-15: 2MutHetDim-IR substrate and active tetramer configuration discrimination.  A) The panel 
shows the three tetramer configurations with a colour code below to indicate which reactions in panel B) 
involve the given configuration.  B) The panel shows the possible reaction pathways for the 2MutHetDim-IR 
substrate with the colour code from A) used to indicate which reactions are performed by a given tetramer 
configuration. The black arrows represent steps where the Z-sites are brought together, while the coloured 
arrows represent steps where recombination reactions take place. See Figure 1-10 if a detailed description 
of the pictorial components of the figure is needed. 
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Table 4-1: Summary of tetramer configurations and reaction outcomes on substrate types 
 ____2MutHomDim____ ___2MutHetDim-DR___ ___2MutHetDim-IR___ 
 1° 2° 1° 2° 1° 2° 
UNC  RHD  AHD  MHD 
INV AHD  RHD   MHD  
DEL AHD MHD MHD AHD RHD RHD 
1° indicates the primary reactions, while 2° indicates secondary reactions that may take place only if the 
inversion product has been produced by a primary reaction. 
UNC = unchanged substrate, INV = inversion product, DEL = deletion/excision product 
 
4.3.2.4 ZFR pairs used for the experiment 
 For this experiment, two pairs of differentially mutated ZFRs were constructed. 
The catalytic domains used were the Tn3[NY] domain and the Tn3[NY G70C] domain. The 
'N' and 'Y' designations represent the tertiary mutations R2A and E56K, and the primary 
activating mutation D102Y, respectively (see Chapter 1; Section 1.6.5 to see how 
'primary', 'secondary', and 'tertiary' activating mutations are defined). Importantly, 
although an enzyme (either Tn3 resolvase or Tn3-based ZFR) with the NY mutation set 
contains activating mutations, this combination abolishes the activity of the protein when 
used on its own. Therefore, the ZFR with the Tn3[NY] domain is inactive by itself, and thus 
will be referred to as a 'sleepy' partner as it requires the unlocked partner to wake it up. 
The unlocked ZFR partner possesses the Tn3[NY G70C] catalytic domain, which contains a 
G70C secondary mutation in addition to NY. The G70C mutation, as mentioned in Section 
4.3.2.2, disrupts the proposed locking interaction, and enzymes (either Tn3 resolvase or 
Tn3-based ZFR) with a Tn3[NY G70C] catalytic domain are active when used alone.  
 
 Although the binding activity of the Z2 and Z3 domains was shown to be 
approximately equal in the experiments of Chapter 3 (Section 3.5), both ZFAs were 
attached to both the sleepy and active catalytic domains (Tn3[NY] and Tn3[NY G70C], 
respectively), so that any minor differences in binding activity could be controlled for. 
Thus, the sleepy ZFRs, Tn3[NY]-Z2 and Tn3[NY]-Z3, and the active ZFRs, Tn3[NY G70C]-Z2 
and Tn3[NY G70C]-Z3, were generated.  
 
4.3.2.5 Substrates used for the experiment 
 As an additional control against any unexpected behaviour of the substrate 
plasmids, two substrates of each substrate type (2MutHomDim, 2MutHetDim-DR or 
2MutHetDim-IR) with opposite binding sites arrangements were used (e.g. Z2/Z2 x Z3/Z3 
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and Z3/Z3 x Z2/Z2). Although the use of two varieties of each substrate, which should 
behave in an identical fashion, might seem redundant, there is a promoter somewhere 
upstream of one of the Z-sites, and so without having a lot of experience with these 
substrates it was thought prudent to control for variables of this nature. 1MutHomDim 
substrates were also used in order to confirm the expected activity levels of the sleepy 
and active ZFRs.  
 
4.3.2.6 The experiment 
 A proof-of-principle experiment was conducted in which each set of sleepy + 
active ZFR pairs (Tn3[NY]-Z2 + Tn3[NY G70C]-Z3, and Tn3[NY]-Z3 + Tn3[NY G70C]-Z2) was 
tested on both varieties (see Section 4.3.2.5) of all substrate types (1MutHomDim, 
2MutHomDim, 2MutHetDim-DR, and 2MutHetDim-IR), in order to test the asymmetric 
dimer interface-unlocking hypothesis. The experiment was carried out using the 17 Hour 
Recombination Assay. 
 
 The initial results from the experiment showed only very small amounts of 
recombination taking place and relevant signals observed by gel electrophoresis analysis 
were very faint. Therefore, the experiment was run again, and this time, instead of 
harvesting the cells at 17 hours, they were grown on in culture for another approximately 
24 hour period to allow the apparently slow reaction to proceed further. It is the results 
from this cell passage that are described below. A second passage was also performed, 
and results from this passage showed even further conversion of substrate to reaction 
products; however, only results of the first passage are shown below. Catching the 
conversion of substrate to recombination products in an intermediate stage is most ideal 
for interpreting the results of the reaction because in some cases the inversion product of 
the reaction may disappear due to secondary conversion to excision product (see Table 
4-1). 
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4.3.3 Results  
4.3.3.1 Observations 
 The results of the experiment are shown in Figure 4-16 Panel A and B, and are 
summarized in Table 4-2. Panels A and B represent the same experiment but with the 
catalytic domain type and ZFA type combination, swapped. The controls on the 
1MutHomDim substrates (lanes 2 and 3) confirm that the sleepy ZFR with the Tn3[NY] 
catalytic domain is inactive on its own, and that the active ZFR with the Tn3[NY G70C] 
catalytic domain produces a total conversion of substrate to recombination product, as 
was expected from the combinations of primary, secondary, and tertiary mutations used 
(see Chapter 1, Section 1.6.5).  
 
Table 4-2: Summary of ostensible correlations between reaction results and configuration activity. 
 
 The primary experimental data can be viewed in lanes 5 and 6, 8 and 9, and 11 
and 12 (Figure 4-16 A and B), representing the sleepy + active ZFR pair complementation 
reactions on the 2MutHomDim, 2MutHetDim-DR, and 2MutHetDim-IR substrates, 
respectively. The first observation that can be made is that reactions on the 
2MutHomDim substrates produced both inversion and excision product (lanes 5 and 6), 
indicating that the AHD tetramer configuration is active (see Table 4-1). This result 
falsifies the prediction that the AHD configuration would not be active due to E-helix and 
α/β sub-domain pairing modes (see Section 4.3.1.7).  
 
 
  
 ____2MutHomDim____ ___2MutHetDim-DR___ ___2MutHetDim-IR___ 
 1° 2° 1° 2° 1° 2° 
UNC  RHD?  AHD  MHD 
INV AHD  RHD   MHD  
DEL AHD MHD MHD AHD RHD RHD? 
1° indicates the primary reactions, while 2° indicates secondary reactions that may take place only if the 
inversion product has been produced by a primary reaction. 
UNC = unchanged substrate, INV = inversion product, DEL = deletion/excision product 
Bold is used to indicate configurations that appear to be active, or in the case of secondary reactions, can 
be deduced as active from the results of the primary reactions. Strikethrough is used to indicate 
configurations that clearly do not appear to be active in the assay. A question mark is used in secondary 
reactions when configuration activity cannot be clearly deduced from the primary reactions of the assay. 
The colour red is used to indicate disagreement between a complementary set of reactions that should 
have produce the same results.   
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 The second observation that can be made is that reactions on the 2MutHetDim-
DR substrates produced only excision product, but no inversion product (lanes 8 and 9). 
This result appears to indicate a dimer-dimer orientation specificity bias, as lack of 
inversion product from the 2MutHetDim-DR substrate indicates that the RHD 
configuration is inactive, while production of excision product indicates the MHD 
configuration is active (see Table 4-1). The RHD and MHD configurations represent the 
two possible orientations of the heterodimer dimer-dimer interactions (Figure 4-11), and 
so activity with one configuration and not the other, suggests a dimer-dimer orientation 
specificity bias. However, there is an alternative explanation for this result (see below). 
 
 The third observation that can be made is that there is disagreement between the 
two complementary 2MutHetDim-IR reactions in lanes 11 and 12. The appearance of 
inversion product in both lanes indicates that the MHD configuration is active (see Table 
4-1), and this result is consistent with the previously observed results in lanes 8 and 9 that 
also indicate that the MHD configuration is active. However, in Panel A, an excision 
product signal is absent from lane 11, while a strong excision product signal appears in 
lane 12. In Panel B, this pattern is reversed with the excision product signal appearing in 
lane 11, but not in lane 12. In the lanes where the excision product band is absent, the 
result indicates the RHD configuration is inactive (consistent with the previously observed 
results in lanes 8 and 9), while its presence in the other lanes contradicts this result and 
indicates RHD configuration is, in fact, active (see Table 4-1). 
 
 The reactions indicated by lanes 11 and 12 in Panel A and B were expected to be 
functionally equivalent as they are all reactions on a 2MutHetDim-IR substrate. The 
reversed pattern of occurrence for the excision product between Panels A and B indicates 
Figure 4-16:  Asymmetric dimer interface-unlocking activation proof-of-principle experiment.  The results 
of a 17 Hour Recombination Assay which was further passaged in cell culture, are shown. To the left of the 
gel image, are given the sizes of each band of the molecular marker ladder shown in lane 1. To the right of 
the image, indicators are given to describe the origin of the bands on the gel (UNC = unchanged substrate, 
INV = inversion product, DEL = deletion (excision) product, and EXP = expression vector plasmid). Above the 
gel image is a table which indicates which ZFRs were used in conjunction with each substrate for the 
complementation reactions. Above the table the substrate types are indicated. Please note the restriction 
digest used for this experiment (AgeI + KpnI) was slightly different than that which is used for all the other 
experiments, and so the location of expression plasmid bands is somewhat different. This change was only 
made because of the availability of restriction enzymes on the day the digest was carried out. The bands of 
interest representing the substrate plasmid and its recombination products are still in their usual locations.  
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that the excision product is only produced when the sleepy ZFR subunits occupy the Z-site 
half-sites that are located on the same side as the origin of replication.5 This correlation 
indicates that the excision product plasmids that contain sleepy ZFR homodimer Z-sites 
are present in the results, but those that contain active ZFR homodimer Z-sites are not.  
 
4.3.3.2 Explanation based on the signal attenuation effect  
 One potential explanation that might explain all of the results is that the pattern 
of activity is caused by the product signal attenuation (SA) effect described in Chapter 3 
(Section 3.10.5). This SA effect can occur in reactions involving the ZFRs utilizing the Z2 
and Z3 ZFAs, especially when two active ZFRs are expressed simultaneously. In the 
current experiment, the cells had to be additionally passaged because the recombination 
product signals initially observed from the 17 Hour Recombination Assay experiment 
were weak, apart from the positive control (17 hour time point data not shown). The SA 
effect was proposed in Chapter 3 to result from unregulated cleavage of the DNA by ZFR 
dimers at a Z-site as the result of contact from non-DNA-bound ZFR subunits. Because the 
ZFR complementations of the current experiment produce slow reaction rates, as 
observed from the result before the additional cell passage, this is the type of scenario 
where the SA effect might significantly interfere with the results; i.e. the SA effect activity 
may outcompete the slow DNA recombination activity.  
 
 If the SA effect is caused by DNA cleavage from hyperactivated Tn3 catalytic 
domains as proposed, then the sleepy ZFR subunits used in this experiment might not 
produce the SA effect when bound to homodimer Z-sites. The sleepy ZFR subunits 
possess a Tn3 catalytic domain (NY) that is inactive without help from active ZFR subunits 
(and this is demonstrated by the negative controls in lanes 2 and 3 of Panel A and B, 
respectively, of Figure 4-16).  If sleepy ZFR homodimers do not produce the SA effect, 
then what is expected is that substrates and substrate products that possess homodimer 
Z-sites cognate to the active ZFRs will be differentially prone to the SA effect. Under this 
assumption, the reaction products that would be most affected by the SA effect are the 
inversion products from reactions on the 2MutHetDim-DR substrates, and the excision 
products from the subset of reactions on 2MutHetDim-IR substrates that produce 
                                                     
5 When looking at the substrates in Figure 4-16, one may recall from Table 3-2  that the format used to 
describe individual substrate plasmids is such that the half Z-sites which are on the same side as the 'x' are 
on the same side as the origin of replication. 
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product plasmids with active ZFR homodimer Z-site. The foregoing reaction products are 
the ones that are not observed in the results. Therefore, no conclusions from this 
experiment can be drawn with respect to the ability of the sleepy + active ZFR pair to 
produce dimer-dimer orientation specificity, in spite of the fact that some of the results 
ostensibly appear consistent with that possibility.  
 
 It can be additionally noted that it is unknown whether the single co-expression of 
sleepy ZFRs with active ZFRs would increase the SA effect in the same way that the dual 
expression active ZFRs does. However, since the signals observed after the 17 hour time 
point DNA harvest were weak, it is possible that signals at this level might be interfered 
with by even the SA effect produced by the single expression of the active ZFR in the 
reaction.   
 
4.3.4 Increasing ZFR expression of the sleepy + active ZFR pair  
4.3.4.1 Rationale for the experiment 
 Because it was not known how the sleepy ZFR subunits may interact with the SA 
effect, one way to attempt to determine this was to increase the expression of all the 
ZFRs in the reaction so that more obvious effects could be observed. Running the same 
experiment with double the expression level allows observations to be made about 
whether the sleepy ZFRs produce the SA effect when used alone at a higher expression 
level, and also whether they produce the SA effect when participating with active ZFRs in 
binding to heterodimer Z-sites. Additionally, the requirement of a cell passage and over 
40 hours of total time to acquire the results from the sleepy + active ZFR pair 
complementations in the proof-of-principle experiment, implies the activity of this ZFR 
combination to be low. This low rate of recombination is not ideal for further 
experimental work. If the ZFR occupancy at the Z-sites is not saturated at the level of 
expression in the previous experiment, then increasing the expression of ZFRs would 
improve the rate of the reaction. Therefore, it was deemed worthwhile to perform the 
previous experiment again but with increased ZFR expression.  
 
4.3.4.2  Experimental design 
 The sleepy ZFR (Tn3[NY]-Z2) and active ZFR (Tn3[NY G70C]-Z3) were loaded into 
double expression vectors (DEVs). Since there did not appear to be any confounding 
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effect produced by ZFA activity differences in the previous proof-of-principle experiment, 
only one sleepy and active ZFR pair were used for this DEV experiment. A 
complementation experiment using the sleepy + active ZFR pair was carried out in the 
precisely the same way as described for the previous proof-of-principle experiment, with 
the only change being that two copies of each ZFR were expressed from DEVs. For this 
experiment, select ZFR complementations in single expression mode were also performed 
again so that they could be placed side-by-side with the DEV-based complementations for 
comparison on the gel. Like the previous proof-of-principle experiment, results were 
collected at the initial 17 hour point, and again after one cell passage; the results 
collected at both of time points are shown bellow. 
 
4.3.4.3 Results 
 The results of the sleepy + active ZFR complementation experiment using DEVs 
(displayed in Figure 4-17 and Figure 4-18) indicate that increasing ZFR expression does not 
substantially increase the rate of the reaction. As indicated in the table above the gels, for 
each substrate type, the single expression mode complementations are shown next to 
the DEV mode complementations. A comparison of the single expression mode and DEV 
mode complementations at the 17 hour time point (Figure 4-17), shows almost no 
difference between them; a larger difference in substrate recombination rate can be seen 
after one cell passage (Figure 4-18). The increase in the rate of the reaction, due to 
increasing the ZFR expression within the cells, is not sufficient to obviate the need for a 
cell passage, which was one of the goals of the DEV augmentation to the experiment.  
 
 The first observation that can be made regarding the SA effect is that the dual 
expression of the active ZFR cognate for the 1MutHomDim, in addition to dual expression 
of the sleepy ZFR that is not cognate for the substrate, produces a significant level of SA 
effect (Figure 4-17, lane 3).  Conversely, dual expression of the sleepy ZFR cognate for the 
1MutHomDim, in addition to dual expression of the active ZFR that is not cognate for the 
substrate, does not appear to produce the SA effect at all (Figure 4-17, lane 2). This 
provides a strong indication that the SA effect is the result of ZFR catalytic activity, rather 
than binding alone. Additionally, this result also indicates that the co-expression of active 
ZFRs along with sleepy ZFRs, will not activate those sleepy ZFRs to produce the SA effect 
when only sleepy ZFR Z-sites are contained in the substrate. This is a noteworthy 
observation given that in Chapter 3 it was observed that active ZFRs that were not 
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cognate for a substrate increased the SA effect when co-expressed with active ZFRs for 
that were cognate for the substrate (see Section 3.10.5). 
 
 The second observation that can be made regarding the SA effect is that 
compared with the lane 2 (Figure 4-17), where no SA effect was observed, the co-
expression from two single expression vectors of the sleepy and active ZFR pair, produced 
a notable SA effect on the 2MutHomDim substrate (Figure 4-17, lane 5). This result 
confirms that the results of the previous proof-of-principle experiment may have indeed 
been affected by the SA effect under these expression conditions. Additionally, it can be 
observed that under the co-expression from two single-expression vectors condition, a 
detectable level of SA effect can also be observed on the reactions involving the 
2MutHetDim substrates (Figure 4-17, lanes 9 and 13). The SA effect on the 2MutHetDim 
substrates is less pronounced than on the 2MutHomDim substrate.  
 
 A final observation can be made that the SA effect occurs on the 2MutHetDim 
substrates when the sleepy + active ZFR pair are co-expressed (in both single expression 
vector and DEV expression conditions), but at reduced level compared with reaction on 
the 2MutHomDim substrates. This indicates that when the sleepy + active ZFR pair is co-
expressed, sleepy ZFRs can participate in producing a modest level of SA effect when 
cooperating with active ZFRs at heterodimer Z-sites. Conversely, as previously mentioned, 
the lack of SA effect on the 1MutHomDim substrate when cognate sleepy ZFRs are co-
expressed with active ZFRs in DEV mode, indicates that sleepy ZFRs cannot be stimulated 
to produce the SA effect by non-bound active ZFRs when bound to Z-sites as homodimers.  
 
 By making a comparison of the unchanged substrate signals across the lanes in 
Figure 4-17 a general characterization of the size of the SA effect under different 
conditions of expression and active ZFR binding can be made. Comparing the results in 
lanes 1 to lanes 9 and 13 it can be concluded that at single expression vector expression 
levels, when one Tn3[NY G70C]  ZFR participates in heterodimer Z-site binding, the SA 
effect is modest (perhaps 25% reduction in signal strength). Comparing the results in 
lanes 1 to lane 5 it can be concluded that at single expression vector expression levels, 
when two Tn3[NY G70C]  ZFRs participate in homodimer Z-site binding, the SA effect is 
intermediate (perhaps 50% reduction in signal strength). Comparing the results in lanes 1 
to lanes 10, 11, 12, and 15 it can be concluded that at DEV expression levels, when one 
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Tn3[NY G70C]  ZFR participates in heterodimer Z-site binding the SA effect is intermediate 
(perhaps 50% reduction in signal strength). Comparing the results in lanes 1 to lanes 6 
and 7 it can be concluded that at DEV expression levels, when two Tn3[NY G70C]  ZFRs 
participate in homodimer Z-site binding the SA effect is profound (perhaps 90% reduction 
in signal strength). These observations are summarized in Table 4-3. 
  
 
 
 
 
 
 
 
 
Figure 4-17:  Sleepy and unlocked ZFRs complementation reaction using DEVs, at the 17 hour time 
point.  To the left of the gel image, are given the sizes of each band of the molecular marker ladder 
shown in lane 1. To the right of the image, indicators are given to describe the origin of the bands on 
the gel (UNC = unchanged substrate, INV = inversion product, DEL = deletion (excision) product, and 
EXP = expression vector plasmid). Above the gel image is a table which indicates which ZFRs were 
used in conjunction with each substrate for the complementation reactions. Above the table the 
substrate types are indicated. 
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Table 4-3: Summary of the SA effect size relative to expression and binding conditions 
 Tn3[NY G70C]  Heterodimer Tn3[NY G70C]  Homodimer 
SEV expression Modest  ~25% reduction Intermediate ~50% reduction 
DEV expression Intermediate ~50% reduction Profound ~90% reduction 
SEV = single expression vector, DEV = double expression vector 
The percentages given in the table are just visual estimates. 
 
 
Figure 4-18:  Sleepy and unlocked ZFRs complementation reaction using DEVs after one cell passage.  To 
the left of the gel image, are given the sizes of each band of the molecular marker ladder shown in lane 1. 
To the right of the image, indicators are given to describe the origin of the bands on the gel (UNC = 
unchanged substrate, INV = inversion product, DEL = deletion product, and EXP = expression vector 
plasmid). Above the gel image is a table which indicates which ZFRs were used in conjunction with each 
substrate for the complementation reactions. Above the table the substrate types are indicated. The 
doubling of the bands seen in the gel is an artefact resulting from sloping of the wells, and the fact that the 
DNA at the top of the sloped wells appears to have stained more strongly than the DNA throughout the rest 
of the sloped well. 
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4.3.5 Activity screen for other potential interface-unlocking 
activation mutants 
4.3.5.1 Rationale for the experiment 
 The results of the previous experiment were confounded by the SA effect both 
because the active ZFR mutant was capable of producing it, and because the reactions 
using the sleepy + active ZFR pair were so slow that the SA effect outcompeted the small 
amount of reaction products being produced. Additionally, this slow reaction, which 
required passaging the cells, is not ideal for further experimental work, and increasing the 
expression of ZFRs was also not successful in increasing the reaction rate. However, the 
experiment did demonstrate that an inactive ZFR mutant can be activated through 
cooperation with a more active ZFR mutant. This discovery is potentially valuable in and 
of itself, as gene therapy applications might benefit from such a ZFR set up in an 
integration scenario. The use of sleepy ZFRs at the Z-site(s) on the DNA to be integrated 
would reduce the possibilities for off-target reactions. Toxicity has been observed when 
ZFRs were used in mammalian cells, which appears to be due to off-target reactions (Gaj 
et al., 2014). Therefore, two desirable goals, in order to further the utility of the sleepy + 
active ZFR strategy, were to increase the reaction rate, and to reduce the SA effect from 
the active ZFR of the pair. 
 
 The sleepy ZFR used in the previous experiment did not produce the SA effect 
when bound as a homodimer to a Z-site, but it was able to participate in proper ZFR 
recombination reactions with the help of the active ZFR, albeit these reactions were slow. 
One approach taken to increase the activity in the sleepy + active ZFR reaction was to 
attempt to discover a new ZFR mutant to act as the sleepy ZFR which affords more 
activity to the reaction when used in complementation with the active ZFR, but yet still 
retains inactivity when operating on its own. Likewise, an attempt to discover a new ZFR 
mutant to act as the active ZFR, but which is less prone to producing the SA effect, was 
also made.  
 
 Although the hypothesis that E-helix and α/β sub-domain pairing modes might 
give rise to differential tetramer configuration activity was likely falsified by the results in 
Section 4.3.3, the basic premise that activation of the Tn3 catalytic domain occurs by an 
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E-helix and α/β sub-domain unlocking mechanism is still a viable model to work through. 
One way to test and exploit that model is to attempt to determine whether different 
levels of activation occur depending on whether two locking interface mutations, which 
act from opposite sides of the interface, are in a co-localized or distributed arrangement 
in a differentially mutated ZFR dimer pair (Figure 4-19). In this set up one ZFR would carry 
a mutation in the E-helix side of the interface, and the other ZFR would carry a mutation 
in the α/β sub-domain side of the interface. In a co-localized arrangement, heterodimers 
would be formed where both mutations would be paired in the same locking interface on 
one side of the dimer, while the other locking interface on the other side of the dimer 
would contain no mutations. In a distributed arrangement, two alternate homodimers 
would be formed that either contained the two E-helix locking interface mutations, one in 
each side of the dimer, or two α/β sub-domain locking interface mutations, one in each 
side of the dimer. Differential activity of the between the AHD and RHD tetramer 
configurations could lead to a desirable recombination reaction directionality bias. 
 
4.3.5.2 Selection of mutations 
 Known Tn3 secondary activating mutations were categorized into those that might 
disrupt the locking interface from the E-helix side of the interaction, and those that might 
disrupt the interface from the α/β sub-domain side of the interaction (Table 4-4). The 
mutations that potentially interfere with the α/β sub-domain side of the locking 
interaction are either located at positions that directly participate in the interaction, 
positions that might destabilize the α/β sub-domain core, or positions that may help 
stabilize the unlocked conformation.6 The mutations were selected primarily from Burke 
et al. (2004) (Burke et al., 2004), but also from a compendium of mutations compiled 
from unpublished work within the Stark lab. Because of the low activity produced by the 
sleepy + active ZFR pair in the proof-of-principle experiment, it was deemed prudent to 
first screen potential mutants for their base level of activity in the ZFR system prior to any 
complementation experiments.  
 
 
 
                                                     
6 G101S was used in the γδ resolvase of the 1ZR4 structure and appears to stabilize the unlocked E-helix and 
α/β sub-domain conformation through a hydrogen bond from the serine side chain to the backbone 
nitrogen of Gly104. This is displayed later in Figure 4-21. 
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Figure 4-19: Differential locking interface mutation arrangements.  A) The panel shows a co-localized and 
distributed arrangement of the locking interface mutations on the left and right, respectively. The locking 
interface mutation are indicated by small blue and magenta circles and are located in the E-helix or α/β sub-
domain, respectively. The co-localized arrangement is shown in a RHD configuration, while the distributed 
arrangement must occur in the AHD configuration.  B) The panel shows the same two dimer-dimer 
configurations as in A), but rotated 90°. This panel shows how during a recombination reaction the RHD 
configuration becomes the AHD configuration, and vice versa. Therefore, recombination reactions 
transform the co-localized locking interface mutation arrangement into the distributed arrangement (which 
produces a reaction directionality bias if one of the arrangements is more active than the other). 
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Table 4-4: Categorization of selected mutants 
 
4.3.5.3 Experiment design 
 For this preliminary experiment, designed to measure the activity level of known 
Tn3 secondary mutations in the ZFR system, the mutations were incorporated into the 
Tn3[NY] (sleepy ZFR) background that was used in the previous experiments (see Section 
4.3.2). The new catalytic domains were then attached to the Z3 ZFA, and the new ZFRs 
were tested on their cognate 1MutHomDim substrate in a 17 Hour Recombination Assay. 
Additionally, Tn3[N G70C]-Z3 and Tn3[NY]-Z3 were included in the experiment as 
negative controls, while Tn3[NY G70C]-Z3  and Tn3[NM]-Z3 acted as a positive controls. 
 
4.3.5.4 Results 
 The results of the experiment (shown in Figure 4-20) were surprising in that 
almost all of the ZFRs created were not active. This result contrasts with the behaviour of 
these mutations in Tn3 resolvase, as the Burke et al. (2004) study and unpublished work 
within the Stark lab clearly demonstrated these mutant catalytic domains had surpassed 
the hyperactivity threshold (see Chapter 1, Section 1.6.5 for a description of 
hyperactivity). This indicates the Tn3-based ZFR system is intrinsically much less active in 
comparison with Tn3 resolvase. 
 
  Of the mutants that were notably active in the screen, Tn3[NY L66I]-Z3 produced 
a faint, but detectable, amount of recombination product (Figure 4-20 A, lane 4), Tn3[NY 
G70A]-Z3, Tn3[NY G101S]-Z3, and Tn3[NY V108A]-Z3 demonstrated a low level of 
recombination activity (Figure 4-20 A, lanes 6, 14, and 20, respectively), and, as expected, 
Tn3[NY G70C]-Z3 and Tn3[NM]-Z3 produced a total conversion of substrate to 
recombination product (Figure 4-20 A, lane 7 and Figure 4-20 B, lane 10, respectively). 
The results of this experiment suggested that G70A, G101S, and V108A might be suitable 
as replacement secondary mutations for G70C in the active ZFR of the sleepy + active ZFR 
pair, provided the sleepy ZFR has increased activation potential through the inclusion of 
its own secondary mutation. Likewise, the results also suggest that the remaining 
E-helix side α/β sub-domain side 
T109I, A117V, R121K/M/S, E124Q 
L66I/F, G70A/C, I77T, A89T, F92S, I97M, T99S, 
G101S/C,  M103I/V,  Q105L, V107F/M, V108A 
The mutations shown in red also have alternative or additional explanations for the activity they produce 
(see Section 4.4). 
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mutations might be suitable for inclusion in the sleepy ZFR of a sleepy + active ZFR pair as 
these catalytic domains possess no substantial activity on their own in the ZFR system.   
 
 The mutations G101S and V108A might prove particularly useful if used in concert. 
It can be derived from analysing the 1ZR4 crystal structure of an activated resolvase 
tetramer that contains the G101S mutation, that G101S may stabilize the unlocked 
conformation producing a stabilizing hydrogen bond between the Ser101 hydroxyl and 
Gly104 backbone amide (Figure 4-21 B). Additionally, using the 'morph' tool of the UCSF 
Chimera molecular modelling software package (http://www.cgl.ucsf.edu/chimera) to 
interpolate the conformational states between a locked 1GDT subunit and an unlocked 
1ZR4 subunit, it can be seen that the V108A mutation might produce a dimer interface-
unlocking effect by removing a potential steric energy barrier between Val108, and Thr99 
and Ile80 as the α/β sub-domain translocates across the E-helix in (Figure 4-22). The 
potential clash between Thr99 and Val108 is particularly sustained throughout the 
conformational transition, and this is interesting given that T99S is also a known 
activating mutation and T99S potentially removes this steric energy barrier as well. 
Because G101S and V108A may support the formation of the unlocked conformation 
without actually knocking out the locking interface, they might still require some 
stimulation from tetramer formation in order to engage in catalytic activity. Thus, these 
mutations might be less prone to the SA effect than G70C, which directly produces a 
locking interface disruption and thus may be more ready to produce unregulated 
cleavage when stimulated by unbound subunits (see Section 3.10.5 for a description of 
how the SA effect is proposed to operate). 
 
 One notable feature of the results is that they support the prediction that G70C 
would produce a disproportionately large locking interface disruption compared with 
other locking interface activating mutations (see Section 4.3.2.2). It appears in a 
comparison of the results from the Tn3[NY G70C]-Z3 ZFR and the Tn3[NM]-Z3 ZFR, that 
within this experiment the former may be as active as the latter; although, the reaction 
would have to be caught at an earlier stage to confirm that their activity level is actually 
equal, as all the substrate had already been converted to recombination product. This 
result is notable because the 'M' collection of mutations is considered highly active and 
requires several secondary mutations used in conjunction to produce this level of activity. 
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Figure 4-20:  Base activity level screen of other potential locking interaction knock-down mutants in the 
ZFR system.  The results of a 17 Hour Recombination Assay are shown spread across two gels, A) and B). To 
the left of the gel image, are given the sizes of each band of the molecular marker ladder shown in lane 1. 
To the right of the image, indicators are given to describe the origin of the bands on the gel (UNC = 
unchanged substrate, INV = inversion product, DEL = deletion (excision) product, and EXP = expression 
vector plasmid). Above the gel image is a table which indicates which ZFRs were used in conjunction with 
each substrate for the complementation reactions. The sample shown A) lane 17 appeared to be heavily 
contaminated with chromosomal DNA left over from the mini prep, and therefore that experiment was 
repeated and is displayed again in B) lane 2. Tn3[N G70C]-Z3 and Tn3[NY]-Z3 were included in the 
experiment as negative controls, and are shown in gel A) lanes 2 and 3, respectively. Tn3[NM]-Z3 was also 
included, as a positive control, and appears in gel B) lane 10. 
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Figure 4-21: G101S stabilizes unlocked conformation.  A) The panel shows a 1GDT subunit in the locked 
conformation, with Gly101 highlighted in magenta.  B) The panel shows a 1ZR4 subunit in the unlocked 
conformation, with Ser101 (G101S) highlighted in magenta.  Compared with the E-helix of the 1GDT 
subunit, the E-helix of the 1ZR4 subunit has been slightly extended by the hydrogen bond from Ser101 
which stabilizes and extra loop of the helix. This conformational change in the E-helix appears to support 
the change in position of the α/β sub-domain relative to the E-helix seen between the 1GDT subunit and 
the 1ZR4 subunit. The Ser101 side chain makes a 2.8 Å hydrogen bond contact to the nitrogen in the 
backbone of Gly104, while the backbone oxygen of the Ser101 makes a 3.2 Å hydrogen bond contact to the 
nitrogen in the backbone of Lys105 (side chains and backbone atoms of these contacts are not displayed). 
The HTH domains are not shown in the figure. 
199 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.6 Å 
6.7 Å 
3.1 Å 
4.3 Å Val108 Thr99 
Ile80 
A) B) 
3.2 Å 3.4 Å 
C) 
4.5 Å 4.1 Å 
D) 
NH2 
NH2 
NH2 NH2 
Figure 4-22: Potential clashes between Val108, and Ile80 and Thr99 during conformational transformation.  
The figure shows a morph conformational interpolation between a 1GDT subunit conformation and a 1ZR4 
subunit conformation. All panels display the resolvase subunit in identical orientation relative to the position 
of the E-helix. The DNA and HTH domain, along with some of the E-helix, is not shown.  A) The panel displays 
the 1GDT subunit, which is the beginning of the conformational transition from locked to unlocked state. The 
distances between the methyl groups of Ile80 and Val108, and Thr99 and Val108 are indicated, and these 
amino acid are labelled.  B) The panel shows a transitional conformational state (modelled using Chimera's 
morph interpolation tool) between a 1GDT subunit conformation and a 1ZR4 subunit conformation, where 
the methyl group of Thr99 is 3.1 Å from a methyl group of Val108.  C) The panel shows a transitional 
conformational between a 1GDT subunit conformation and a 1ZR4 subunit conformation, where the methyl 
group of Ile80 is 3.1 Å from a methyl group of Val108.  D) The panel shows a 1ZR4 subunit which represents 
the end of the conformational transition. 
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4.3.5.5 DEV repeat of the experiment 
 The activity screen of the mutants was performed again using DEV-based double 
expression levels, in order to attempt to increase the recombination activity, and thus, 
increase the sensitivity of the experiment for detecting differences in activation level 
imparted by the various mutations. Tn3[NY G70C]-Z3 and Tn3[NM]-Z3 were not included 
in this experiment because they had already produced complete conversion of substrate 
to recombination product in the previous single expression vector assay. The negative 
controls, Tn3[N G70C]-Z3 and Tn3[NY]-Z3, were also dispensed with, as it was expected 
that, given the results of the previous experiment, there would be many mutants in the 
set that would effectively act as negative controls.  
 
4.3.5.6 Results 
 There was almost no change observed in the results (shown in Figure 4-23) 
relative to the previous experiment, with only the Tn3[NY G70A]-Z3 ZFR showing an 
appreciably increased level of activity (Figure 4-23 A, lane 4). The results of the Tn3[NY 
G70A]-Z3 ZFR reaction also produced the familiar SA effect, in contrast to the inactive 
mutants that did not produce this effect. This result confirms the conclusion drawn from 
the results in Section 4.3.4.3 that the SA effect requires active catalytic domains in order 
to occur, likely indicating that the SA effect is the product of unregulated cleavage of the 
DNA, rather than being a product of ZFR binding itself.  
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4.3.6 Testing new sleepy + active ZFR pairs 
4.3.6.1 Rationale for the experiment 
 As outlined in Section 4.3.5.1, it would be desirable to have a sleepy ZFR with 
increased activation in a sleepy + active ZFR complementation, but which is not active 
when used alone. It would also be desirable to have an active ZFR that had a lower 
tendency to produce the SA effect. Additionally, if two sleepy ZFRs could be used in 
concert to produce activation, this would also be desirable. Therefore, an experiment was 
designed to test whether the new ZFR mutants, which were previously assayed for base-
level activity, could increase the reaction rate of sleepy + active ZFR complementations. In 
addition, because most the mutations in the previous base-level activity experiment are 
proposed to operate through a locking interface knockdown, some inferences can be 
made from the following experiment about that model. In particular, if a robust locking 
interface knockdown mutation, such as G70C, is paired in a co-localized arrangement (see 
Figure 4-19) with another locking interface knockdown mutation that operates in the 
same region of the interface, the second mutation might be expected to produce no 
additional activity due to redundancy.  
 
4.3.6.2 Experiment design 
 The secondary mutations used in the previous experiment can be categorized into 
those that may operate by interfering with the locking interface from the E-helix side or 
α/β sub-domain side of the interaction (see Table 4-4). For this experiment, select ZFRs 
with secondary mutations that may knockdown the locking interaction from the α/β sub-
domain side of the interface, were paired with all of the ZFRs containing secondary 
mutations that may operate by knocking down the locking interaction from the E-helix 
side of the interface. In order to test whether two sleepy ZFRs can be used in concert to 
achieve activity, Tn3[NY L66I]-Z3 was used as the α/β sub-domain side knockdown ZFR. In 
Figure 4-23:  DEV-based activity level screen of other potential locking interaction knock-down mutants in 
the ZFR system.  The results of a 17 Hour Recombination Assay are shown spread across two gels, A) and B). 
DEVs were used to increase the concentration of ZFRs in the cells. To the left of the gel image, are given 
the sizes of each band of the molecular marker ladder shown in lane 1. To the right of the image, indicators 
are given to describe the origin of the bands on the gel (UNC = unchanged substrate, INV = inversion 
product, DEL = deletion (excision) product, and EXP = expression vector plasmid). Above the gel image is a 
table which indicates which ZFRs were used in conjunction with each substrate for the complementation 
reactions.  
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order to test whether a lower-activity active ZFR, which may have less tendency to 
produce the SA effect, can be used to achieve activity in a sleepy + active ZFR 
complementation, Tn3[NY G101S]-Z3 was selected as the α/β sub-domain side 
knockdown ZFR. In order to test whether sleepy mutants carrying a secondary mutation 
might be able to increase the activity in a sleepy + active ZFR complementation, Tn3[NY 
G70C]-Z3 was used as the as the α/β sub-domain side knockdown ZFR. In order to reduce 
the volume of work for this experiment, only a 2MutHetDim-DR substrate was used to 
determine whether complementations were significantly active. The experiment was 
carried out using the 17 Hour Recombination Assay. 
   
4.3.6.3 Results 
 The results of this experiment are shown in Figure 4-24. The results of the 
complementations between the sleepy + unlocked ZFR pairs on the 2MutHetDim-DR 
substrate show: no noteworthy recombination activity for any of the complementations 
involving the Tn3[NY L66I]-Z3 sleepy ZFR (paired with other sleepy ZFRs); faint levels of 
recombination activity for complementations using the Tn3[NY G101S]-Z3 active ZFR + 
Tn3[NY R121K]-Z2, Tn3[NY R121M]-Z2, and Tn3[NY R121S]-Z2 sleepy ZFRs (Figure 4-24 A, 
lanes 15, 16, and 17, respectively); and, importantly, a substantial conversion of substrate 
to recombination product for the Tn3[NY G70C]-Z3 active ZFR + Tn3[NY T109I]-Z2 sleepy 
ZFR pair (Figure 4-24 B, lane 3). The Tn3[NY A117V]-Z2 and Tn3[NY E124Q]-Z2 sleepy ZFRs 
in complementation with the Tn3[NY G70C]-Z3 active ZFR (Figure 4-24 B, lanes 4 and 9, 
respectively), also showed a weak level of recombination activity. However, this 
recombination activity was not above the level of recombination seen for the 
complementation involving the Tn3[NY]-Z2 sleepy ZFR (Figure 4-24 B, lane 2), which does 
not possess any secondary unlocking mutation at all. Trace levels of activity can be seen in 
several additional lanes when the original image file is viewed on a computer screen. 
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 One interesting aspect of the results is that Tn3[NY R121K]-Z2 and Tn3[NY 
R121M]-Z2 had more activity when paired with Tn3[NY G101S]-Z3 than they did when 
paired with Tn3[NY G70C]-Z3. This result supports the locking interface activation model 
because the expectation was that if the model was correct, the co-localization of a robust 
knockdown mutation, such as G70C, with another interface knockdown mutation 
operating in the same region from the other side of the interface, would produce no 
additional activating effect because it is redundant. If these ZFRs pairs produced activity 
in a distributed arrangement, this would lead to a desirable bias in recombination 
reaction directionality, which might allow the stable integration reactions to be 
performed (see Figure 4-19). This differential activity profile can occur because co-
localization pairs locking interface mutations redundantly on one side of the dimer, while 
leaving the other side of the dimer locked. Conversely, a distributed arrangement, using 
the same ZFR pair, places activating mutations in locking interfaces on both sides of the 
dimer, and thus this arrangement may be more active. Essentially, the co-localization 
arrangement may cancel out the activity contribution from two one of the ZFRs in the 
pair, while the distributed arrangement benefits from the activity contribution provided 
by both ZFRs. 
 
 Even more interesting is that the Tn3[NY G70C]-Z3 + Tn3[NY R121G]-Z2, Tn3[NY 
R121K]-Z2, Tn3[NY R121M]-Z2, Tn3[NY R121S]-Z2, and Tn3[NY E124Q]-Z2 
complementations (Panel B, lanes 5–9), produce no activity, while the Tn3[NY G70C]-Z3 + 
Tn3[NY]-Z2 complementation produced minimal recombination activity. This implies that 
the inclusion of secondary activating mutation at position 121 within the sleepy ZFR 
actually reduced the recombination activity of the reaction. Since Tn3[NY R121K]-Z2 and 
Tn3[NY R121M]-Z2 did increase recombination activity over the use of Tn3[NY]-Z2, when 
paired with Tn3[NY G101S]-Z3, it can be concluded that the reduction in activity seen 
when paired with Tn3[NY G70C]-Z3 is unique to the complementation with Tn3[NY G70C]-
Z3. One possible explanation for this effect, is that knocking out the locking interface 
Figure 4-24:  Synergistic knock-down of both sides of the locking interaction.  The results of a 17 Hour 
Recombination Assay are shown spread across two gels, A) and B). To the left of the gel image, are given 
the sizes of each band of the molecular marker ladder shown in lane 1. To the right of the image, indicators 
are given to describe the origin of the bands on the gel (UNC = unchanged substrate, INV = inversion 
product, DEL = deletion (excision) product, and EXP = expression vector plasmid). Above the gel image is a 
table which indicates which ZFRs were used in conjunction with each substrate for the complementation 
reactions. 
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completely (as opposed to partial disruption), deactivates the enzyme. Since the locking 
interface comprises the major portion of the dimer interface, it may be the case that 
completely knocking out this region prevents dimers from forming, or prevent dimers 
from forming properly. Data from Burke et al. (2004) may also support this possibility. In 
Burke et al.'s experiments, several E-helix side locking interface mutations (A117V, R121K, 
and E124Q) that produced a high level of recombination activity when used as the sole 
secondary mutation, produced an inactive resolvase when combined together. If co-
localization of locking interface mutations can be used to abolish the activity of the ZFR, 
then a high fidelity recombination reaction directionality bias should be possible by 
arranging ZFR mutants such that an active AHD configuration results in an inactive RHD 
configuration. 
 
 Unfortunately, there was insufficient time available to carry out a follow-up 
experiment to further test the foregoing approaches to achieving a recombination 
reaction directionality bias.  There was also insufficient time to carry out further 
experiments to test whether a combination of secondary mutations, such as G101S and 
V108A would be able to produce an active ZFR that is less prone to the SA effect (see 
Section 4.3.5.4).  
 
4.4 Residue 102 and E-helix 'landing pad' 
4.4.1 Introduction 
4.4.1.1 The residue at position 102 is the lead contact during catalytic dimer-
dimer synapsis  
 The results of Section 4.2 demonstrated that the activating effect provided by 
primary mutations (e.g. D102Y) is likely not caused by the removal of a critical ionic 
energy barrier between counterpart Asp102 residues across the initial dimer-dimer 
interface. Therefore, the question remains: why are the primary activating mutations so 
important for hyperactivation of Tn3 resolvase? All of the possible residue substitutions 
at position 102 have been attempted within the Stark lab, and the primary mutations 
capable of producing hyperactivation of Tn3 resolvase are as follows Y, F > I > V > T > W 
(ranked in  order of the level of activating effect they provide; Burke et al. (2004) and 
unpublished work within the Stark lab). The first thing that can be noted is that all of the 
primary activating mutations are hydrophobic, with the exception of threonine—the only 
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polar residue with a methyl group in its side chain. Additionally, almost all of the possible 
hydrophobic amino acid substitutions are capable of acting as primary activating 
mutations. Therefore, it would appear that hydrophobicity at position 102 is correlated 
with activation.  
 
 During the initial stage of tetramer formation, the N-terminal ends of the E-helices 
of the dimers must make contact with each other in order to form the antiparallel 
interactions between the E-helices seen in the 1ZR4 activated tetramer structure (Figure 
1-13 and Figure 1-12; (Li et al., 2005)).  All of the activating mutations located on the face 
of the N-terminal end of the E-helix that presumably make this initial contact, are 
hydrophobic substitutions (e.g. D102Y, M103I, Q105L, T109I; see Figure 4-25). An 
explanation for the activating effect of these hydrophobic mutations is that they enable 
favourable hydrophobic contacts between opposing E-helices during the initial stage of 
dimer-dimer interaction. It should also be noted, that in spite of the results of Section 4.2, 
it is still possible that favourable hydrophobic interactions between counterpart 102 
residues plays a role in activation.   
 
 The second thing that may be considered, is that in order for the tetramer to 
form, the E-helices, with residue 102 at the lead, must pass through a hydrophobic region 
that is occupied by the contacts of the locking interface in the pre-tetramer configuration 
of the dimer (Figure 4-4, Figure 4-8, and Figure 4-25 A). It is possible that mutating the 
lead residues of the E-helix to hydrophobic residues, allows the E-helix to more 
successfully displaces these hydrophobic locking region interactions during tetramer 
formation by replacing one set of hydrophobic contacts for another, perhaps stimulating 
the conformational change that leads to activation. This hypothesis of the E-helix 
interaction is functionally related to the locking interface unlocking model, as the locking 
interface knockdown mutations would also facilitate this same conformational transition, 
which allows the α/β sub-domain to move as the E-helix from an opposing subunit takes 
its place. It may also be noted that in the case of D102Y, modelling using the UCSF 
Chimera and the Dumbrack rotamer library (Dunbrack, 2002) indicated that the hydroxyl 
group of the tyrosine side chain at position 102 is most likely to face away from the 
hydrophobic contact region D102Y potentially makes contact with (model not shown). 
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 The potentially unfavourable interaction between Tn3 resolvase wild-type residue, 
aspartic acid (or glutamic acid in the case of γδ resolvase), during initial contact with the 
hydrophobic region on the opposing E-helix (Figure 4-4, Figure 4-8, and Figure 4-25 A), 
might serve the wild-type enzyme as an energy barrier that prevents activation of the 
enzyme outside of proper synaptosome formation. Energy to overcome this potential 
energy barrier would presumably be provided by the synaptosome in the wild-type 
system. This explanation builds a connection between the activity of the primary 
mutations (at position 102) and the activity of the secondary activating mutations (most 
of which potentially affect the locking interaction), which may explain why they appear to 
work synergistically to activate the enzyme. The secondary mutations may make it easier 
for the locking interaction to be disrupted, but only if the lead residue of the E-helix is 
predisposed to favourable interaction with the hydrophobic portion of the locking region. 
 
 The activating mutation G101S should also be mentioned with respect to its 
potential effect on this hypothetical activity of D102Y negotiating the hydrophobic region 
of an opposing E-helix. Although G101S may produce its activating effect by stabilizing the 
unlocked conformation (see Figure 4-21), it is also true that this conformational change, 
which slightly extends the E-helix, also results in changing the position and orientation of 
the residue at position 102. Therefore, in addition to potentially stabilizing the unlocked 
Figure 4-25: Early contacts during dimer-dimer synapsis.  A) The panel shows the anti-parallel contacts 
being formed between two E-helices (cyan and green cylinders) of the catalytic tetramer during synapsis. 
Only the E-helices of the cyan and green subunits are shown. In addition, the adjacent dimer subunit 
partner of the green subunit is displayed (transparent yellow) with only its α/β sub-domain (oval) and E-
helix shown. The adjacent dimer subunit partner of the cyan is not displayed at all for clarity of the image. 
The cyan E-helix makes contact with an opposing green E-helix in the dimer-dimer interface. The space the 
cyan E-helix must pass through is initially blocked by the α/β sub-domain of the dimer partner of the green 
subunit, the yellow subunit. As the initial dimer-dimer interface complex transitions to the catalytic 
tetramer complex, the α/β sub-domain of the yellow subunit translocates around the E-helix of the yellow 
subunit, freeing the space and allowing the E-helix of the cyan subunit to form its anti-parallel interaction 
with the E-helix of the green subunit.  B) The panel shows the protrusion of the lead residue of the E-helix 
at position 102. In the 1GDT γδ resolvase structure shown the Glu102 of the yellow subunit is shown in 
space-filling mode.  C) The panel shows the same image as in B) but rotated 90° for a different perspective.  
D) The panel shows the 'landing pad' region which the residue at position 102 of an opposing E-helix in the 
dimer-dimer interface must negotiate in order to achieve the anti-parallel E-helix-E-helix interface of the 
catalytic tetramer. The seven residues which make up the landing pad (Green subunit: Glu102, Met103, 
Lys105, Met106, and Thr109, and green subunit Ile97, and Met103) are shown in space-filling mode.  E) 
This panel shows the same region as in D) but enlarged and with the seven landing pad residues labelled 
and shown in stick mode. It should be noted that regarding the image displayed in panels B) and C), that in 
the green subunit of the 1GDT structure, which has an unlocked α/β sub-domain, Glu102 is in a somewhat 
different position (not shown) than that of the yellow subunit (shown). However, even in the green subunit, 
Glu102 is still the leading residue on the face of the helix which must make the E-helix-E-helix dimer-dimer 
contacts.  
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conformation, G101S might also promote more favourable contact between the D102Y 
and the hydrophobic region on the opposing E-helix. 
 
 Unfortunately, during this stage in the experimental work, there was insufficient 
time to meticulously test the hypothesis concerning the activity of the residue at position 
102 and its contact with the opposing E-helix during the initial stage of tetramer 
formation. However, rudimentary experiment based on this hypothesis was possible. It 
was considered that this type of interaction might be exploited to produce the sought 
after biases in tetramer configuration activity, which might produce dimer-dimer 
orientation specificity and/or recombination reaction directionality. Therefore, this 
premise was considered when designing the current experiment.  
 
4.4.1.2 Residue 102 and the 'landing pad' 
 A region at the N-terminal of the E-helix, termed here as the 'landing pad', can be 
proposed as the initial contact interface between residue 102 and opposing E-helix it 
must contact during catalytic dimer-dimer synapsis (Figure 4-25 D and E). The proposal of 
this region as the initial contact point during synapsis is consistent with the modelling 
shown in Figure 4-10, and the dimer-dimer synapsis trajectory proposed by Li et al., 
(2005). Of the seven residues that make up the landing pad, five are locations of known 
activating mutations (D102X,7 M103I/V, Q105L, and T109I; note that two Met103 
residues on adjacent subunits participate in the same landing pad, see Figure 4-25 D and 
E). All of these activating mutations replace polar residues with hydrophobic ones, with 
the exception of the substitutions at position 103, which can be said to increase the 
hydrophobicity at that position. Therefore, all of these secondary activating mutations 
could be proposed to produce their effect by creating a more favourable environment for 
the hydrophobic primary activating mutation residue to negotiate during the initial stage 
of catalytic dimer-dimer synapsis. It should also be considered that the dimers, and thus 
the E-helix N-terminal regions, likely do not initially contact with each in a perfectly 
symmetrical fashion. Therefore, increasing the general hydrophobicity at the N-terminal 
ends of the E-helices may help allow this initially imprecise contact to stabilise the 
interaction between the E-helices, facilitating a transition to a more bona fide initial 
synaptic state. 
                                                     
7 'X' represents the lists of activating substitutions at position 102 given in Section 4.4.1.1. 
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 Aside from the potential contacts between residue 102 and the landing pad 
(Figure 4-25) and hydrophobic portion of the locking region (Figure 4-4), there are also 
two potential specific contacts that my take place between counterpart residues of the 
landing during dimer-dimer formation. Molecular modelling using the 1GDT dimer 
structure suggests that it is highly probable that opposite-adjacent counterpart residues 
at position 103 make contact with each other (the molecular model not shown, but a 
diagram depicting this interaction is displayed in Figure 4-26).  Therefore, it is possible 
that the activating effect provided by mutations such as M103I is the result of either a 
favourable interaction between counterpart 103 residues, or the removal of an 
unfavourable interaction between counterpart 103 residues.  Additionally, it is possible 
that opposite counterpart residues at position 105 also make contact with each other 
during an early stage of dimer-dimer interaction (Figure 4-26). Therefore, Q105L might 
also produce its effect by either generating a favourable counterpart interaction, or 
removing an unfavourable one. The tetramer configuration activity profile that would be 
predicted from favourable counterpart residue interaction between M103I or Q105L is as 
follows: the opposite-adjacent subunit interaction of M103I would be expected to 
increase the activity of only the RHD configuration, while the opposite subunit interaction 
of Q105L would be expected to increase the activity of only the MHD configuration.  
 
 It should also be noted that because of their participation in the locking 
interaction, alternative explanations exist for the activating effect of several secondary 
mutations of the landing pad.  Mutations at position 103 might break a potential 
hydrophobic locking interface contact (Figure 4-25 E), which could destabilize the locked 
conformation.  Q105L may help facilitate conformational transformation from the locked 
to unlocked dimer state, by making more favourable interactions during the transition 
(UCSF Chimera morph model not shown). Finally, T109I might produce its effect by 
destabilizing a potential hydrophobic contact between Thr109 and Ile97 that may help to 
stabilize the locking interaction (Figure 4-25 E). 
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 Finally, it because the landing pad mutations may help stabilize or facilitate the E-
helix–E-helix interactions that initiate the unlocking of the α/β sub-domain from the E-
helix, the landing pad mutations located on the E-helix may be functionally equivalent to 
E-helix-side interface unlocking mutations that also promote the unlocking 
transformation from the E-helix side of the interaction. Q105L and G101S may be unique 
in this sense, as they might either act as α/β sub-domain-side activators or E-helix-side 
activators. 
 
4.4.2 Experiment design 
4.4.2.1 Experimental variables 
 In order to test whether the interaction between position of 102 of the E-helix and 
the landing pad of an opposing E-helix may be used to produce a dimer-dimer orientation 
specificity bias, or recombination reaction directionality bias, a new sleepy + active ZFR 
complementation experiment was designed. This experiment operated over three 
variable conditions: the presence or absence of a primary mutation in the absence of 
activating landing pad mutations, the presence or absence of a primary mutation in the 
presence of activating landing pad mutations, and the presence or absence of activating 
landing pad mutations in the presence of a primary mutation. In all cases D102Y was used 
as the primary mutation, while G70C was used as the secondary mutation under the 
experimental condition where no landing pad activating mutations were present. 
However the options for manipulating the landing pad mutation variable were limited by 
both the activity profiles of these mutations, and the time available to conduct the 
experiment, and thus, the mutation collection known as 'M' was used to test this variable 
(see below). 
 
 
 
 
Figure 4-26: E-helices dimer-dimer contact descriptions and mutations.  A) This panel shows paired 
dimers, and provides a visual depiction of the subunit contact descriptions which are given above the 
diagrams.  B) This panel shows hypothetical anti-parallel E-helix-E-helix contacts at the initial dimer-dimer 
interface of the catalytic tetramer. At the left is provided a reference diagram in order to make the images 
to the right easier to interpret. At the right and in the middle are diagrams showing potential self-
complementary interactions (orange oval) between residues of the mutations given below. 
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4.4.2.2 Rationale for using M as the landing pad variable 
 The data collected in Section 4.3.5 (Figure 4-20 and Figure 4-23) demonstrate that 
none of the landing pad activating mutations are sufficient to impart the ZFR with 
significant base-level activity when used as the sole secondary mutation. Therefore, in 
order to test the effect of the landing pad activating mutations, they must be 
incorporated into a background with other secondary activating mutations in order to 
produce ZFRs with sufficient activity. Ideally each landing pad activating mutation might 
have been paired alone with one or more secondary mutations sufficient to activate the 
ZFR. At the point where the work for this segment of the project was undertaken, there 
was insufficient time available to determine what secondary mutation background might 
be sufficient to activate mutants containing single landing pad activating mutations. Even 
G70C, for instance, does not produce a robust level of recombination activity when paired 
with sleepy Tn3[NY] ZFR. This experiment utilizes not only a Tn3[NY] sleepy ZFR but also a 
Tn3[N] sleepy ZFR, which was predicted to impart even less of an activity contribution 
than Tn3[NY] to the sleepy + active ZFR complementations. However, the mutation 
collection known as M (G101S, D102Y, M103I, and Q105L) was known to produce high-
level baseline activity (Figure 4-20), and also contains all of the known landing pad 
activating mutations apart from T109I.  Therefore, M was used as the independent 
variable in the experimental conditions where the presence or absence of the landing pad 
mutations was tested.  
 
4.4.2.3 Substrate selections 
 In order to detect a dimer-dimer orientation specificity or reaction directionality 
bias, the 2MutHomDim, 2MutHetDim-DR, and 2MutHetDim-IR substrates were used as in 
the previous experiments. In order to reduce the volume of work for this experiment, 
only one of the two varieties of each substrate (e.g. Z2/Z2 x Z3/Z3 and Z3/Z3 x Z2/Z2) was 
used. It should be noted that the choice of 2MutHetDim-IR substrate variety, relative to 
the catalytic domain and ZFA combinations that are used, produces a bias when 
comparing the excision product signal from 2MutHetDim-DR and 2MutHetDim-IR 
substrates. This bias results because, while the excision product from either variety of 
2MutHetDim-DR substrate is subject to an intermediate level of SA effect due to its 
heterodimer Z-site, the excision product from 2MutHetDim-IR substrates will be subject 
to ether a strong SA effect, or no SA effect at depending on whether its homodimer Z-site 
specifies the sleepy or active ZFR. If the homodimer Z-site in the 2MutHetDim-IR excision 
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product specifies the active ZFR, the SA effect will be strong, but if it specifies sleepy ZFR, 
then the SA effect will not be present. For this experiment, the Z2/Z3 x Z3/Z2 
2MutHetDim-IR substrate was used, which produces an excision product with a 
homodimer Z-site that specifies the active ZFRs, and thus, is subject to a strong SA effect.  
 
4.4.2.4 The experiment 
 The sleepy + active ZFR pairs, Tn3[N G70C]-Z2 + Tn3[NY G70C]-Z3, Tn3[N]-Z2 + 
Tn3[NM]-Z3, and Tn3[NY]-Z2 + Tn3[NM]-Z3, were assayed in the 17 Hour Recombination 
Assay on the 2MutHomDim (Z2/Z2 x Z3/Z3), 2MutHetDim-DR (Z2/Z3 x Z2/Z3), and 
2MutHetDim-IR (Z2/Z3 x Z3/Z2) substrates. As in previous experiments, the production of 
the various reaction products (unchanged, inversion, and excision) from the various 
substrates indicates the activity level of the various possible tetramer configurations 
(AHD, MHD, and RHD). Differential activity of the AHD and RHD configurations indicates 
the potential for a recombination reaction directionality bias, while differential activity 
between of the MHD and RHD configurations indicates a dimer-dimer orientation 
specificity bias. A table is provided below the gel image in the results (Figure 4-27) that 
indicates the relationships between tetramer configuration activity and reaction products 
from the various substrates. 
 
4.4.3 Results 
4.4.3.1 Y independent variable in an N G70C background 
 The results from the complementations between the Tn3[N G70C]-Z2 + Tn3[NY 
G70C]-Z3 ZFRs (Figure 4-27, lanes 2–4) indicates that this pair is almost inactive. In fact, 
these results are very similar to those seen for the Tn3[NY]-Z2 + Tn3[NY G70C]-Z3 pair 
used in the Section 4.3.3 preliminary experiment (for which the results are not shown) 
and the comparable set of reactions in 4.3.4.3 (Figure 4-17, lanes 5, 9, and 13). Although 
the signals are very weak, it can be observed that the signal for the 2MutHetDim-DR 
excision product (lane 3) is stronger than that for the 2MutHomDim excision product 
(lane 2), indicating the MHD configuration may be slightly more active than the AHD 
configuration. There is no excision product visible for the 2MutHetDim-IR substrate (lane 
4), but this is likely the result of the SA effect.  The SA effect can also be observed when 
comparing the unchanged substrate bands between the three lanes, with the expected 
greater level SA effect occurring in lane 2.  
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4.4.3.2 M independent variable in a N background 
 The complementation between the Tn3[N]-Z2 + Tn3[NM]-Z3 ZFR pair (lanes 6–8) 
produced no recombination activity at all, but the SA effect can be seen for the 
unchanged substrate signal from the 2MutHomDim substrate (lane 6) when comparing 
the signal strength to the unchanged substrate signal from the 2MutHetDim reactions 
(lanes 7 and 8). This result provides important information for the next set of results by 
indicating the relative SA effect production by Tn3[NM]-Z3 on plasmids with a homodimer 
binding site (lane 6), compared to those with heterodimer binding sites (lanes 7 and 8).  
The signal strength for the unchanged substrate signal from the 2MutHetDim-DR (lane 7) 
substrate is also noticeably stronger than that from the 2MutHetDim-IR substrate (lane 
8). However, this difference can be accounted for by an increased overall concentration 
of the DNA loaded into the lane 7 as deduced by comparing the signal strength of the 
digested expression plasmid bands (most obvious in the bands just below the 1.6 kb 
marker).  
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 ____2MutHomDim____ ___2MutHetDim-DR___ ___2MutHetDim-IR___ 
 1° 2° 1° 2° 1° 2° 
UNC  RHD  AHD  MHD 
INV AHD  RHD   MHD  
DEL AHD MHD MHD AHD RHD RHD 
1° indicates the primary reactions, while 2° indicates secondary reactions that may take place only if the 
inversion product has been produced by a primary reaction. 
UNC = unchanged substrate, INV = inversion product, DEL = deletion/excision product 
Pink fields indicate reactions leading to a product that is most susceptible to the SA effect, while yellow 
fields indicate reactions leading to product that are only partially susceptible to the SA effect. 
     1         2        3        4        5         6        7        8       9       10      11      12 
  A B C  A B C  A B C  
 
M Z2
/Z
2 
x 
Z3
/Z
3
 
Z2
/Z
3 
x 
Z2
/Z
3
 
Z2
/Z
3 
x 
Z3
/Z
2
 
 Z2
/Z
2 
x 
Z3
/Z
3
 
Z2
/Z
3 
x 
Z2
/Z
3
 
Z2
/Z
3 
x 
Z3
/Z
2
 
 Z2
/Z
2 
x 
Z3
/Z
3
 
Z2
/Z
3 
x 
Z2
/Z
3
 
Z2
/Z
3 
x 
Z3
/Z
2
 
 
Tn3[N G70C]-Z2  + + +  - - -  - - -  
Tn3[NY G70C]-Z3  + + +  - - -  - - -  
Tn3[N]-Z2  - - -  + + +  - - -  
Tn3[NM]-Z3  - - -  + + +  + + +  
Tn3[NY]-Z2  - - -  - - -  + + +  
 
Substrate ZFR type 
A = 2MutHomDim   B = 2MutHetDim-DR     C = 2MutHetDim-IR 
Substrate configuration 
UNC 
INV 
DEL 
UNC 
EXP 
EXP 
506, 517 
396 
2036 
1636 
1018 
298 
220 
3054 
201 
154 
4072 
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4.4.3.3 G101S + M103I + Q105L independent variable in an NY background 
 The results from the complementations involving the Tn3[NY]-Z2 + Tn3[NM]-Z3 
ZFR pair (lanes 10–12) indicate a strong bias in the activity of tetramer conformations. 
The first thing that should be considered is that the difference in signal strength between 
the excision product from the 2MutHetDim-DR (lane 11) and 2MutHetDim-IR substrate 
(lane 12) is likely at least partially the result of the SA effect. The excision product in lane 
12 contains a Tn3[NM]-Z3 homodimer binding site, which is expected to be more affected 
by the SA effect than the excision product in lane 11 that contains a heterodimer binding 
site. When looking at the size of the SA effect caused by Tn3[NM]-Z3 ZFR in lanes 6 and 8 
of the previous set of reactions, it can be seen that this difference is somewhat 
comparable with the difference seen for the excision products in lanes 11 and 12 for this 
set of reactions. At the very least, the SA effect precludes drawing any conclusion about 
the differences in activity between the MHD and RHD configurations from observations of 
the excision products in lanes 11 and 12).  
 
 The largest difference in signal strength for excision products observed in this set 
of reactions is between those in lane 10 and 11. The difference in signal strength 
observed between these lanes is definitely not the result of the SA effect, as the excision 
products in these lanes both contain heterodimer binding sites, and thus, are subject to 
the same level of SA effect. The difference in excision product signals in lanes 10 and 11 
indicates a significant difference in the activity of the AHD and MHD configurations, 
respectively. This difference is much larger than the difference observed between these 
configurations in previous sleepy + active ZFR complementations (Section 4.3.3 and 
4.3.4.3). Furthermore, since at least some of the difference seen between excision 
products from the 2MutHetDim-DR (lane 11) and 2MutHetDim-IR (lane 12) substrate 
reactions is likely the result of the SA effect (and thus, the activities of the MHD and RHD 
Figure 4-27:  Differential substrate assay testing the primary mutation (D102Y) and landing pad mutations 
(M) variables using differentially mutated sleepy + active ZFR pairs.  The results of a 17 Hour 
Recombination Assay are shown. To the left of the gel image, are given the sizes of each band of the 
molecular marker ladder shown in lane 1. To the right of the image, indicators are given to describe the 
origin of the bands on the gel (UNC = unchanged substrate, INV = inversion product, DEL = deletion 
(excision) product, and EXP = expression vector plasmid). Above the gel image is a table which indicates 
which ZFRs were used in conjunction with each substrate for the complementation reactions. A table 
provided underneath the gel image provides a key for understanding the tetramer configuration and 
reaction outcome relationships. This key includes information about which product bands are susceptible to 
the SA effect. 
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configuration are probably more equal than they appear from comparison of the excision 
products), it may be further concluded that there is likely an even more significant 
difference between the activity of the AHD and RHD configurations than appears from a 
comparison of the excision products in lanes 10 and 12. A significant difference in activity 
between the AHD and RHD configurations, such as is implied here, indicates that Tn3[NY]-
Z2 + Tn3[NM]-Z3 ZFR pair might be used to produce a recombination reaction 
directionality bias, which could help stabilize integration reactions.  
 
 It should be noted, the conclusion that the RHD configuration is significantly more 
active than the AHD configuration could be reinforced by using the alternative 
2MutHetDim-IR substrate (Z3/Z2 x Z2/Z3 as opposed to Z2/Z3 x Z3/Z2). Using the same 
sleepy + active ZFR pair, the Z3/Z2 x Z2/Z3 substrate will produce an excision product with 
a homodimer Z-site that specifies sleepy ZFRs, and thus, no SA effect will appear. 
However, there would still be a signal bias, now in the opposite direction, as the 
heterodimer Z-sites of the excision products of the 2MutHomDim and 2MutHetDim-DR 
substrates will be subject to a modest SA effect, while the excision product this 
2MutHetDim-IR substrate will not.  
 
 The inversion products of the reactions also provide information about the activity 
of tetramer configurations, although they are somewhat more difficult to interpret due to 
the possibility of secondary reactions converting the substrate to other products. While 
the excision products accumulate as end products, the inversion products do not if 
secondary reaction can take place, and thus, may be more transient in the reaction. In the 
case of the 2MutHetDim-DR substrate (lane 11), the inversion products would be 
expected to accumulate to some degree due to the apparently low activity of the AHD 
configuration. However, the inversion product from the 2MutHetDim-DR substrate 
contains homodimer Z-sites, one of which specifies the active ZFR (Tn3[NM]-Z3). Thus, 
this inversion product is also subject to an intermediate SA effect. The intermediate SA 
effect might not be expected to completely eliminate this product signal if it were 
sufficiently strong, but the combination of the SA effect and recombination activity from 
the AHD configuration makes interpretations of the significance of the absence of this 
product signal difficult. As with the analysis of the excision product band from the 
2MutHetDim-IR substrate (lane 12), while this reaction might suggest there is a difference 
in activity between the MHD and RHD configuration (implying a dimer-dimer orientation 
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specificity bias), no conclusions may drawn.  In the case of the 2MutHetDim-IR substrate, 
the RHD and MHD configurations, which catalyse secondary reactions on this inversion 
product, both appear to be sufficiently active to greatly reduce the strength of this signal. 
Therefore, the absence of this signal is not surprising, and is consistent with the near 
absence of inversion products often observed in ZFR reactions that have not gone to 
completion.  
 
 Finally, it is tempting to speculate that the reason the difference between AHD 
and MHD or RHD configuration was enhanced in this reaction compared with previous 
sleepy + active ZFR complementations, might be because of the predicted interactions 
between counterpart M103I and Q105L residues (see Section 4.4.1.2). Neither of these 
interactions is predicted to an increase the activity of the AHD configuration, while M103I 
was predicted to increase the activity of the RHD configuration, and Q105L was predicted 
to increase the activity of the MHD configuration. However, because these mutations 
were used in combination, the pattern of activity is expected to resemble that already 
observed for sleepy + active ZFR pairs based on locking interface mutations. Additionally, 
because of the SA effect, no conclusion may be drawn about a potential difference 
between the RHD and MHD configurations. Furthermore, M includes a G101S, which is 
predicted to stabilize the unlocked conformation (Figure 4-21), and both M103I and 
Q105L, themselves, have alternative explanations for their activity suggesting they could 
facilitate locking interface disruption or locking interface conformational transformation, 
respectively (see Section 4.4.1.2) Therefore, it is impossible to know from this experiment 
whether the enhanced differential activity between the AHD and MHD or RHD 
configuration was the result of any unique interaction, or was simply the result of a more 
activated sleepy + active ZFR pair operating through the same mechanism as previous 
sleepy + active ZFR pair complementations. 
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4.5 Conclusions 
4.5.1 Interaction between counterpart residues at position 102 
across the dimer-dimer interface  
 In Section 4.2, the hypothesis that residues at position 102 interact with their 
counterparts across the dimer interface at the initial stage of tetramer formation was 
tested. This hypothesis followed from the observation that in the 1GDT γδ resolvase 
structure, Glu102 residues protrude from the resolvase. If two dimers are brought 
together during tetramer formation in a fashion similar to that described by Li et al. 
(2004), these residues at position 102 might come in contact with one another. 
Furthermore, mutation of residue 102 (e.g. D102Y in Tn3 resolvase) is key to the 
hyperactivation of the resolvase enzyme (see Section 1.6.4). It was hypothesised that 
mutation at residue 102 might act by removing a hypothetical ionic repulsion barrier 
between counterpart Asp102 (or Glu102 in the case of γ/δ resolvase) residues during 
dimer-dimer synapsis.  
 
 In order to test the hypothesis and determine whether it might be exploited to 
produce a dimer-dimer orientation specificity bias, ZFRs with all possible ionic 
substitutions at position 102 were generated and tested in complementation with one 
another. The results of this experiment (Section 4.2.3, Figure 4-3) showed no indication of 
any favourable interactions between oppositely charged residue 102 substitution 
mutants. Therefore, this approach to achieving the project aims was abandoned.  
 
4.5.2 The interface-unlocking model of ZFR activation  
 In Section 4.3, a model of Tn3 catalytic tetramer activation was postulated based 
on analysis of 1GDT dimer and 1ZR4 tetramer γδ resolvase structures. In this model the 
catalytic dimers are activated by 2-3′ interface contacts from the regulatory module, 
which allosterically disengages a sub-region of the dimer interface seen in the 1GDT 
dimer structure (Figure 4-6). This region of the dimer interface was termed the 'locking 
interface' and it can be seen from comparison of the 1GDT and 1ZR4 structures that it 
must be disengaged in order for the resolvase to become active. Furthermore, the 
locations of several secondary activating mutations are also consistent with this dimer 
unlocking model. The hypothesis was generated from this model that since in the wild-
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type resolvase system, the catalytic dimers would be unlocked on one side only, 
asymmetric unlocking of the dimers might produce a conformation that produces a 
dimer-dimer orientation specificity bias.  
 
 Due to its location, the secondary activating mutation G70C was postulated to 
produce a particularly robust disruptive effect on the locking interface. A differentially 
mutated ZFR pair, which either contained or did not contain G70C, in an NY background 
was then generated and termed the sleepy + active ZFR pair, as only a ZFR containing 
G70C is able to produce recombination activity when used alone. The sleepy + active ZFR 
pair was then tested in complementations reactions on three substrates that allow the 
detection of a dimer-dimer orientation specificity bias, and/or a recombination reaction 
directionality bias. The results of the experiments with the sleepy + active ZFR pair 
(Section 4.3.3 and Section 4.3.4.3) refuted the hypothesis that asymmetric dimer 
unlocking could be used to produce a dimer-dimer orientation specificity bias. However, 
the results also indicated that the sleepy + active ZFR pair produced a significant potential 
recombination reaction directionality bias as indicated by a difference in the reaction 
products of the AHD and RHD tetramer configurations (Figure 4-17, lanes 7 and 8). Also 
importantly, the experiments demonstrated that an active ZFR can be used to activate an 
inactive ZFR when used in complementation. However, the overall level of activity 
produced by the sleepy + active ZFR pair using these experiments was low. 
 
4.5.3 Screening for new interface-unlocking mutants 
 Because the activity of the sleepy + active ZFR pair was low in the previous 
experiments, an attempt was made in Section 4.3.5 to look for new mutants that might 
be used in a sleepy + unlocked ZFR pair strategy. Twenty-four existing Tn3 resolvase 
secondary activating mutations in positions that fit the interface-unlocking model 
(including G70C from the previous experiment) were incorporated into ZFRs and screened 
for base-level activity. Surprisingly, in spite of these secondary mutations surpassing the 
hyperactivation threshold in Tn3 resolvase, all but four were found to be insufficient to 
significantly activate the ZFR (Figure 4-20 and Figure 4-23). Of those four, G70C (of the 
previous experiment) imparted the ZFR with sufficient recombination activity to 
completely convert the substrate to product. The remaining three mutations, G70A, 
G101S, and V108A, imparted their ZFRs with only modest recombination activity. The 
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results of this experiment indicated that new active mutants for sleepy + active ZFR pairs 
would have to be generated from combinations of secondary mutations, and 
demonstrated that the activation threshold for a Tn3-based ZFR is far higher than it is for 
Tn3 resolvase.  
 
4.5.4 Testing for synergistic activity in new ZFR pair 
complementations 
 In Section 4.3.6, a selection of the secondary activating mutations screened in the 
previous experiment were used to test three hypotheses (see below). Mutant ZFRs with a 
secondary mutation in either the E-helix or α/β sub-domain were paired in these 
experiments such that the secondary mutations they possessed would synergistically 
disrupt the locking interface from both sides of the interaction.  
 
 The first hypothesis tested, was that two sleepy ZFRs might be able to 
synergistically activate each other when used in complementation. The results of this 
experiment (Figure 4-24 A, lanes 2–9) demonstrated that this was not accomplished using 
the mutations selected.  
 
 The second hypothesis tested, was whether a lower activity active ZFR might be 
able to activate sleepy ZFRs when used in complementation. The results of this 
experiment (Figure 4-24 A, lanes 11–18) demonstrated that no substantial recombination 
activity was produced using this strategy. However, a minimal amount of recombination 
product was seen for the complementations involving NY G101S + NY R121K and NY 
G101S + NY R121M (Figure 4-24 A, lanes 15 and 16, respectively).  
 
 The third hypothesis tested was that a sleepy ZFR containing a secondary 
mutation might produce a higher level of recombination activity when used in 
complementation with the original active ZFR (NY G70C), than the original sleepy ZFR (NY) 
which did not contain a secondary mutation. Two important results were gained from this 
experiment. First, a sleepy ZFR incorporating T109I was able to substantially increase the 
activity of the sleepy + active ZFR complementation (Figure 4-24 B, lanes 3), in spite of the 
sleepy ZFR being inactive on its own (Figure 4-20 B, lane 3). Second, sleepy ZFRs 
incorporating R121K and R121M produced less activity when paired with NY G70C (Figure 
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4-20 B, lane 6 and 7, respectively), than they did when paired with ZFRs incorporating NY 
G101S (Figure 4-24 A, lanes 15 and 16, respectively). Because G70C is proposed to have a 
robust disruption effect on the locking interface, and because R121K/M is located in the 
same region of that interface, it was predicted that the effect of R121K/M might be made 
redundant when co-localized across the interface with the G70C mutation. Indeed, this 
may appear to be the case (see Section 4.3.6.3). It should be noted, however, that the 
observed difference was small because even the complementations using G101S and 
R121K/M produced a very low level of recombination activity. 
 
 An additional and interesting observation from the foregoing set of reactions can 
be made. All of the complementations between NY G70C, and NY R121G/K/M/S and NY 
E124Q produced virtually no activity (Figure 4-24 B, lanes 5–9), while the 
complementation between NY G70C and NY had minimal activity (Figure 4-24 B, lanes 2). 
This result may suggest that pairing G70C, and R121G/K/M/S or NY E124Q within the 
same locking interface actually reduces the activity of the protein. Interestingly, Burke et 
al. (2004) reported that although A117V, R121K, and E124Q produced hyperactivity when 
used as lone secondary mutations, using a combination of these three mutations at once 
abolished the activity of Tn3 resolvase. Because the locations of A117V, R121K, and 
E124Q indicate they would all be expected to disrupt the slightly different portions of the 
locking interface (Figure 4-4), it is possible that results of the current experiment, and 
Burke et al. (2004), suggest that a complete knockout of this interface produces an 
unviable catalytic domain. The locking interface comprises a major portion of the dimer 
interface, and completely knocking out the interactions of this region may prevent the 
dimer from forming a proper quaternary conformation, or perhaps from forming at all. 
One consequence, were this the case, is that ZFR complementations might be designed 
that produce post-reaction tetramer configurations that are completely inactive due to 
the pairing of multiple locking interface mutations from both sides of the interaction. If 
such a strategy were successful it could lead to a high fidelity recombination reaction 
directionality bias.  
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4.5.5 Sleepy + active ZFR pairs based on position 102 and landing 
pad mutations 
 Experiments were carried out in Section 4.4 based on the model that the residue 
at position 102 of the E-helix must negotiate contact with a region of the N-terminal end 
of an opposing E-helix (termed here the landing pad) as the dimer-dimer interface forms. 
This model is suggested from analysis of the structural transformation that must take 
place in order to allow the 1GDT γδ resolvase structure to transform into the 1GDT 
tetramer structure, the tetramer formation trajectory proposed by Li et al. (2005), and 
manual docking 1GDT dimers together into a tetramer initiation structure (Figure 4-10). 
Additionally, this model explains the function of the primary mutations at residue 102 and 
several secondary activating mutations within the landing pad regions, all of which are 
hydrophobic resides, and thus are proposed to cause activation through mutual 
hydrophobic interaction during the initial stage of tetramer formation. 
 
 An experiment was designed to test whether using a mutation at 102 (Y), or a 
collection of landing pad mutations (M), as an independent variable, could produce a 
dimer-dimer orientation specificity bias or a recombination reaction directionality bias. 
The results of this experiment (Figure 4-27) demonstrated that all subunits in a ZFR sleepy 
+ active ZFR complementation must possess a primary mutation in order to achieve 
significant activity. Impressively, the NY + NM complementations (lanes 10–12) appeared 
to produce a strong activity bias between the AHD, and MHD and RHD configurations. 
This activity bias between tetramer configurations indicates a strong potential for a 
recombination reaction directionality bias. Whether this differential configuration activity 
is a result of the interactions proposed by the landing pad model, is the product of 
alternative activities of a specific subset of mutations within M, or is simply a by product 
of any sleepy + active ZFR pair with sufficient activity, would require further 
experimentation to determine. However, the desired recombination reaction 
directionality bias that this project set out to generate does appear to have been 
achieved at some level. It can also be noted that a recombination reaction directionality 
bias based on these tetramer configurations may lead to an integration orientation 
specificity bias as well, as one integration orientation will be reversible and stochastically 
disfavoured, while the other integration orientation will be more stable; however, this 
topic will be covered in detail in the next chapter.  
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4.5.6 The sleepy + active complementation strategy may 
improve the targeting fidelity of the ZFR system. 
 Even apart from producing a recombination reaction directionality bias, the 
discovery that inactive ZFRs may be activated by active ZFRs in a sleepy + active 
complementation strategy is potentially valuable for increasing the targeting fidelity of 
the system. Cytotoxicity has been observed when using ZFRs in mammalians cells, which 
has been linked to off-target activity (Gaj et al., 2014). Because sleepy ZFRs are inactive 
when used alone or in combination with one another, the incorporation of sleepy ZFRs in 
a ZFR reaction reduces the number of possible aberrant recombination reaction that may 
take place as a result of unintended pairing of subunits at off-target sites.  
 
4.5.7 Use of DEVs to increase activity levels in ZFR 
complementation experiments 
 In Sections 4.3.4 and 4.3.5.5, DEVs were used to increase the expression of ZFRs in 
an attempt to increase the rate of the reaction; however, this strategy was not successful. 
While it was observed in Chapter 3 that increasing expression of ZFRs with the Z5 ZFA 
(which have low activity) does produce increased recombination activity (Figure 3-4 and 
Figure 3-5 D), the results from Sections 4.3.4 and 4.3.5.5 indicate this effect plateaus 
somewhere between double expression and quadruple expression of the enzyme.  This 
plateau may be the result of Z-site occupancy saturation. 
 
4.5.8 Confirmation of SA effect hypothesis  
 A useful piece of information was regarding the SA effect was gained from an 
experiment in Section 4.3.4. In Figure 4-17 it can be observed that co-expression of sleepy 
+ active ZFRs from two DEVs simultaneously, produces a profound SA effect for any 
plasmids that contain an active ZFR homodimer Z-site. Additionally, it may be observed 
that an intermediate SA effect is produced on any plasmid with a heterodimer Z-site. 
However, the reaction in lane 2 of Figure 4-17 clearly indicates that when the plasmid 
contains only homodimer Z-sites for the sleepy ZFR, no SA effect is produced. This result 
confirms that the SA effect results from the catalytic activity of the ZFR rather than simply 
from its binding activity. As outlined in Section 3.10.5.4, the SA effect is likely the result of 
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DNA-bound ZFR dimers being activated to cleave DNA outwith proper recombination 
reactions through interaction with non-DNA-bound ZFRs.  
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Chapter 5: ZFR Binding Domain Modifications  
 
5.1 Introduction 
5.1.1 Conspectus 
 Another avenue through which the action of the ZFR might be altered in order to 
achieve the project aims (i.e. integration orientation specificity, recombination reaction 
directionality bias, and loosening of the ZFR specificity requirements) is modification of 
the ZFA DNA-binding domain. Two novel approaches were developed in order to explore 
this idea:  the use of subunits with non-specific ZFAs, and the use of subunits with 
reduced binding affinity. Both of these approaches are based on the principle of 
generating a heterodimer comprised of one normal binding activity subunit and one 
modified binding activity subunit. The strategies used for both approaches, which will be 
discussed in the following sections, were designed to address all three project aims.  
 
 The experiments utilizing subunits with non-specific ZFAs produced only inactive 
ZFRs (with the exception of one potentially toxic ZFR) and were not successful in 
achieving any of the project aims. The experiments utilizing subunits with reduced 
binding affinity were successful in demonstrating active ZFR heterodimers, but the results 
suggest that if these enzymes were used for integration reactions one of the product Z-
sites might not be re-ligated after recombination. Thus, this strategy does appear to have 
produced a useful modified ZFR system. However, a final experiment, which attempted to 
use a subunit with a Tn3 resolvase HTH domain as a non-specific and reduced binding 
affinity heterodimer partner, appears to have been completely successful in achieving all 
project aims. This strategy appears to produce an extremely robust recombination 
reaction directionality bias that will likely give rise to orientation specific integrations (see 
Section 5.3), and also reduces the binding recognition requirements for the ZFR dimer. 
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5.1.2 Binding specificity manipulation to reduce sequence-
recognition limitations 
5.1.2.1 Complementation with reduced binding specificity ZFRs 
 Non-specific DNA-binding domains could be used to loosen the DNA binding 
specificity requirements of the ZFR system. Heretofore there has been little use for a non-
specific DNA binding domain in the ZFR system, as it would be expected to produce 
dimers with very low DNA-sequence recognition capability, leading to unwanted off-
target recombination reactions. However, the work in Chapter 4 (Sections 4.3 and 4.4) 
has demonstrated the use of a ZFR complementation system where one subunit (the 
'sleepy' subunit) has no activity when used alone, and requires an active heterodimer 
partner in order to function in recombination reactions. Were the sleepy subunits 
outfitted with the non-specific DNA-binding domain, homodimers comprised of them 
would be expected to produce no recombination activity on their own, thus obviating the 
problem of off-target reactions by the binding specificity reduced subunits.  
 
5.1.2.2 Remaining sequence selectivity of reduced specificity ZFR 
heterodimers 
 In the reduced specificity ZFR heterodimer system, ZFR subunits with normal 
binding specificity are used in complementation with the subunits possessing a non-
specific DNA-binding domain. Although the incorporation of a subunit with a non-specific 
DNA binding domain produces a ZFR heterodimer with reduced site-specificity, it still 
maintains enough sequence selection throughout to specify a theoretically unique target 
site within a human size genome.  The human genome is approximately 3 billion bp in 
length; in order to achieve unique sequence selectivity within both strands of a 3 billion 
bp genome, a theoretical requirement of 17 bp of site-specific recognition is required (see 
Footnote 2 on page 42).  
  
 The Tn3 resolvase catalytic domain and its arm region, which are incorporated 
into the ZFR, retain DNA sequence recognition capability of 8 bp per subunit; although, in 
practice, this sequence recognition is reduced by a degree of non-specific binding 
tolerance ((Gaj et al., 2013b) and M. Prorocic, (2009), PhD thesis, Stark lab). The number 
of changes that are tolerated depends on the identity of the base changes and position of 
the changes within the recognition sequence (see Section 1.5.2.4). As a general rule, the 
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eighth and final base at the flank of the central portion of Z-site that has been carried 
over from Tn3 resolvase (see Chapter 3, Figure 3-2 A), is very permissive to base changes.  
In addition to changes at this permissive eighth base in a subunit recognition sequence, 
evidence from the work of M. Prorocic suggests that one to three additional base changes 
might be tolerated across the whole 16 bp portion of a ZFR dimer-binding recognition 
sequence contacting the Tn3 resolvase module of the ZFR enzyme.  Whether one or three 
additional changes are tolerated depends on the identity of the changes.  This 
consideration of site recognition tolerance of the Tn3 resolvase module of the ZFR 
indicates that perhaps 11 bp of reliable recognition specificity are contributed to the 
overall sequent-selective capability of a ZFR dimer. 
  
 While the ZFA module of the ZFR enzyme may contribute 9–11 bp (see Section 
1.7.1.2 for discussion of the 5′ extended base recognition and 3′ overlap recognition of 
ZFAs) of sequence selectivity to the recognition capability of a ZFR subunit, some level of 
non-specific recognition tolerance is often present. A binding characterization of zinc 
finger nucleases based on the same ZFAs as the Z2 and Z3 domains used in this project, 
provides some idea of the non-specific recognition tolerance that might be expected 
when using ZFAs produced through the OPEN platform (Pattanayak et al., 2011).  The 
data collected by Pattanayak et al. (2011) suggests that for each ZFA, one position within 
the 9 bp ZFA recognition site core will readily tolerate a variety of base changes. 
Additionally, the data from Pattanayak et al. suggests the 5′ extended base recognition 
and 3′ overlap recognition are not robustly specified. Correspondingly, the OPEN ZFAs 
might be expected to contribute 8 bp of reliable recognition specificity to each ZFR 
subunit binding at a recognition site. 
 
  It should be noted, that data from Pattanayak et al. (2011) also suggests that, at 
least in a ZFN context, a properly bound subunit may be able to compensate for incorrect 
binding of the other subunit in a dimer context, allowing for a wider array of specificity 
tolerance. Therefore, in a ZFR context, a subunit containing a high affinity non-specific 
binding domain might facilitate greater sequence recognition tolerance at the half-site of 
the other subunit with a sequence-specific ZFA. However, this problem, which would 
further reduce the recognition specificity of a ZFR dimer, would only present itself if the 
non-specific binding domain has sufficient binding affinity to compensate for the 
sequence changes to the half-site of its subunit partner.  
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 The assessment of the non-specific sequence recognition tolerability of both the 
catalytic and binding modules of the ZFR, suggest that even if one non-specific binding 
domain were incorporated into a ZFR heterodimer, there is sufficient recognition 
capability to uniquely bind targets within a human-size genome. As mentioned above, 
statistically unique binding site recognition within the human genome requires at least 17 
bp of sequence selectivity. The two Tn3 catalytic modules of a ZFR dimer have been 
estimated above to collectively contribute 11 bp of reliable sequence recognition. Even if 
the non-specific recognition tolerance of a sequence-specific ZFA used in one subunit 
were higher than discussed above—which in some cases it may be (Paillard et al., 2004, 
Lam et al., 2011)—unique genomic targeting by a ZFR heterodimer incorporating one 
non-specific binding domain, could still be achieved so long as the sequence-specific ZFA 
of the other subunit could reliably specify at least 6 bp.  
 
5.1.3 Binding affinity manipulation for unidirectional 
recombination reactions 
5.1.3.1 ZFR integration and excision reactions 
 The major barrier preventing the application of ZFRs to gene therapy is their 
inability to catalyse stable orientation-specific integration reactions (see Chapter 6 for a 
discussion of how ZFRs might be used in a therapeutic gene correction strategy provided 
they were able to achieve stable orientation-specific integration reactions). Currently, the 
orientation of integrations catalysed by ZFRs cannot be controlled. Furthermore, 
integration reactions catalysed by ZFRs are of low efficiency (0.13–1.6%) (Gordley et al., 
2009, Gaj et al., 2011, Gersbach et al., 2011, Gaj et al., 2013b, Gaj et al., 2014). This low 
integration efficiency is the result of the bidirectional recombination activity of the ZFR. 
While ZFRs are capable of catalysing integration reactions, they are also capable of 
catalysing excision reactions. ZFR integration reactions involve two separate DNA 
molecules, each containing a Z-site, which must be brought into contact with one another 
so that the DNA may be recombined in order to produce one DNA molecule. Conversely, 
ZFR excision reactions involve one DNA molecule with two Z-sites, which must be brought 
into contact with each other so that they may be recombined in order to produce two 
separate DNA molecules. Thus, excision reactions are the reverse of integration reactions.  
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 Within an in vitro system, the equilibrium between ZFR integration and excision 
reactions will be somewhat skewed towards excision reactions because the Z-sites on 
which the ZFR operates will be kept in closer proximity to one another, due to being 
located on the same DNA molecule. Conversely, the Z-sites involved in an integration 
reaction are able to travel much farther from each other, reducing the efficiency of 
insertion reactions relative to excision reactions. However, in an in vivo system within 
replicated cells, the equilibrium between ZFR integration and excision reactions is heavily 
skewed towards the excision reaction. This is because the Z-sites involved in the 
integration reactions are not just able to move away from each other, but are also 
capable of being distributed to different daughter cells during cellular replication, thus 
entirely preventing the possibility of an integration reaction. Additionally, in the case of 
integration reactions performed on cellular chromosomes, the DNA molecule to be 
integrated may not be capable of replicating with the cells, resulting in a decrease in the 
ratio of DNA donor molecules relative to chromosomal targets within the cell population.   
 
5.1.3.2 Non-reversible recombination reactions in other systems 
 The most effective way of reducing the reaction equilibrium bias towards excision 
reactions is to make the excision reaction non-viable. Several integrase systems exist in 
nature that utilize site-specific recombinases, like the ZFR, but which possess 
unidirectional reaction capability. This unidirectional reaction capability is often based on 
the generation of post-recombination binding sites that are no longer able to facilitate 
the activation of the recombinases. In the case of the large serine integrases, this effect is 
achieved by utilizing a pair of recombinase binding sites (attP and attB), whose half-sites 
are reciprocally rearranged during DNA recombination to produce a new pair of 
recombinase binding sites (attL and attR) (Smith et al., 2010). These two pairs of binding 
sites produce different DNA-recombinase docking conformations resulting in two 
recombinase dimers (one bound at each site) either having, or not having, geometries 
that facilitate catalytic tetramer formation.    
 
5.1.3.3 Exploiting reciprocal half-site rearrangements 
 Engineering the ZFR to produce unique DNA-subunit docking conformations is 
probably not a feasible approach to achieving a recombination reaction directionality 
bias. However, the basic principle of exploiting the reciprocal rearrangement of half-sites 
during recombination to generate recombinase dimers that are active versus inactive may 
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be feasible using a more rudimentary approach. The DNA binding domain of a ZFR subunit 
could be modified such that it lacked adequate binding affinity to allow homodimer 
reactions comprised of two of these subunits. These reduced affinity binding domain 
(RABD) subunits might then be used in conjunction with functional 'helper' subunits that 
could compensate for the reduced binding activity when participating in heterodimer 
interactions. Because the dimer interface of the ZFR is quite extensive, it was 
hypothesized that the negative energy it provides might be sufficient to allow a helper 
subunit to stabilize a RABD subunit. The key to achieving success with this strategy is to 
find a balance  of binding activity attenuation that is sufficient to knock out binding 
activity of an RABD homodimer, but which still allows for binding activity compensation 
from a helper ZFR participating in a heterodimer. 
 
5.1.3.4 Tetramer configurations and the RABD subunit 
 Another beneficial repercussion of using the RABD + helper ZFR strategy is that it 
may lead to orientation specific insertions. In order to understand why this would happen 
we must first revisit the concept of tetramer subunit configurations discussed in Chapter 
4. As described in Section 4.3.1.6, tetramers comprised of an equal number of two types 
of ZFR subunits (i.e. two subunits of each type) may form in three different 
configurations: AHD, MHD, and RHD (Figure 4-11). The configuration that is formed 
depends on both the configuration of the Z-site (homodimer-binding versus heterodimer-
binding), and on the orientation of the dimers relative to one another in the dimer-dimer 
complex. The AHD configuration forms when ZFR dimers are bound to homodimer Z-sites, 
while the MHD and RHD configurations may form when ZFR dimers are bound to 
heterodimer Z-sites. The MHD and RHD configurations differ by the orientation of the 
heterodimers relative to one another. Importantly, subunit rotation during recombination 
reactions starting from the AHD configuration results in its conversion into the RHD 
configuration, and vice versa. However, subunit rotation during recombination reactions 
starting from the MHD configuration results only in the regeneration of the MHD 
configuration.   
 
 In the RABD + helper ZFR strategy, a homodimer comprised of two RABD subunits 
will not be active because they have insufficient collective binding affinity to bind their Z-
site. However, the RABD subunits are able to participate in heterodimer-based reactions 
because the binding affinity of the helper subunit and negative energy of the dimer 
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interface allows the helper subunit to stabilize the RABD subunit on the RABD subunit 
half-site. Therefore, in the RABD + helper ZFR strategy, the MHD and RHD configurations 
are active, while the AHD configuration cannot form, because RABD homodimers are 
unable to bind at their Z-sites, leading to a non-reversible reaction (Figure 5-1 A). 
 
5.1.3.5 'Try and try again' orientation specific integration reactions 
  If the MHD and RHD configurations are active, while the AHD configuration is not, 
this can lead to the stochastic production of orientation specific insertions (Figure 5-1 B). 
In the scenario of a ZFR integration reaction targeting an endogenous chromosome, the 
two half-sites of the chromosomal Z-site are likely to require two different ZFAs to target 
them (i.e. the sequences of the two half-sites will not be the same). If the same Z-site was 
used on the DNA to be integrated (which would minimize the variety of ZFRs needed for 
the reaction), this would imply the tetramer configuration of the integration reaction 
would either be MHD or RHD (the two configurations possible by heterodimers).  
 
 If the ZFR tetramer carries out integration from the RHD configuration, then the 
integration will be irreversible, because the product Z-sites of the reaction are 
homodimer sites, one of which specifies the RABD homodimer, which cannot bind its Z-
site. However, if the ZFR tetramer carries out integration from the MHD configuration, 
one of two subsequent reactions may follow. A subsequent inversion reaction, starting 
from an RHD tetramer, will again produce product homodimer Z-sites, one of which 
cannot be bound by its RABD homodimer. Alternatively, an excision reaction, starting 
from an MHD configuration, may reverse the integration reaction and return the system 
to its original state. If the system is returned to its original state, then the same set of 
reaction possibilities once again present themselves. Because only one orientation of the 
integrated DNA produces a product Z-site that can no longer be acted on by its ZFRs 
(whether by the initial integration reaction, or a secondary inversion reaction) the 
recombination equilibrium will ultimately favour that outcome. In short, if at first 
orientation specific integration does not succeed, the ZFR will try and try again.  
 
 
 
 
 
235 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) 
A) 
236 
 
 
 
 
 
 
 
 
 
 
 
5.2 Non-specific ZFAs subunit + helper subunit 
complementations  
5.2.1 Introduction 
 As described in Section 5.1.2, non-specific binding modules might be used to 
reduce the sequence recognition limitations of the ZFR system. This section describes 
experiments that were conducted using non-specific ZFAs constructed by modular 
assembly. The success rates of ZFAs constructed through modular assembly are reported 
to be quite low (Ramirez et al., 2008), and one study has indicated the factors influencing 
this low rate of success may be independent of site-specificity (Lam et al., 2011). 
Therefore, it was expected that the majority of these newly constructed non-site-specific 
ZFAs would have low binding affinity. Because the binding affinity of the modules was 
expected to be low, they also were intended to serve as a test of the RABD + helper ZFR 
strategy (see Section 5.1.3). However, the initial experiments to test their base-level 
activity showed they were not active, and thus, they did not make it to the stage where 
recombination reaction directionality bias could be assayed. 
 
5.2.2 Modular assembly of non-specific ZFAs and their 
incorporation into ZFRs 
5.2.2.1 Selection of non-specific ZFA monomers 
 Although any type of non-specific DNA binding domains might be incorporated 
into a chimeric recombinase, non-specific ZFAs were an obvious choice for this first 
experiment because the parameters for incorporating ZFAs into ZFRs are well understood. 
Figure 5-1:  RABD + helper non-reversible reaction, and 'try and try again' integration orientation 
specificity.  Two DNA molecules are depicted in yellow and orange with shading used to indicates 
directionality of the DNA, where relevant. The ZFR subunits are depicted with rose coloured boxes 
representing the catalytic domain, and blue ovals representing the ZFA binding domain. Dark blue is used to 
indicate a ZFA with strong binding affinity, while light blue is used to depict a ZFA with weak binding affinity. 
Black arrows are used to indicate spatial translocations of the ZFR subunits and DNA.  A) At the left the 
figure depicts two DNA-bound heterodimers comprised of subunits with differing binding strength, which 
are moving into association. The middle drawing shows the two DNA-bound heterodimers in synapsis, about 
to undergo subunit rotation and DNA recombination. The image at the right depicts the subsequent post-
recombination state, where the weak binding affinity ZFR subunits are no longer capable of associating with 
each other and the DNA.  B) Depicts a pathway diagram showing how a circular molecule of DNA being 
integrated by differing binding affinity system will have a stochastic tendency towards insertion in a 
particular orientation. White arrows are used to indicate reaction directionality.  
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Three engineered zinc finger monomers have been reported in the literature that are 
described as binding to DNA without any detectable sequence specificity ('SPG-H-LIE', 
'RKWLRL'/'LZF25', and 'QRH-H-LVE') (Dreier et al., 2005, Joung et al., 2000, Lee et al., 
2011). It should be noted, that although these ZFAs were shown to bind successfully to all 
substrate sequences on which they were tested (see Table 5-2), the experiments in which 
they were discovered were not designed to test the full range of sequence possibilities. 
The 'SPG-H-LIE' and 'QRH-H-LVE' zinc finger monomers were said to bind with 'high 
affinity' in addition to being non-specific, though no dissociation constant or other form 
of quantification was provided for them in the report by Dreier et al., (2005). To the best 
knowledge of this author, a completely non-specific ZFA has never been constructed, and 
these non-specific zinc finger monomers have never been assembled to each other. 
 
Table 5-2: Site that the non-specific ZFAs were shown bind (Joung et al., 2000, Dreier et al., 2005).  
Z2 site RKWLRL SPG-H-LIE QRH-H-LVE 
GAC GCT GCT AAA CAA CAA 
 TCA CAC CAC 
 TGT CAT CAG 
  CCA CAT 
  CCC CCA 
  CCG CCG 
  CTT CCT 
   CGC 
   CTC 
   CTT 
 
5.2.2.2 Rationale for construction strategy 
 The success of a ZFA comprised of randomly selected monomers may be affected 
by many variables including: the binding affinity contribution of each zinc finger 
monomer; whether the monomers have position specificity preference (e.g. finger 1, 
finger 2, and finger 3 in the array); and compatibility between adjacent monomers within 
the array. Using all combinations of the three non-specific zinc finger monomers, 27 
three-fingered ZFAs and nine two-fingered ZFAs may be constructed. Because the ZFAs 
were not guaranteed to work, it was necessary to construct and test all 36 possible ZFAs 
in order to thoroughly test the principle. 
 
 The direct synthesis of 36 ZFAs is cost-prohibitive and so a strategy was devised to 
construct the 36 ZFAs from a minimal amount of starting material, and using a minimal 
number of construction steps. Architecturally, a Zif268-like ZFA amino acid sequence can 
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be broken down into two different types of components: the zinc finger monomers, 
which contain the recognition helices responsible for DNA-base recognition; and the 
monomer-flanking motifs (the N-terminal motif, inter-monomer linkers, and C-terminal 
motif; Figure 5-3). The zinc finger monomers selected for this experiment were all taken 
from projects based on a Zif268-like architecture, and so Zif268-like architecture motifs 
were used for the N-terminal motif, inter-monomer linkers, and C-terminal motif. The ZFA 
construction strategy used here was to synthesize the sequences for the monomers and 
monomer-flanking motifs separately, and then recombine the elements to produce all of 
the two- and three-fingered non-specific ZFAs.  This avoided the need to synthesize whole 
ZFAs, or the need to synthesize the same monomer repeatedly in each position context 
(i.e. the same monomer flanked by the position-specific monomer-flanking motifs). 
 
 
 
 
  
 
 
 
 
MERPYACPVESCDRRFSQKTNLDTHIRIHTGQKPFQCRICMRNFSQHTGLNQHIRTHTGEKPFACDICGRKFATLHTRDRHTKIHLRQKD 
Figure 5-3: Zif268-like ZFA architectural elements.  The figure shows the crystal structure of TATAZF* (PDB: 
1G2D), an engineered ZFA based on Zif268 architecture. Colours are used to delineate the structural 
elements. The zinc finger monomers are coloured blue, while the N-terminal motif, inter-monomer linkers, 
and C-terminal motif are coloured yellow, magenta, and orange, respectively. Below the structure is the 
amino acid sequence of the ZFA with the sequence highlighted to match the structure. The final Aspartic 
acid in the sequence is disordered in the crystal structure above and does not appear within it. Additionally, 
amino acids of the recognition helix have been underlined, and the residues involved in base recognition 
bolded (Wolfe et al., 2001).  
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5.2.2.3 Construction strategy 
 The amino acid sequences for 'SPG-H-LIE', 'RKWLRL'/'LZF25', and 'QRH-H-LVE' 
were extracted from the published literature, and then translated into DNA sequences 
appropriate for E. coli. These sequences were then flanked by BsaI sites. BsaI is a Type IIS 
restriction endonuclease that cleaves DNA at a distance from its recognition site, allowing 
DNA sequences flanked by BsaI sites to be extracted with custom overhangs that are not 
dependent on BsaI.  
 
 Sequences for the monomer-flanking motifs were arranged into three modules 
containing the flanking sequences for finger 1 (N-terminal motif and linker), finger 2 
(linker and linker) and finger 3 (linker and C-terminal motif).  Within each module, the 
two monomer-flanking motif sequences were separated by a filler sequence, but which 
contained BsaI recognition sites. This arrangement allowed the non-specific monomers to 
be 'plugged' into their position context, which contained the appropriate monomer 
flanking sequences (Figure 5-4 A).   
 
 The inter-monomer linker sequences, themselves, were designed to contain AgeI 
and SgrAI isocaudomer sites, whose overhangs when ligated together produce a hybrid 
site on which neither of the isocaudomers are active (Figure 5-4 B). This allowed for a 
one-way assembly procedure where the zinc finger domains could be sequentially 
attached to one another, without the restriction enzymes that liberate the next 
attachment overhang, also re-cleaving zinc finger monomers that were already joined.  
 
 The DNA sequences for the N-terminal and C-terminal motifs were designed to 
contain restriction sites SpeI and SacI, respectively, which allow fully constructed ZFAs to 
then be cloned into an expression plasmid containing the desired Tn3 catalytic domain 
mutant sequence.  
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A) 
C) 
A 
B 
C 
Zinc finger monomer Monomer-flanking motifs module 
BsaI 
BsaI 
BsaI 
BsaI 
Monomers Two-fingered ZFAs Three-fingered ZFAs 
B) 
SpeI AgeI 
N-terminal ZF module 
SgrAI AgeI 
Medial ZF module 
SgrAI SacI 
C-terminal ZF module 
SgrAI site 
···CACCGGCG··· 
···GTGGCCGC··· 
AgeI site 
···TACCGGTG··· 
···ATGGCCAC··· 
Hybrid product 
···TACCGGCG··· 
···ATGGCCGC··· 
+ 
SgrAI 
AgeI 
AlwNI 
A 
AlwNI 
SpeI 
AgeI 
A 
+ 
AgeI 
SpeI 
AlwNI 
SacI 
SgrAI 
AlwNI 
A 
A 
A 
SpeI 
SacI 
A 
A 
A 
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5.2.2.4 ZFA Assembly and incorporation into ZFRs 
 DNA sequences for the non-specific zinc finger monomers ('SPG-H-LIE', 
'RKWLRL'/'LZF25', and 'QRH-H-LVE') and monomer-flanking motif modules were 
synthesized by GeneArt® (Life Technologies Ltd, Paisley, UK), and assembled in the 
fashion described above to create coding sequences for nine two-fingered, and 27 three-
fingered ZFAs (Figure 5-4 C). At this point, the 'SPG-H-LIE', 'RKWLRL'/'LZF25', and 'QRH-H-
LVE' zinc finger monomers were also renamed 'A', 'B', and 'C', respectively, to provide a 
simplified naming convention for describing the ZFAs. The success rates of ZFAs 
constructed through modular assembly are reported to be quite low (Ramirez et al., 
2008), and one study has indicated the factors influencing this low rate of success may be 
independent of site-specificity (Lam et al., 2011). Therefore, it was expected that the 
majority of these newly constructed non-site-specific ZFAs would have low of binding 
activity. Because the Tn3[NY G70C] mutant catalytic domain is highly active (see Chapter 
4, Section 4.3.5; see Figure 4-20), it was chosen for these experiments as its high level of 
activity was thought a good match for these potentially low binding affinity domains. 
Thus, the ZFA coding sequences were extracted from their parent plasmids and cloned 
into an expression vector downstream of a Tn3[NY G70C] catalytic domain.  
 
 
 
 
Figure 5-4:  Minimal materials assembly strategy for 38 non-specific ZFAs.  A) The panel depicts the initial 
assembly step where DNA sequences for zinc finger monomers are loaded into 'monomer-flanking motif 
modules' which provide DNA sequences for the linker and terminal amino acid motifs which determine zinc 
finger position within a ZFA. The relevant DNA sequences are represented by the blue portion of the 
rectangles. The BsaI restriction enzyme is shown cutting at a distance from its own recognition sites, which 
are contained within the segments of DNA to be discarded.  B) The panel depicts the one-way sequential 
monomer assembly process which relies on the use of isocaudomer restriction sites (SgrAI and AgeI) to 
produce ZFAs. The three types of position-specific zinc finger modules and their embedded restriction sites 
are shown at the top. Underneath, a box depicts the SgrAI and AgeI isocaudomer sites, along with a hybrid 
ligation product which is no longer recognized by either enzyme. Blue and red coloured bases are used to 
indicate the limit of the recognition sequences and overhangs while dark grey is used to depict relevant 
bases which are not recognized by the restriction enzymes. Bellow the box is a depiction of the one-way 
assembly of a three-fingered ZFA. As new zinc finger modules are added to build the ZFA (by digestion and 
relegation of plasmids containing the modules), only two restriction sites, flanking the total sequence, are 
left after each step. These restriction sites are used to add additional modules and extract ZFA when 
assembly is complete.  C) The panel depicts the combinatorial possibilities for two- and three-fingered 
combinations based on three zinc finger monomers. 
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5.2.2.5 The CAC ZFA may be toxic 
 During the final construction stage, when the ZFAs were joined to the activated 
Tn3[NY G70C] catalytic domain within an expression vector, it was particularly notable 
that no transformants were recovered from transformation of the plasmid construct 
containing the Tn3[NY G70C]-CAC ZFR, which appeared to be  toxic to the E. coli cells that 
had been transformed with it. Cell toxicity is what one would expect if a ZFR with a highly 
affinity non-specific binding domain were to be expressed within cells, as it may allow the 
ZFR to perform random recombination reactions on both the expression vector and the 
circular E. coli chromosome (given sufficient homology to the central portion of the Z-site, 
which is bound by the Tn3 resolvase catalytic domain and arm region). However, this 
result was not confirmed, and also might have arisen as the result from an error in the 
transformation procedure. Nevertheless, the Tn3[NY G70C]-CAC ZFR is omitted from the 
experiment that follows.  
 
 It should be noted, that the possibility of toxicity for a few ZFRs with these 
domains was not entirely unexpected. However, the activity of most ZFRs produced by 
modularly assembled ZFRs is generally so poor (Ramirez et al., 2008) that it was expected 
that the majority of ZFRs with these domains would not have enough activity to produce 
cellular toxicity.  It is important to remember that for the goal of this experiment was to 
produce non-specific ZFAs with low binding activity, so they could be used as RABD ZFR in 
RABD + helper complementations. Therefore, the appearance of toxicity in the 
construction stage essentially eliminates those ZFRs that will not function as RABD ZFRs.  
  
5.2.3 Experiment design 
 Experiments were designed to test the ability of the ZFRs with non-specific ZFAs to 
bind at half of a heterodimer-binding Z-site, in conjunction with a helper ZFR, bound site-
specifically to the other half-site. The 26 available ZFRs containing three-fingered non-
specific ZFAs comprised of all combinations of A, B, and C (see Section 5.2.2.4), with the 
exception of CAC (see Section 5.2.2.5), and nine available ZFR containing two-fingered 
non-specific ZFAs comprised of all combinations of A, B, and C (see Section 5.2.2.4), were 
used as the non-binding-specific ZFR subunits for this experiment. The Tn3[NY G70C]-Z3 
ZFR was chosen as the site-specific helper ZFR for this experiment because the Tn3[NY 
G70C] catalytic domain mutation set imparts high activity (see Chapter4, Section 4.3.5) 
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and the Z3 ZFA imparts slightly more activity to the ZFR than the other available domains 
(see Chapter 3, Section 3.5). For these experiments, a 2MutHetDim-DR substrate was 
used, which contained two heterodimer-binding Z-sites (Z2/Z3 x Z2/Z3). Thus, a 
complementation experiment was carried out using the 17 Hour Recombination Assay. 
 
5.2.4 Results 
 The results of both complementation experiments involving ZFRs with three-
fingered non-specific ZFAs (Figure 5-5), and two-fingered non-specific ZFAs (Figure 5-6), 
and partnered with helper ZFRs, show only trace levels of recombination activity for all of 
the ZFRs pairs tested. 
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Figure 5-5:  Results of complementation 
experiments involving ZFRs with non-
specific ZFAs.  The results are displayed 
across two gels. DNA ladder and fragment 
sizes are shown at the left of the images, 
while the origin of each of the experimental 
digests are indicated at the right (UNC = 
unchanged substrate, INV = inversion 
product, DEL = deletion (excision) product, 
and EXP = expression plasmids). Above the 
gel images, the substrate which was used for 
all experiments is indicated at the left, while 
directly above each gel track, the identity of 
each non-specific ZFA is given. All 
experiments were carried out as 
complementations between the Tn3[NY 
G70C]-Z3 ZFR and Tn3[NY G70C]-NF3 ZFRs, 
where 'NF3' indicates a non-specific three-
fingered ZFA.   
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5.3 RABD subunit + helper subunit complementations  
5.3.1 Introduction 
 As discussed in Section 5.1.3, two ZFR subunits with differing binding affinity might 
be employed in a complementation system to produce a non-reversible reaction.  The 
non-reversible reaction would take the form of two DNA binding-competent 
heterodimers bound to their Z-sites, which interact through a typical recombination 
reaction to produce two homodimers, one of which binds its Z-site competently, but the 
other of which does not. Because these product Z-sites are specific for their cognate 
homodimers, these product sites cannot be rearranged with one another to reverse the 
reaction, as one of the cognate homodimers would be non-functional. Additionally, this 
mode of non-reversible reaction would also likely enable an orientation specificity 
integration bias when used for integration reactions (see Section 5.1.3.5).  
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Figure 5-6:  Results of 
complementation experiments 
involving two-fingered non-specific 
ZFAs.  Marker ladder and fragment 
sizes are shown to the left of the gel 
image, while the origin of the 
plasmid fragments in each gel lane 
is indicated to the right of the image 
(UNC = unchanged substrate, INV = 
inversion product, DEL = deletion 
(excision) product, and EXP = 
expression plasmids). Above the 
image, and to left, is indicated the 
substrate which was used for all 
experiments. Directly above the gel 
image the identity of the non-
specific ZFAs which were varied 
between experiments and 
represented by each gel track are 
indicated. All experiments were 
complementations between ZFR 
Tn3[NY G70C]-Z3 and Tn3[NY 
G70C]-NF2, where 'NF2'indicates a 
non-specific two-fingered ZFA. 
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5.3.2 Recombination directionality bias recap 
 In the RABD + helper ZFR scheme, one of the subunits binds DNA with normal 
affinity, while the other subunit binds with much lower affinity. Because of the stabilizing 
negative energy of the extensive ZFR dimer interface during a heterodimeric subunit 
pairing, the subunits with normal binding affinity might act as 'helpers' to the subunits 
with a reduced affinity binding domain (RABD). However, homodimeric pairing of the 
subunits with RABD might not be possible because the total binding affinity of that 
homodimer might be insufficient to stabilize it on its cognate Z-site. Therefore, a 
significant difference between the binding capability of heterodimer and homodimer 
subunit pairs, might lead to a non-reversible reaction in the condition where the two 
heterodimers come together in the RHD tetramer configuration (as opposed to MHD 
tetramer configuration; see Figure 4-11), where recombination produces homodimers, 
one of which would be non-viable (Figure 5-1 A).   
 
5.3.3 'Try and try again' integration orientation specificity recap 
 The alternative possible heterodimer-heterodimer arrangement to the RHD 
configuration, the MHD configuration, cannot produce a non-reversible reaction because 
the product of subunit rearrangement is the regeneration of the MHD configuration, 
identical to that which initiated the reaction. However, this may be a desirable property. 
Specifically, if one is interested in using the ZFR system to integrate DNA in an 
orientation-specific fashion (perhaps within a chromosome), this property of the RABD + 
helper ZFR scheme could allow the desired integration orientation to be stable, while the 
non-desired integration orientation would be highly unstable, producing a stochastic 
orientation-specific integration effect (see Figure 5-1 B).  
 
5.3.4  Approaches to reducing ZFA binding affinity 
 Two straightforward approaches for identifying or generating ZFAs with reduced 
binding affinity are: screening of a large number of available ZFA for differences in binding 
affinity; and reduction of the number of fingers in the ZFA. Bacterial-2-hybrid (B2H) 
activity scores are provided by the Zinc Finger Consortium for all of the OPEN ZFAs (see 
Chapter 3, Section 3.2). These B2H scores are intended to indirectly indicate information 
about the binding activity of each domain. However, when the OPEN ZFAs used for this 
project were transferred into the ZFR system, the B2H activity scores (Table 3-1) did not 
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correlate entirely with the variability in ZFR activity levels observed in the 17 Hour 
Recombination Assay (Figure 3-4). It is certainly possible that by utilizing OPEN ZFAs with 
greater differences in their B2H activity scores, corresponding differences in ZFR activity 
would become apparent; however, within this current work, that approach was not 
explored. 
 
 The alternative method for producing ZFAs with reduced binding affinity is to 
reduce the number of finger modules within available functional arrays. There is a 
relationship between the number of fingers in a ZFA and its overall binding affinity, as 
each finger contributes to the strength of binding (though not necessarily to the same 
degree). Therefore, it is a straightforward assumption that reducing the number of fingers 
in a ZFA will reduce its binding affinity. The challenge to using this approach is that, 
without knowing the affinity contributions that each finger is making within the ZFA, it is 
impossible to predict how large a change in binding affinity will be produced by removing 
any given finger. Additionally, truncated ZFAs are not are not guaranteed to work at all, 
since there may be important synergistic interactions between the fingers within a ZFA 
that contribute to overall binding affinity and specificity. However, one potential 
advantage to this approach, within the context of this project's goals, is that reducing the 
number of fingers within a ZFA would also loosen the binding specificity requirements the 
ZFR system. This approach of reducing ZFA binding affinity, by truncating fingers from the 
array, is what was chosen for the work that follows.  
 
5.3.5 Construction of truncated ZFAs 
 Zinc finger arrays rely on cooperative effects between adjacent fingers to produce 
their overall binding specificity and affinity. Because of these cooperative effects, it is 
sensible when constructing two-fingered ZFAs from known three-fingered ZFAs, to 
construct the two-fingered ZFA in such a way as to preserve adjacent pairs of fingers (that 
is, ZFAs consisting of finger 1 and finger 3 would be less likely work). In this work, a simple 
approach was taken to construct one-fingered zinc finger domains, and two-fingered ZFAs 
by truncating fingers from the Z1, Z2, Z3, and Z4 ZFAs (described in Chapter 3, Section 
3.2). 
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  During the initial design phase for the ZFAs, the DNA sequences coding for Z2, Z3, 
Z4, and Z5 had restriction sites incorporated into them, to allow finger 3 and finger 2 to 
be successively truncated from the three finger arrays, while preserving the ZFA C-
terminal motif (see Section 3.2).  This strategy allows for the production of zinc finger 
domains consisting of finger 1, or finger 1 and finger 2. The Tn3[NY G70C] catalytic 
domain was again chosen for this work because of its high activity and for comparability 
with other experiments in this work, which also use this domain. Thus, expression 
plasmids of ZFRs: Tn3[NY G70C]-Z2, Tn3[NY G70C]-Z3, Tn3[NY G70C]-Z4, Tn3[NY G70C]-
Z5, were digested with AleI to produce expression plasmids coding for Tn3[NY G70C]-
Z2F2, Tn3[NY G70C]-Z3F2, Tn3[NY G70C]-Z4F2, Tn3[NY G70C]-Z5F2 (where F2 indicates a 
two finger array consisting of finger 1 and finger 2), and then subsequently digested with 
BsiWI to produce expression plasmids coding for Tn3[NY G70C]-Z2F1, Tn3[NY G70C]-Z3F1, 
Tn3[NY G70C]-Z4F1, Tn3[NY G70C]-Z5F1 (where F1 indicates a binding domain containing 
only finger 1 of the parent array).  
 
5.3.6 Experiment design  
5.3.6.1 Overview 
 In order to test the capability of the new RABD ZFRs with one- and two-fingered 
ZFAs to produce non-reversible reactions, a complementation experiment was designed 
where the RABD ZFRs were used in conjunction with normal ZFRs, which act as 'helpers' 
to the weakly bound RABD subunits when heterodimers are formed. This experiment 
primarily relied upon 2MutHetDim-DR substrates, which are able to directly detect non-
reversible reactions in the form of abnormal accumulation of inversion product if the AHD 
configuration (homodimers) is inactive. However, 2MutHomDim substrates were also 
employed to confirm that AHD configuration were inactive (more below). 
 
5.3.6.2 Tetramer configurations tested 
 The two tetramer subunit configurations, which form the basis of this approach to 
a non-reversible reaction, are the RHD configuration, and the AHD configuration. The RHD 
configuration and the AHD configuration are interchangeable products of subunit 
rotation, which is to say, that after subunit rotation, the RHD configuration will transform 
into the AHD configuration, and vice versa (Figure 4-11). An additional tetramer subunit 
configuration is also possible, called the MHD configuration. The MHD configuration 
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differs from the two other tetramer subunit configurations in that subunit rotation results 
in the production of another MHD configuration tetramer (Figure 4-11). Because the 
starting configuration and product configurations are the same, the MHD configuration is 
not capable of producing a non-reversible reaction.  
 
5.3.6.3 Substrate-mediated and enzyme-mediated reaction non-reversibility 
 Before continuing, it is important to lay out a fundamental aspect of ZFR 
recombination reaction reversibility. There are two basic ways in which a recombination 
reaction in the 17 Hour Recombination Assay could be non-reversible. The first type of 
non-reversibility is substrate-mediated. A non-reversible reaction that is substrate-
mediated is non-reversible because of the form that the substrate product of the reaction 
takes, rather than being the result of any properties of the enzymes themselves.  An 
inversion product is usually capable of being converted into either an excision product or 
back into the unchanged substrate form. Therefore, a reaction that produces inversion 
product allows for reversible reactions. Conversely, an excision product is not capable of 
being converted into anything else, because the segment of DNA that is excised from the 
substrate plasmid does not possess an origin of replication and is quickly lost as the E. coli 
hosts of the reaction divide.  
 
 The second type of non-reversibility is enzyme-mediated.  A non-reversible 
reaction that is enzyme-mediated, is non-reversible because of intrinsic properties of the 
ZFRs used, and the non-reversibility of the reaction is independent of substrate product 
form. However, when considering the outcome when both substrate-mediated and 
enzyme-mediated reaction reversibility potentials might be in play, in either case, 
reaction non-reversibility dominates over reversibility.  
 
5.3.6.4 Substrate selection 
 The 2MutHetDim-DR substrate type was chosen as the primary information 
production substrate type for this experiment, because (unlike 2MutHetDim-IR 
substrates) when using this substrate type, the recombination product of reactions 
involving an RDH configuration is the inversion product. Ordinarily, in the 17 Hour 
Recombination Assay, inversion product can be further converted into either excision 
product, or back into the unchanged substrate form. The excision product on the other 
hand, is a true end product that cannot be further converted to anything.  Therefore, 
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when looking at the recombination activity results on a gel, there is usually a great 
preponderance of excision product over the inversion product. However, if the RABD 
ZFRs, in complementation with helper ZFRs, are able to produce a non-reversible 
reaction, then the inversion product would conspicuously accumulate. Likewise, when 
using 2MutHetDim-DR substrates, the product of a reaction involving an MHD 
configuration, which is not capable of producing a non-reversible reaction, would be the 
excision product, which is inherently non-reversible. Thus, the 2MutHetDim-DR substrate 
type matches the substrate-mediated reversible reaction with the enzyme-mediated non-
reversible reaction, and the substrate-mediated non-reversible reaction with the enzyme-
mediated reversible reaction, so that both reaction products are potentially stable and 
are not further converted to anything else.   
 
 In order to provide an additional layer of information about the activity of 
tetramer subunit configurations, the 2MutHomDim substrate was also employed for this 
experiment. The 2MutHomDim substrates bind two alternate homodimers, and are 
therefore able to provide information about whether the AHD configuration is active. 
Since the AHD configuration is the product configuration of a recombination reaction 
beginning with the RHD configuration, if the AHD configuration is determined to be 
inactive, while the RHD configuration is determined to be active, this strongly indicates 
potential for a non-reversible reaction. Therefore, if recombination activity—and 
particularly in the form of inversion product (see above)—is observed in 
complementation experiments utilizing the 2MutHetDim-DR substrates, while no activity 
is observed in complementation experiments utilizing the 2MutHomDim substrates, this 
would provide additional support for a conclusion that the ZFR complementation pair was 
capable of producing a non-reversible reaction. 
 
 1MutHomDim substrates were also used in this experiment in order to provide 
information about the base activity level of the RABD ZFRs. The 1MutHomDim substrates 
bind homodimers comprised of only one type of subunit, detecting the activity of a 
tetramers consisting of four identical subunits. Therefore, in addition to the 
complementation experiments, the RABD ZFRs were also tested on cognate 
1MutHomDim substrates in order to test their activity level when used without the 
normal ZFR subunits acting as helpers.  
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 It should be noted that the lack of inclusion of a 2MutHetDim-IR substrate proved 
to be a major deficiency in the experimental design. In spite of the order in which the 
experiments are laid out in this thesis, much of the work was being conducted in parallel, 
and at the point where this experiment was undertaken, insufficient data analysis and 
results collection had been carried out to accurately characterize the parameters for the 
SA effect. This experiment requires the detection of reactions where the RHD 
configuration is active. The SA effect is strongest on substrates that contain homodimer Z-
sites for active ZFRs. All products of RHD reactions produce homodimer Z-sites.  In light of 
the current understanding of the SA effect (Sections 3.10.5 and 4.5.8), it becomes 
apparent that only by using the variety of 2MutHetDim-IR substrate that place the RABD 
subunits on the homodimer Z-site of the excision product, can a result be produced for 
RHD reactions that is unaffected by the SA effect. The RABD subunits would presumably 
not cause the SA effect on a homodimer Z-site because they are unable to bind to it. 
Unfortunately, at the point where the implications of the SA effect for this experiment 
became fully appreciated, there was no longer sufficient time to re-run the experiment 
with the inclusion of the appropriate 2MutHetDim-IR substrate 
 
5.3.6.5 Catalytic domain and ZFRs 
 The Tn3[NY G70C] mutant catalytic domain was again chosen for these 
experiments, both because it is highly active (see Chapter 4, Figure 4-20) and because it 
was used in many of the other experiments throughout this project, making the observed 
results comparable to others. Where the catalytic domain was attached to the four two-
fingered ZFAs, they were named Tn3[NY G70C]-Z2F2, Tn3[NY G70C]-Z3F2, Tn3[NY G70C]-
Z4F2, and Tn3[NY G70C]-Z5F2 , respectively. Where the catalytic domain was attached to 
the four one-fingered ZFAs, they were named Tn3[NY G70C]-Z2F1, Tn3[NY G70C]-Z3F1, 
Tn3[NY G70C]-Z4F1, and Tn3[NY G70C]-Z5F1 , respectively. The Tn3[NY G70C]-Z2 ZFR was 
used as the helper ZFR in these experiments, except in the complementations involving 
the Tn3[NY G70C]-Z2F2, and Tn3[NY G70C]-Z2F1 RABD ZFRs, where the Tn3[NY G70C]-Z3 
ZFR was used instead to avoid the obvious problem of cross-specificity between the Z2 
and Z2F2 or Z2F1 binding domains. Applicable subunit-specific varieties (Z2, Z3, Z4, and 
Z5) of the 1MutHomDim, 2MutHomDim, and 2MutHetDim-DR substrates were used for 
the experiment. Thus, a 17 Hour Resolution Assay was conducted using the above 
materials. 
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5.3.7 Results: two-fingered RABD + helper ZFRs  
 The results from the 17 Hour Resolution Assay measuring activity of two-fingered 
RABD + helper ZFR complementations on the 2MutHomDim and 2MutHetDim-IR 
substrates (shown in Figure 5-7) suggest that they MHD configurations are active, while 
AHD configuration are not. However, the RHD configuration either destroys DNA, or the 
SA effect has confounded the result. 
 
 The first thing that can be observed is that for complementations on the 
1MutHomDim substrates (lanes 5–8), no recombination products are observed and the 
unchanged substrate signals are approximately equal to that of the negative control (lane 
3), indicating that homodimers comprised of two-fingered RABD ZFRs are not able to 
form active tetramers with other homodimers comprised of two-fingered RABD ZFRs.  
 
 The second thing that can be observed is that there are no recombination 
products from the RABD + helper complementations on the 2MutHomDim substrates, 
indicating that the AHD configuration is inactive. While almost no recombination product 
can be seen in any of the complementations on the 2MutHomDim substrates (lanes 10–
13), the unchanged substrate signals in these lanes are considerably attenuated when 
compared with that of either the negative control (lane 3), or the complementations on 
the 1MutHomDim substrates (lanes 5–8). These attenuated signals for the unchanged 
substrate product are consistent with the expected activity of the SA effect in plasmids 
with homodimer Z-sites for active ZFRs. The level of SA effect on the 2MutHomDim 
substrate compared with the 1MutHomDim substrates allows the observer to gauge the 
level of SA effect operating within the experiment on homodimer Z-sites binding the 
helper ZFRs. Since no recombination activity has taken place on the 2MutHomDim 
substrates it can be inferred that the RABD ZFRs do not bind their homodimer Z-sites well.  
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 Finally, the results of the complementations on the 2MutHetDim-DR substrates 
(lanes 15–18) show that in three instances (lanes 15, 17 and 18) the excision product is 
being produced, while only trace levels of inversion product can be observed. The 
excision products from the 2MutHetDim-DR substrates indicate the activity of the MHD 
configuration, while inversion products indicate the activity of the RHD configuration (the 
MHD and RHD configurations are the two possible heterodimer-based tetramer 
configurations). The RABD + helper ZFR complementations are not expected to produce 
any dimer-dimer orientation specificity, and this is probably not responsible for the 
Figure 5-7:  Complementation experiment to test ZFR-F2s for non-reversible reaction capability.  The 
figure shows the results of a 17 Hour Resolution Assay involving complementation of ZFR-F2 with normal 
ZFRs on various substrate types where differential activity indirectly indicates non-reversible reaction 
potential. 1KB ladder markers are shown to the left of the image, while the origin of each restriction 
fragment is indicated to the right (UNC = unchanged substrate, INV = inversion product, DEL = deletion 
(excision) product, and EXP = expression plasmids). Above the gel image, a grid is shown which indicates 
ZFRs and substrates complementations which are shown in each track. 
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difference observed between inversion and excision product signals. There are two 
explanations for the ostensible difference in the activity of the MHD and RHD 
configurations. The first explanation is that since the inversion product of the 
2MutHetDim-DR substrates contain homodimer Z-sites, it is possible that the SA effect 
has destroyed these plasmids. The second explanation is that the RHD configuration is 
active, but the RABD subunits are unable to rejoin the DNA after subunit rotation, 
perhaps because their binding domains disassociate from the DNA. Although, it should be 
kept mind that if the DNA is not re-ligated after subunit rotation the ZFR would remain 
covalently attached to the DNA. There is no way to discriminate between these two 
possibilities by making deductions from the current results.  
 
 Since the results on the 2MutHomDim substrates clearly indicate that the AHD 
configuration is inactive, the appearance of excision product likely indicates that both 
heterodimer tetramer configurations (MHD and RHD) are active, as a dimer-dimer 
orientation specificity effect would be unlikely to arise using the RABD + helper ZFR 
system. Therefore, the question of whether the SA effect has destroyed the inversion 
product or whether the RABD subunits are unable to re-ligate the DNA is an important 
one. Fortunately, this could be easily determined by running the experiment again using 
the variety 2MutHetDim-IR substrates that place the homodimer Z-sites for the RABD 
subunits on the excision product (see Section 5.3.6.4). Unfortunately, however, there was 
no time available to carry out this additional experiment. 
 
5.3.8 Result: one-fingered RABD + helper ZFRs 
 The results from the complementation experiment involving one-fingered + helper 
ZFRs (seen in Figure 5-8) show only trace amounts of recombination products across the 
lanes of the gel. Curiously, the highest level of trace activity appear in the 
complementations on the 1MutHomDim substrates (lanes 5–8), while the lowest level of 
trace activity appears in complementations on the 2MutHetDim-DR substrates (lanes 15–
18). This pattern of activity is opposite to that observed for the two-fingered RABD + 
helper complementations in Section 5.3.7. However, the recombination activity from this 
experiment is so minimal that it is hard to observe unless the gel image is viewed on a 
computer screen. The one-fingered RABD + helper ZFR pairs do not appear capable of 
producing useful recombination reactions. 
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Figure 5-8:  Complementation experiment to test ZFR-F1s for non-reversible reaction capability.  The 
figure shows the results of a 17 Hour Resolution Assay involving complementation of ZFR-F1 with normal 
ZFRs on various substrate types where differential activity indirectly indicates non-reversible reaction 
potential. 1KB ladder markers are shown to the left of the image, while the origin of each restriction 
fragment is indicated to the right (UNC = unchanged substrate, INV = inversion product, DEL = deletion 
(excision) product, and EXP = expression plasmids). Above the gel image, a grid is shown which indicates 
ZFRs and substrates complementations which are shown in each track. The restriction digest which is 
designed to cleave the expression plasmids into small enough fragments that they do no occlude the 
substrate product signals, did not run to completion for the positive control (shown in lane 2). However, the 
band of interest, representing the deletion product of the substrate, is still visible in spite of the partial 
digest of the expression plasmids seen in that gel track. 
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5.4 Using the Tn3 resolvase HTH domain a non-site-
specific RABD 
5.4.1 Background 
 It was noticed during an initial set of complementation experiments (data not 
shown) that relied on the Zif268 ZFA and the Tn3 resolvase HTH (H1, so named to give it a 
comparable nomenclature to the ZFA) domain for targeting—that is, complementation 
experiments that paired a ZFR with a mutant Tn3 resolvase (MTR)—that the MTR was 
cross-reactive for the ZFR half of the hybrid binding site. This cross-reactivity was 
particularly apparent on heterodimer binding sites, where a properly bound Tn3[NY 
G70C]-HTH MTR could effectively co-opt another MTR subunit to incorrectly bind the ZFR 
half of the heterodimer binding site, forming a homodimer.  In a control experiment 
where only the MTR was expressed, using a MRT/ZFR heterodimer-binding substrate, a 
total conversion of substrate to recombination products was observed. Although this 
cross-reactivity of the MTR for the Tn3-Zif268 Z-site revealed that complementation 
experiment design to be unreliable, it also raised the question of whether the H1 domain 
could be used intentionally as a non-site-specific binding domain. It was also considered 
that the H1 domain binding in a non-site-specific fashion would probably making low 
affinity contacts, and thus, may also simultaneously function as an RABD. As discussed in 
Section 5.3.2, RABD + helper complementations may be used to produce non-reversible 
reactions. 
 
 One question that arises is whether a system such as this could have utility in a 
mammalian cells system. It has been demonstrated that a properly bound MTR is capable 
of co-opting other MTR subunits to bind to sites that the H1 domain of that subunit does 
not bind site-specifically (see above). This implies that if the MTR + ZFR complementation 
were performed in a mammalian cell system, there might be some risk of the MTRs 
performing unintended recombination reactions at unintended binding sites. However, 
the discovery in Chapter 4 that inactive ZFRs can be activated by complementation with 
active ZFRs (the sleepy + active ZFR strategy), provides a way to eliminate that potential 
problem. The MTRs could be made into sleepy subunits that would have no activity on 
their own. Therefore, it was deemed worthwhile to explore the possibility of using MTRs 
to act as non-site-specific RABDs in complementation with helper ZFRs. 
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5.4.2 Experiment design 
5.4.2.1 Overview 
 An RABD + helper subunit complementation experiment was designed to test the 
capability of the H1 domain to function as a non-site-specific RABD. The experiment 
design, where the H1 domain is used intentionally in this fashion, differs from the 
aforementioned preliminary experiment where the MTRs non-specific activity was first 
noticed, described in the previous section. Instead of a properly bound MTR co-opting 
another MTR to improperly form a homodimer at an MTR/ZFR hybrid binding site, in this 
experiment a ZFR bound at a Z-site attempts to co-opt the MTR to bind the other half of 
the full Z-site. The experiment was designed to test both non-specific binding capability of 
the H1 RABD, and the ability of the RABD + helper complementation to produce a non-
reversible reaction. 
 
5.4.2.2 Catalytic and binding domains for RABD + helper 
 The Tn3[NY G70C] catalytic domain was used for both the RABD and helper 
subunits because it is highly active, and also for comparability with the results of other 
experiments that utilized this domain. The Z3 ZFA was used for the helper subunit, 
because the Z3 domain imparts higher activity to ZFRs than any of the other available 
ZFAs (see Chapter 3, Section 3.5), giving the complementation experiment the best 
possible chance of success. The H1 domain was used for the RABD subunit. 
 
5.4.2.3 Substrates selection 
 Non-reversible reactions may be generated as the result of differential activity 
between the RHD and AHD configurations in a RABD + helper complementation (Section 
5.3.2; Figure 4-11; and Figure 5-1 A). In order to demonstrate a non-reversible reaction, 
2MutHetDim-DR substrates were selected for this experiment. If the RHD and MHD 
configurations are active then the complementations on the 2MutHetDim-DR substrate 
will produce inversion and excision products, respectively (see Table 4-1). However, if the 
AHD configuration is also active, then the inversion products will be readily converted by 
secondary reactions back into unchanged substrates or into excision products. In 
reactions that go to completion, if all three tetramer configurations are active, the 
substrate will be completely converted to the stochastically favoured excision end 
product (see Figure 4-14). However, if the RHD and MHD configurations are active, while 
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the AHD configuration is inactive, the inversion product will accumulate and should equal 
the excision product at the end of the reaction. However, the SA effect must also be 
taken into consideration when interpreting the results as the inversion product from 
2MutHetDim-DR substrate contains two homodimer Z-sites, and thus, its signal strength 
may be reduced. 
 
 2MutHomDim substrates were also used to confirm that the AHD configuration is 
not active. If the ADH configuration is active, then reactions on 2MutHomDim substrates 
will produce both inversion and excision products (see Table 4-1 and Figure 4-13). 
Conversely, if the AHD configuration is not active, then no recombination products will be 
produced from the 2MutHomDim substrates.  
 
 In order to demonstrate the H1 domain could be used on a non-site-specific 
fashion, this experiment utilized a set of 2MutHetDim-DR and 2MutHomDim substrates 
that contained binding sites for the Tn3-Z3 ZFR in conjunction with Tn3-Z1, Tn3-Z2, Tn3-
Z4, or Tn3-Z5 ZFR binding sites. All four Z-site varieties, which were available in addition 
to the Tn3-Z3 Z-site, were used to test the maximum range of non-specific binding 
tolerance possible with available materials. It should be noted, that all of the Z-sites 
retain 2 bp of the 6 bp H1 binding site in their spacer sequences that separate the Tn3 site 
I core sequence from the 11 bp (including the 3′ F1 overlap position and the 5′ extended 
position, see Section 1.7.1.2) sequence of the ZFA sites (Figure 5-9). Although, it should be 
noted that the 5′ extended position of the ZFA sites, in all cases, of has the same base pair 
as either the left or right half-site of site I, at this position. However, even within this 3 bp 
region (the 2 bp spacer + the 1 bp that incidentally overlaps) that is common to site I, the 
left and right half-site versions of the site I sequences over these positions, are only the 
same at one position within the 3 bp sequence (Figure 5-9)—indicating a degree of 
binding tolerance by the H1 domain.  
 
 For the controls, the relevant portion of the preliminary experiment descried in 
Section 5.4.1 (data not shown) was essentially replicated. A Tn3-Z1 1MutHomDim 
substrate was used as a negative control, while a MTR/Tn3-Z1 2MutHetDim-DR substrate 
was used as the positive control. The experiment was conducted using the 17 Hour 
Recombination Assay. 
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5.4.3 Results 
5.4.3.1 Overview 
 The results of this experiment, which are displayed in Figure 5-10, show the H1 
domain is able to act as a non-specific, or at least reduced specificity, binding domain, and 
that these RABD + helper complementations indeed produce an extremely robust non-
reversible reaction effect. The negative control, shown in lane 2, shows that the Tn3[NY 
G70C]-H1 MTR, alone, is completely inactive on a Tn3-Z1 Z-site. The positive control, 
shown in lane 3, tested the ability of the Tn3[NY G70C]-H1 MTR, alone, to recombine 
H1/Z1 x H1/Z1 2MutHetDim-DR substrate. The MTR in the positive control is provided 
one cognate half-site, and it is co-opting another MTR subunit to bind the other (Tn3-Z1) 
half-site. This positive control replicates the result from a preliminary experiment 
described in Section 5.4.1 (data not shown), and demonstrates that the MRT, alone, can 
recombine the substrate when provided with only one cognate half-site. The positive 
control also demonstrates complete conversion of the substrate plasmid into 
recombination products (inversion product and excision product).  
 
 
 
 
 
 
_    ___Tn3 site I core _____ _Left H1 _  Right H1_ 
_   _ Right ZFA _   _  _ _   Left ZFA   _ __ 
LH/RH 
RH/LH 
 Z1/Z1 
 Z2/Z2 
 Z3/Z3 
 Z4/Z4 
 Z5/Z5 
 Z-site spacer Z-site spacer 
Figure 5-9: Alignment of binding sites sequences.  The figure shows an alignment of binding sites in order 
to display the sequences which the H1 domain tolerates and is being tested on. The 11 bp ZFA sites, 6 bp H1 
sites, 16 bp Tn3 site I core, and 2 bp Z-site spacers are labelled above and below the alignment. LH/RH site 
is Tn3 site I. The RH/LH is site I with the left and right H1 binding sites swapped. The RH/LH site is not 
included within the experiment, but is provided in the alignment to show additional sequence variations 
tolerated by the H1 domain. Within the experiment, the H1 domain is only tested against the left half of the 
Z-sites. 
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Figure 5-10:  Complementation experiments with the ZFR acting as a helper subunit to an MTR bound to 
non-cognate sites.  The figure shows the results of the complementation experiments using the MTR and 
ZFR on 2MutHetDim-DR and 2MutHomDim substrates. In gel track 1, the 1 kb marker ladder is show with its 
fragment sizes indicated to the left of the image. At the right of the image are indicators which describe the 
origin of the plasmid fragments, where 'UNC' indicates un-recombined substrate, 'INV' indicates substrate 
inversion product, 'DEL' indicates substrate deletion (excision) product, and 'EXP' indicates expression 
plasmid fragments. Above the gel image and to the left, the MTR and ZFR types used in the experiment are 
shown, while directly above the gel the substrate and substrate type used in each experiment are shown. 
Tracks 2 and 3 contain negative and positive controls, respectively, for which the results were known from a 
previous experiment (data not shown). Tracks 3–7 show the complementation experiments using the 
2MutHetDim-DR substrates which test the ability of a ZFR subunit bound to its cognate Z-half-site to 
cooperate with a MRT bound to a non-cognate Z-half-site. (While the control experiment is shown in track 2 
also uses a 2MutHetDim-DR substrate, this experiment is fundamentally different from the experiments 
shown in tracks 3–7 in that its 2MutHetDim-DR substrate contains cognate binding sites for the MTR, while 
the experiments in tracks 3–7 contain no MTR cognate sites.) Tracks 8–11 show the complementation 
experiments using the 2MutHomDim substrates, which test the ability of the ZFR homodimer bound to a 
cognate Z-site to cooperate with a MTR homodimer bound non-cognately to a Z-site. The Z1 designation 
indicates the Zif268 ZFA and its binding site, while the H1 designation indicates the Tn3 resolvase HTH 
domain and its binding site. 
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5.4.3.2 Non-site-specific capability of the HT domain 
 The tracks showing the RABD + helper complementation on the 2MutHetDim-DR 
substrates containing only Z-sites (lanes 4–7) show full levels of recombination. These 
results indicate that the MTR is able to act as a highly efficient non-specific, or reduced 
specificity, heterodimer partner to a ZFR. Total conversion of substrate to products takes 
place even when the MTR is acting on sites that contain all possible base changes at two 
of the three positions in the H1 binding site that do not vary between the left and right 
sides of site I (lanes 4, 6, and 7; and Figure 5-9). Additionally, total conversion of substrate 
plasmid to products is also observed when the H1 domain is binding at the Z5 site, which 
contains only 2 of 6 bp in common with either the left or right H1 binding sites of site I 
(lane 7; and Figure 5-9). However, it should be noted that all of the Z-sites contain 3 bp in 
common with the HT sites of site I when considering both the HT sites at once (i.e. when 
considering the variability from HT sites in a non-contiguous fashion; Figure 5-9). 
 
5.4.3.3 Non-reversible reaction capability of the RABD + helper subunit 
complementations 
 The inversion product signal in experiments utilizing the 2MutHetDim-DR 
(including the positive control) is conspicuously strong (lanes 4–7). In no other 
experiments that the author has witnessed, has the inversion product band been so 
pronounced relative to the excision product band. The fact that the inversion band is 
even still present after the recombination reaction has gone to competition (i.e. after 
total conversion of substrate to products) is, in itself, a completely unique result. 
Inversion products are subject to secondary reactions, which results in the inversion 
products existing only transiently during reactions that go to completion. The only stable 
end product of recombination reactions is the excision product. Thus, when a typical 
reaction goes to completion, all of the substrate is inevitably converted to excision 
product, both directly, and via secondary reactions on the inversion product. However, if 
an RABD + helper complementation is successful in producing an RHD configuration that 
is active, and an AHD configuration that is inactive, then such reactions carried out on 
2MutHetDim-DR  substrates will produce a stable inversion product that is no longer 
subject to secondary reactions. The presence of a robust inversion product signal in the 
absence of the unchanged substrate signal (indicating the reaction has gone to 
completion) in lanes 3–7, directly demonstrates that a non-reversible reaction has been 
achieved using the RABD + helper subunit strategy.  
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 The presence of excision product in lanes 3–7, indicates the MHD configuration is 
also active. Since no dimer-dimer orientation specificity effect is expected from RABD + 
helper complementations, the RHD and MHD configuration would be expected to product 
equal levels of activity. Equal activity of the RHD and MHD configurations on a 
2MutHetDim-DR substrate would be expected to produce equal rates of production of 
the inversion product and excision product, respectively. The excision product signals in 
lanes 3–7 are stronger than the inversion product signals.  However, the inversion 
product from the 2MutHetDim-DR substrate contains two homodimer Z-sites, while the 
excision product contains a heterodimer Z-site, making the inversion product subject to a 
much stronger SA effect (see Table 4-3). The difference in signal strength observed 
between the inversion product and excision product in lanes 3–7, is almost certainly the 
result of the SA effect, indicating there is probably no difference between the RHD and 
MHD recombination rates.  
  
 The results of the complementation experiments that were carried out on the 
2MutHomDim substrates (lanes 8–11) also fully support the conclusion that an enzyme-
mediated non-reversible reaction has been achieved in these complementation 
experiments. The 2MutHomDim substrates test the ability of a substrate-bound MTR 
homodimer to cooperate with a substrate-bound ZFR homodimer in the AHD 
configuration. The lack of significant reaction products from the reaction on the 
2MutHomDim substrates confirms the AHD configuration in these RABD + helper 
complementations is inactive. Because the AHD configuration is the subunit configuration 
state produced after subunit rotation of the RHD configuration (see Figure 4-11), the 
presence of the inversion product from the 2MutHetDim-DR substrates (lanes 3–7), and 
the lack of significant reaction products from the 2MutHomDim (lanes 8–11) provides 
additional evidence of a non-reversible reaction using the RABD + helper subunit pair.    
 
 Small amounts of excision product can be seen in the in the lanes containing the 
2MutHomDim substrates. This indicates the non-reversibility of the RABD + helper 
reactions are not perfectly tight, at least not on the 2MutHomDim substrates where the 
HT domain binds the Z1 and Z2 sites. If the MTR homodimer is still able to interact 
productively with the ZFR homodimers at a low level, this problem might be overcome by 
incorporating one of the sleepy subunit mutation sets described in Chapter 4 (such as 
those from Section 4.4), which are also capable of producing a recombination reaction 
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directionality bias. Additionally, transforming the RABD subunits into sleepy RABD 
subunits would reduce the potential for off-target reactions in a genomic integration 
context. 
 
5.4.3.4 SA effect and H1 binding on Z2 
 It might also be noted that the SA effect appears strongest on the 2MutHetDim-
DR substrate containing Z2, while the unchanged substrate signal of the 2MutHomDim 
substrate also appears to be relatively more affected. There are three bases conserved 
between the H1 binding sites on the left and right side of Tn3 site I. The Z2 site contains a 
thymine that is common with one of these conserved positions and that none of the 
other ZFA sites contain. This likely indicates that the SA effect for substrates containing Z2 
is increased because of increased binding of the H1 domain.   
 
5.4.3.5 Stochastic integration orientation specificity 
 Finally, although a conclusive demonstration would require an intermolecular 
integration reaction, it can be assumed that this RABD + helper complementation would 
be capable of achieving an integration orientation specificity effect via the stochastic 'try 
and try gain' pathway described in Section 5.1.3.5.  
 
5.5 Conclusions 
5.5.1 Complementations using ZFRs with non-specific ZFAs 
 The experiments utilizing the two- and three-fingered non-specific RABDs in 
complementation with normal ZFRs were not successful, and no significant amount of 
recombination was observed in any of the reactions. Among the 36 ZFAs that were 
produced, one ZFA (CAC) may have been active. No transformants were recovered after it 
was ligated to an active ZFR catalytic domain (Tn3[NY G70C]), indicating the ZFR might 
have been toxic to the cells. Further attempts to recover this ZFR were not pursued 
because it was assumed that if the ZFA did impart the ZFR with enough binding activity to 
produce toxicity, it would not be useful as an RABD. However, given that the other ZFAs 
did not function even in RABD + helper ZFR complementations, it might be worth 
exploring whether the CAC ZFA could be used purely as a non-specific binding domain (i.e. 
not as a RABD domain as well). If the CAC domain does have enough binding affinity to 
make active ZFRs toxic, then combining it with a sleepy catalytic domain (Chapter 4), 
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would obviate that problem. The sleepy catalytic domain would allow the CAC ZFA to be 
used in sleepy + active ZFR complementations, which could test whether the CAC could 
be used to relax the site-specificity parameters of the ZFR system. 
 
 A better approach may have been to attempt a similar type of experiment but 
setting for previously characterized ZFAs with reduced specificity ZFAs instead of 
attempting to generate entirely new non-specific ZFAs. Additionally, because the zinc 
finger monomers that were used had never been proven to be completely non-specific 
(see Table 5-2), it may have been interesting to test the non-specific ZFAs at sites that the 
monomers had previously been demonstrated to bind to, in order to determine whether 
these ZFA were, in fact, reduced specificity ZFAs.   
 
5.5.2 Truncated ZFAs for RABD + helper complementations 
 Some of the experiments utilizing truncated versions of the Z2, Z3, Z4, and Z4 ZFAs 
as RABDs for RABD + helper complementations produced interesting results. While all of 
the one-fingered RABDs showed no activity on any substrates tested, the Z2F2, Z4F2, and 
Z5F2 domains did impart their ZFRs with significant recombination activity on the 
2MutHetDim-DR substrates. The experiments were designed to test the RABD + helper 
ZFR pairs for their ability to produce a non-reversible reaction. Non-reversible reactions 
on from RABD + helper complementations would arise as the result of RHD configurations 
being active while the AHD configuration is not. The AHD configuration is the tetramer 
configuration produced after RHD subunit rotation. Thus, if the RHD configuration is 
active while the AHD configuration is not, then the reaction is irreversible.  
 
 The lack of recombination products produced by RABD + helper 
complementations on the 2MutHomDim substrates clearly indicates that the AHD 
configuration is inactive in these reactions. The presence of excision product on the 
2MutHetDim-DR substrates indicates that the MHD configuration was active. Because no 
dimer-dimer orientation specific effect was expected from RABD + helper 
complementations, the RHD configuration should also have been active. However, an 
active RHD configuration should produce inversion products on the 2MutHetDim-DR 
substrate, and there were no inversion products present in any of the reactions that 
produced excision products. One explanation for this is that the SA effect destroyed the 
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inversion product signals. The inversion product from the 2MutHetDim-DR substrates 
would be expected to carry two homodimer Z-sites making them subject to the strongest 
level of SA effect. However, another possible explanation is that these RABD subunits are 
unable to rejoin the DNA, possibly because the binding domains of the RABD homodimers 
that are generated disassociate from the DNA before the DNA is re-ligated (in spite of the 
fact the catalytic modules are still covalently attached to the DNA).  
 
 A simple experiment could be conducted to test whether the lack of inversion 
products from the 2MutHetDim-DR substrates was caused by the SA effect or was the 
result of the RABD ZFRs being unable to re-ligate the DNA. Active RHD configurations 
produce excision products from reactions on the 2MutHetDim-IR substrates. If the RABD 
+ helper complementations were performed on the 2MutHetDim-IR substrate variety that 
place the homodimer Z-site for the RABD subunits on the excision product, then the 
production of excision product would indicate that the RHD configuration was active and 
the RABD subunits are able to re-ligate the DNA. Additionally, the SA effect should be 
minimal under this condition as the RABD subunits should not be able to bind the excision 
product well. If the RABD subunits are able to re-ligate the DNA, this would indicate that 
the RABD + helper strategy does indeed produce a non-reversible reaction. The addition 
of the 2MutHetDim-IR substrates to the experiment was not considered because, at the 
time the experiment was conducted, the SA effect had not been fully characterized. A 
further experiment was not carried out because of insufficient available time. 
 
5.5.3 H1 domain as a non-site-specific RABD for RABD + helper 
subunit complementations 
5.5.3.1 RABD + helper complementations produced a non-reversible reaction 
 The experiment utilizing the MTR as non-site-specific RABD, in RABD + helper 
complementations, appears to have been entirely successful in producing a non-
reversible reaction.  The experiment demonstrated an accumulation of inversion products 
from a 2MutHomDim-DR substrate in a reaction that had gone to completion, which 
would not be possible without a non-reversible reaction. Ordinarily, the inversion product 
in ZFR reactions only exist transiently as they are further converted by secondary reaction 
either back into unchanged substrate, or into excision products. In reactions that go to 
competition, inevitably all substrate is converted to excision products, as it is the only 
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stable end product. The production of the both inversion product and excision product 
from the RABD + helper reactions on the 2MutHetDim-DR substrate in this experiment 
demonstrated the RHD and MHD configurations were active. Additionally, the lack of 
activity on the 2MutHomDim substrates, and inability of the RABD + helper pair to 
catalyse secondary reaction on the inversion products from the 2MutHetDim-DR 
substrates, indicates the AHD configuration is inactive. The non-reversibility of the 
recombination reaction is the result of the RHD configuration transforming the 
heterodimer-binding substrate into a substrate with homodimer binding sites that cannot 
be bound by the RABD subunits.  
 
5.5.3.2 Differences in strength of the inversion and excision product signals  
 The inversion and excision product signal from the 2MutHetDim-DR reactions 
were not of the same strength, in spite of both products being formed as the result of 
heterodimer reactions (MHD and RHD configurations). However, the reduction in signal 
strength of the inversion product was the result SA effect, which is expected to reduce 
the signal strength of products, such as the 2MutHetDim-DR inversion product, which 
contain homodimer binding sites for active recombinases. The reduction in signal 
strength of the inversion product is not significant enough to challenge the conclusion 
that a non-reversible reaction has been produced. 
 
 The MHD and RHD configurations could be demonstrated as being comparably 
active by running the RABD + helper complementation on both the 2MutHetDim-DR and 
2MutHetDim-IR substrates, and comparing the excision products. The excision products 
from the 2MutHetDim-DR substrate would indicate MHD activity, while excision products 
from the 2MutHetDim-IR substrates would indicate RHD activity. A 2MutHetDim-IR 
substrate could be used that would place the RABD subunits on the homodimer site of 
the excision product. Because the RABD subunits are not expected to bind a homodimer 
site well, the excision product from a 2MutHetDim-IR substrate that specified them would 
not be affected by the SA effect. This would make the excision product from the 
2MutHetDim-IR substrate more comparable with the excision product from the 
2MutHetDim-DR substrate, which contains a heterodimer site, and is subject to only a low 
level of SA effect.  
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5.5.3.3  The H1 domain as a non-specific RABD 
 The H1 domain was also demonstrated to act as a non-specific binding domain 
within the limits of detection of the experiment. The sites to which the H1 domain was 
applied were quite divergent, and only 2 of 6 bp were conserved among all the Z-sites 
sequence (Figure 5-9). Additionally, there is some variability in the sites that the H1 
domain binds to in the left and right half-sites of Tn3 site I, also indicating a level of site-
specific recognition tolerance of the domain. The base pairs at the two foregoing 
conserved positions among the Z-sites, can be found in either the right or left half-sites of 
site I. Additionally, of these 2 bp, 1 bp is at one of the three positions that are non-
variable among the H1 binding sites in the left and right half-sites of site I. Overall, all of 
the Z-sites shared 3–4 bp with either the left or right H1 binding sites of site I, some of 
which were at positions that varied between the left and right half H1 binding sites of site 
I.  Therefore, it is currently unknown whether the H1 domain would work as effectively at 
sites that altered these positions, with the one position conserved between both H1 sites 
of site I being of special interest.  
 
5.5.3.4 The utility of non-specific RABDs 
 Although the repertoire of available engineered ZFAs is increasing versatile, they 
are still a major limiting factor in the application of ZFR system to genomic contexts, and 
so the reduction of the recognition specificity constraint is significant. Although the arrival 
of TALERs may circumvent the problem of ZFA availability (Mercer et al., 2012), TALE are 
still difficult to construct and their size may present a barrier to certain modes of delivery 
(e.g. using AAV vectors). The ZFR system possesses an important difference with the 
similar ZFN system, in that the catalytic domain in the ZFR system brings with it its own 
site-specific capability. The site-specific capability of the ZFR catalytic domain, although 
imposing its own set of constraints when locating a target site, obviates the need to have 
two ZFAs in the system to produce a unique binding site in a human-size genomic context. 
The primary contention with using a non-specific RABD in a gene therapy recombination 
strategy would likely be that the non-specific RABD might product undesirable off-target 
activity.  However, work on the sleepy + active partners described in Chapter 4 (Section 
4.3), may be able to address that concern by making RABD subunits catalytically inactive 
when binding sites on their own.  
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5.5.3.5 The experiment succeeded in achieve all of the project aims 
 The data indicates that complementation reactions between RABD + helper 
subunits can be orchestrated to produce a non-reversible reaction. This is the first ever 
demonstration of a non-reversible reaction using the ZFR system. Furthermore, this 
setup, when utilized for integrations reactions, should be able to produce an orientation 
specific integration outcome through stochastic selection (see Figure 5-1). Finally, 
because the RABD can be used in a non-specific or reduced specificity fashion, it 
significantly reduces the specificity constraints of the ZFR system that requires locating a 
Z-site that will accommodate two available ZFAs. Thus, with this experiment, all three 
objectives of this project (to impart the ZFR system with non-reversible reaction 
capability, to impart the ZFR system with orientation-specific integration capability, and to 
reduce the specificity constraints imposed by limitations in the repertoire of  available 
ZFAs) would appear to have been achieved, within the limits of detection of the 
experimental system used. 
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Chapter 6: Discussion 
 
6.1 Introduction 
6.1.1 A case for the ZFR system 
 The ZFR is an enzyme system for site-specific genome editing which features 
alongside its better known cousins, the ZFN, TALEN, and CRISPR-Cas9. Based on a 
recombinase platform, the ZFR has the potential to overcome several of the 
disadvantages of the nuclease-based systems that currently dominate the field of 
targeted genome editing. The reliance of nuclease-based systems on HDR to perform 
gene correction, prevents their use in non-dividing cell types. Additionally, commonly 
occurring off-target activity by the nuclease-based systems generates unintended 
genomic rearrangements, such as translocations, inversions, and large deletions (Frock et 
al., 2015, Tsai et al., 2015), which may present a danger to their use as an in vivo gene 
therapy system.  
 
 However, the greatest barrier to consideration of nuclease-based systems as a 
high fidelity mode of gene correction, suitable for in vivo therapeutic applications, is that 
the rate of indel production at the target site outcompetes the rate of gene correction 
(Ramirez et al., 2012, Kim et al., 2012, Wang et al., 2012).  Greater indels production at a 
therapeutic target site has the potential to damage functional alleles in situations where 
correction of a heterozygous allele is desired (e.g. familial hypercholesterolemia, or p53 
dysfunction). Additionally, the dominance of NHEJ over HDR may result in translocations 
between target sites and naturally occurring DSB hotspots (Frock et al., 2015, Tsai et al., 
2015), and also between both homologous chromosomes containing the target site, 
potentially resulting in the production of oncogenic breakage-fusion-bridge cycles (Frock 
et al., 2015). Nickases-based strategies may greatly reduce the production of indels at 
target sites, but suffer from a significant reduction in gene correction efficiency (Ramirez 
et al., 2012, Kim et al., 2012, Wang et al., 2012), and do not prevent translocations 
between homologous chromosome containing the target site (Frock et al., 2015).   
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 Because the ZFR relies on a recombinase-mediated DNA recombination, it is 
better suited to driving high-fidelity reactions at the target site than nuclease-based 
systems, and is also not limited to use in dividing cells. Additionally, although the off-
target activity of the ZFR in a genomic context has not been well characterized, the 
reliance of the ZFR on two dimers, bound to both target sites of the reaction, may present 
opportunities to limit the possibility of unwanted recombination reactions by modifying 
the subunits such that they will only interact in specified tetramer configurations. This 
strategy might also prevent on-target homologous translocation events, which while not 
yet reported for the ZFR system, are hypothetically possible. However, before such 
advancements to the ZFR system can be deemed worthwhile, basic control over 
parameters of the ZFR recombination reaction must first be achieved. To this end, this 
project set out to accomplish three goals: the generation of non-reversible reaction, 
integration orientation specificity control, and reduction of the sequence recognition 
specificity requirements of the ZFR system.  
 
6.1.2 Addressing the challenges 
 The experiments in this work explored several lines of reasoning in order to 
address the challenges in making the ZFR a more viable system for gene therapy and 
genomic editing. The approaches taken primarily revolved around attempting to alter the 
residue or geometric contact between two dimers forming a ZFR tetramer, exploiting a 
model of ZFR activation called the 'dimer interface unlocking' hypothesis, and altering the 
activity parameters of the binding domains. Of these approaches, the attempts to modify 
the dimer-dimer interaction contacts or geometry were unsuccessful (Sections 4.2 and 
4.3). Conversely, working through the dimer interface unlocking model, sleepy + active 
ZFR pairs were produce that have the capacity to limit off-target activity, produce a 
significant recombination reaction directionality bias, and as a consequence of that 
directionality bias, should be capable of producing some level of integration orientation 
specificity bias (Sections 4.3 and 4.4). The attempts to modify the activity parameters of 
binding domains produced RABD + helper ZFR pairs capable of an extremely robust non-
reversible recombination reaction effect (Section Chapter 5: 5.4). This non-reversible 
reaction potential of the RABD + helper pair system is expected to likewise produce a 
robust integration orientation specificity effect through the stochastic reaction pathway 
processes described as 'try and try again' integration orientation specificity (Section 
271 
 
5.1.3.5). Additionally, RABD + helper strategy succeeded in reducing some of the 
sequence recognition specificity limitations of the system. 
 
 The 'sleepy + active' strategy and 'RABD + helper' strategy might be combined to 
produce sleepy-RABD + active-helper subunits that unite the benefits of both strategies, 
preventing possible off-target activity, which the RABD subunits might carry out due to 
the reduce specificity of their binding domains. Importantly, this project also 
characterized the parameters of the SA effect, which illustrates the need to reduce the 
number of recombinase subunits that are active on their own within a reaction. The SA 
effect results from cleavage of DNA by active subunits outside of recombination 
reactions, but is not produced by sleepy subunits (Sections 3.10.5 and 4.5.8).  
 
6.2 Disproved hypotheses 
6.2.1 Ionic energy barrier between counterpart 102 residues at 
dimer-dimer formation 
 Based on the observation that mutations at position 102 in Tn3 resolvase play the 
most important role in the hyperactivation of the enzyme, and models of the dimer-dimer 
synapsis based on existing crystal structures, it was suspected that the counterpart 
residues at position 102 might come in direct contact with one another during the initial 
stage of synapsis (Section 4.2). It was hypothesized that the reason mutations at 102 may 
play such an important role in Tn3 resolvase hyperactivation, is that the negative charges 
at the wild-type residue Asp102 may play a role in negative regulation of the resolvase by 
creating ionic repulsion between opposing dimers.  
 
 The hypothesis above was tested by generating ZFR mutants with oppositely 
charged residues at position 102, and arranging these ZFRs in complementation reactions 
such that opposing dimers, within a dimer-dimer interaction, carried either similar or 
oppositely charged 102 residues. The expectation was that, if the primary activating 
mutations at 102 exert their effect by removing a negative ionic energy barrier between 
opposing dimer at tetramer formation, then placing oppositely charged residues at 
position 102 between dimers, should produce at least as strong an activating effect as 
activating mutations such as D102Y.  
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 All combinations of opposition charged 102 residues were tested in these 
complementation reactions, and none showed any activity. Thus, it was concluded that 
the ionic charge of Asp102 does not produce a crucial ionic charge barrier that regulates 
the activity of the resolvase, and that placing alternately charged residues at this position 
in complementation reactions is not a strategy that can be used to further the goals of 
this project. 
 
6.2.2 Conformational dimer asymmetric to produce dimer-dimer 
orientation specificity 
 It was hypothesized that conformational asymmetry might be generated within a 
ZFR dimer to allow a dimer-dimer orientation specificity bias (Section 4.3). According to 
existing models of wild-type small serine recombinase activation, the dimers of the 
catalytic module are contacted on one side by the subunits of the regulatory module, and 
this contact appears to be important for activation of the enzyme (Rowland et al., 2009, 
Rice et al., 2010). Almost all of the secondary activating mutations can be proposed to 
produce their effect by destabilizing a region of the dimer-interface that was termed the 
'locking interface' in Section 4.3. Additionally, it can be seen from the 1GDT γδ resolvase 
dimer structure (a close homologue of Tn3 resolvase) that one of these locking regions is 
in an unlocked configuration, similar to what might be produced by the secondary 
activating mutations. It can also been seen in the 1GDT resolvase dimer structure that 
asymmetric unlocking of the dimer leads to a conformational asymmetry that might 
affect the dimer-dimer interaction during the initial stage of tetramer formation. Thus, it 
was proposed that differential inclusion of activating mutations in a ZFR heterodimer 
could produce a conformational change that might lead to a dimer-dimer orientation 
specificity bias. However, the experiments of Section 4.3 demonstrated that this was not 
the case. 
 
6.3 Discoveries and their potential applications 
6.3.1 The sleepy + active complementation strategy 
 One of the most important discoveries made in this work, was that activated ZFR 
subunits can be used to activate inactive subunits when used in complementation 
reactions. This discovery is important because within a genomic context the use of 
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inactive ZFRs limits the potential for off-target reactions by reducing the number of active 
tetramer configuration that may be produced from the ZFR set used. This strategy 
appears especially valuable in light of the SA effect, which was commonly observed and 
has been linked to cleavage of DNA, by activated ZFRs, outside of recombination 
reactions. Such cleavage could pose a problem for gene therapy applications of the ZFR. 
Ideally, the ZFR system could be further modified such that all ZFR subunits within a 
reaction only produced activity when used in combination with one another.  
 
 Another important discovery that was made using the sleepy + active ZFR pairs 
was that they can produce a strong recombination reaction directionality bias (Figure 
4-27).  The heterodimer reactions are significantly more active than reactions where the 
same set of ZFRs are paired as homodimers.  
 
6.3.2 The RABD + helper complementation strategy 
 Perhaps the most important discovery that was made during the course of this 
work was that RABD + helper subunit pairs can be used to produce a robust non-
reversible reaction effect. Chapter 5 set out to both reduce the sequence recognition 
specificity limitations of the ZFR system and generate RABDs with the goal of producing a 
non-reversible reaction based differential binding capability of subunits. These RABD 
subunits are inactive on their own because they possess insufficient binding affinity for 
their target sites as homodimers. However, RABDs still retain enough binding affinity that 
they can bind target sites when paired in heterodimers with helper ZFRs that possesses 
normal binding capability. Three approaches were used to generate RABDs, and each had 
varying degrees of sequence specificity reduction as well.  
 
 The first strategy attempted to generate non-specific ZFAs through modular 
assembly, with the expectation that many of the ZFAs would possess weak binding 
affinity as well. All of the ZFRs produced through this strategy were inactive, presumably 
because the binding affinity of the ZFAs was too weak.  
 
 A second strategy attempted to determine whether the number of fingers in 
active ZFAs could be reduced, in order to reduce both their sequence specificity and 
binding affinity. Reducing the number of zinc fingers required for one ZFR in a 
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heterodimer would allow a greater range of sites to be targeted, as shorter ZFA binding 
sites are easier to target with the existent repertoire of zinc finger modules. These RABDs 
imparted their ZFRs with an intermediate level of activity when participating in 
heterodimers, and showed no activity when forming homodimers. However, the product 
from the key heterodimer configuration that could directly indicate a non-reversible 
reaction was not present in the result, possibly due to being destroyed by the SA effect.   
 
 The third strategy proved to be the most successful (Section 5.4). The H1 domain 
was used as the non-specific RABD, and these RABD + helper complementations were 
tested for both the ability to produce a non-reversible reaction, as well as the ability of 
the RABD to act as a non-specific binding domain. These reactions demonstrated a robust 
non-reversible reaction, and the RABDs were able to bind non-specifically to all of the 
sites they were tested on (although these sites did share, at minimum, 2 of 6 bp in 
common with either of the H1 domains natural binding sites within Tn3 site I). 
Additionally, the non-reversible reaction generated by the RABD + helper pair should also 
be capable of producing an orientation-specific integration reaction via the 'try and try 
again' stochastic pathway (Section 5.1.3.5).  
 
 It is possible that the RABD approach based on truncated versions of active ZFAs, 
might have worked just as well as the approach based on the H1 domain. The overall 
activity level of RABD + helper complementation reactions involving the truncated active 
ZFAs was much lower than it was for those involving the H1 domain. Since the inversion 
product band signalling success in the reaction involving the H1 domain was obviously 
reduced by the SA effect, it is possible that the lower overall level of activity in the 
reactions involving truncated active ZFA domains, allowed the SA effect to hide the 
success of the experiment. In any case, the success of the H1-based RABD + helper 
complementations demonstrates the success of the RABD + helper approach, and 
represents the first ever demonstration of a non-reversible reaction utilizing ZFRs. This 
result represents a major advance for the ZFR system and should allow for a dramatic 
increase in the efficiency of integration reactions, with the added benefit of producing 
orientation-specific integrations. 
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6.3.3 The SA effect 
 Through the use of ZFRs with variably active binding domains (Chapter 3 and 5), 
and the use of sleepy + helper complementations (Chapter 4), the experiments within this 
project were able to characterize  the SA effect and definitively determine that it is 
caused by DNA cleavage, rather than simply being a product of tight ZFR DNA binding.  
Although cleavage by ZFRs outside of recombination reactions has been observed or 
suspected in previous experiments conducted within the Stark lab, the work in this 
volume contains the first characterization of the SA effect parameters within ZFR 
complementations reactions (Sections 3.10.5 and 4.5.8). The data and observations 
collected here provide useful guidance for interpreting results from experiments where 
ZFRs with differential activity are co-expressed and tested on the variety of substrates 
capable of detecting the activity of the various possible tetramer configurations 
comprised of given ZFR variants. Consideration of the derived rule-sets for the 
appearance of the SA effect (Table 4-3 and Figure 4-27) will be important for effective 
design of experiments like these in the future.   
 
 The fact that active ZFRs are able to cleave DNA outside of recombination 
reactions may present a problem for their use as high fidelity genome editing tools, in 
their current state. However, it should also be considered that the nuclease-based 
genome editing tools are unable to produce greater levels of gene correction than indels 
at the sites they target.  The structural complexity of the ZFR system, may provide 
opportunities to operate over the problem of non-recombination reaction DNA cleavage. 
Indeed, the use of sleepy + active subunits, demonstrated in this work, may be an 
important step towards that goal.  
 
6.3.4 Activity level of the ZFR system compared with the Tn3 
resolvase system 
 Finally, the experiments of Section 4.3.5 demonstrated that the intrinsic activity 
level of the ZFR system is well below that of the hyperactive Tn3 resolvase system. An 
experiment was conducted where 24 secondary mutations that were sufficient to 
produce hyperactivity in the Tn3 resolvase system in conjunction with Y, were tested in 
the ZFR system in conjunction with NY. Only four of these secondary mutations imparted 
their ZFRs with any significant recombination activity. The NY background used for the 
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ZFR experiments is more activated than the Y background in which these secondary 
mutations had previously been characterized in. Thus, the inactivity of 20 of the 24 ZFRs, 
each carrying one of these secondary mutations, indicates the use of a ZFA binding 
module over the natural H1 binding module significantly reduces the activity of the 
system. This difference in activity might be a due to superior binding by the H1 domain 
relative to ZFAs, or it might be that the natural H1 domain affords some conformational 
flexibility to the arm region that better enables the enzyme. This result should be taken 
into consideration when attempting to transport activating mutations from the Tn3 
resolvase system into the Tn3-based ZFR system. 
 
6.4 Experiments to further this work 
6.4.1 Sleepy + sleepy subunit complementations 
 In vivo gene therapy applications of the ZFR system will require that off-target 
reactions do not happen. Although this might be accomplished by optimizing the binding 
domains, there is an obvious benefit to having a ZFR system where the catalytic domains 
are only active when used in combination with one another. Therefore, if a sleepy + 
sleepy strategy could be made to work, it would represent one way to achieve this goal.  
 
 Although an experiment in Section 4.3.6 tested the ability of sleepy ZFR carrying 
the L66I secondary mutation, to produce recombination with other sleepy ZFRs carrying 
various secondary mutation on the other side of the locking interface, this was not a 
robust test of the sleepy + sleepy complementation strategy. L66I was one of the 20 of 24 
secondary mutations that showed no activity in the base-level ZFR activity screen (Figure 
4-20 A). Because these mutants all produced no recombination activity, it is impossible to 
know how far below the activation threshold they actually are.  Additionally, it can be 
seen from the sleepy + active ZFR reactions where a G70C mutant was tested against 
several other sleepy ZFRs that have locking interface mutation on the other side of the 
interface, that one (T109I) was easily woken up while the other did not produce activity 
(Figure 4-20 B).  
 
 Therefore, since some sleepy mutants appear to be closer to the activation 
threshold then others, it would be sensible to attempt other combinations of sleepy + 
sleepy ZFR, in order to look for a synergistic activating effect. The logical place to start 
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would be testing T109I against all of the other sleepy ZFRs with secondary mutations 
operating from the other side of the locking interface. Additionally, secondary mutations 
from sleepy ZFRs might be combined in order to look for combinations that remain 
sleepy. Sleepy ZFRs with combinations of secondary mutations would likely be closer to 
the activation threshold than the sleepy ZFRs in which the individual mutations produced 
no effect. It is perhaps worthwhile to remind the reader that, in spite of their activity in 
the ZFR system, all of the secondary mutation used for the experiments of this project 
were known to have a robust activating effect on the Tn3 resolvase catalytic domain from 
experiments generating hyperactive Tn3 resolvase mutants (i.e. these mutation were all 
sufficient to hyperactivate the resolvase when used as the sole secondary mutation in 
combination with D102Y).   
 
6.4.2 Co-localized versus distributed locking interface mutation 
aggregation 
 In Section 4.3.5.1, the idea was put forward that two ZFR mutants that possessed 
secondary mutations on opposite sides of the locking interface, might display differential 
levels of activity depending on whether the locations of the mutations within a tetramer 
were orchestrated in a co-localized or distributed arrangement (see Figure 4-19). Within 
the RHD and MHD configurations the mutations would co-localize and the two mutations 
would exist on opposite sides of one locking interface per dimer, with the other locking 
interface of the dimer containing no mutations. Within the AHD configuration, the 
mutations would be distributed, one mutation only, per locking interface. 
 
 There are two ways the co-localized versus distributed arrangement strategy 
might be employed. The first is that mutations on opposite sides of the locking interface 
could be chosen so they would amplify the disruption of the interface when co-localized. 
This strategy would involve selecting secondary mutations in slightly different regions of 
the locking interface so they would each disrupt a different set of specific contacts. In this 
scenario, mutations that were too weak to sufficiently disrupt the locking interface when 
used in distributed arrangement might create a synergistic activating effect when used in 
the co-localized arrangement. If differential levels of activity arose between the RHD and 
AHD configurations, this would give rise to a recombination reaction directionality bias. 
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This scenario, in effect, demonstrates how a successful sleepy + sleepy ZFR 
complementation might operate.  
 
 In Section 4.3.6, sleepy + active ZFR complementations were carried out that 
tested a ZFR with G70C, against a variety of ZFRs with secondary mutations operating 
from the other side of the locking interface (Figure 4-24 B). The complementation 
between a ZFR carrying G70C and a ZFR carrying T109I was observed to produce more 
activity than any of the other reactions in this set. This might have resulted from the fact 
that G70C and T109I would be expected to disrupt different portions of the locking 
interface, due to their locations (Figure 6-1). It should be noted that the term 'disruption', 
as used here, also includes the potential unlocking effect mediated by E-helix 'landing 
pad' interactions, described in Section 4.4. The experiment was able to detect activity 
from the MHD configuration, and thus, this complementation represented a test of the 
co-localized arrangement of interface unlocking mutations. Unfortunately, there was 
insufficient time to carry out further experiments to test difference between the activity 
of the RHD and AHD configuration, which might have revealed recombination reaction 
directionality bias, and, less likely, a dimer-dimer orientation specificity bias. Therefore, 
the experiment using this sleepy + active ZFR pair should be carried out again on the full 
complement of substrate types designed to detect the activities of all tetramer 
configurations.   
 
 The other type of co-localized versus distributed arrangement strategy involves 
pairing locking interface mutations for redundancy. In this strategy, interface locking 
knockdown mutations that affect the same contacts from opposite sides of the interface, 
would be paired such that they would produce an additive effect when co-localized. 
Success of this strategy would represent the ability to activate AHD configuration, instead 
of the RHD and MHD configurations, providing an additional option for control over the 
ZFR reaction parameters.  
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6.4.3 Complete locking interface disruption 
 There is evidence from Burke et al. (2004) that placing too many locking interface 
knockdown mutations in combination can abolish the activity of Tn3 resolvase. The 
mutations A117V, R121K, and E124Q (collectively termed 'C') all produce an 
hyperactivation when used as the sole secondary mutation, but when all three are used in 
concert, Tn3 resolvase is inactive (Burke et al., 2004). One explanation for this activity is 
that this combination of mutation completely knocks out the locking interface. The 
locking interface comprises the majority of the dimer interface, and so completely 
knocking out the locking interface may disrupt the dimer interface to such a degree that 
T109I 
G70C 
NH2 
NH2 
COOH 
COOH 
Figure 6-1: Locations of G70C and T109I.  The figures shows the 1GDT crystal structure with the location of 
G70C indicated in magenta and labelled for the gold subunit, and the locations of T109I indicated in 
magenta and labelled for the green subunit. 
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dimers are no longer able to form. There is support for this hypothesis in the form of 
evidence that some activated resolvase mutants have an increased monomeric character 
when studied in vitro (Arnold et al., 1999). Further support for this hypothesis can be 
found in Burke et al. (2004) where it was shown that D102Y + C  is active only on a res x 
res substrate, but not on either res x site I, or site I x site I substrates. The fact that D102Y 
+ C is only active on the res x res substrate may suggest that the accessory module of the 
synaptosome is helping to stabilize the catalytic dimer subunits, compensating for the 
disruption of their dimer interface.   
 
 One way this hypothesis might be tested and exploited would be to generate a 
pair of ZFRs that are designed to differentially knock out the locking interface, entirely, 
when either used as homodimers or heterodimers. This strategy could take two forms. In 
the first strategy, both ZFR subunits could contain redundant mutations operating from 
both sides of the locking interface, but located in different regions of the locking 
interface. For example, consider a pair of mutants (both with an NY background) where 
one subunit might have L66I + A117V, while the other might have G70A + R121K. These 
mutation sets operate within two discrete and separate locations within the locking 
interface. Within homodimers, the effect might be redundancy, but when used in a 
heterodimer context, the effect might be additive. If the additive effect was strong 
enough to completely knock out the locking interface, then homodimers might be active 
while the heterodimers were inactive.   
 
 However, the most impressive strategy, if it worked, would be to use the pair NY 
and NYC. Both of these resolvase mutants are inactive on their own. If the NYC mutant is 
inactive for the reasons stated above, then perhaps it can be brought back to life by 
combining it in a heterodimer with NY. If NYC is inactive because its dimer interface so 
sufficiently disrupted that dimers may not form, then perhaps it can be brought back to 
life in a NY/NYC heterodimer. In this heterodimer configuration, one locking interface of 
the dimer would be preserved. If this strategy were to work, it would represent the 
creation of a functional sleepy + sleepy ZFR pair, which would abolish the SA effect, and 
produce a ZFR pair where the subunits were only active when used in concert, greatly 
reducing opportunities for off-target reactions in a genomic context.  
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6.4.4 Dissection of M 
 It was postulated in Section 4.4 that the collection of mutations known as 'M' 
(G101S, D102Y, M103I, and Q105L), may produce their effect via the E-helix landing pad 
interaction aspect of the dimer interface unlocking model. Additionally, specific contacts 
between counterpart landing pad residues were proposed. It was proposed that M103V 
and Q105L might produce their activating effect by generating more favourable 
interactions between these residues and their counterparts during tetramer formation 
(Figure 4-26 B). Both of these interactions, involving M103V and Q105L, could have 
implications for directly controlling the compatibility of the two possible orientations at 
the dimer-dimer interface. The possibility of counterpart contact between M103V 
residues seems particularly plausible. The sleepy + active complementation utilizing M 
appeared to produce a robust recombination reaction directionality bias (Figure 4-27). 
However, it is not yet clear whether this recombination reaction directionality bias is of 
the same nature as that observed for previous sleepy + active ZFR pairs, but with an 
overall increase in activity level due to the increased activity level of M, or whether there 
were different fundamental mechanisms underpinning the outcome, such as counterpart 
residue interaction between M103V and Q105L. 
 
 The secondary mutations included in M cannot be tested independently in sleepy 
+ active ZFR pairs because they do not possess enough activity to activate a ZFR (Figure 
4-20 A). However, from the three secondary mutations included in M (G101S, M103I, and 
Q105L), three pairs of two could be tested in a differential substrate assay. The assay 
would determine whether tetramer configuration activities differ from the typical pattern 
of activity observed locking interface mutants (i.e. RHD and MHD are equally active while 
AHD is less active). Conversely, the alternative hypotheses for M103V and Q105L would 
both be predicted to produce a difference in the activity of the RHD and MHD 
configurations.  
 
6.4.5 Landing pad-based dimer-dimer compatibility 
 The residues involved in the E-helix landing pad interaction may represent the 
best opportunity for controlling dimer-dimer interaction compatibility. This region is 
where the first contact between opposing E-helices of the dimer-dimer interaction are 
made, and thus, this is where compatibility or incompatibility between opposing dimers 
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may be specified. Generating selectively compatible dimers would not only provide a 
direct route to generating a dimer-dimer orientation specific reaction, but might also 
provide a strategy to prevent possible recombination between Z-sites on homologous 
chromosomes, and  allow the generation of sets of ZFRs that could be used for 
recombinase-mediated cassette exchange (RMCE). RMCE utilizes two separate 
recombination reactions in order to facilitate the exchange of a segment of DNA between 
two DNA molecules (similar to the replacement vector strategy depicted in Figure 1-1). In 
order for ZFR-based RMCE to be performed efficiently, two sets of ZFRs would need to be 
generated that are not compatible with each other, in order that only the intended pairs 
of recombination sites would react with one another. It should be noted, that another 
obvious strategy for RMCE using ZFRs is simply to generate two sets of ZFRs with 
incompatible catalytic domains from two different serine recombinases. 
 
 Because some of the contacts of the E-helix landing pad are likely made between 
opposite subunits (e.g. 102-109 or105-105), while other are likely made between 
opposite-adjacent subunits (e.g. 103-103) of the dimer-dimer interface (see Figure 4-26), 
there may be potential for generating selective compatibility between both type of 
interactions. Three general approaches for attempting to generate selective compatibility 
between subunits are: (1) Place large hydrophobic residues on one side of the interaction 
and small hydrophobic residues on the other. (2) Place hydrophobic residues on one side 
of the interaction and polar residues on the other. (3) Place charged residues on one side 
of the interaction and oppositely charged residues on the other. 
 
6.4.6 Truncated ZFA RABD + helper re-test 
 The experiment utilizing truncated ZFAs as RABDs for a RABD + helper 
complementation was essentially left unfinished (Section 5.3). It is possible that this 
experiment was successful in generating a non-reversible reaction, but because of the 
intermediate overall activity of this RABD + helper system, a key result (inversion on the 
2MutHetDim-DR substrate indicating RHD configuration activity) may have been hidden 
by the SA effect. However, an alternative explanation is that the RABD subunits might not 
have been able to re-ligate the DNA. The SA effect had not been fully characterized at the 
time of this experiment and the activity information for the RHD configuration could have 
been easily obtained through the inclusion of the variety of 2MutHetDim-IR substrates 
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that place the RABD ZFRs on the excision product. The inclusion of these substrates would 
have provided an alternative method of detecting RHD activity and demonstrated 
whether the RABD subunits are able to re-ligate the DNA. Because the excision product 
from this variety of 2MutHetDim-IR substrates would contain homodimer binding sites 
for the RABD subunits (which do not bind well) it would also be less affected by the SA 
effect, making the result clear. The experiment should be repeated with the inclusion of 
this variety of 2MutHetDim-IR substrates. 
 
6.5 Conclusion 
 Currently, the most popular tools for site-specific genome editing are the site-
specific nuclease and nickase systems. The site-specific nuclease systems have the 
drawback that they produce unwanted indel mutations at their target sites at a rate that 
is equal or higher than that of desired gene correction (Ramirez et al., 2012, Kim et al., 
2012, Wang et al., 2012). This drawback alone, likely makes them poor candidates for in 
vivo gene therapy applications. Additionally, they are capable of producing wide-spread 
off-target reactions, leading to genomic rearrangements (Tsai et al., 2015, Frock et al., 
2015). The nickase systems largely ameliorate the problem of on-target indel production, 
and have reduced off-target activity leading to genomic rearrangements, but suffer from 
a considerable loss in efficiency (Ramirez et al., 2012, Kim et al., 2012, Wang et al., 2012). 
It is possible that the gene correction efficiency of nuclease and nickase systems cannot 
be easily improved because they are limited by the level of endogenous cellular HDR 
activity. Additionally, neither site-specific nuclease nor nickase systems may be used for 
gene correction in dividing cell types because they rely on HDR which is only active during 
S phase and G2 phase of the cell cycle. The site-specific recombinase ZFR system may 
have the potential overcome the limitations of the nuclease and nickases systems, but a 
basic level of control over its recombination reactions must first be achieved in order for 
the tool to become useful.    
 
 The work described in this thesis attempted to generate control over fundamental 
ZFR reaction parameters such as recombination reaction directionality, and integration 
orientation control. The RABD + helper ZFR strategy using the H1 domain appears to have 
been completely successful in achieving the goal of producing a non-reversible reaction 
(Section 5.5.3.5). Additionally, this strategy is predicted to produce orientation-specific 
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integrations via a stochastic selection pathway (Section 5.1.3.5). The sleepy + active ZFR 
strategy, based on the locking interface model, also appears to have been successful in 
producing a recombination reaction directionality bias (Section 6.3.1). In addition, the 
sleepy + active strategy also represents the generation of a ZFR with reduced potential for 
off-target activity, as one ZFR of the pair is inactive without the activating effect of the 
other. By uniting the RABD + helper ZFR strategy and sleepy + active ZFR strategy, it 
should be possible to generate a robust system for stable orientation-specific ZFR-
mediated integration reactions, with reduced potential for off-target reactions. 
Ultimately, it is the level of efficiency of these reactions in a mammalian cell system that 
will determine whether the ZFR can offer advantages over the nuclease and nickase 
systems as a tool for gene therapy.  
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